@article{Hopsu-Havu:1966zr,
  author = {Hopsu-Havu, V. K. and Glenner, G. G.},
  title = {{A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide}},
  journal = {Histochemie},
  volume = {7},
  number = {3},
  pages = {197-201},
  note = {Hopsu-Havu, V K Glenner, G G GERMANY, WEST Histochemie. 1966;7(3):197-201.},
  keywords = {*Amides *Amidohydrolases Chemistry, Organic *Dipeptides *Naphthalenes Organic Chemistry Phenomena},
  issn = {0018-2222 (Print) 0018-2222 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/5959122},
  year = {1966},
  type = {Journal Article},
}


@article{Edman1967,
  author = {Edman, P. and Begg, G.},
  title = {{A protein sequenator}},
  journal = {Eur J Biochem},
  volume = {1},
  number = {1},
  pages = {80-91},
  note = {Edman, P Begg, G GERMANY, WEST Eur J Biochem. 1967 Mar;1(1):80-91.},
  keywords = {*Amino Acid Sequence Animals Biochemistry/*instrumentation Cetacea/analysis Chromatography, Thin Layer Indicators and Reagents Thiocyanates},
  issn = {0014-2956 (Print) 0014-2956 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/6059350 http://onlinelibrary.wiley.com/store/10.1111/j.1432-1033.1967.tb00047.x/asset/j.1432-1033.1967.tb00047.x.pdf?v=1&t=iev3bk31&s=968fa46736179699346ebe73f123282f182e1450},
  year = {1967},
  type = {Journal Article},
}


@article{Niall1973,
  author = {Niall, H. D.},
  title = {{Automated Edman degradation: the protein sequenator}},
  journal = {Methods Enzymol},
  volume = {27},
  pages = {942-1010},
  note = {Niall, H D Methods Enzymol. 1973;27:942-1010.},
  keywords = {*Amino Acid Sequence Amino Acids/analysis Arginine/analysis *Autoanalysis Chromatography, Gas Chromatography, Thin Layer Cysteine/analysis Evaluation Studies as Topic Filtration Histidine/analysis Hydrolysis Isoleucine/analysis Leucine/analysis Mass Spectrometry Methods Peptide Fragments/analysis Proteins/*analysis Solubility Thiocyanates},
  issn = {0076-6879 (Print) 0076-6879 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/4773306 http://www.sciencedirect.com/science/article/pii/S0076687973270398},
  year = {1973},
  type = {Journal Article},
}


@article{Bradford:1976aa,
  author = {Bradford, M. M.},
  title = {{A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding}},
  journal = {Anal Biochem},
  volume = {72},
  number = {1--2},
  pages = {248-54},
  note = {Bradford, M M Anal Biochem. 1976 May 7;72:248-54.},
  keywords = {Binding Sites Colorimetry Methods Microchemistry Protein Binding Proteins/*analysis Rosaniline Dyes Time Factors},
  issn = {0003-2697 (Print) 0003-2697 (Linking)},
  doi = {http://dx.doi.org/10.1016/0003-2697(76)90527-3},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/942051},
  year = {1976},
  type = {Journal Article},
}


@article{Kraut:1977bs,
  author = {Kraut, J.},
  title = {{Serine proteases: structure and mechanism of catalysis}},
  journal = {Annu Rev Biochem},
  volume = {46},
  pages = {331-58},
  note = {Kraut, J Annu Rev Biochem. 1977;46:331-58.},
  keywords = {Amino Acid Sequence Binding Sites Drug Stability Kinetics *Peptide Hydrolases/metabolism Peptides Protein Binding Serine Structure-Activity Relationship Subtilisins/metabolism Trypsin/metabolism},
  issn = {0066-4154 (Print) 0066-4154 (Linking)},
  doi = {10.1146/annurev.bi.46.070177.001555},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/332063 http://www.annualreviews.org/doi/pdf/10.1146/annurev.bi.46.070177.001555},
  year = {1977},
  type = {Journal Article},
}


@article{Heymann:1978aa,
  author = {Heymann, E. and Mentlein, R.},
  title = {{Liver dipeptidyl aminopeptidase IV hydrolyzes substance P}},
  journal = {FEBS Lett},
  volume = {91},
  number = {2},
  pages = {360-4},
  note = {Heymann, E Mentlein, R NETHERLANDS FEBS Lett. 1978 Jul 15;91(2):360-4.},
  keywords = {Animals Dipeptides Endopeptidases/isolation & purification/*metabolism Liver/*enzymology Organophosphorus Compounds/pharmacology Rats *Substance P},
  issn = {0014-5793 (Print) 0014-5793 (Linking)},
  doi = {http://dx.doi.org/10.1016/0014-5793(78)81210-1},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/680144 http://onlinelibrary.wiley.com/doi/10.1016/0014-5793(78)81210-1/abstract http://onlinelibrary.wiley.com/store/10.1016/0014-5793(78)81210-1/asset/feb20014579378812101.pdf?v=1&t=iyasu0ur&s=04b4d16aaa65a29cdc7d423a276fe7d0b6b057ca},
  year = {1978},
  type = {Journal Article},
}


@article{Kullertz:1978aa,
  author = {Kullertz, G. and Fischer, G. and Barth, A.},
  title = {{[Catalytic mechanism of dipeptidyl-peptidase IV]}},
  journal = {Acta Biol Med Ger},
  volume = {37},
  number = {4},
  pages = {559-67},
  note = {Kullertz, G Fischer, G Barth, A GERMANY, EAST Acta Biol Med Ger. 1978;37(4):559-67.},
  abstract = {Dipeptidyl-peptidase IV isolated from pig kidney microsomes catalyses hydrolysis in a number of dipeptidylaryl-amides of types L-AS-L-Ala-R and L-AS-L-Pro-R. Kinetic studies involving two competing substrates suggest the probable existence of a catalytic centre for both groups of substrates. The speed-determining steps in enzymatic hydrolysis differ in the order L-AS-L-Pro-R and L-AS-L-Ala-R. The secondary enzymatic deuterium-isotopic effects in the hydrolysis of L-Ala-L-Ala-2-d1-pNA are fixed at KHM/KDM = 1.24 and VHmax/VDmax = 1.27. The existence of an acyl-enzyme mechanism is considered likely.},
  keywords = {Animals Dipeptides Endopeptidases/*metabolism Kidney/enzymology Kinetics Microsomes/enzymology Substrate Specificity Swine},
  issn = {0001-5318 (Print) 0001-5318 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/735626},
  year = {1978},
  type = {Journal Article},
}


@article{Hartrodt:1982aa,
  author = {Hartrodt, B. and Neubert, K. and Fischer, G. and Demuth, U. and Yoshimoto, T. and Barth, A.},
  title = {{Degradation of beta-casomorphin-5 by proline-specific-endopeptidase (PSE) and post-proline- cleaving-enzyme (PPCE). Comparative studies of the beta-casomorphin-5 cleavage by dipeptidyl-peptidase IV}},
  journal = {Pharmazie},
  volume = {37},
  number = {1},
  pages = {72-3},
  note = {Hartrodt, B Neubert, K Fischer, G Demuth, U Yoshimoto, T Barth, A GERMANY, EAST Pharmazie. 1982 Jan;37(1):72-3.},
  keywords = {Animals Caseins/*metabolism/pharmacology Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/*metabolism Endopeptidases/*metabolism Endorphins/*metabolism/pharmacology Guinea Pigs Hydrolysis Muscle Contraction/drug effects Muscle, Smooth/drug effects *Serine Endopeptidases Substrate Specificity},
  issn = {0031-7144 (Print) 0031-7144 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/7041139},
  year = {1982},
  type = {Journal Article},
}


@article{Fischer:1983wo,
  author = {Fischer, G. and Heins, J. and Barth, A.},
  title = {{The Conformation around the Peptide-Bond between the P1-Positions and P2-Positions Is Important for Catalytic Activity of Some Proline-Specific Proteases}},
  journal = {Biochimica Et Biophysica Acta},
  volume = {742},
  number = {3},
  pages = {452-462},
  note = {Qf459 Times Cited:61 Cited References Count:29},
  abstract = {Proline-containing dipeptidyl-4-nitroanilides have been synthesised and subjected to dipeptidyl peptidase IV-catalysed hydrolysis at high enzyme concentrations to collect information on the conformational specificity of the enzyme active site for a nonscissile bond. Descriptions of the biphasic kinetics were carried out in terms of cis/trans interconversion of the substrates. The results show that the enzyme can cleave only the trans-conformation of the substrate. The competitive inhibition by Gly-Pro-OH and Ala-Pro-OH is also specific for the trans form of the dipeptides. The interpretation of the results obtained from these kinetic studies has led to proposals for the stepwise cleavage of biologically active peptides like substance P and beta-casomorphine by dipeptidyl peptidase IV.},
  issn = {0006-3002},
  doi = {Doi 10.1016/0167-4838(83)90261-3},
  url = {<Go to ISI>://A1983QF45900003},
  year = {1983},
  type = {Journal Article},
}


@article{Kikuchi:1988aa,
  author = {Kikuchi, M. and Fukuyama, K. and Epstein, W. L.},
  title = {{Soluble dipeptidyl peptidase IV from terminal differentiated rat epidermal cells: purification and its activity on synthetic and natural peptides}},
  journal = {Arch Biochem Biophys},
  volume = {266},
  number = {2},
  pages = {369-76},
  note = {Kikuchi, M Fukuyama, K Epstein, W L AR12433/AR/NIAMS NIH HHS/ Arch Biochem Biophys. 1988 Nov 1;266(2):369-76.},
  abstract = {In terminally differentiated epidermal cells dipeptidyl peptidase IV (EC 3.4.14.5) (DPP IV) is present mainly in a soluble form. We purified the enzyme from 2-day-old rat cornified cells to homogeneity by Sephadex G-200 and Mono-Q column chromatography and finally HPLC gel filtration on G3000SW. The enzyme was estimated to be Mr 190,000 by HPLC gel filtration and Mr 90,000 by sodium dodecyl sulfate-electrophoresis. The enzyme showed general properties reported for detergent-solubilized DPP IV from other tissues. It was Con A binding and almost completely inhibited by 1 mM diisopropyl fluorophosphate and Diprotin A. The pI was 5.6 and the pH optimum was 7.5. The specific activity for Gly-Pro-p-nitroanilide was 31.9 units/mg. HPLC analysis demonstrated the release of dipeptides of the N-terminal of substance P, beta-casomorphin, and their related peptides. A stoichiometric reaction of the enzyme on substance P was observed. The epidermal DPP IV had a Km of 0.3 mM and a kcat of 50.3 s-1 for substance P and the Km value decreased by shortening the peptide from the carboxyl-terminal amino acids. The enzyme hydrolyzed human and bovine beta-casomorphin with Km values of 0.025 and 0.05 mM, respectively. Shortening the bovine beta-casomorphin peptide chain did not affect enzyme affinity.},
  keywords = {Animals Cattle Cell Differentiation Chromatography, Gel Chromatography, High Pressure Liquid Detergents Dipeptidyl Peptidase 4 Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/*isolation & purification Endorphins/analysis Epidermis/*enzymology Peptide Fragments/analysis Rats Solubility Substance P/analysis},
  issn = {0003-9861 (Print) 0003-9861 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/2461166},
  year = {1988},
  type = {Journal Article},
}


@article{Mentlein:1988eu,
  author = {Mentlein, R.},
  title = {{Proline residues in the maturation and degradation of peptide hormones and neuropeptides}},
  journal = {FEBS Lett},
  volume = {234},
  number = {2},
  pages = {251-6},
  note = {Mentlein, R NETHERLANDS FEBS Lett. 1988 Jul 18;234(2):251-6.},
  abstract = {The proteases involved in the maturation of regulatory peptides like those of broader specificity normally fail to cleave peptide bonds linked to the cyclic amino acid proline. This generates several mature peptides with N-terminal X-Pro-sequences. However, in certain non-mammalian tissues repetitive pre-sequences of this type are removed by specialized dipeptidyl (amino)peptidases during maturation. In mammals, proline-specific proteases are not involved in the biosynthesis of regulatory peptides, but due to their unique specificity they could play an important role in the degradation of them. Evidence exists that dipeptidyl (amino)peptidase IV at the cell surface of endothelial cells sequesters circulating peptide hormones which are then susceptible to broader aminopeptidase attack. The cleavage of several neuropeptides by prolyl endopeptidase has been demonstrated in vitro, but its role in the brain is questionable since the precise localization of the protease is not clarified.},
  keywords = {Animals Hormones/*metabolism Neuropeptides/*metabolism Peptide Hydrolases/*metabolism *Proline Substrate Specificity},
  issn = {0014-5793 (Print) 0014-5793 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/3292288 http://onlinelibrary.wiley.com/doi/10.1016/0014-5793(88)80092-9/abstract http://onlinelibrary.wiley.com/store/10.1016/0014-5793(88)80092-9/asset/feb20014579388800929.pdf?v=1&t=iyb6ntiz&s=55e1569e1d410a431b6f0fc31e057a2498de40fc},
  year = {1988},
  type = {Journal Article},
}


@article{White1988,
  author = {White, Jason M. and Rumbold, Gregory R.},
  title = {{Behavioural effects of histamine and its antagonists: a review}},
  journal = {Psychopharmacology},
  volume = {95},
  number = {1},
  pages = {1-14},
  abstract = {This review focusses on the behavioural effects of histamine and drugs which affect histaminergic function, particularly the H1- and H2-receptors antagonists. Research in this area has assumed considerable importance with increasing interest in the role of brain histamine, the clinical use of both H1 and H2 antagonists and evidence of nonmedical use of H1 antagonists. Results from a number of studies show that H1 and H2 antagonists have clear, but distinct subjective effects and that H1 antagonists have discriminative effects in animals. While H1 antagonists are reinforcers in certain conditions, histamine itself is a punisher. Moderate doses of H1 antagonists affect psychomotor performance in some situations, but the results are variable. The exceptions are terfenadine and astemizole, which do not seem to penetrate the blood-brain barrier readily. In studies of schedule-controlled behaviour, marked changes in response rate have been observed following administration of H1 antagonists, with the magnitude and direction dependent on the dose and the baseline behaviour. Histamine reduces avoidance responding, an effect mediated via H1-receptors. Changes in drinking and aggressive behaviour have also been observed following histamine administration and distinct roles for H1- and H2-receptors have been delineated. Separate H1- and H2-receptor mechanisms have also been suggested to account for changes in activity level. While the H2 antagonists do not always have strong behavioural effects when administered peripherally, there is evidence that cimetidine has a depressant effect on sexual function. These and other findings reveal an important role for histaminergic systems in a wide range of behaviour.},
  issn = {1432-2072},
  doi = {10.1007/bf00212757},
  url = {http://dx.doi.org/10.1007/BF00212757 http://link.springer.com/article/10.1007%2FBF00212757 http://download.springer.com/static/pdf/424/art%253A10.1007%252FBF00212757.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2FBF00212757&token2=exp=1485573971~acl=%2Fstatic%2Fpdf%2F424%2Fart%25253A10.1007%25252FBF00212757.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252FBF00212757*~hmac=79c0e26e33681e9583b27f02b61bde9a1fb594565189cbc4f99f0f53ac3c1529},
  year = {1988},
  type = {Journal Article},
}


@inbook{Addicks1989,
  author = {Addicks, K. and Forssmann, W. G. and Henkel, H. and Holthausen, U. and Menz, V. and Rippegather, G. and Ziskoven, D.},
  title = {{Calcium-Calmodulinantagonists Influence Release of Cardiodilatin/ANP from Atrial Cardiocytes}},
  booktitle = {Endocrinology of the Heart},
  editor = {Kaufmann, W. and Wambach, G.},
  publisher = {Springer Berlin Heidelberg},
  address = {Berlin, Heidelberg},
  pages = {233-234},
  isbn = {978-3-642-83858-3},
  doi = {10.1007/978-3-642-83858-3_48},
  url = {http://dx.doi.org/10.1007/978-3-642-83858-3_48 http://download.springer.com/static/pdf/388/chp%253A10.1007%252F978-3-642-83858-3_48.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Fchapter%2F10.1007%2F978-3-642-83858-3_48&token2=exp=1473934986~acl=%2Fstatic%2Fpdf%2F388%2Fchp%25253A10.1007%25252F978-3-642-83858-3_48.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Fchapter%252F10.1007%252F978-3-642-83858-3_48*~hmac=54bff60053958b13250467e8b56a721f8b4bb7ab949ff359a2a28a15b1a8efda},
  year = {1989},
  type = {Book Section},
}


@article{Frohman:1989aa,
  author = {Frohman, L. A. and Downs, T. R. and Heimer, E. P. and Felix, A. M.},
  title = {{Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma}},
  journal = {J Clin Invest},
  volume = {83},
  number = {5},
  pages = {1533-40},
  note = {Frohman, L A Downs, T R Heimer, E P Felix, A M AM-30067/AM/NIADDK NIH HHS/ J Clin Invest. 1989 May;83(5):1533-40.},
  abstract = {The plasma enzyme responsible for primary proteolytic cleavage of growth hormone-releasing hormone (GRH) at the 2-3 amino acid bond was characterized. Native GRH[GRH(1-44)-NH2 and GRH(1-40)-OH], and COOH-terminally shortened fragments [GRH(1-32)-NH2 and GRH(1-29)-NH2] were rapidly cleaved, while GRH(2-32)-NH2 was not degraded at this site. Moreover, degradation to GRH(3-44)-NH2 was unaffected by an aminopeptidase inhibitor, indicating that this metabolite was generated from a single step cleavage by a dipeptidylpeptidase (DPP) rather than sequential aminopeptidase cleavages. Conversion to GRH(3-44)-NH2 was blocked by diprotin A, a DPP type IV (DPP IV) competitive inhibitor. D-Amino acid substitution at either position 1 or 2 also prevented hydrolysis, characteristic of DPP IV. Analysis of endogenous plasma GRH immunoreactivity from a human GRH transgenic pig revealed that the major peak coeluted with GRH(3-44)-NH2. Native GRH exhibited trypsin-like degradation at the 11-12 position but cleavage at the 12-13 site occurred only with GRH(1-32)-NH2 and GRH(1-29)-NH2. Formation of these metabolites was independent of prior DPP IV hydrolysis but was greatly reduced by trypsin inhibitors. Evaluation of plasma stability of potential GRH super analogues, designed to resist degradation by these enzymes, confirmed that GRH degradation in plasma occurs primarily by DPP IV, and to a lesser extent by trypsin-like enzyme(s).},
  keywords = {Amino Acid Sequence Aminopeptidases/blood/physiology Animals Animals, Genetically Modified Chromatography, High Pressure Liquid Dipeptidyl Peptidase 4 Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/*blood/physiology Growth Hormone-Releasing Hormone/*blood/isolation & purification Humans Hydrolysis Molecular Sequence Data Plasma/physiology Swine Trypsin/*blood/physiology},
  issn = {0021-9738 (Print) 0021-9738 (Linking)},
  doi = {10.1172/JCI114049},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/2565342 http://www.jci.org/articles/view/114049 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC303858/pdf/jcinvest00086-0095.pdf},
  year = {1989},
  type = {Journal Article},
}


@article{Nausch:1990aa,
  author = {Nausch, I. and Mentlein, R. and Heymann, E.},
  title = {{The degradation of bioactive peptides and proteins by dipeptidyl peptidase IV from human placenta}},
  journal = {Biol Chem Hoppe Seyler},
  volume = {371},
  number = {11},
  pages = {1113-8},
  note = {Nausch, I Mentlein, R Heymann, E GERMANY Biol Chem Hoppe Seyler. 1990 Nov;371(11):1113-8.},
  abstract = {The degradation of several bioactive peptides and proteins by purified human dipeptidyl peptidase IV is reported. It was hitherto unknown that human gastrin-releasing peptide, human chorionic gonadotropin, human pancreatic polypeptide, sheep prolactin, aprotinin, corticotropin-like intermediate lobe peptide and (Tyr-)melanostatin are substrates of this peptidase. Kinetic constants were determined for the degradation of a number of other natural peptides, including substance P, the degradation of which has been described earlier in a qualitative manner. Generally, small peptides are degraded much more rapidly than proteins. However, the Km-values seem to be independent of the peptide chain length. The influence of the action of dipeptidyl peptidase IV on the biological function of peptides and proteins is discussed.},
  keywords = {Amino Acid Sequence Dipeptidyl Peptidase 4 Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/*metabolism Humans Hydrolysis Kinetics Molecular Sequence Data Peptides/metabolism Placenta/*enzymology Substrate Specificity},
  issn = {0177-3593 (Print) 0177-3593 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/1982212},
  year = {1990},
  type = {Journal Article},
}


@article{Schneider:1990aa,
  author = {Schneider, T. D. and Stephens, R. M.},
  title = {{Sequence logos: a new way to display consensus sequences}},
  journal = {Nucleic Acids Res},
  volume = {18},
  number = {20},
  pages = {6097-100},
  note = {Schneider, T D Stephens, R M ENGLAND Nucleic Acids Res. 1990 Oct 25;18(20):6097-100.},
  abstract = {A graphical method is presented for displaying the patterns in a set of aligned sequences. The characters representing the sequence are stacked on top of each other for each position in the aligned sequences. The height of each letter is made proportional to its frequency, and the letters are sorted so the most common one is on top. The height of the entire stack is then adjusted to signify the information content of the sequences at that position. From these 'sequence logos', one can determine not only the consensus sequence but also the relative frequency of bases and the information content (measured in bits) at every position in a site or sequence. The logo displays both significant residues and subtle sequence patterns.},
  keywords = {*Amino Acid Sequence Bacteriophage lambda/genetics *Base Sequence Binding Sites Chromosome Deletion DNA Transposable Elements DNA-Directed RNA Polymerases/metabolism Escherichia coli/genetics *Genes, Viral *Genetic Techniques Globins/genetics Humans Molecular Sequence Data T-Phages/enzymology/genetics},
  issn = {0305-1048 (Print) 0305-1048 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/2172928 http://nar.oxfordjournals.org/content/18/20/6097.full.pdf},
  year = {1990},
  type = {Journal Article},
}


@article{Danchin:1991aa,
  author = {Danchin, A. and Medigue, C. and Gascuel, O. and Soldano, H. and Henaut, A.},
  title = {{From data banks to data bases}},
  journal = {Res Microbiol},
  volume = {142},
  number = {7-8},
  pages = {913-6},
  note = {Danchin, A Medigue, C Gascuel, O Soldano, H Henaut, A FRANCE Res Microbiol. 1991 Sep-Oct;142(7-8):913-6.},
  abstract = {The information collected in national and international libraries on nucleotide and protein sequences cannot be directly treated for proper handling by existing software. Therefore we evaluated the feasibility of constructing a data base for Escherichia coli using the data present in the banks. The knowhow thus acquired was applied to Bacillus subtilis. Specific examples of the general procedure are given.},
  keywords = {Bacillus subtilis/genetics/*ultrastructure Base Sequence/genetics Chromosomes, Bacterial/*ultrastructure DNA, Bacterial/genetics/*ultrastructure Database Management Systems Databases, Bibliographic *Databases, Factual Escherichia coli/genetics/*ultrastructure Molecular Sequence Data},
  issn = {0923-2508 (Print) 0923-2508 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/1784830},
  year = {1991},
  type = {Journal Article},
}


@article{Ahmad:1992aa,
  author = {Ahmad, S. and Wang, L. and Ward, P. E.},
  title = {{Dipeptidyl(amino)peptidase IV and aminopeptidase M metabolize circulating substance P in vivo}},
  journal = {J Pharmacol Exp Ther},
  volume = {260},
  number = {3},
  pages = {1257-61},
  note = {Ahmad, S Wang, L Ward, P E R01 HL 45791/HL/NHLBI NIH HHS/ J Pharmacol Exp Ther. 1992 Mar;260(3):1257-61.},
  abstract = {Recent studies have demonstrated that Fischer-344 rats from Japanese Charles River Inc. specifically lack dipeptidyl(amino)peptidase IV (DAP IV-negative; EC 3.4.14.5), whereas Fischer-344 rats from sources within the United States (DAP IV-positive) possess normal DAP IV activity. In the present study, plasma from DAP IV-positive rats metabolized substance P (SP) (5.37 +/- 0.25 nmol/min/ml) via the actions of angiotensin-converting enzyme (EC 3.4.15.1) (1.86 +/- 0.50 nmol/min/ml) and DAP IV (2.56 +/- 0.42 nmol/min/ml). DAP IV sequentially converted SP to SP[3-11] and SP[5-11]. The SP[5-11] metabolite was then rapidly hydrolyzed by plasma aminopeptidase M (AmM; EC 3.4.11.2) (36.2 +/- 4.2 nmol/min/ml). In contrast, SP metabolism by plasma from DAP IV-negative rats was less than half that of control animals (2.14 +/- 0.06 nmol/min/ml), due to a complete lack of DAP IV hydrolysis. The absence of DAP IV was not associated with any differences in angiotensin-converting enzyme-mediated hydrolysis of SP (1.45 +/- 0.11 nmol/min/ml) or AmM-mediated hydrolysis of SP[5-11] (37.1 +/- 0.9 nmol/min/ml). Consistent with this deficiency in SP metabolism, SP was more potent in vivo in stimulating salivary secretion in DAP IV-negative rats compared to DAP IV-positive animals. Potentiation was specific in that SP[5-11], an SP fragment resistant to DAP IV, was equipotent in DAP IV-negative and positive animals. SP[5-11]-induced salivary secretion was potentiated in both strains when AmM-mediated hydrolysis was inhibited by amastatin (20 nmol/min, i.v.). These data provide direct evidence for a significant role for DAP IV and AmM in the in vivo processing of SP and active SP metabolites.},
  keywords = {Aminopeptidases/*physiology Animals Antigens, CD13 Dipeptidyl Peptidase 4 Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/*physiology Female Male Peptide Fragments/metabolism Rats Substance P/*metabolism},
  issn = {0022-3565 (Print) 0022-3565 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/1372050 http://jpet.aspetjournals.org/content/260/3/1257.full.pdf},
  year = {1992},
  type = {Journal Article},
}


@article{Bongers:1992aa,
  author = {Bongers, J. and Lambros, T. and Ahmad, M. and Heimer, E. P.},
  title = {{Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs}},
  journal = {Biochim Biophys Acta},
  volume = {1122},
  number = {2},
  pages = {147-53},
  note = {Bongers, J Lambros, T Ahmad, M Heimer, E P NETHERLANDS Biochim Biophys Acta. 1992 Jul 31;1122(2):147-53.},
  abstract = {The kinetics and selectivity of proteolysis of synthetic human growth hormone-releasing factor and analogs by purified human placental dipeptidyl peptidase IV (DPP IV) were studied by HPLC. The initial rates of Ala2-Asp3 cleavage (pH 7.8, 37 degrees C, So = 0.15 mM) were all approx. 5 mumol min-1 mg-1 for the parent hormone, GRF(1-44)-NH2, and the fragments, GRF(1-29)-NH2 and GRF(1-20)-NH2. Lower activities observed for GRF(1-11)-OH, GRF(1-3)-OH, and cyclic lactam analogs indicate S1'-Sn' binding. Assays of [Trp6]-GRF(1-29)-NH2 versus [D-Trp6]-GFR(1-29)-NH2 indicate an S4' binding cavity. Peptides with D-configuration at P2, P1 or P1' and desNH2Tyr1 and N-MeTyr1 analogs of GRF were not cleaved. Catalytic parameters for the P1-substituted analogs [X2,Ala15]-GRF(1-29)-NH2 were found to vary with X as follows, Km: Abu less than Ala less than Pro less than Val less than Ser less than Gly much less than Leu; kcat: Pro greater than Ala greater than Abu greater than Ser greater than Gly much greater than Leu greater than Val; kcat/Km: Abu greater than Pro greater than Ala much greater than Ser greater than Gly = Val much greater than Leu. Km is at a minimum and kcat/Km at a maximum, for a hydrophobic P1 side-chain of about 0.25 nm in length, i.e., the ethyl side-chain of alpha-aminobutyric acid (Abu) is very close to optimal. These results further define the S1 selectivity of DPP IV and may be useful in the design of DPP IV resistant GRF analogs that can be produced by recombinant DNA methods and the design of DPP IV inhibitors.},
  keywords = {Amino Acid Sequence Catalysis Dipeptidyl Peptidase 4 Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/*metabolism Growth Hormone-Releasing Hormone/analogs & derivatives/*metabolism Humans Kinetics Molecular Sequence Data Placenta/enzymology Substrate Specificity},
  issn = {0006-3002 (Print) 0006-3002 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/1353684},
  year = {1992},
  type = {Journal Article},
}


@article{Boulanger:1992aa,
  author = {Boulanger, L. and Roughly, P. and Gaudreau, P.},
  title = {{Catabolism of rat growth hormone-releasing factor(1-29) amide in rat serum and liver}},
  journal = {Peptides},
  volume = {13},
  number = {4},
  pages = {681-9},
  note = {Boulanger, L Roughly, P Gaudreau, P Peptides. 1992 Jul-Aug;13(4):681-9.},
  abstract = {Clinical and veterinary uses of growth hormone-releasing factor [GRF(1- 29)NH2] require the design of analogs that are resistant to proteolysis by serum and liver degrading enzymes. This study investigated rat GRF(1-29)NH2 processing in serum and liver homogenate by means of high pressure liquid chromatography (HPLC). Synthetic rGRF(1-29)NH2 (30 microM) was incubated (0-120 min, 37 degrees C) in serum (49 +/- 8 mg prot./ml). The rGRF(1-29)NH2 (10 microM) was also incubated (0-120 min, 37 degrees C) with liver homogenate (200 +/- 6 micrograms prot./ml). Time course studies of rGRF(1-29)NH2 disappearance showed apparent half-lives of 18 +/- 4 min and 13 +/- 3 min in serum and liver homogenate, respectively. This was accompanied by the appearance of degradation products that were all less hydrophobic than the native peptide. In the serum, two major metabolites were detected and isolated by preparative HPLC. Combined results of amino acid analysis, sequencing, and chromatography with synthetic homologs revealed the presence of rGRF(1-20)OH and (3-20)OH. A small amount of rGRF(12-29)NH2, coeluting with rGRF(3-20)OH, was also found by sequencing. In the liver, rGRF(1-18)OH, (3-18)OH, and (1-10)OH were identified. The peptide bond Ala2-Asp3 (DPP IV cleavage site) was hydrolyzed in both serum and liver. Other tissue-specific cleavage sites were Arg11-Arg12 and Arg20-Lys21 (trypsin-like cleavage site) in the serum, and Tyr10-Arg11 and Tyr18-Ala19 (chymotrypsin-like cleavage site) in the liver.(ABSTRACT TRUNCATED AT 250 WORDS)},
  keywords = {Amino Acid Sequence Animals *Drug Design Drug Stability Liver/*metabolism Male Molecular Sequence Data Organ Specificity/physiology Pituitary Gland/metabolism Protease Inhibitors/pharmacology Rats Rats, Sprague-Dawley Recombinant Proteins/chemistry/metabolism Sermorelin/blood/*metabolism Species Specificity},
  issn = {0196-9781 (Print) 0196-9781 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/1437711},
  year = {1992},
  type = {Journal Article},
}


@book{:1992aa,
  author = {Keil, Borivoj},
  title = {{Specificity of proteolysis}},
  publisher = {Berlin},
  year = {1992},
  type = {Book},
}


@article{Pesquero:1992aa,
  author = {Pesquero, J. B. and Jubilut, G. N. and Lindsey, C. J. and Paiva, A. C.},
  title = {{Bradykinin metabolism pathway in the rat pulmonary circulation}},
  journal = {J Hypertens},
  volume = {10},
  number = {12},
  pages = {1471-8},
  note = {Pesquero, J B Jubilut, G N Lindsey, C J Paiva, A C ENGLAND J Hypertens. 1992 Dec;10(12):1471-8.},
  abstract = {OBJECTIVE: The contribution made by different enzymes to the degradation of bradykinin in physiological conditions was estimated by examining bradykinin metabolism in rat serum, in the in situ perfused lung and in vivo. METHODS: Dose-response curves for the hypotensive effect of intra-arterially and intravenously injected bradykinin were obtained in unanaesthetized rats. High-performance liquid chromatography was used to analyse the products of bradykinin breakdown after incubation with rat serum and perfusion through in situ lung preparations. RESULTS: In rat serum, kininase I degraded 34% and kininase II 11% of bradykinin, no evidence for other activities being detected. In the awake rat, D,L-2-mercaptomethyl-3-guanidino-ethylthiopropionic acid, an inhibitor of kininase I, did not reduce the percentage of bradykinin inactivation in the pulmonary circulation. In the in situ perfused lung 65% of bradykinin was metabolized and the main products were BK1-7, BK1-5 and BK4-9. Enalaprilat (an inhibitor of kininase II) blocked the formation of BK1-7 and BK1-5 and increased the recovery of BK4-9. beta-Mercapto-ethanol, which inhibits aminopeptidase P, and diprotin A, a specific inhibitor of dipeptidylaminopeptidase IV, both reduced the formation of BK4-9. Diprotin A also allowed the recovery of BK2-9. Bradykinin degradation and BK4-9 recovery were not affected by endopeptidase inhibitors. CONCLUSIONS: Our results show that the main degradation pathway of bradykinin in the lung is through the action of kininase II at the carboxyl terminus, and sequential cleavage by aminopeptidase P followed by dipeptidylaminopeptidase IV at the amino terminus. The amino-terminal degradation of bradykinin represents about 38% of the total lung kininase activity.},
  keywords = {Aminopeptidases/metabolism Angiotensin I/metabolism Animals Blood Pressure/physiology Bradykinin/administration & dosage/blood/*metabolism Dipeptidyl Peptidase 4 Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/metabolism Dose-Response Relationship, Drug Lung/enzymology/*metabolism Lysine Carboxypeptidase/metabolism Male Peptidyl-Dipeptidase A/metabolism Pulmonary Circulation/*physiology Rats Rats, Wistar},
  issn = {0263-6352 (Print) 0263-6352 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/1363432},
  year = {1992},
  type = {Journal Article},
}


@article{Grandt:1993aa,
  author = {Grandt, D. and Dahms, P. and Schimiczek, M. and Eysselein, V. E. and Reeve, J. R., Jr. and Mentlein, R.},
  title = {{[Proteolytic processing by dipeptidyl aminopeptidase IV generates receptor selectivity for peptide YY (PYY)]}},
  journal = {Med Klin (Munich)},
  volume = {88},
  number = {3},
  pages = {143-5},
  note = {Grandt, D Dahms, P Schimiczek, M Eysselein, V E Reeve, J R Jr Mentlein, R GERMANY Munich, Germany : 1983 Med Klin (Munich). 1993 Mar 15;88(3):143-5.},
  abstract = {Two receptor subtypes, Y1 and Y2, are known to mediate PYY biological activity. PYY 1-36 binds to Y1 and Y2 receptors with equal affinity, whereas the second endogenous form of PYY, PYY 3-36, selectively binds to Y2 receptors. Dipeptidyl cleavage thus transforms an unselective Y agonist into a highly selective Y2 agonist, PYY 3-36. The enzyme responsible for this processing is unknown. Since PYY has a proline in the penultimate position it is protected from the attack of most unspecific exopeptidases. Only a few exopeptidases are theoretically capable of generating PYY 3-36 from PYY 1-36. Of the enzymes tested only the dipeptidyl aminopeptidase IV (DPP IV, E.C. 3.4.14.5) cleaved Tyr-Pro from PYY 1-36 with high activity. Since DPP IV is found on the endothelial surface and brush border membranes it can be considered a candidate enzyme for generating PYY 3-36 in vivo, thereby regulating the ratio of Y1/Y2 receptor stimulation by PYY.},
  keywords = {Dipeptidyl Peptidase 4 Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/*physiology Humans Peptide Fragments/*metabolism Peptide YY Peptides/*metabolism Receptors, Neuropeptide Y/*metabolism},
  issn = {0723-5003 (Print) 0723-5003 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/8097274},
  year = {1993},
  type = {Journal Article},
}


@article{Mentlein:1993aa,
  author = {Mentlein, R. and Dahms, P. and Grandt, D. and Kruger, R.},
  title = {{Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV}},
  journal = {Regul Pept},
  volume = {49},
  number = {2},
  pages = {133-44},
  note = {Mentlein, R Dahms, P Grandt, D Kruger, R NETHERLANDS Regul Pept. 1993 Dec 10;49(2):133-44.},
  abstract = {Neuropeptide Y, peptide YY and pancreatic polypeptide share an evolutionary conserved proline-rich N-terminal sequence, a structure generally known to be inert to the attack of common proteinases, but a potential target for specialized proline-specific aminopeptidases. Purified human dipeptidyl peptidase IV (also termed CD 26) liberated N-terminal Tyr-Pro from both, neuropeptide Y and peptide YY, with very high specific activities and Km values in the micromolar range, but almost no Ala-Pro from pancreatic polypeptide. Other proline-specific aminopeptidases exhibited low (aminopeptidase P, liberation of N-terminal Tyr) or totally no activity (dipeptidyl peptidase II), as was also observed with less-specific aminopeptidases (aminopeptidase M, leucine aminopeptidase). When human serum was incubated with neuropeptide Y or peptide YY at micro- and nanomolar concentrations, Tyr-Pro was detected as a metabolite of both peptides. Formation of Tyr-Pro in serum was blocked in the presence of Lys-pyrrolidine and diprotin A (Ile-Pro-Ile), specific, competitive inhibitors of dipeptidyl peptidase IV. Incubation of neuropeptide Y or peptide YY with immunocytochemically defined, cultivated endothelial cells from human umbilical cord also yielded Tyr-Pro. Dipeptidyl peptidase IV could be immunostained on most endothelial cells by a specific antibody. We suggest that dipeptidyl peptidase IV might be involved in the degradation of neuropeptide Y and peptide YY to N-terminal truncated neuropeptide Y(3-36) and peptide YY(3-36). Since specific binding to Y1, but not to Y2 subtype of neuropeptide Y/peptide YY receptors requires intact N- as well as C-termini of neuropeptide Y and peptide YY, removal of their amino-terminal dipeptides by dipeptidyl peptidase IV inactivates them for binding to one receptor subtype.},
  keywords = {Amino Acid Sequence Animals Cells, Cultured Dipeptidyl Peptidase 4 Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/*metabolism Endothelium, Vascular/cytology/metabolism Humans Molecular Sequence Data Neuropeptide Y/blood/*metabolism Peptide YY Peptides/blood/*metabolism *Protein Processing, Post-Translational Sequence Homology, Amino Acid},
  issn = {0167-0115 (Print) 0167-0115 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/7907802},
  year = {1993},
  type = {Journal Article},
}


@article{Mentlein:1993pb,
  author = {Mentlein, R and Gallwitz, B and Schmidt, W E},
  title = {{Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum}},
  journal = {Eur J Biochem},
  volume = {214},
  number = {3},
  pages = {829-35},
  abstract = {Peptides of the glucagon/vasoactive-intestinal-peptide (VIP) peptide family share a considerable sequence similarity at their N-terminus. They either start with Tyr-Ala, His-Ala or His-Ser which might be in part potential targets for dipeptidyl-peptidase IV, a highly specialized aminopeptidase removing dipeptides only from peptides with N-terminal penultimate proline or alanine. Growth-hormone-releasing factor (1-29)amide and gastric inhibitory peptide/glucose-dependent insulinotropic peptide (GIP) with terminal Tyr-Ala as well as glucagon-like peptide-1(7-36)amide/insulinotropin [GLP-1(7-36)amide] and peptide histidine methionine (PHM) with terminal His-Ala were hydrolysed to their des-Xaa-Ala derivatives by dipeptidyl-peptidase IV purified from human placenta. VIP with terminal His-Ser was not significantly degraded by the peptidase. The kinetics of the hydrolysis of GIP, GLP-1(7-36)amide and PHM were analyzed in detail. For these peptides Km values of 4-34 microM and Vmax values of 0.6-3.8 mumol.min-1.mg protein-1 were determined for the purified peptidase which should allow their enzymic degradation also at physiological, nanomolar concentrations. When human serum was incubated with GIP or GLP-1(7-36)amide the same fragments as with the purified dipeptidyl-peptidase IV, namely the des-Xaa-Ala peptides and Tyr-Ala in the case of GIP or His-Ala in the case of GLP-1(7-36)amide, were identified as the main degradation products of these peptide hormones. Incorporation of inhibitors specific for dipeptidyl-peptidase IV, 1 mM Lys-pyrrolidide or 0.1 mM diprotin A (Ile-Pro-Ile), completely abolished the production of these fragments by serum. It is concluded that dipeptidyl-peptidase IV initiates the metabolism of GIP and GLP-1(7-36)amide in human serum. Since an intact N-terminus is obligate for the biological activity of the members of the glucagon/VIP peptide family [e. g. GIP(3-42) is known to be inactive to release insulin in the presence of glucose as does intact GIP], dipeptidyl-peptidase-IV action inactivates these peptide hormones. The relevance of this finding for their inactivation and their determination by immunoassays is discussed.},
  url = {http://onlinelibrary.wiley.com/store/10.1111/j.1432-1033.1993.tb17986.x/asset/j.1432-1033.1993.tb17986.x.pdf?v=1&t=i9r7w063&s=a3c378c6799b693095f07d2449b3aeb9e9457df2},
  year = {1993},
  type = {Journal Article},
}


@article{Tiruppathi:1993aa,
  author = {Tiruppathi, C. and Miyamoto, Y. and Ganapathy, V. and Leibach, F. H.},
  title = {{Genetic evidence for role of DPP IV in intestinal hydrolysis and assimilation of prolyl peptides}},
  journal = {Am J Physiol},
  volume = {265},
  number = {1 Pt 1},
  pages = {G81-9},
  note = {Tiruppathi, C Miyamoto, Y Ganapathy, V Leibach, F H DK-42069/DK/NIDDK NIH HHS/ Am J Physiol. 1993 Jul;265(1 Pt 1):G81-9.},
  abstract = {The functional role of dipeptidyl peptidase IV (DPP IV) in the intestinal hydrolysis and assimilation of prolyl peptides was investigated using Japan F344 rats, which genetically lack this enzyme. USA F344 rats possess normal activity of this enzyme and served as matched controls. Intestinal brush-border membranes from the control rats were able to hydrolyze several proline-containing peptides. The hydrolytic ability of the brush-border membranes from the Japan rats against these peptides was markedly low. The difference in the hydrolytic activities between the two groups of rats was solely due to the absence of DPP IV in the Japan rats. There was no difference in the growth rate between the two groups of rats fed a reference diet whose protein constituents were not rich in proline. When the protein source was changed to gliadin, a proline-rich protein, USA F344 rats maintained their body weight for a 4-wk period on this diet, whereas the Japan rats experienced a significant weight loss under similar conditions. In situ perfusion experiments in intact animals revealed that the ability of morphiceptin (a peptide primarily hydrolyzable by DPP IV), when administered into the intestinal lumen, to block the cholera toxin-induced water secretion was significantly greater in Japan F344 rats than in USA F344 rats, indicating the resistance of morphiceptin to hydrolytic breakdown in the intestinal lumen of the Japan rats. It is concluded that the intestinal DPP IV plays a significant role in the hydrolysis of prolyl peptides and assimilation of proline-rich proteins.},
  keywords = {Animals Body Water/metabolism Cholera Toxin/pharmacology Diet Dietary Proteins/metabolism Dipeptidyl Peptidase 4 Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/genetics/*physiology Endorphins/pharmacology Gliadin/administration & dosage Humans Hydrolysis Infant, Newborn Intestinal Mucosa/metabolism Intestines/*metabolism Microvilli/enzymology Peptides/*metabolism Proline/*metabolism Rats Rats, Inbred F344},
  issn = {0002-9513 (Print) 0002-9513 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/8101699},
  year = {1993},
  type = {Journal Article},
}


@article{Yates1993397,
  author = {Yates, J. R., 3rd and Speicher, S. and Griffin, P. R. and Hunkapiller, T.},
  title = {{Peptide mass maps: a highly informative approach to protein identification}},
  journal = {Anal Biochem},
  volume = {214},
  number = {2},
  pages = {397-408},
  note = {Yates, J R 3rd Speicher, S Griffin, P R Hunkapiller, T Anal Biochem. 1993 Nov 1;214(2):397-408.},
  abstract = {A computer searching algorithm has been used to identify protein sequences in the Protein Information Resource (PIR) database with peptide mass information (mass map) obtained from proteolytic digests of proteins analyzed by microcapillary high-performance liquid chromatography electrospray ionization mass spectrometry. A theoretical analysis of the cytochrome c family demonstrates the ability to identify protein sequences in the PIR database with a high degree of accuracy using a set of six predicted tryptic peptide masses. This method was also applied to experimentally determined peptide masses for a small GTP-binding protein, a protein from pig uterus, the human sex steroid binding protein, and a thermostable DNA polymerase. The results demonstrate that a set of observed masses which is less than 50% of the total number of predicted masses can be used to identify a protein sequence in the database. For the analysis presented in this paper, a mass matching tolerance of 1 amu is used. Under these conditions, mass maps created by fast atom bombardment mass spectrometry and matrix-assisted laser desorption time-of-flight would also be applicable. In cases where multiple matches are observed or verification of the protein identification is needed, tandem mass spectrometry sequencing can be used to establish sequence similarity.},
  keywords = {Algorithms Amino Acid Sequence Cytochrome c Group/*chemistry Databases, Factual Mass Spectrometry Molecular Sequence Data Molecular Weight Peptide Mapping/*methods},
  issn = {0003-2697 (Print) 0003-2697 (Linking)},
  doi = {10.1006/abio.1993.1514},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/8109726 http://ac.els-cdn.com/S0003269783715149/1-s2.0-S0003269783715149-main.pdf?_tid=768ac24a-fbdd-11e4-afc4-00000aacb360&acdnat=1431789112_bd610982e82fbb869f7d8b1152390ea9},
  year = {1993},
  type = {Journal Article},
}


@article{Scanlan:1994ly,
  author = {Scanlan, M. J. and Raj, B. K. and Calvo, B. and Garin-Chesa, P. and Sanz-Moncasi, M. P. and Healey, J. H. and Old, L. J. and Rettig, W. J.},
  title = {{Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers}},
  journal = {Proc Natl Acad Sci U S A},
  volume = {91},
  number = {12},
  pages = {5657-61},
  note = {Scanlan, M J Raj, B K Calvo, B Garin-Chesa, P Sanz-Moncasi, M P Healey, J H Old, L J Rettig, W J CA-08748/CA/NCI NIH HHS/ CA-09149/CA/NCI NIH HHS/ CA-57486/CA/NCI NIH HHS/ Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5657-61.},
  abstract = {The human fibroblast activation protein alpha (FAP alpha) is a M(r) 95,000 cell surface antigen selectively expressed in reactive stromal fibroblasts of epithelial cancers, granulation tissue of healing wounds, and malignant cells of bone and soft tissue sarcomas. Normal adult tissues are generally FAP alpha-, but some fetal mesenchymal tissues transiently express the molecule. Because of its restricted normal tissue distribution and abundant expression in the stroma of over 90% of breast, colorectal, and lung carcinomas, FAP alpha is under clinical evaluation as a target for immunodetection and immunotherapy of epithelial cancers. In the present study, we have isolated a full-length cDNA for FAP alpha through expression cloning in COS-1 cells. The FAP alpha cDNA codes for a type II integral membrane protein with a large extracellular domain, transmembrane segment, and short cytoplasmic tail. FAP alpha shows 48% amino acid sequence identity to the T-cell activation antigen CD26, a membrane-bound protein with dipeptidyl peptidase IV (DPPIV) activity; however, unlike FAP alpha, CD26 is widely expressed in normal tissues. Three catalytic domains shared by DPPIV homologues in different species and by other serine proteases are conserved in FAP alpha. Immunochemical analysis of COS-1 cells coexpressing FAP alpha and CD26 revealed that the two molecules form heteromeric cell surface complexes, suggesting that a previously identified FAP alpha-associated M(r) 105,000 protein of cultured fibroblasts and growth factor-stimulated melanocytes, FAP beta, is identical to CD26. In vivo coexpression of FAP alpha and CD26 is found in reactive fibroblasts of healing wounds but not in tumor stromal fibroblasts or sarcomas (FAP alpha +/CD26-). The putative serine protease activity of FAP alpha and its in vivo induction pattern may indicate a role for this molecule in the control of fibroblast growth or epithelial-mesenchymal interactions during development, tissue repair, and epithelial carcinogenesis.},
  keywords = {Amino Acid Sequence Antigens, Differentiation, T-Lymphocyte/genetics Cell Line Cloning, Molecular DNA, Complementary/genetics Dipeptidyl Peptidase 4 Fibroblasts *Gelatinases Gene Expression Humans Membrane Glycoproteins/*genetics Membrane Proteins/*genetics Molecular Sequence Data RNA, Messenger/genetics RNA, Neoplasm/genetics Sarcoma/genetics Sequence Alignment Sequence Homology, Amino Acid Serine Endopeptidases/*genetics},
  issn = {0027-8424 (Print) 0027-8424 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/7911242},
  year = {1994},
  type = {Journal Article},
}


@article{Bouras:1995aa,
  author = {Bouras, M. and Huneau, J. F. and Luengo, C. and Erlanson-Albertsson, C. and Tome, D.},
  title = {{Metabolism of enterostatin in rat intestine, brain membranes, and serum: differential involvement of proline-specific peptidases}},
  journal = {Peptides},
  volume = {16},
  number = {3},
  pages = {399-405},
  note = {Bouras, M Huneau, J F Luengo, C Erlanson-Albertsson, C Tome, D Peptides. 1995;16(3):399-405.},
  abstract = {The degradation of enterostatin (VPDPR), a potent inhibitor of food intake, by intestinal brush-border membranes, brain membranes, and rat serum has been investigated in the presence of specific inhibitors. Hydrolysis by intestinal membranes was found to be 10 and 100 times faster than in serum and brain membranes, respectively. Enterostatin hydrolysis by intestinal and brain membranes involves the removal of C-terminal arginine by carboxypeptidase P, leading to the production of des-Arg-enterostatin, and the splitting of the Pro2-Asp3 bond by dipeptidyl aminopeptidase IV (DPP IV). A small amount of the potent anorectic peptide Pro2-Asp3-Pro4 was released during hydrolysis of des-Arg-enterostatin by brain membranes and rat serum. In rat serum, enterostatin degradation was mainly due to DPP IV.},
  keywords = {Amino Acid Sequence Animals Brain/*metabolism/ultrastructure Carboxypeptidases/*antagonists & inhibitors Chromatography, High Pressure Liquid Colipases/blood/*metabolism Dipeptidyl Peptidase 4/*metabolism Enzyme Precursors Hydrolysis Intestines/*metabolism Membranes/metabolism Microvilli/metabolism Molecular Sequence Data Oligopeptides/metabolism Proline Protein Precursors/blood/*metabolism Rats Rats, Inbred F344 Serine Proteinase Inhibitors/pharmacology Substrate Specificity},
  issn = {0196-9781 (Print) 0196-9781 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/7651891},
  year = {1995},
  type = {Journal Article},
}


@article{Deacon:1995aa,
  author = {Deacon, C. F. and Johnsen, A. H. and Holst, J. J.},
  title = {{Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo}},
  journal = {J Clin Endocrinol Metab},
  volume = {80},
  number = {3},
  pages = {952-7},
  note = {Deacon, C F Johnsen, A H Holst, J J J Clin Endocrinol Metab. 1995 Mar;80(3):952-7.},
  abstract = {The metabolism of glucagon-like peptide-1 (GLP-1) has not been studied in detail, but it is known to be rapidly cleared from the circulation. Measurement by RIA is hampered by the fact that most antisera are side-viewing or C-terminally directed, and recognize both intact GLP-1 and biologically inactive. N-terminally truncated fragments. Using high pressure liquid chromatography in combination with RIAs, methodology allowing specific determination of both intact GLP-1 and its metabolites was developed. Human plasma was shown to degrade GLP-1-(7-36)amide, forming an N-terminally truncated peptide with a t1/2 of 20.4 +/- 1.4 min at 37 C (n = 6). This was unaffected by EDTA or aprotinin. Inhibitors of dipeptidyl peptidase-IV or low temperature (4 C) completely prevented formation of the metabolite, which was confirmed to be GLP-1-(9-36)amide by mass spectrometry and sequence analysis. High pressure liquid chromatography revealed the concentration of GLP-1-(9-36)amide to be 53.5 +/- 13.7% of the concentration of endogenous intact GLP-1 in the fasted state, which increased to 130.8 +/- 10.0% (P < 0.01; n = 6) 1 h postprandially. Metabolism at the C-terminus was not observed. This study suggests that dipeptidyl peptidase-IV is the primary mechanism for GLP-1 degradation in human plasma in vitro and may have a role in inactivating the peptide in vivo.},
  keywords = {Chromatography, High Pressure Liquid Female Glucagon/blood/*metabolism Glucagon-Like Peptide 1 Humans Male Peptide Fragments/blood/*metabolism Protein Precursors/blood/*metabolism},
  issn = {0021-972X (Print) 0021-972X (Linking)},
  doi = {10.1210/jcem.80.3.7883856},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/7883856 http://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jcem/80/3/10.1210_jcem.80.3.7883856/2/jcem0952.pdf?Expires=1486257158&Signature=ZD7hEh6kreIKi9hrdyDZD7FgKrFjnVzackhtBswbtXD978FQfxJk1~kRsfdja7kRPE-UjdhssVqr2tvxHCxU744WJW2yD66psolaQzZlc7xh3DRo4qPDZRgzUNrFydz2pBn0C74MvpTfypkQpNmyRr-T8lWkVlc1-LgJZLz-7qnE1zeKuOyOdpJ7Y3WoM7PO8sNAFIjSH9981xyrpluIhb4NLOEpHvGG5YB2iQOllIo6i3o2jeKpYwUyhVfYw0TOKT0V1YHb-WQcR3LmGG02s6AridkaMtnB7pbglrZRV2vadX5ulofNmeYdtOG~oVsxd8nFAci9enIp6j8abpE6Vw__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q},
  year = {1995},
  type = {Journal Article},
}


@article{Goossens:1995rw,
  author = {Goossens, F. and Demeester, I. and Vanhoof, G. and Hendriks, D. and Vriend, G. and Scharpe, S.},
  title = {{The Purification, Characterization and Analysis of Primary and Secondary-Structure of Prolyl Oligopeptidase from Human-Lymphocytes - Evidence That the Enzyme Belongs to the Alpha/Beta Hydrolase Fold Family}},
  journal = {European Journal of Biochemistry},
  volume = {233},
  number = {2},
  pages = {432-441},
  note = {Tb207 Times Cited:46 Cited References Count:49},
  abstract = {Prolyl oligopeptidase was isolated and purified to homogeneity from human lymphocytes, yielding a specific activity of 7780 mU/mg. The molecular mass using size-exclusion chromatography matches the 76 kDa obtained by SDS/PAGE. This provides evidence that prolyl oligopeptidase is a monomer. The isoelectric point is 4.8 as judged by isoelectric focusing in free solution. Di-isopropyl fluorophosphate and phenylmethylsulphonyl fluoride completely abolish the activity, classifying the enzyme as a serine proteinase. The inhibition by p-chloromercuribenzoic acid indicates the importance of a free sulfhydryl group near the active-site. alpha(1)-Casein and ornithine decarboxylase, two proteins containing a PEST sequence, inhibit prolyl oligopeptidase, but were not hydrolyzed. This demonstrates that prolyl oligopeptidase is not participating in the metabolism of proteins according to a PEST-dependent pathway. alpha(1)-Antitrypsin partially inhibits the enzyme but in contrast, aprotinin does not. Its inability to cleave corticotropin-releasing factor, ubiquitin, albumin and aprotinin, together with the hydrolysis of bradykinin between Pro7-Arg8 confirms the affinity of prolyl oligopeptidase for small peptides. Multiple sequence alignment does not reveal any similarity with proteases of known tertiary structure. Secondary-structure prediction displays striking similarity with dipeptidyl peptidase IV and acylaminoacyl peptidase. Two characteristic features of the members of the prolyl oligopeptidase family of serine proteases are highlighted: the linear arrangement of the catalytic triad is nucleophile-acid-base and the proteolytic cleavage releasing the catalytically active C-terminal region of around 500 amino acids from the N-terminal sequence. Secondary structure prediction and comparison of the active-site of serine proteinases with known three-dimensional coordinates prove that Asp641 is the third member of the catalytic triad. The secondary structural organization of the protease domain of prolyl oligopeptidase is in accordance with the alpha/beta hydrolase fold.},
  keywords = {prolyl oligopeptidase sequence analysis purification pest hypothesis alpha/beta hydrolase fold flavobacterium-meningosepticum acylpeptide hydrolase sensitive method pest hypothesis endopeptidase protein sequence cloning peptidases serine},
  issn = {0014-2956},
  doi = {DOI 10.1111/j.1432-1033.1995.432_2.x},
  url = {<Go to ISI>://A1995TB20700006 http://onlinelibrary.wiley.com/store/10.1111/j.1432-1033.1995.432_2.x/asset/j.1432-1033.1995.432_2.x.pdf?v=1&t=i8vcaobl&s=9409a3fccbbba8f4333faaa4d171b6188c9035e1 http://onlinelibrary.wiley.com/store/10.1111/j.1432-1033.1995.432_2.x/asset/j.1432-1033.1995.432_2.x.pdf?v=1&t=i9r6673v&s=2f49ac203731b4fe17a98cd9bc47bc3b00a0a29b},
  year = {1995},
  type = {Journal Article},
}


@article{Kieffer:1995aa,
  author = {Kieffer, T. J. and McIntosh, C. H. and Pederson, R. A.},
  title = {{Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV}},
  journal = {Endocrinology},
  volume = {136},
  number = {8},
  pages = {3585-96},
  note = {Kieffer, T J McIntosh, C H Pederson, R A Endocrinology. 1995 Aug;136(8):3585-96.},
  abstract = {The combined actions of glucose-dependent insulinotropic polypeptide (GIP) and truncated glucagon-like peptide-1 (tGLP-1) may fully account for the incretin effect. These hormones are released from the small intestine in response to oral glucose and stimulate insulin release. Recently, evidence has been provided demonstrating the degradation of GIP-(1-42) and GLP-1-(7-36)NH2 by the serum enzyme dipeptidyl peptidase IV (DPP IV) into the biologically inactive products GIP-(3-42) and GLP-1-(9-36)NH2. The objective of the current investigation was to develop a method to monitor the degradation of these hormones in vivo. Synthetic peptides were radiolabeled and purified by HPLC. Subsequent degradation of the peptides under various conditions was then monitored by further HPLC analysis. Incubation of [125I]GIP-(1-42) or [125I]GLP-1-(7-36)NH2 with Wistar rat serum or purified DPP IV resulted in the major N-terminal-truncated products [125I]GIP-(3-42) and [125I]GLP-1-(9-36)NH2. These products were significantly reduced when the specific DPP IV inhibitor diprotin A was included in the incubation mixture and were absent when serum from DPP IV-deficient rats was used. When the labeled peptides were infused into rats at hormone levels within the physiological range, over 50% was metabolized to the truncated forms within 2 min. These products were absent when the tracers were infused into DPP IV-deficient animals. It is concluded that DPP IV may be a primary inactivating enzyme of both GIP and tGLP-1 in vivo. As the N-terminal-truncated products of the DPP IV cleavage may not be distinguished from the biologically active hormone by currently employed assays, reports of circulating hormone levels should be reconsidered. The method described in this manuscript may be useful for investigating the durations of action of GIP and tGLP-1 in normal and pathophysiological conditions.},
  keywords = {Animals Blood Physiological Phenomena Dipeptidyl Peptidase 4/*metabolism Glucagon/*metabolism Glucagon-Like Peptide 1 Glucagon-Like Peptides Glucose/*physiology Peptide Fragments/*metabolism Peptides/*metabolism Protein Precursors/*metabolism Rats Rats, Inbred F344 Rats, Wistar},
  issn = {0013-7227 (Print) 0013-7227 (Linking)},
  doi = {10.1210/endo.136.8.7628397},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/7628397 https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/endo/136/8/10.1210_endo.136.8.7628397/2/endo3585.pdf?Expires=1488246981&Signature=acVSab8X3ijGAdcSlhK9KMg1-~kLsIxbmq5-9Sz7VqdiPoTFVdqrAcji~ccWM-cuRUF0PBlDJ5zvC61v-SgULn4wPKKgfurH4y-N-D3JXl1sIVakh0ezUjOnG0jpaHLJv-K9vwg7qMJuuy8A9xesNvTIBltXQw1TnJw50od~RQglR0IPnjKbtCq3Bnm-y64~2T0L-vO3Jm~e26ZqZGFNt00hvGLunG0uT3TQAioIlHaPgdhUDLWgPYelGlI9s7lK1wm1Vll1zpqPIqh0PVYPWvKe0SzCsWldVWWutMOfF57EqhAw8O4TTMgfL2YWLm8l5ogC0BAVIl320D5aPu7FBw__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q},
  year = {1995},
  type = {Journal Article},
}


@article{Perona:1995uq,
  author = {Perona, J. J. and Craik, C. S.},
  title = {{Structural basis of substrate specificity in the serine proteases}},
  journal = {Protein Sci},
  volume = {4},
  number = {3},
  pages = {337-60},
  note = {Perona, J J Craik, C S GM 13818-03/GM/NIGMS NIH HHS/ Protein Sci. 1995 Mar;4(3):337-60.},
  abstract = {Structure-based mutational analysis of serine protease specificity has produced a large database of information useful in addressing biological function and in establishing a basis for targeted design efforts. Critical issues examined include the function of water molecules in providing strength and specificity of binding, the extent to which binding subsites are interdependent, and the roles of polypeptide chain flexibility and distal structural elements in contributing to specificity profiles. The studies also provide a foundation for exploring why specificity modification can be either straightforward or complex, depending on the particular system.},
  keywords = {Amino Acid Sequence Binding Sites DNA Mutational Analysis Molecular Sequence Data Protein Engineering Serine Endopeptidases/chemistry/classification/genetics/*metabolism Structure-Activity Relationship Substrate Specificity},
  issn = {0961-8368 (Print) 0961-8368 (Linking)},
  doi = {10.1002/pro.5560040301},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/7795518 http://onlinelibrary.wiley.com/store/10.1002/pro.5560040301/asset/5560040301_ftp.pdf?v=1&t=i9r66jzd&s=ec81bc87d05bd912daf858370411f17778277e0c},
  year = {1995},
  type = {Journal Article},
}


@article{Vanhoof:1995uq,
  author = {Vanhoof, G. and Goossens, F. and Demeester, I. and Hendriks, D. and Scharpe, S.},
  title = {{Proline Motifs in Peptides and Their Biological Processing}},
  journal = {Faseb Journal},
  volume = {9},
  number = {9},
  pages = {736-744},
  note = {Rh982 Times Cited:280 Cited References Count:68},
  abstract = {Many biologically important peptide sequences contain proline. It confers unique conformational constraints on the peptide chain in that the side-chain is cyclized back onto the backbone amide position. Inside an alpha-helix the possibility of making hydrogen bonds to the preceding turn is lost and a kink will be introduced. The conformational restrictions imposed by proline motifs in a peptide chain appear to imply important structural or biological functions as can be deduced from their often remarkably high degree of conservation as found in many proteins and peptides, especially cytokines, growth factors, G-protein-coupled receptors, V3 loops of the HIV envelope glycoprotein gp120, and neuro- and vasoactive peptides. Only a limited number of peptidases are known to be able to hydrolyze proline adjacent bonds. Their activity is influenced by the isomeric state (cis-trans) as well as the position of proline in the peptide chain. The three proline specific metallo-peptidases (aminopeptidase P, carboxypeptidase P and prolidase) are activated by Mn2+, whereas the three serine type peptidases cleaving a post proline bond (prolyl oligopeptidase, dipeptidyl peptidase IV, and prolylcarboxypeptidase) share the sequential order of the catalytic Ser-Asp-His triade, which differentiates them from the chymotrypsin (His-Asp-Ser) and subtilisin (Asp-His-Ser) families. An endo or C terminal Pro-Pro bond and an endo pre-Pro peptide bond possess a high degree of resistance to any mammalian proteolytic enzyme.},
  keywords = {cytokines dipeptidyl peptidase iv prolyl oligopeptidase cis-trans isomerization substance p iga proteases cell activation antigen aminopeptidase-p antimicrobial peptides transmembrane helices converting enzyme human-lymphocytes human-leukocytes alpha-chain rat-brain iv cd26},
  issn = {0892-6638},
  url = {<Go to ISI>://A1995RH98200007 http://www.fasebj.org/content/9/9/736.full.pdf},
  year = {1995},
  type = {Journal Article},
}


@article{Varshavsky:1996aa,
  author = {Varshavsky, A.},
  title = {{The N-end rule: functions, mysteries, uses}},
  journal = {Proc Natl Acad Sci U S A},
  volume = {93},
  number = {22},
  pages = {12142-9},
  note = {Varshavsky, A Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12142-9.},
  abstract = {The N-end rule relates the in vivo half-life of a protein to the identity of its N-terminal residue. Similar but distinct versions of the N-end rule operate in all organisms examined, from mammals to fungi and bacteria. In eukaryotes, the N-end rule pathway is a part of the ubiquitin system. I discuss the mechanisms and functions of this pathway, and consider its applications.},
  keywords = {Acyltransferases/metabolism Amidohydrolases/metabolism *Amino Acid Sequence Animals Evolution, Molecular Female Fungal Proteins/chemistry/metabolism GTP-Binding Proteins/chemistry/metabolism Half-Life Ligases/metabolism Male Mice *Models, Biological *Models, Chemical Protein Conformation Proteins/*metabolism Proto-Oncogene Proteins c-mos/metabolism Rabbits *Saccharomyces cerevisiae Proteins *Ubiquitin-Protein Ligases},
  issn = {0027-8424 (Print) 0027-8424 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/8901547},
  year = {1996},
  type = {Journal Article},
}


@article{Cunningham1997160,
  author = {Cunningham, D. F. and O'Connor, B.},
  title = {{Proline specific peptidases}},
  journal = {Biochim Biophys Acta},
  volume = {1343},
  number = {2},
  pages = {160-86},
  note = {Cunningham, D F O'Connor, B NETHERLANDS Biochim Biophys Acta. 1997 Dec 5;1343(2):160-86.},
  abstract = {Proline is unique among the 20 amino acids due to its cyclic structure. This specific conformation imposes many restrictions on the structural aspects of peptides and proteins and confers particular biological properties upon a wide range of physiologically important biomolecules. In order to adequately deal with such peptides, nature has developed a group of enzymes that recognise this residue specifically. These peptidases cover practically all situations where a proline residue might occur in a potential substrate. In this paper we endeavour to discuss these enzymes, particularly those responsible for peptide or protein hydrolysis at proline sites. We have detailed their discovery, biochemical attributes and substrate specificities and have provided information as to the methodology used to detect and manipulate their activities. We have also described the roles, or potential roles that these enzymes may play physiologically and the consequences of their dysfunction in varied disease states.},
  keywords = {Amino Acid Sequence Animals Endopeptidases/chemistry/*metabolism/physiology Enzyme Inhibitors/pharmacology Humans Molecular Sequence Data Molecular Structure Peptides/chemistry/*metabolism Proline/chemistry/*metabolism Substrate Specificity},
  issn = {0006-3002 (Print) 0006-3002 (Linking)},
  doi = {http://dx.doi.org/10.1016/S0167-4838(97)00134-9},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/9434107 http://ac.els-cdn.com/S0167483897001349/1-s2.0-S0167483897001349-main.pdf?_tid=86e132b4-fbdd-11e4-8a46-00000aab0f02&acdnat=1431789139_099a68d4dd7a46829619972b5147abfb http://ac.els-cdn.com/S0167483897001349/1-s2.0-S0167483897001349-main.pdf?_tid=92185834-c125-11e5-84b6-00000aab0f02&acdnat=1453480461_106a5592c80d1f5379bdcc782634cc44},
  year = {1997},
  type = {Journal Article},
}


@article{Drucker:1997aa,
  author = {Drucker, D. J. and Shi, Q. and Crivici, A. and Sumner-Smith, M. and Tavares, W. and Hill, M. and DeForest, L. and Cooper, S. and Brubaker, P. L.},
  title = {{Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV}},
  journal = {Nat Biotechnol},
  volume = {15},
  number = {7},
  pages = {673-7},
  note = {Drucker, D J Shi, Q Crivici, A Sumner-Smith, M Tavares, W Hill, M DeForest, L Cooper, S Brubaker, P L Nat Biotechnol. 1997 Jul;15(7):673-7.},
  abstract = {Species-specific differences in the enzymatic inactivation of peptides is an important consideration in the evaluation of therapeutic efficacy. We demonstrate that glucagon-like peptide 2 (GLP-2), shown to be highly intestinotrophic in mice, promotes an increase in intestinal villus height but has no trophic effect on small bowel weight in rats. The reduced intestinotrophic activity of GLP-2 in rats is attributable to inactivation by the enzyme dipeptidyl peptidase IV (DPP-IV). GLP-2(1-33) was degraded to GLP-2(3-33) following incubation with human placental DPP-IV or rat serum but not by serum from DPP-IV-deficient rats. Administration of rat GLP-2 to DPP-IV-deficient rats was associated with markedly increased bioactivity of rat GLP-2 resulting in a significant increase in small bowel weight. A synthetic GLP-2 analog, r[Gly2]GLP-2, with an alanine to glycine substitution at position 2, was resistant to cleavage by both DPP-IV and rat serum in vitro. Treatment of wild-type rats with r[Gly2]GLP-2 produced a statistically significant increase in small bowel mass. DPP-IV-mediated inactivation of GLP-2 is a critical determinant of the growth factor-like properties of GLP-2.},
  keywords = {Animals Biotechnology Dipeptidyl Peptidase 4/*metabolism Glucagon/antagonists & inhibitors/metabolism/*pharmacology Glucagon-Like Peptide 2 Glucagon-Like Peptides Humans Intestine, Small/drug effects/growth & development Mice Peptides/antagonists & inhibitors/metabolism/*pharmacology Protein Engineering Rats Rats, Inbred F344 Recombinant Proteins/genetics/metabolism/pharmacology},
  issn = {1087-0156 (Print) 1087-0156 (Linking)},
  doi = {10.1038/nbt0797-673},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/9219272 http://www.nature.com/nbt/journal/v15/n7/pdf/nbt0797-673.pdf},
  year = {1997},
  type = {Journal Article},
}


@article{Oravecz:1997aa,
  author = {Oravecz, T. and Pall, M. and Roderiquez, G. and Gorrell, M. D. and Ditto, M. and Nguyen, N. Y. and Boykins, R. and Unsworth, E. and Norcross, M. A.},
  title = {{Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage}},
  journal = {J Exp Med},
  volume = {186},
  number = {11},
  pages = {1865-72},
  note = {Oravecz, T Pall, M Roderiquez, G Gorrell, M D Ditto, M Nguyen, N Y Boykins, R Unsworth, E Norcross, M A J Exp Med. 1997 Dec 1;186(11):1865-72.},
  abstract = {CD26 is a leukocyte activation marker that possesses dipeptidyl peptidase IV activity but whose natural substrates and immunological functions have not been clearly defined. Several chemo-kines, including RANTES (regulated on activation, normal T cell expressed and secreted), have now been shown to be substrates for recombinant soluble human CD26. The truncated RANTES(3-68) lacked the ability of native RANTES(1-68) to increase the cytosolic calcium concentration in human monocytes, but still induced this response in macrophages activated with macrophage colony-stimulating factor. Analysis of chemokine receptor messenger RNAs and patterns of desensitization of chemokine responses showed that the differential activity of the truncated molecule results from an altered receptor specificity. RANTES(3-68) showed a reduced activity, relative to that of RANTES(1-68), with cells expressing the recombinant CCR1 chemokine receptor, but retained the ability to stimulate CCR5 receptors and to inhibit the cytopathic effects of HIV-1. Our results indicate that CD26-mediated processing together with cell activation-induced changes in receptor expression provides an integrated mechanism for differential cell recruitment and for the regulation of target cell specificity of RANTES, and possibly other chemokines.},
  keywords = {Calcium/metabolism Cell Differentiation Chemokine CCL11 Chemokine CCL2/metabolism Chemokine CCL5/chemistry/*metabolism Chemokine CCL8 Chemokine CXCL10 Chemokines/metabolism *Chemokines, CC *Chemokines, CXC Cytokines/metabolism Cytopathogenic Effect, Viral/drug effects Dipeptidyl Peptidase 4/*metabolism HIV-1/physiology Humans Macrophage Activation/drug effects Macrophage Colony-Stimulating Factor/pharmacology Macrophages/drug effects/metabolism Monocyte Chemoattractant Proteins/metabolism Monocytes/drug effects/metabolism Receptors, CCR1 Receptors, CCR5/drug effects/genetics/metabolism Receptors, Chemokine/drug effects/genetics/*metabolism Recombinant Fusion Proteins/metabolism Structure-Activity Relationship Substrate Specificity},
  issn = {0022-1007 (Print) 0022-1007 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/9382885 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2199148/pdf/97-0969.pdf},
  year = {1997},
  type = {Journal Article},
}


@article{Pineiro-Sanchez:1997zr,
  author = {Pineiro-Sanchez, M L and Goldstein, L A and Dodt, J and Howard, L and Yeh, Y and Tran, H and Argraves, W S and Chen, W T},
  title = {{Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease.}},
  journal = {J Biol Chem},
  volume = {272},
  number = {12},
  pages = {7595--7601},
  abstract = {The 170-kDa membrane-bound gelatinase, seprase, is a cell surface protease, the expression of which correlates with the invasive phenotype of human melanoma and carcinoma cells. We have isolated seprase from cell membranes and shed vesicles of LOX human melanoma cells. The active enzyme is a dimer of N-glycosylated 97-kDa subunits. Sequence analysis of three internal proteolytic fragments of the 97-kDa polypeptide revealed up to 87.5% identity to the 95-kDa fibroblast activation protein alpha (FAPalpha), the function of which is unknown. Thus, we used reverse transcription-polymerase chain reaction to generate a 2.4-kilobase cDNA from LOX mRNA with FAPalpha primers. COS-7 cells transfected with this cDNA expressed a 170-kDa gelatinase that is recognized by monoclonal antibodies directed against seprase. Sequence analysis also showed similarities to the 110-kDa subunit of dipeptidyl peptidase IV (DPPIV). Like DPPIV, the gelatinase activity of seprase was completely blocked by serine-protease inhibitors, including diisopropyl fluorophosphate. Seprase could be affinity-labeled by [3H]diisopropyl fluorophosphate, but the proteolytically inactive 97-kDa subunit could not, confirming the existence of a serine protease active site on the dimeric form. Proteolytic activity is lost upon dissociation into its 97-kDa subunit following treatment with acid, heat, or cysteine and histidine-modifying agents. We conclude that seprase, FAPalpha, and DPPIV are related serine integral membrane proteases and that seprase is similar to DPPIV, the proteolytic activities of which are dependent upon subunit association.},
  issn = {0021-9258 (Print); 0021-9258 (Linking)},
  url = {http://www.jbc.org/content/272/12/7595.full.pdf},
  year = {1997},
  type = {Journal Article},
}


@article{Cheng:1998kb,
  author = {Cheng, H. C. and Abdel-Ghany, M. and Elble, R. C. and Pauli, B. U.},
  title = {{Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumor cell surface-associated fibronectin}},
  journal = {J Biol Chem},
  volume = {273},
  number = {37},
  pages = {24207-15},
  note = {Cheng, H C Abdel-Ghany, M Elble, R C Pauli, B U CA47668/CA/NCI NIH HHS/ CA71626/CA/NCI NIH HHS/ J Biol Chem. 1998 Sep 11;273(37):24207-15.},
  abstract = {Endothelial cell adhesion molecules are partly responsible for the distinct organ distribution of cancer metastases. Dipeptidyl peptidase IV (DPP IV) expressed on rat lung capillary endothelia is shown here to be an adhesion receptor for rat breast cancer cells and to mediate lung colonization by these tumor cells. Fibronectin (FN) assembled on breast cancer cell surfaces into multiple, randomly dispersed globules from cellular and plasma FN is identified as the principal ligand for DPP IV. Ligand expression correlates quantitatively with the tumor cells' capabilities to bind to DPP IV and to metastasize to the lungs. DPP IV/FN-mediated adhesion and metastasis are blocked when tumor cells are incubated with soluble DPP IV prior to conducting adhesion and lung colony assays. Adhesion is also blocked by anti-DPP IV monoclonal antibody 6A3 and anti-FN antiserum. However, adhesion to immobilized FN is unaffected by soluble plasma FN and, thus, can happen during hematogenous spread of cancer cells at high plasma FN concentrations. The ability of many cancer cells to capture FN molecules on their surface and to augment such deposits by FN self-association during passage in the blood suggests that DPP IV/FN binding may be a relatively common mechanism for lung metastasis.},
  keywords = {Adenocarcinoma/pathology/physiopathology Animals Capillaries Cell Adhesion Cell Line Cell Membrane/physiology Dipeptidyl Peptidase 4/biosynthesis/isolation & purification/*metabolism Endothelium, Vascular/*enzymology Female Fibronectins/*physiology Humans Kinetics Lung/enzymology Lung Neoplasms/pathology/*secondary Mammary Neoplasms, Experimental/*pathology/*physiopathology Neoplasm Metastasis *Pulmonary Circulation Rats Rats, Inbred F344 Recombinant Proteins/biosynthesis/isolation & purification/metabolism Transfection Tumor Cells, Cultured},
  issn = {0021-9258 (Print) 0021-9258 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/9727044 http://www.jbc.org/content/273/37/24207.full.pdf},
  year = {1998},
  type = {Journal Article},
}


@article{Ohtsuki:1998aa,
  author = {Ohtsuki, T. and Hosono, O. and Kobayashi, H. and Munakata, Y. and Souta, A. and Shioda, T. and Morimoto, C.},
  title = {{Negative regulation of the anti-human immunodeficiency virus and chemotactic activity of human stromal cell-derived factor 1alpha by CD26/dipeptidyl peptidase IV}},
  journal = {FEBS Lett},
  volume = {431},
  number = {2},
  pages = {236-40},
  note = {Ohtsuki, T Hosono, O Kobayashi, H Munakata, Y Souta, A Shioda, T Morimoto, C AI29530/AI/NIAID NIH HHS/ AR33713/AR/NIAMS NIH HHS/ NETHERLANDS FEBS Lett. 1998 Jul 17;431(2):236-40.},
  abstract = {Stromal cell-derived factor 1alpha (SDF-1alpha) is a chemokine that has been shown to prevent infection of T-tropic HIV strains and is a possible substrate of CD26/dipeptidyl peptidase IV (DPPIV). In this study, we show that SDF-1alpha was cleaved at the N-terminal region by CD26/DPPIV and as a result the inhibitory activity of SDF-1alpha against HIV infection disappeared. Moreover, the chemotactic activity of SDF-1alpha also disappeared specifically by DPPIV activity of recombinant soluble CD26. These results suggested that dissemination of T-tropic HIV strains in vivo may be facilitated by CD26/DPPIV via inactivation of functional SDF-1alpha.},
  keywords = {Animals Antiviral Agents/metabolism/*physiology Cells, Cultured Chemokine CXCL12 Chemokines, CXC/metabolism/*physiology Chemotactic Factors/metabolism/*physiology Chemotaxis Dipeptidyl Peptidase 4/metabolism/*pharmacology HIV-1/*immunology Humans Jurkat Cells L Cells (Cell Line) Leukocytes, Mononuclear/physiology Mice T-Lymphocytes/immunology},
  issn = {0014-5793 (Print) 0014-5793 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/9708910 http://ac.els-cdn.com/S0014579398007637/1-s2.0-S0014579398007637-main.pdf?_tid=045da968-ea5c-11e4-a005-00000aacb35d&acdnat=1429864345_093247024d2d64957d7a296edf3c776b http://ac.els-cdn.com/S0014579398007637/1-s2.0-S0014579398007637-main.pdf?_tid=b241bf46-fbdd-11e4-9485-00000aacb362&acdnat=1431789212_5ae26ea2b8cb8b1b851b964c8e2cf032},
  year = {1998},
  type = {Journal Article},
}


@article{Proost:1998kl,
  author = {Proost, P and De Meester, I and Schols, D and Struyf, S and Lambeir, A M and Wuyts, A and Opdenakker, G and De Clercq, E and Scharpe, S and Van Damme, J},
  title = {{Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection.}},
  journal = {J Biol Chem},
  volume = {273},
  number = {13},
  pages = {7222--7227},
  abstract = {Chemokines are key players in inflammation and infection. Natural forms of the C-X-C chemokine granulocyte chemotactic protein-2 (GCP-2) and the C-C chemokine regulated on activation normal T cell expressed and secreted (RANTES), which miss two NH2-terminal residues, including a Pro in the penultimate position, have been isolated from leukocytes or tumor cells. In chemotaxis and intracellular calcium mobilization assays, the truncation caused a reduction in the specific activity of RANTES but not of GCP-2. The serine protease CD26/dipeptidyl-peptidase IV (CD26/DPP IV) could induce this observed NH2-terminal truncation of GCP-2 and RANTES but not that of the monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. No significant difference in neutrophil activation was detected between intact and CD26/DPP IV-truncated GCP-2. In contrast to intact natural RANTES(1-68), which still chemoattracts monocytes at 10 ng/ml, CD26/DPP IV-truncated RANTES(3-68) was inactive at 300 ng/ml and behaved as a natural chemotaxis inhibitor. Compared with intact RANTES, only a 10-fold higher concentration of RANTES(3-68) induced a significant Ca2+ response. Furthermore, RANTES(3-68) inhibited infection of mononuclear cells by an M-tropic HIV-1 strain 5-fold more efficiently than intact RANTES. Thus, proteolytic processing of RANTES by CD26/DPP IV may constitute an important regulatory mechanism during anti-inflammatory and antiviral responses.},
  issn = {0021-9258 (Print); 0021-9258 (Linking)},
  url = {http://www.jbc.org/content/273/13/7222.full.pdf},
  year = {1998},
  type = {Journal Article},
}


@article{Shioda:1998aa,
  author = {Shioda, T. and Kato, H. and Ohnishi, Y. and Tashiro, K. and Ikegawa, M. and Nakayama, E. E. and Hu, H. and Kato, A. and Sakai, Y. and Liu, H. and Honjo, T. and Nomoto, A. and Iwamoto, A. and Morimoto, C. and Nagai, Y.},
  title = {{Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage}},
  journal = {Proc Natl Acad Sci U S A},
  volume = {95},
  number = {11},
  pages = {6331-6},
  note = {Shioda, T Kato, H Ohnishi, Y Tashiro, K Ikegawa, M Nakayama, E E Hu, H Kato, A Sakai, Y Liu, H Honjo, T Nomoto, A Iwamoto, A Morimoto, C Nagai, Y Proc Natl Acad Sci U S A. 1998 May 26;95(11):6331-6.},
  abstract = {CD26 is a leukocyte-activation antigen that is expressed on T lymphocytes and macrophages and possesses dipeptidyl peptidase IV (DPPIV) activity, whose natural substrates have not been identified yet. CXC chemokines, stromal cell-derived factor 1alpha (SDF-1alpha) and 1beta (SDF-1beta), sharing the receptor CXCR-4, are highly efficacious chemoattractants for resting lymphocytes and CD34(+) progenitor cells, and they efficiently block the CXCR-4-mediated entry into cells of T cell line tropic strains of HIV type 1 (HIV-1). Here we show that both the chemotactic and antiviral activities of these chemokines are abrogated by DPPIV-mediated specific removal of the N-terminal dipeptide, not only when the chemokines are produced in transformed mouse L cell line to express human CD26 but also when they were exposed to a human T cell line (H9) physiologically expressing CD26. Mutagenesis of SDF-1alpha confirmed the critical requirement of the N-terminal dipeptide for its chemotactic and antiviral activities. These data suggest that CD26-mediated cleavage of SDF-1alpha and SDF-1beta likely occurs in human bodies and promotes HIV-1 replication and disease progression. They may also explain why memory function of CD4(+) cells is preferentially lost in HIV-1 infection. Furthermore, CD26 would modulate various other biological processes in which SDF-1alpha and SDF-1beta are involved.},
  keywords = {Animals Cell Line Chemokine CXCL12 Chemokines, CXC/*immunology/metabolism Chemotaxis/immunology Cytokines/*immunology/metabolism Dipeptidyl Peptidase 4/*immunology/metabolism HIV Infections/*immunology/*virology HIV-1/*immunology Humans Mice Signal Transduction/immunology Stromal Cells/immunology T-Lymphocytes/*immunology/*virology},
  issn = {0027-8424 (Print) 0027-8424 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/9600965 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC27682/pdf/pq006331.pdf},
  year = {1998},
  type = {Journal Article},
}


@article{Abbott1999278,
  author = {Abbott, C. A. and McCaughan, G. W. and Gorrell, M. D.},
  title = {{Two highly conserved glutamic acid residues in the predicted beta propeller domain of dipeptidyl peptidase IV are required for its enzyme activity}},
  journal = {FEBS Lett},
  volume = {458},
  number = {3},
  pages = {278-84},
  note = {Abbott, C A McCaughan, G W Gorrell, M D NETHERLANDS FEBS Lett. 1999 Sep 24;458(3):278-84.},
  abstract = {Dipeptidyl peptidase IV (DPP IV) is a member of the prolyl oligopeptidase family and modifies the biological activities of certain chemokines and neuropeptides by cleaving their N-terminal dipeptides. This paper reports the identification and possible significance of a novel conserved sequence motif Asp-Trp-(Val/Ile/Leu)-Tyr-Glu-Glu-Glu (DW(V/I/L)YEEE) in the predicted beta propeller domain of the DPP IV-like gene family. Single amino acid point mutations in this motif identified two glutamates, at positions 205 and 206, as essential for the enzyme activity of human DPP IV. This observation suggests a novel role in proteolysis for residues of DPP IV distant from the Ser-Asp-His catalytic triad.},
  keywords = {Amino Acid Sequence Animals COS Cells Conserved Sequence Dipeptidyl Peptidase 4/*chemistry/genetics Flow Cytometry Fluorescent Antibody Technique Glutamic Acid/*chemistry/genetics Humans Kinetics Molecular Sequence Data Point Mutation Sequence Alignment Serine Endopeptidases/chemistry/genetics Substrate Specificity Transfection},
  issn = {0014-5793 (Print) 0014-5793 (Linking)},
  doi = {10.1016/s0014-5793(99)01166-7},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/10570924 http://ac.els-cdn.com/S0014579399011667/1-s2.0-S0014579399011667-main.pdf?_tid=980763f6-fbdd-11e4-87fa-00000aacb35f&acdnat=1431789168_5cb7e2276026c5f34bb9faf263d06e4d},
  year = {1999},
  type = {Journal Article},
}


@article{Andersson:1999aa,
  author = {Andersson, S. G. and Kurland, C. G.},
  title = {{Origins of mitochondria and hydrogenosomes}},
  journal = {Curr Opin Microbiol},
  volume = {2},
  number = {5},
  pages = {535-41},
  note = {Andersson, S G Kurland, C G ENGLAND Curr Opin Microbiol. 1999 Oct;2(5):535-41.},
  abstract = {Complete genome sequences for many mitochondria, as well as for some bacteria, together with the nuclear genome sequence of yeast have provided a coherent view of the origin of mitochondria. In particular, conventional phylogenetic reconstructions with genes coding for proteins active in energy metabolism and translation have confirmed the simplest version of the endosymbiosis hypothesis. In contrast, the hydrogen and the syntrophy hypotheses for the origin of mitochondria do not receive support from the available data. It remains to be seen how the evolution of hydrogenosomes is related to that of mitochondria.},
  keywords = {*Evolution, Molecular Genome, Bacterial Hydrogen/*metabolism Mitochondria/*genetics Organelles/*genetics},
  issn = {1369-5274 (Print) 1369-5274 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/10508728 http://ac.els-cdn.com/S1369527499000132/1-s2.0-S1369527499000132-main.pdf?_tid=a034b6ec-ea5c-11e4-914c-00000aab0f02&acdnat=1429864607_654230944e8c6e8bbd6cf85161e7bccc http://ac.els-cdn.com/S1369527499000132/1-s2.0-S1369527499000132-main.pdf?_tid=9b69f5f4-fbdd-11e4-8d1c-00000aab0f27&acdnat=1431789174_bcbdb08d0c2a432c6944eedaeb0c9bb4},
  year = {1999},
  type = {Journal Article},
}


@article{Bauvois:1999gf,
  author = {Bauvois, B. and De Meester, I. and Dumont, J. and Rouillard, D. and Zhao, H. X. and Bosmans, E.},
  title = {{Constitutive expression of CD26/dipeptidylpeptidase IV on peripheral blood B lymphocytes of patients with B chronic lymphocytic leukaemia}},
  journal = {Br J Cancer},
  volume = {79},
  number = {7-8},
  pages = {1042-8},
  note = {Bauvois, B De Meester, I Dumont, J Rouillard, D Zhao, H X Bosmans, E SCOTLAND Br J Cancer. 1999 Mar;79(7-8):1042-8.},
  abstract = {We have investigated the expression of the ectoenzyme dipeptidylpeptidase IV (DPP IV)/CD26 on lymphocytes obtained from patients with B chronic lymphocytic leukaemia (B-CLL) and compared it with healthy subjects. Using two-colour immunofluorescence analysis with CD26 and CD20 or CD23 monoclonal antibodies, CD26 was found undetectable on peripheral resting B-cells (CD20+ CD23-) from normal donors whereas it was expressed on B-cells activated in vitro with interleukin (IL)-4 and Staphylococcus aureus strain cowan I (CD20+ CD23+). The expression of CD26 on leukaemic B-cells (CD20+ CD23+) was clearly induced in 22 out of 25 patients examined. Consequently, induced levels of CD26 cell surface expression on either normal activated and malignant B-cells coincided with the enhancement of DPP IV activity detected on the surface of these cells. Reverse transcription polymerase chain reaction analyses showed that the transcript levels of the CD26 gene was higher in normal activated B-cells and B-CLL cells than in resting B-cells, suggesting that CD26 was expressed at the level of transcriptional activation. These observations provide evidence of the abnormal expression of DPPIV/CD26 in B-CLL which, therefore, may be considered as a novel marker for B-CLL. Further investigation in relation to CD26 expression and other B malignancies needs to be defined.},
  keywords = {Adult Antigens, Surface/*metabolism B-Lymphocytes/*metabolism Dipeptidyl Peptidase 4/*metabolism Fluorescent Antibody Technique Humans Leukemia, Lymphocytic, Chronic, B-Cell/immunology/*metabolism Polymerase Chain Reaction},
  issn = {0007-0920 (Print) 0007-0920 (Linking)},
  doi = {10.1038/sj.bjc.6690167},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/10098734 http://www.nature.com/bjc/journal/v79/n7/pdf/6690167a.pdf http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362248/pdf/79-6690167a.pdf},
  year = {1999},
  type = {Journal Article},
}


@article{Levy:1999kx,
  author = {Levy, M. T. and McCaughan, G. W. and Abbott, C. A. and Park, J. E. and Cunningham, A. M. and Muller, E. and Rettig, W. J. and Gorrell, M. D.},
  title = {{Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis}},
  journal = {Hepatology},
  volume = {29},
  number = {6},
  pages = {1768-78},
  note = {Levy, M T McCaughan, G W Abbott, C A Park, J E Cunningham, A M Muller, E Rettig, W J Gorrell, M D Baltimore, Md. Hepatology. 1999 Jun;29(6):1768-78.},
  abstract = {Fibroblast activation protein (FAP) is a cell surface-bound protease of the prolyl oligopeptidase gene family expressed at sites of tissue remodelling. This study aimed to delineate the expression of FAP in cirrhotic human liver and examine its biochemical activities. Seventeen cirrhotic and 8 normal liver samples were examined by immunohistochemistry and reverse-transcriptase polymerase chain reaction (RT-PCR). Hepatic stellate cells (HSC) were isolated and immunostained. Recombinant FAP and immunopurified, natural FAP were analyzed for protease activities and similarities to dipeptidyl peptidase IV (DPPIV), a structurally related enzyme. FAP-specific messenger RNA and immunoreactivity were detected in cirrhotic, but not normal, livers. FAP immunoreactivity was most intense on perisinusoidal cells of the periseptal regions within regenerative nodules (15 of 15 cases); this pattern coincides with the tissue remodelling interface. In addition, human FAP was expressed by cells within the fibrous septa (10 of 15 cases). Cell morphology, location, and colocalization with glial fibrillary acidic protein (GFAP) indicated that FAP is present on HSC in vivo. Similarly, isolated HSC expressed FAP in vitro. Both natural FAP from cirrhotic liver and recombinant FAP were shown to have gelatinase and dipeptidyl peptidase activities. FAP is a cell-bound, dual-specificity dipeptidyl peptidase and gelatinase expressed by activated HSC at the tissue remodelling interface in human cirrhosis. FAP may contribute to the HSC-induced extracellular matrix (ECM) changes of cirrhosis.},
  keywords = {Actins/genetics *Antigens, Neoplasm Carcinoma, Hepatocellular/enzymology Cholangitis, Sclerosing/enzymology Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/*genetics Gelatinases/*genetics Glial Fibrillary Acidic Protein/analysis Growth Substances/biosynthesis/*genetics Humans Liver/cytology/*enzymology/pathology Liver Cirrhosis/enzymology/genetics/pathology Liver Cirrhosis, Alcoholic/enzymology Membrane Proteins RNA, Messenger/genetics Reference Values Reverse Transcriptase Polymerase Chain Reaction Serine Endopeptidases/biosynthesis/*genetics Transcription, Genetic *Tumor Markers, Biological},
  issn = {0270-9139 (Print) 0270-9139 (Linking)},
  doi = {10.1002/hep.510290631},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/10347120 http://onlinelibrary.wiley.com/store/10.1002/hep.510290631/asset/510290631_ftp.pdf?v=1&t=i9r68qd1&s=1a9e12b6726b0962cc9c792b659b82eb2e3aa48e},
  year = {1999},
  type = {Journal Article},
}


@article{Perkins1999,
  author = {Perkins, D. N. and Pappin, D. J. C. and Creasy, D. M. and Cottrell, J. S.},
  title = {{Probability-based protein identification by searching sequence databases using mass spectrometry data}},
  journal = {ELECTROPHORESIS},
  volume = {20},
  number = {18},
  pages = {3551-3567},
  note = {279LH Times Cited:4172 Cited References Count:33},
  abstract = {Several algorithms have been described in the literature for protein identification by searching a sequence database using mass spectrometry data. In some approaches, the experimental data are peptide molecular weights from the digestion of a protein by an enzyme. Other approaches use tandem mass spectrometry (MS/MS) data from one or more peptides. Still others combine mass data with amino acid sequence data. We present results from a new computer program, Mascot, which integrates all three types of search. The scoring algorithm is probability based, which has a number of advantages: (i) A simple rule can be used to judge whether a result is significant or not. This is particularly useful in guarding against false positives. (ii) Scores can be compared with those from other types of search, such as sequence homology. (iii) Search parameters can be readily optimised by iteration. The strengths and limitations of probability-based scoring are discussed, particularly in the context of high throughput, fully automated protein identification.},
  keywords = {protein identification mass spectrometry bioinformatics peptides spectra information tags gels},
  issn = {0173-0835},
  doi = {Doi 10.1002/(Sici)1522-2683(19991201)20:18<3551::Aid-Elps3551>3.0.Co;2-2},
  url = {<Go to ISI>://000085044900009 http://onlinelibrary.wiley.com/store/10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2/asset/3551_ftp.pdf?v=1&t=i8vc77hu&s=d1e9c4f8b0c232cda9c40342c064fa2ff1abe675 http://onlinelibrary.wiley.com/store/10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2/asset/3551_ftp.pdf?v=1&t=i9r68xqt&s=de3ab244ebd4b35925c580dc9e14550ddf55193e},
  year = {1999},
  type = {Journal Article},
}


@article{Proost:1999aa,
  author = {Proost, P. and Struyf, S. and Schols, D. and Opdenakker, G. and Sozzani, S. and Allavena, P. and Mantovani, A. and Augustyns, K. and Bal, G. and Haemers, A. and Lambeir, A. M. and Scharpe, S. and Van Damme, J. and De Meester, I.},
  title = {{Truncation of macrophage-derived chemokine by CD26/dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction}},
  journal = {Journal of Biological Chemistry},
  volume = {274},
  number = {7},
  pages = {3988-3993},
  note = {166KQ Times Cited:100 Cited References Count:32},
  abstract = {The serine protease CD26/dipeptidyl-peptidase IV (CD26/DPP IV) and chemokines are known key players in immunological processes; Surprisingly, CD26/DPP IV not only removed the expected Gly(1)-Pro(2) dipeptide from the NH(2) terminus of macrophage-derived chemokine (MDC) but subsequently also the Tyr(3)-Gly(4) dipeptide, generating MDC(5-69). This second cleavage after a Gly residue demonstrated that the substrate specificity of this protease is less restricted than anticipated. The unusual processing of MDC by CD26/DPP TV was confirmed on the synthetic peptides GPYGANMED (MDC(1-9)) and YGANMED (MDC(3-9)). Compared with intact MDC(1-69), CD26/DPP IV-processed MDC(5-69) had reduced chemotactic activity on lymphocytes and monocyte-derived dendritic cells, showed impaired mobilization of intracellular Ca(2+) through CC chemokine receptor 4 (CCR4), and was unable to desensitize for MDC-induced Ca(2+)-responses in CCR4 transfectants. However, MDC(5-69) remained equally chemotactic as intact MDC(1-69) on monocytes. In contrast to the reduced binding to lymphocytes and CCR4 transfectants, MDC(5-69) retained its binding properties to monocytes and its anti-HIV-l activity. Thus, NH(2)-terminal truncation of MDC by CD26/DPP TV has profound biological consequences and may be an important regulatory mechanism during the migration of Th2 lymphocytes and dendritic cells to germinal centers and to sites of inflammation.},
  keywords = {dipeptidyl peptidase-iv in-vivo inhibition cd26 mdc},
  issn = {0021-9258},
  doi = {DOI 10.1074/jbc.274.7.3988},
  url = {<Go to ISI>://000078575500013 http://www.jbc.org/content/274/7/3988.full.pdf},
  year = {1999},
  type = {Journal Article},
}


@article{Shane:1999aa,
  author = {Shane, R. and Wilk, S. and Bodnar, R. J.},
  title = {{Modulation of endomorphin-2-induced analgesia by dipeptidyl peptidase IV}},
  journal = {Brain Res},
  volume = {815},
  number = {2},
  pages = {278-86},
  note = {Shane, R Wilk, S Bodnar, R J NS17392/NS/NINDS NIH HHS/ NETHERLANDS Brain Res. 1999 Jan 9;815(2):278-86.},
  abstract = {The tetrapeptide, endomorphin-2 (Tyr-Pro-Phe-PheNH2) possesses high affinity for mu opioid receptors, and produces potent analgesia in mice. Its structure appears to satisfy the substrate requirements of the proteinase, dipeptidyl peptidase IV which removes dipeptides from the amino terminus of peptides containing proline as the penultimate amino acid. A potent, stable and specific inhibitor of this enzyme, Ala-Pyrrolidonyl-2-nitrile, has been described which should potentiate endomorphin-2-induced analgesia. Further, since dipeptidyl peptidase IV has an absolute requirement for l-Pro, a more metabolically-stable d-Pro2-endomorphin-2 analog should produce longer analgesic actions at lower doses. The present study found that endomorphin-2 was degraded approximately twice as fast than the chromogenic substrate, Ala-Pro-2naphthylamide, by dipeptidyl peptidase IV, whereas d-Pro2-endomorphin-2 was totally resistant to this enzyme's action. d-Pro2-endomorphin-2 (ED50=0.05 microg) was more potent than endomorphin-2 (ED50=30 microg) in significantly increasing tail-flick latencies with longer durations of action. Both the peptide and analogue were equipotent (ED50=0.5 microg) in significantly increasing jump thresholds. Ala-Pyrrolidonyl-2-nitrile (10-75 nmol) elicited a dose-dependent analgesia, and potentiated the analgesic actions of endomorphin-2, particularly on the tail-flick test. Whereas systemic naltrexone (2.5, 10 mg/kg) dose-dependently eliminated each of the three forms of analgesia on the jump test as well as the peak (15 min) effect on the tail-flick test, analgesia elicited by either endomorphin-2, d-Pro2-endomorphin-2 or Ala-Pyrrolidonyl-2-nitrile returned after 30-60 min in naltrexone-treated rats on the tail-flick test. These data strongly suggest that dipeptidyl peptidase IV plays a role in the inactivation of endomorphin-2 in vivo, and thereby modulates its central analgesic actions.},
  keywords = {Analgesics, Opioid/*administration & dosage/antagonists & inhibitors/metabolism Animals Dipeptidyl Peptidase 4/drug effects/*metabolism Enzyme Inhibitors/metabolism Injections, Intraventricular Male Naltrexone/administration & dosage Oligopeptides/*administration & dosage/antagonists & inhibitors/metabolism Pain Measurement/drug effects Rats Rats, Sprague-Dawley Receptors, Opioid, mu/agonists},
  issn = {0006-8993 (Print) 0006-8993 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/9878785 http://ac.els-cdn.com/S0006899398011214/1-s2.0-S0006899398011214-main.pdf?_tid=e2324df8-ea5b-11e4-b9b9-00000aab0f6c&acdnat=1429864288_4f08a59a908252638747ab94a0ad0b1a http://ac.els-cdn.com/S0006899398011214/1-s2.0-S0006899398011214-main.pdf?_tid=c7ef0f60-fbdd-11e4-811c-00000aab0f01&acdnat=1431789248_861ce7a6bf7d0955d58587d4552948c0},
  year = {1999},
  type = {Journal Article},
}


@article{Struyf:1999aa,
  author = {Struyf, S and Proost, P and Schols, D and De Clercq, E and Opdenakker, G and Lenaerts, J P and Detheux, M and Parmentier, M and De Meester, I and Scharpe, S and Van Damme, J},
  title = {{CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3.}},
  journal = {J Immunol},
  volume = {162},
  number = {8},
  pages = {4903--4909},
  abstract = {Chemokines attract and activate distinct sets of leukocytes. The CC chemokine eotaxin has been characterized as an important mediator in allergic reactions because it selectively attracts eosinophils, Th2 lymphocytes, and basophils. Human eotaxin has a penultimate proline, indicating that it might be a substrate for dipeptidyl-peptidase IV (CD26/DPP IV). In this study we demonstrate that eotaxin is efficiently cleaved by CD26/DPP IV and that the NH2-terminal truncation affects its biological activity. CD26/DPP IV-truncated eotaxin(3-74) showed reduced chemotactic activity for eosinophils and impaired binding and signaling properties through the CC chemokine receptor 3. Moreover, eotaxin(3-74) desensitized calcium signaling and inhibited chemotaxis toward intact eotaxin. In addition, HIV-2 infection of CC chemokine receptor 3-transfected cells was inhibited to a similar extent by eotaxin and eotaxin(3-74). Thus, CD26/DPP IV differently regulates the chemotactic and antiviral potencies of eotaxin by the removal of two NH2-terminal residues. This physiological processing may be an important down-regulatory mechanism, limiting eotaxin-mediated inflammatory responses.},
  issn = {0022-1767 (Print); 0022-1767 (Linking)},
  url = {http://www.jimmunol.org/content/162/8/4903.full.pdf},
  year = {1999},
  type = {Journal Article},
}


@article{Vanaman:1999aa,
  author = {Vanaman, T. C. and Bradshaw, R. A.},
  title = {{Proteases in cellular regulation minireview series}},
  journal = {J Biol Chem},
  volume = {274},
  number = {29},
  pages = {20047},
  note = {Vanaman, T C Bradshaw, R A J Biol Chem. 1999 Jul 16;274(29):20047.},
  keywords = {Endopeptidases/*metabolism},
  issn = {0021-9258 (Print) 0021-9258 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/10400608 http://www.jbc.org/content/274/29/20047.full.pdf},
  year = {1999},
  type = {Journal Article},
}


@article{Wesley:1999ec,
  author = {Wesley, U. V. and Albino, A. P. and Tiwari, S. and Houghton, A. N.},
  title = {{A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells}},
  journal = {J Exp Med},
  volume = {190},
  number = {3},
  pages = {311-22},
  note = {Wesley, U V Albino, A P Tiwari, S Houghton, A N J Exp Med. 1999 Aug 2;190(3):311-22.},
  abstract = {Dipeptidyl peptidase IV (DPPIV) is a cell surface peptidase expressed by normal melanocytes, epithelial cells, and other cells. Malignant cells, including melanomas and carcinomas, frequently lose or alter DPPIV cell surface expression. Loss of DPPIV expression occurs during melanoma progression at a stage where transformed melanocytes become independent of exogenous growth factors for survival. Tetracycline-inducible expression vectors were constructed to express DPPIV in human melanoma cells. Reexpressing DPPIV in melanoma cells at or below levels expressed by normal melanocytes induced a profound change in phenotype that was characteristic of normal melanocytes. DPPIV expression led to a loss of tumorigenicity, anchorage-independent growth, a reversal in a block in differentiation, and an acquired dependence on exogenous growth factors for cell survival. Suppression of tumorigenicity and reversal of a block in differentiation were dependent on serine protease activity, assessed using mutant DPPIV molecules containing serine-->alanine substitutions. Surprisingly, dependence on exogenous growth factors was not dependent on serine protease activity. Reexpression of either wild-type or mutant DPPIV rescued expression of a second putative cell surface serine peptidase, fibroblast activation protein alpha, which can form a heterodimer with DPPIV. This observation suggests that rescue of fibroblast activation protein alpha may play a role in regulating growth of melanocytic cells. These results support the view that downregulation of DPPIV is an important early event in the pathogenesis of melanoma.},
  keywords = {Apoptosis/immunology Cell Cycle/immunology Cell Division/immunology Culture Media, Conditioned Dipeptidyl Peptidase 4/biosynthesis/*physiology *Gelatinases Growth Inhibitors/biosynthesis/physiology Humans Immunosuppressive Agents/*pharmacology Melanocytes/*enzymology/immunology/*pathology Melanoma/enzymology/genetics/*immunology/*pathology Membrane Proteins/biosynthesis/deficiency Phenotype Serine Endopeptidases/biosynthesis/deficiency Tumor Cells, Cultured},
  issn = {0022-1007 (Print) 0022-1007 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/10430620 http://jem.rupress.org/content/190/3/311.full.pdf},
  year = {1999},
  type = {Journal Article},
}


@article{Zhang:1999fk,
  author = {Zhang, X. Y. and De Meester, I. and Lambeir, A. M. and Dillen, L. and Van Dongen, W. and Esmans, E. L. and Haemers, A. and Scharpe, S. and Claeys, M.},
  title = {{Study of the enzymatic degradation of vasostatin I and II and their precursor chromogranin A by dipeptidyl peptidase IV using high-performance liquid chromatography electrospray mass spectrometry}},
  journal = {Journal of Mass Spectrometry},
  volume = {34},
  number = {4},
  pages = {255-263},
  note = {186RX Times Cited:8 Cited References Count:32},
  abstract = {The interaction of dipeptidyl peptidase IV with structurally related proteins differing in chain length, namely vasostatin I and II and their precursor protein chromogranin A, was examined using high-performance liquid chromatography in combination with electrospray mass spectrometry. Suitable analytical procedures were developed involving the use of reversed-phase high-performance liquid chromatography for purification of the enzymatic degradation products and a peptide mapping procedure for evaluating the enzymatic degradation of the large precursor protein chromogranin A. While vasostatin I was found to be a substrate for dipeptidyl peptidase IV, no N-terminal cleavage of Leu-Pro could be noted for chromogranin A. With respect to vasostatin II, N-terminal degradation was only observed after degradation in the C-terminal domain to proteins containing less than or equal to 78 amino acids. The specificity of the N-terminal release of Leu-Pro was proved by addition of a DPP IV specific inhibitor. Copyright (C) 1999 John Wiley & Sons, Ltd.},
  keywords = {dipeptidyl peptidase iv vasostatin i vasostatin ii chromogranin a electrospray mass spectrometry hormone releasing hormone a-derived protein chromaffin granules processing enzyme cell activation fragment identification specificity segments receptor},
  issn = {1076-5174},
  doi = {Doi 10.1002/(Sici)1096-9888(199904)34:4<255::Aid-Jms752>3.3.Co;2-Z},
  url = {<Go to ISI>://000079743700004 http://onlinelibrary.wiley.com/store/10.1002/(SICI)1096-9888(199904)34:4<255::AID-JMS752>3.0.CO;2-7/asset/752_ftp.pdf?v=1&t=i8vc4m2q&s=b4493a62e6dfd4800f11af1c611531301d1ad278 http://onlinelibrary.wiley.com/store/10.1002/(SICI)1096-9888(199904)34:4<255::AID-JMS752>3.0.CO;2-7/asset/752_ftp.pdf?v=1&t=i9r698zs&s=e2655f0e5817861ed778f9af7d807364ab2dd8f2},
  year = {1999},
  type = {Journal Article},
}


@article{Zhou:1999aa,
  author = {Zhou, A. and Webb, G. and Zhu, X. and Steiner, D. F.},
  title = {{Proteolytic processing in the secretory pathway}},
  journal = {J Biol Chem},
  volume = {274},
  number = {30},
  pages = {20745-8},
  note = {Zhou, A Webb, G Zhu, X Steiner, D F DK-13914/DK/NIDDK NIH HHS/ DK-20595/DK/NIDDK NIH HHS/ J Biol Chem. 1999 Jul 23;274(30):20745-8.},
  keywords = {Animals Biological Transport/physiology Humans Protein Biosynthesis *Proteins/secretion Serine Endopeptidases/*physiology},
  issn = {0021-9258 (Print) 0021-9258 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/10409610 http://www.jbc.org/content/274/30/20745.full.pdf},
  year = {1999},
  type = {Journal Article},
}


@article{Zozulya1999,
  author = {Zozulya, S. and Lioubin, M. and Hill, R. J. and Abram, C. and Gishizky, M. L.},
  title = {{Mapping signal transduction pathways by phage display}},
  journal = {Nat Biotechnol},
  volume = {17},
  number = {12},
  pages = {1193-8},
  note = {Zozulya, S Lioubin, M Hill, R J Abram, C Gishizky, M L Nat Biotechnol. 1999 Dec;17(12):1193-8.},
  abstract = {Rapid identification of proteins that interact with a novel gene product is an important element of functional genomics. Here we describe a phage display-based technique for interaction screening of complex cDNA libraries using proteins or synthetic peptides as baits. Starting with the epidermal growth factor receptor (EGFR) cytoplasmic tail, we identified known protein interactions that link EGFR to the Ras/MAP kinase signal transduction cascade and several novel interactions. This approach can be used as a rapid and efficient tool for elucidating protein networks and mapping intracellular signal transduction pathways.},
  keywords = {3T3 Cells *Adaptor Proteins, Signal Transducing Amino Acid Sequence Animals Bacteriophages/*genetics Base Sequence DNA Primers GRB2 Adaptor Protein Humans Mice Molecular Sequence Data Protein Binding Proteins/metabolism Receptor, Epidermal Growth Factor/*metabolism *Signal Transduction Tumor Cells, Cultured ras Proteins/*metabolism},
  issn = {1087-0156 (Print) 1087-0156 (Linking)},
  doi = {10.1038/70736},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/10585717},
  year = {1999},
  type = {Journal Article},
}


@article{Abbott:2000qr,
  author = {Abbott, C. A. and Yu, D. and McCaughan, G. W. and Gorrell, M. D.},
  title = {{Post-proline-cleaving peptidases having DP IV like enzyme activity. Post-proline peptidases}},
  journal = {Adv Exp Med Biol},
  volume = {477},
  pages = {103-9},
  note = {Abbott, C A Yu, D McCaughan, G W Gorrell, M D Adv Exp Med Biol. 2000;477:103-9.},
  abstract = {DP IV has been studied extensively in disease and in the immune system by the use of enzyme assays which detect hydrolysis of Gly-Pro or Ala-Pro substrate. In addition many studies have used inhibitors of DP IV enzyme activity. The characterisation of a novel DP IV like protein, DPP4R, and of other proteases which have a substrate specificity similar to DP IV or that bind DP IV inhibitors suggests that these studies require further evaluation.},
  keywords = {Animals Dipeptidyl Peptidase 4/*metabolism Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/chemistry/metabolism Humans Hydrolysis Membrane Proteins/classification/metabolism Peptide Hydrolases/classification/*metabolism Proline/*chemistry Protein Structure, Tertiary Substrate Specificity Swine},
  issn = {0065-2598 (Print) 0065-2598 (Linking)},
  doi = {10.1007/0-306-46826-3_10},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/10849735 http://download-v2.springer.com/static/pdf/720/chp%253A10.1007%252F0-306-46826-3_10.pdf?token2=exp=1431790292~acl=%2Fstatic%2Fpdf%2F720%2Fchp%25253A10.1007%25252F0-306-46826-3_10.pdf*~hmac=8f7a84bc92f55dff3ed47229ff299bc8294ac1b7f0d3191f624dde2ccba40c3c http://download.springer.com/static/pdf/720/chp%253A10.1007%252F0-306-46826-3_10.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Fchapter%2F10.1007%2F0-306-46826-3_10&token2=exp=1453481455~acl=%2Fstatic%2Fpdf%2F720%2Fchp%25253A10.1007%25252F0-306-46826-3_10.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Fchapter%252F10.1007%252F0-306-46826-3_10*~hmac=1bc14447ff8c0b2649785b80840c53ccecd8cb7ded44e2936c5d36623c318d5b},
  year = {2000},
  type = {Journal Article},
}


@article{Abbott:2000kn,
  author = {Abbott, C. A. and Yu, D. M. and Woollatt, E. and Sutherland, G. R. and McCaughan, G. W. and Gorrell, M. D.},
  title = {{Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8}},
  journal = {Eur J Biochem},
  volume = {267},
  number = {20},
  pages = {6140-50},
  note = {Abbott, C A Yu, D M Woollatt, E Sutherland, G R McCaughan, G W Gorrell, M D GERMANY Eur J Biochem. 2000 Oct;267(20):6140-50.},
  abstract = {Dipeptidyl peptidase (DPP) IV has roles in T-cell costimulation, chemokine biology, type-II diabetes and tumor biology. Fibroblast activation protein (FAP) has been implicated in tumor growth and cirrhosis. Here we describe DPP8, a novel human postproline dipeptidyl aminopeptidase that is homologous to DPPIV and FAP. Northern-blot hybridization showed that the tissue expression of DPP8 mRNA is ubiquitous, similar to that of DPPIV. The DPP8 gene was localized to chromosome 15q22, distinct from a closely related gene at 19p13.3 which we named DPP9. The full-length DPP8 cDNA codes for an 882-amino-acid protein that has about 27% identity and 51% similarity to DPPIV and FAP, but no transmembrane domain and no N-linked or O-linked glycosylation. Western blots and confocal microscopy of transfected COS-7 cells showed DPP8 to be a 100-kDa monomeric protein expressed in the cytoplasm. Purified recombinant DPP8 hydrolyzed the DPPIV substrates Ala-Pro, Arg-Pro and Gly-Pro. Thus recombinant DPP8 shares a postproline dipeptidyl aminopeptidase activity with DPPIV and FAP. DPP8 enzyme activity had a neutral pH optimum consistent with it being nonlysosomal. The similarities between DPP8 and DPPIV in tissue expression pattern and substrates suggests a potential role for DPP8 in T-cell activation and immune function.},
  keywords = {Amino Acid Sequence *Antigens, Neoplasm Cell Line Chromosome Mapping *Chromosomes, Human, Pair 15 Chromosomes, Human, Pair 19 Cloning, Molecular Dipeptidyl Peptidase 4/chemistry/*genetics Gelatinases Growth Substances/chemistry Humans Lymphocytes/enzymology Membrane Proteins Molecular Sequence Data Monocytes/enzymology Recombinant Proteins/biosynthesis/chemistry Sequence Alignment Sequence Homology, Amino Acid Serine Endopeptidases/chemistry *Tumor Markers, Biological},
  issn = {0014-2956 (Print) 0014-2956 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/11012666 http://onlinelibrary.wiley.com/store/10.1046/j.1432-1327.2000.01617.x/asset/j.1432-1327.2000.01617.x.pdf?v=1&t=i9r69h3b&s=8b87eedc2c343ebf612e87763e41922f0b12d7de http://onlinelibrary.wiley.com/store/10.1046/j.1432-1327.2000.01617.x/asset/j.1432-1327.2000.01617.x.pdf?v=1&t=ijpwm0kf&s=71f2788014e971c4137a61ba053df78c62f6c954},
  year = {2000},
  type = {Journal Article},
}


@article{Cordero:2000jw,
  author = {Cordero, O. J. and Ayude, D. and Nogueira, M. and Rodriguez-Berrocal, F. J. and de la Cadena, M. P.},
  title = {{Preoperative serum CD26 levels: diagnostic efficiency and predictive value for colorectal cancer}},
  journal = {Br J Cancer},
  volume = {83},
  number = {9},
  pages = {1139-46},
  note = {Cordero, O J Ayude, D Nogueira, M Rodriguez-Berrocal, F J de la Cadena, M P SCOTLAND Br J Cancer. 2000 Nov;83(9):1139-46.},
  abstract = {CD26 is an ectoenzyme with dipeptidyl peptidase IV activity expressed on a variety of cell types. Although the function of the high concentration of serum-soluble CD26 (sCD26) is unknown, it may be related to the cleavage of biologically active polypeptides. As CD26 or enzymatic activity levels were previously associated with cancer, we examined the potential diagnostic and prognostic value of preoperative sCD26 measurements by ELISA in colorectal carcinoma patients. We found a highly significant difference between sCD26 levels in healthy donors (mean 559.7 +/- 125.5 microg l(-1)) and cancer patients (mean 261.7 +/- 138.1 microg l(-1)) (P< 0.001). A cut-off at 410 microg l(-1)gave 90% sensitivity with 90% specificity which means that the diagnostic efficiency of sCD26 is higher than that shown by other markers, particularly in patients at early stages. Moreover, sCD26 as a variable is not related with Dukes' stage classification, age, gender, tumour location or degree of differentiation. With a follow-up of 2 years until recurrence, preliminary data show that sCD26 can be managed as a prognostic variable of early carcinoma patients. In addition, the origin of sCD26 is discussed.},
  keywords = {Adult Aged Aged, 80 and over Carcinoembryonic Antigen/blood Colorectal Neoplasms/*blood/diagnosis/surgery Crohn Disease/blood/pathology Dipeptidyl Peptidase 4/*blood Disease-Free Survival Female Hematologic Neoplasms/blood/pathology Humans Male Middle Aged Neoplasm Staging Predictive Value of Tests Prognosis Sensitivity and Specificity Stomach Neoplasms/blood/pathology},
  issn = {0007-0920 (Print) 0007-0920 (Linking)},
  doi = {10.1054/bjoc.2000.1410},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/11027426 http://www.nature.com/bjc/journal/v83/n9/pdf/6691410a.pdf},
  year = {2000},
  type = {Journal Article},
}


@article{Hartmann:2000aa,
  author = {Hartmann, B. and Harr, M. B. and Jeppesen, P. B. and Wojdemann, M. and Deacon, C. F. and Mortensen, P. B. and Holst, J. J.},
  title = {{In vivo and in vitro degradation of glucagon-like peptide-2 in humans}},
  journal = {J Clin Endocrinol Metab},
  volume = {85},
  number = {8},
  pages = {2884-8},
  note = {Hartmann, B Harr, M B Jeppesen, P B Wojdemann, M Deacon, C F Mortensen, P B Holst, J J J Clin Endocrinol Metab. 2000 Aug;85(8):2884-8.},
  abstract = {Glucagon-like peptide-2 (GLP-2), an intestinal product of glucagon gene expression which induces intestinal growth in mice, has been proposed as a treatment for intestinal insufficiency. GLP-2 is metabolized extensively by dipeptidyl peptidase IV (DPP-IV) in rats, but less is known about its fate in humans. Therefore, GLP-2 metabolism was investigated in healthy volunteers after 1) a 500-Cal mixed meal (n = 6), 2) iv infusion of synthetic human GLP-2 (0.8 pmol/kg x min; n = 8), 3) a sc bolus injection (400 microg; n = 9), and 4) in vitro incubation in plasma and blood (1,000 pmol/L; n = 4). GLP-2 concentrations were determined by N-terminal RIA measuring only intact GLP-2, side-viewing RIA measuring intact and degraded forms [e.g. GLP-2-(3-33) arising from DPP-IV degradation], and high performance liquid chromatography (HPLC). Meal ingestion elevated plasma GLP-2 (intact, 16 +/- 3 to 73 +/- 10 pmol/L at 90 min), and HPLC revealed two immunoreactive components: intact GLP-2 (57 +/- 2%) and GLP-2-(3-33). GLP-2 infusion increased plasma levels [intact, 9 +/- 4 to 131 +/- 11 pmol/L; total, 23 +/- 7 to 350 +/- 18 pmol/L; the differences represent GLP-2-(3-33)]. The elimination t(1/2) values were 7.2 +/- 2 min (intact GLP-2) and 27.4 +/- 5.4 min [GLP-2-(3-33)], and MCRs were 6.8 +/- 0.6 and 1.9 +/- 0.3 mL/kg x min, respectively. Subcutaneous injection increased intact GLP-2 to maximally 1,493 +/- 250 pmol/L at 45 min, whereas total GLP-2 increased to 2,793 +/- 477 pmol/L at 90 min. At 60 min, plasma contained 69 +/- 1% intact GLP-2. In vitro the t(1/2) values were 8.0 +/- 1.5 h (plasma) and 3.3 +/- 0.3 h (blood). GLP-2-(3-33) was the only degradation product identified by HPLC, and a DPP-IV inhibitor abolished the degradation of GLP-2 in vitro. We conclude that GLP-2 is extensively degraded to GLP-2-(3-33) in humans, presumably by DPP-IV. Nevertheless, 69% remains intact 1 h after GLP-2 injection, supporting the possibility of sc use in patients with intestinal insufficiency.},
  keywords = {Adult Animals Female Glucagon-Like Peptide 2 Glucagon-Like Peptides Humans Infusions, Intravenous Injections, Subcutaneous Kinetics Male Mice Middle Aged Peptide Fragments/administration & dosage/blood/*metabolism Peptides/administration & dosage/blood/*metabolism Postprandial Period Rats Recombinant Proteins/administration & dosage/blood/metabolism},
  issn = {0021-972X (Print) 0021-972X (Linking)},
  doi = {10.1210/jcem.85.8.6717},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/10946898 http://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/jcem/85/8/10.1210_jcem.85.8.6717/2/jcem2884.pdf?Expires=1486257283&Signature=GyCLXCbDUCehit30aTHOJ12ENNujXurwjviGl6KkvWndWx9-wuGf70-ixiJ8ADaEkROPK6fVwNCYFxuakEPy3RTeNmc~qQOAFJP3jg9jkimvVyN7184RNbjvPIjHt1TOhn-TppkYTY92S3GPLCWDndrVQzD4ODs5uTICOBxim~Xt-Rh5VmStxoZpQxyH68578hKvoNOpO9Rh6VFyoMaZO551Dkjnllgecz1BOUtro2wJsbHu6sz3yqM1XGyGOa8YFpF8y-EYUF6H0w7XgW6OGX3VL9Vj6uLXnXv19DAcXbX5l86Zb7MAv4lEmcQjd--2dxARmG75v9K~cWT8hT8wfA__&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q},
  year = {2000},
  type = {Journal Article},
}


@article{Hinke:2000aa,
  author = {Hinke, S. A. and Pospisilik, J. A. and Demuth, H. U. and Mannhart, S. and Kuhn-Wache, K. and Hoffmann, T. and Nishimura, E. and Pederson, R. A. and McIntosh, C. H.},
  title = {{Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon. Characterization of glucagon degradation products and DPIV-resistant analogs}},
  journal = {J Biol Chem},
  volume = {275},
  number = {6},
  pages = {3827-34},
  note = {Hinke, S A Pospisilik, J A Demuth, H U Mannhart, S Kuhn-Wache, K Hoffmann, T Nishimura, E Pederson, R A McIntosh, C H J Biol Chem. 2000 Feb 11;275(6):3827-34.},
  abstract = {Over the past decade, numerous studies have been targeted at defining structure-activity relationships of glucagon. Recently, we have found that glucagon(1-29) is hydrolyzed by dipeptidyl peptidase IV (DPIV) to produce glucagon(3-29) and glucagon(5-29); in human serum, [pyroglutamyl (pGlu)(3)]glucagon(3-29) is formed from glucagon(3-29), and this prevents further hydrolysis of glucagon by DPIV (H.-U. Demuth, K. Glund, U. Heiser, J. Pospisilik, S. Hinke, T. Hoffmann, F. Rosche, D. Schlenzig, M. Wermann, C. McIntosh, and R. Pederson, manuscript in preparation). In the current study, the biological activity of these peptides was examined in vitro. The amino-terminally truncated peptides all behaved as partial agonists in cyclic AMP stimulation assays, with Chinese hamster ovary K1 cells overexpressing the human glucagon receptor (potency: glucagon(1-29) > [pGlu(3)]glu- cagon(3-29) > glucagon(3-29) > glucagon(5-29) > [Glu(9)]glu- cagon(2-29)). In competition binding experiments, [pGlu(3)]glucagon(3-29) and glucagon(5-29) both demonstrated 5-fold lower affinity for the receptor than glucagon(1-29), whereas glucagon(3-29) exhibited 18-fold lower affinity. Of the peptides tested, only glucagon(5-29) showed antagonist activity, and this was weak compared with the classical glucagon antagonist, [Glu(9)]glucagon(2-29). Hence, DPIV hydrolysis of glucagon yields low affinity agonists of the glucagon receptor. As a corollary to evidence indicating that DPIV degrades glucagon (Demuth, et al., manuscript in preparation), DPIV-resistant analogs were synthesized. Matrix-assisted laser desorption/ionization-time of flight mass spectrometry was used to assess DPIV resistance, and it allowed kinetic analysis of degradation. Of several analogs generated, only [D-Ser(2)] and [Gly(2)]glucagon retained high affinity binding and biological potency, similar to native glucagon in vitro. [D-Ser(2)]Glucagon exhibited enhanced hyperglycemic activity in a bioassay, whereas [Gly(2)]glucagon was not completely resistant to DPIV degradation.},
  keywords = {Animals Binding, Competitive CHO Cells Cricetinae Cyclic AMP/metabolism Dipeptidyl Peptidase 4/blood/*metabolism Glucagon/analogs & derivatives/blood/*metabolism Humans Peptide Fragments/metabolism/pharmacology Receptors, Glucagon/metabolism Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization},
  issn = {0021-9258 (Print) 0021-9258 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/10660533 http://www.jbc.org/content/275/6/3827.full.pdf},
  year = {2000},
  type = {Journal Article},
}


@article{Pandey2000,
  author = {Pandey, A. and Mann, M.},
  title = {{Proteomics to study genes and genomes}},
  journal = {Nature},
  volume = {405},
  number = {6788},
  pages = {837-46},
  note = {Pandey, A Mann, M ENGLAND Nature. 2000 Jun 15;405(6788):837-46.},
  abstract = {Proteomics, the large-scale analysis of proteins, will contribute greatly to our understanding of gene function in the post-genomic era. Proteomics can be divided into three main areas: (1) protein micro-characterization for large-scale identification of proteins and their post-translational modifications; (2) 'differential display' proteomics for comparison of protein levels with potential application in a wide range of diseases; and (3) studies of protein-protein interactions using techniques such as mass spectrometry or the yeast two-hybrid system. Because it is often difficult to predict the function of a protein based on homology to other proteins or even their three-dimensional structure, determination of components of a protein complex or of a cellular structure is central in functional analysis. This aspect of proteomic studies is perhaps the area of greatest promise. After the revolution in molecular biology exemplified by the ease of cloning by DNA methods, proteomics will add to our understanding of the biochemistry of proteins, processes and pathways for years to come.},
  keywords = {Animals Biotechnology/trends Genes/*physiology *Genome Humans *Proteome},
  issn = {0028-0836 (Print) 0028-0836 (Linking)},
  doi = {10.1038/35015709},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/10866210 http://www.nature.com/nature/journal/v405/n6788/pdf/405837a0.pdf},
  year = {2000},
  type = {Journal Article},
}


@article{Pethiyagoda:2000bv,
  author = {Pethiyagoda, C. L. and Welch, D. R. and Fleming, T. P.},
  title = {{Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells}},
  journal = {Clin Exp Metastasis},
  volume = {18},
  number = {5},
  pages = {391-400},
  note = {Pethiyagoda, C L Welch, D R Fleming, T P CA58314/CA/NCI NIH HHS/ Netherlands Clin Exp Metastasis. 2000;18(5):391-400.},
  abstract = {Dipeptidyl peptidase IV (DPPIV) is a 110-kD, trans-membrane, ectoenzyme, with ubiquitous expression. DPPIV has numerous functions including involvement in T-cell activation, cell adhesion, digestion of proline containing peptides in the kidney and intestines, HIV infection and apoptosis, and regulation of tumorigenicity in certain melanoma cells. Constitutively expressed on numerous epithelial cell types, DPPIV is often disregulated in a variety of human malignancies. The most striking evidence of DPPIV down-regulation is found in transformed melanocytes. where nearly 100% of melanomas lack DPPIV expression. We have identified DPPIV as a gene that can alter the invasive potential of a number of melanoma cell lines. By transfecting the full-length cDNA of DPPIV, we have established stable melanoma cell lines that express comparable levels of the DPPIV protein as normal epidermal melanocytes. Matrigel invasion assays were utilized to study the effects of DPPIV expression on the invasive potential of these cells. The parental and vector transfectants readily migrated across the Matrigel while the invasiveness of DPPIV transfected cells was reduced by greater than 75%. The effects on cellular invasion are not attributed to overall growth characteristics, as both DPPIV expressing and non-expressing cells behave comparably in culture. We have also constructed mutants of DPPIV that lack either the extra-cellular serine protease activity or the six amino acid cytoplasmic domain. Both mutants were stably expressed in melanoma cells. Matrigel invasion assays performed with cells expressing the two mutant forms of the protein revealed phenotypic effects similar to wild type function. In this study. we have demonstrated that expression of a proteolytically active form of the DPPIV protein inhibits the invasiveness of malignant melanoma cell lines lacking endogenous DPPIV expression. Furthermore, we have shown that neither the protease activity nor the cytoplasmic domain of DPPIV is required for its anti-invasive activity.},
  keywords = {Carcinogenicity Tests Cell Division Dipeptidyl Peptidase 4/genetics/*metabolism Humans Melanoma/genetics/*metabolism/*pathology Mutation Neoplasm Invasiveness Tumor Cells, Cultured},
  issn = {0262-0898 (Print) 0262-0898 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/11467771 http://media.proquest.com/media/pq/classic/doc/387040511/fmt/ai/rep/NONE?hl=&cit%3Aauth=Pethiyagoda%2C+C+L%3BWelch%2C+D+R%3BFleming%2C+T+P&cit%3Atitle=Dipeptidyl+peptidase+IV+%28DPPIV%29+inhibits+cellular+invasion+of+melanoma+cells&cit%3Apub=Clinical+%26+Experimental+Metastasis&cit%3Avol=18&cit%3Aiss=5&cit%3Apg=391&cit%3Adate=2000&ic=true&cit%3Aprod=ProQuest+Central&_a=ChgyMDE1MDUxNjE1NTUxNTA2MDo3MTE4MTUSBjEwNDgzNxoKT05FX1NFQVJDSCINMTI5Ljk2Ljg2LjExMSoFMzA5MDkyCTIxNDE1OTE1ODoNRG9jdW1lbnRJbWFnZUIBMFIGT25saW5lWgJGVGIDUEZUagoyMDAwLzA3LzAxcgoyMDAwLzA3LzAxegCCATJQLTEwMDcwNjctMTA5MTAtQ1VTVE9NRVItMTAwMDAwMzkvMTAwMDAxNTUtMzg5NDQwNJIBBk9ubGluZcoBB0VuZE5vdGXSARJTY2hvbGFybHkgSm91cm5hbHOaAgdQcmVQYWlkqgIoT1M6RU1TLVBkZkRvY1ZpZXdCYXNlLWdldE1lZGlhVXJsRm9ySXRlbcoCD0ZlYXR1cmV8QXJ0aWNsZdICAVniAgFO8gIA&_s=grayCrZNZFcRbawx9wf3IY3s%2ByI%3D},
  year = {2000},
  type = {Journal Article},
}


@article{Proost:2000aa,
  author = {Proost, P and Menten, P and Struyf, S and Schutyser, E and De Meester, I and Van Damme, J},
  title = {{Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78beta into a most efficient monocyte attractant and CCR1 agonist.}},
  journal = {Blood},
  volume = {96},
  number = {5},
  pages = {1674--1680},
  abstract = {Chemokines are proinflammatory cytokines that play a role in leukocyte migration and activation. Recent reports showed that RANTES (regulated on activation normal T-cell expressed and secreted chemokine), eotaxin, macrophage-derived chemokine (MDC), and stromal cell-derived factor-1 (SDF-1) are NH(2)-terminally truncated by the lymphocyte surface glycoprotein and protease CD26/dipeptidyl peptidase IV (CD26/DPP IV). Removal of the NH(2)-terminal dipeptide resulted in impaired inflammatory properties of RANTES, eotaxin, MDC, and SDF-1. The potential CD26/DPP IV substrate macrophage inflammatory protein-1beta (MIP-1beta) and the related chemokine, LD78alpha (ie, one of the MIP-1alpha isoforms), were not affected by this protease. However, CD26/DPP IV cleaved LD78beta, a most potent CCR5 binding chemokine and inhibitor of macrophage tropic human immunodeficiency virus-1 (HIV-1) infection, into LD78beta(3-70). Naturally truncated LD78beta(3-70), but not truncated MIP-1beta, was recovered as an abundant chemokine form from peripheral blood mononuclear cells. In contrast to all other chemokines processed by CD26/DPP IV, LD78beta(3-70) had increased chemotactic activity in comparison to intact LD78beta. With a minimal effective concentration of 30 pmol/L, LD78beta(3-70) became the most efficient monocyte chemoattractant. LD78beta(3-70) retained its high capacity to induce an intracellular calcium increase in CCR5-transfected cells. Moreover, on CCR1 transfectants, truncated LD78beta(3-70) was 30-fold more potent than intact LD78beta. Thus, CD26/DPP IV can exert not only a negative but also a positive feedback during inflammation by increasing the specific activity of LD78beta. CD26/DPP IV-cleaved LD78beta(3-70) is the most potent CCR1 and CCR5 agonist that retains strong anti-HIV-1 activity, indicating the importance of the chemokine-protease interaction in normal and pathologic conditions. (Blood. 2000;96:1674-1680)},
  issn = {0006-4971 (Print); 0006-4971 (Linking)},
  url = {http://www.bloodjournal.org/content/96/5/1674.long http://www.bloodjournal.org/content/bloodjournal/96/5/1674.full.pdf},
  year = {2000},
  type = {Journal Article},
}


@article{Shively:2000kx,
  author = {Shively, J. E.},
  title = {{The chemistry of protein sequence analysis}},
  journal = {EXS},
  volume = {88},
  pages = {99-117},
  note = {Shively, J E SWITZERLAND EXS. 2000;88:99-117.},
  abstract = {N-terminal sequence analysis by Edman chemistry continues to play an important role in the structural analysis of proteins and peptides. Improvements in the sensitivity of the method have been achieved mainly at the level of increasing the sensitivity of the on-line analysis of PTH amino acids by RP-HPLC (reverse phase high performance chromatography). Using microbore columns (0.8-1.0 mm), it is possible to run standards at the 0.5-1.0 pmol level and to sequence samples in the 1-5 pmol range. Due to constraints in current chromatographic methods, it is unlikely that further improvements in sensitivity will be achieved by this approach alone. Although alternative Edman reagents, including fluorescent chemistries, have promised to increase the sensitivity of sequencing into the low femtomole range, none of the methods have progressed into routine usage. These reagents and chemistries are critically evaluated in this review, and the problems which have prevented their further development discussed. Instrumental constraints are also considered. It is concluded that the development of more sensitive methods requires further research into both the chemistry and the instrumentation, and that alternative separation and detection methods may also play a role.},
  keywords = {Amino Acid Sequence Glycosylation Indicators and Reagents Protein Processing, Post-Translational Proteins/*chemistry/metabolism *Sequence Analysis, Protein/instrumentation/methods},
  issn = {1023-294X (Print) 1023-294X (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/10803374},
  year = {2000},
  type = {Journal Article},
}


@article{Hof:2000zr,
  author = {van't Hof, W. and Resh, M. D.},
  title = {{Targeting proteins to plasma membrane and membrane microdomains by N-terminal myristoylation and palmitoylation}},
  journal = {Methods Enzymol},
  volume = {327},
  pages = {317-30},
  note = {van't Hof, W Resh, M D Methods Enzymol. 2000;327:317-30.},
  keywords = {Animals Biochemistry/*methods COS Cells Cell Line Cell Membrane/chemistry/*metabolism Cyclohexanes Electrophoresis, Polyacrylamide Gel Fatty Acids/metabolism Fatty Acids, Unsaturated/metabolism Microscopy, Fluorescence Myristic Acid/*metabolism Palmitic Acid/*metabolism Polymerase Chain Reaction Precipitin Tests Protein Structure, Tertiary *Protein Transport Recombinant Fusion Proteins/chemistry/metabolism Sesquiterpenes Subcellular Fractions/metabolism Transfection},
  issn = {0076-6879 (Print) 0076-6879 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/11044994},
  year = {2000},
  type = {Journal Article},
}


@article{Walker:2000ys,
  author = {Walker, L. C. and LeVine, H.},
  title = {{The cerebral proteopathies: neurodegenerative disorders of protein conformation and assembly}},
  journal = {Mol Neurobiol},
  volume = {21},
  number = {1-2},
  pages = {83-95},
  note = {Walker, L C LeVine, H Mol Neurobiol. 2000 Feb-Apr;21(1-2):83-95.},
  abstract = {The abnormal assembly and deposition of specific proteins in the brain is the probable cause of most neurodegenerative disease afflicting the elderly. These cerebral proteopathies include Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), prion diseases, and a variety of other disorders. Evidence is accumulating that the anomalous aggregation of the proteins, and not a loss of protein function, is central to the pathogenesis of these diseases. Thus, therapeutic strategies that reduce the production, accumulation, or polymerization of pathogenic proteins might be applicable to a wide range of some of the most devastating diseases of old age.},
  keywords = {Amyloid beta-Peptides/chemistry/*metabolism Amyloidosis/genetics/pathology/therapy Animals Brain/*metabolism/*pathology Humans Prion Diseases/genetics/*metabolism/*pathology/therapy Protein Conformation},
  issn = {0893-7648 (Print) 0893-7648 (Linking)},
  doi = {10.1385/MN:21:1-2:083},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/11327151 http://download-v2.springer.com/static/pdf/846/art%253A10.1385%252FMN%253A21%253A1-2%253A083.pdf?token2=exp=1431790317~acl=%2Fstatic%2Fpdf%2F846%2Fart%25253A10.1385%25252FMN%25253A21%25253A1-2%25253A083.pdf*~hmac=4acc3b38165b22f45c83183d4caf405aef3e79a987ff837b76eabe9f5272f6e3},
  year = {2000},
  type = {Journal Article},
}


@article{Antczak:2001nx,
  author = {Antczak, C. and De Meester, I. and Bauvois, B.},
  title = {{Transmembrane proteases as disease markers and targets for therapy}},
  journal = {Journal of Biological Regulators and Homeostatic Agents},
  volume = {15},
  number = {2},
  pages = {130-139},
  note = {458PP Times Cited:20 Cited References Count:101},
  abstract = {Transmembrane proteases (i.e. membrane-associated proteases, ectoproteases) are present in a wide variety of tissues and cell types including endothelial, epithelial and hematopoietic cells. Natural and synthetic inhibitors have been characterized and have revealed that certain ectoenzymes are able to modulate bioactive peptide responses and to influence major biological events such as cell proliferation, survival and invasiveness. Dysregulated expression of some of them in human diseases triggers research on their role in pathophysiology, on their value as disease markers and as putative targets for therapy.},
  keywords = {cancer ectoenzyme ectopeptidase inhibitor leukemia vasopeptidase dipeptidyl-peptidase-iv angiotensin-converting enzyme gamma-glutamyl-transpeptidase improved glucose-tolerance acute myeloid-leukemia aminopeptidase-a prodrug therapy heart-failure dpp-iv neutral endopeptidase},
  issn = {0393-974X},
  url = {<Go to ISI>://000170204000003},
  year = {2001},
  type = {Journal Article},
}


@article{Bird:2001aa,
  author = {Bird, A. P. and Faltinek, J. R. and Shojaei, A. H.},
  title = {{Transbuccal peptide delivery: stability and in vitro permeation studies on endomorphin-1}},
  journal = {J Control Release},
  volume = {73},
  number = {1},
  pages = {31-6},
  note = {Bird, A P Faltinek, J R Shojaei, A H Netherlands J Control Release. 2001 May 18;73(1):31-6.},
  abstract = {The purpose of this study was to investigate the feasibility of buccal delivery of a model peptide, endomorphin-1 (ENI), using stability and in vitro permeation studies. ENI is a recently isolated mu-opiate receptor agonist with high selectivity and specificity for this receptor subtype. Stability studies were conducted in various buffers and the drug was shown to be stable in both acidic and basic buffer systems. In the presence of full thickness porcine buccal epithelium, ENI was unstable with only 23.4+/-15.7% intact drug present after 6 h. The region responsible for this degradation was found to coincide with the major barrier region of the buccal epithelium as delineated through stability experiments in the presence of partial thickness buccal epithelium. Various peptidase inhibitors were used to isolate the enzyme(s) responsible for this degradation. Diprotin-A, a potent inhibitor of dipeptidyl peptidase IV, provided significant inhibition of the degradation of ENI in the presence of buccal epithelium. In vitro permeation studies revealed that the permeability coefficient of ENI across porcine buccal epithelium was 5.67+/-4.74x10(-7) cm/s. The enzymatic degradation of ENI was found not to be rate limiting to the drug's permeation across buccal epithelium, as diprotin-A did not increase the permeation of ENI. Sodium glycocholate as well as sodium taurocholate were also ineffective in enhancing the permeation of ENI across porcine buccal epithelium.},
  keywords = {Administration, Buccal Algorithms Analgesics, Opioid/*administration & dosage/chemistry/pharmacokinetics Animals Buffers Chromatography, High Pressure Liquid Drug Delivery Systems Drug Stability Endopeptidases/metabolism Mouth Mucosa/drug effects/enzymology Oligopeptides/*administration & dosage/chemistry/pharmacokinetics Permeability Protease Inhibitors/pharmacology Solutions Swine},
  issn = {0168-3659 (Print) 0168-3659 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/11337057 http://ac.els-cdn.com/S0168365901002462/1-s2.0-S0168365901002462-main.pdf?_tid=8eb3e460-ea5c-11e4-800f-00000aacb35f&acdnat=1429864578_fcb48c7cdfe7ea5c9eff26e785f029cc http://ac.els-cdn.com/S0168365901002462/1-s2.0-S0168365901002462-main.pdf?_tid=ee0c95f0-fbdd-11e4-b963-00000aacb35e&acdnat=1431789312_ac0efb662f48a452f1344ab5fecf4dfb},
  year = {2001},
  type = {Journal Article},
}


@article{Hua2001,
  author = {Hua, S. and Sun, Z.},
  title = {{Support vector machine approach for protein subcellular localization prediction}},
  journal = {Bioinformatics},
  volume = {17},
  number = {8},
  pages = {721-8},
  note = {Hua, S Sun, Z England Oxford, England Bioinformatics. 2001 Aug;17(8):721-8.},
  abstract = {MOTIVATION: Subcellular localization is a key functional characteristic of proteins. A fully automatic and reliable prediction system for protein subcellular localization is needed, especially for the analysis of large-scale genome sequences. RESULTS: In this paper, Support Vector Machine has been introduced to predict the subcellular localization of proteins from their amino acid compositions. The total prediction accuracies reach 91.4% for three subcellular locations in prokaryotic organisms and 79.4% for four locations in eukaryotic organisms. Predictions by our approach are robust to errors in the protein N-terminal sequences. This new approach provides superior prediction performance compared with existing algorithms based on amino acid composition and can be a complementary method to other existing methods based on sorting signals. AVAILABILITY: A web server implementing the prediction method is available at http://www.bioinfo.tsinghua.edu.cn/SubLoc/. SUPPLEMENTARY INFORMATION: Supplementary material is available at http://www.bioinfo.tsinghua.edu.cn/SubLoc/.},
  keywords = {Amino Acid Sequence Amino Acids/analysis Computational Biology *Computer Simulation Databases, Protein Internet *Models, Biological Proteins/chemistry/*metabolism Software Subcellular Fractions/*metabolism},
  issn = {1367-4803 (Print) 1367-4803 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/11524373 http://bioinformatics.oxfordjournals.org/content/17/8/721.full.pdf},
  year = {2001},
  type = {Journal Article},
}


@article{Lambeir:2001ab,
  author = {Lambeir, A. M. and Durinx, C. and Proost, P. and Van Damme, J. and Scharpe, S. and De Meester, I.},
  title = {{Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion}},
  journal = {FEBS Lett},
  volume = {507},
  number = {3},
  pages = {327-30},
  note = {Lambeir, A M Durinx, C Proost, P Van Damme, J Scharpe, S De Meester, I Netherlands FEBS Lett. 2001 Nov 2;507(3):327-30.},
  abstract = {Dipeptidyl-peptidase IV (DPPIV/CD26) metabolizes neuropeptides regulating insulin secretion. We studied the in vitro steady-state kinetics of DPPIV/CD26-mediated truncation of vasoactive intestinal peptide (VIP), pituitary adenylyl cyclase-activating peptide (PACAP27 and PACAP38), gastrin-releasing peptide (GRP) and neuropeptide Y (NPY). DPPIV/CD26 sequentially cleaves off two dipeptides of VIP, PACAP27, PACAP38 and GRP. GRP situates between the best DPPIV/CD26 substrates reported, comparable to NPY. Surprisingly, the C-terminal extension of PACAP38, distant from the scissile bond, improves both PACAP38 binding and turnover. Therefore, residues remote from the scissile bond can modulate DPPIV/CD26 substrate selectivity as well as residues flanking it.},
  keywords = {Dipeptidyl Peptidase 4/*metabolism Gastrin-Releasing Peptide/metabolism Humans Insulin/secretion Kinetics Mass Spectrometry Neuropeptide Y/metabolism Neuropeptides/*metabolism Pancreas/secretion Pituitary Adenylate Cyclase-Activating Polypeptide Substrate Specificity Vasoactive Intestinal Peptide/metabolism},
  issn = {0014-5793 (Print) 0014-5793 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/11696365 http://ac.els-cdn.com/S0014579301029829/1-s2.0-S0014579301029829-main.pdf?_tid=34e1db90-ea5c-11e4-b380-00000aab0f02&acdnat=1429864427_4a4acf52ce9686efe976fde21b99e03d http://ac.els-cdn.com/S0014579301029829/1-s2.0-S0014579301029829-main.pdf?_tid=fcdbc970-fbdd-11e4-8d1c-00000aab0f27&acdnat=1431789337_c3bb5482bceb3bbeebcc26b28ae3e1d8},
  year = {2001},
  type = {Journal Article},
}


@article{Lambeir:2001aa,
  author = {Lambeir, A. M. and Proost, P. and Durinx, C. and Bal, G. and Senten, K. and Augustyns, K. and Scharpe, S. and Van Damme, J. and De Meester, I.},
  title = {{Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family}},
  journal = {J Biol Chem},
  volume = {276},
  number = {32},
  pages = {29839-45},
  note = {Lambeir, A M Proost, P Durinx, C Bal, G Senten, K Augustyns, K Scharpe, S Van Damme, J De Meester, I J Biol Chem. 2001 Aug 10;276(32):29839-45. Epub 2001 Jun 4.},
  abstract = {Chemokines coordinate many aspects of leukocyte migration. As chemoattractants they play an important role in the innate and acquired immune response. There is good experimental evidence that N-terminal truncation by secreted or cell surface proteases is a way of modulating chemokine action. The localization of CD26/dipeptidyl peptidase IV on cell surfaces and in biological fluids, its primary specificity, and the type of naturally occurring truncated chemokines are consistent with such a function. We determined the steady-state catalytic parameters for a relevant selection of chemokines (CCL3b, CCL5, CCL11, CCL22, CXCL9, CXCL10, CXCL11, and CXCL12) previously reported to alter their chemotactic behavior due to CD26/dipeptidyl peptidase IV-catalyzed truncation. The results reveal a striking selectivity for stromal cell-derived factor-1alpha (CXCL12) and macrophage-derived chemokine (CCL22). The kinetic parameters support the hypothesis that CD26/dipeptidyl peptidase IV contributes to the degradation of certain chemokines in vivo. The data not only provide insight into the selectivity of the enzyme for specific chemokines, but they also contribute to the general understanding of CD26/dipeptidyl peptidase IV secondary substrate specificity.},
  keywords = {Amino Acid Sequence Catalysis Chemokine CCL8 Chemokine CXCL11 Chemokine CXCL12 Chemokines/chemistry/*metabolism Chemokines, CXC/biosynthesis/metabolism Dipeptidyl Peptidase 4/*biosynthesis/chemistry Gas Chromatography-Mass Spectrometry Humans Kinetics Mass Spectrometry Molecular Sequence Data Monocyte Chemoattractant Proteins/metabolism Protein Binding Receptors, CCR4 Receptors, CXCR3 Receptors, CXCR4/metabolism Receptors, Chemokine/metabolism Substrate Specificity Time Factors},
  issn = {0021-9258 (Print) 0021-9258 (Linking)},
  doi = {10.1074/jbc.M103106200},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/11390394 http://www.jbc.org/content/276/32/29839.full.pdf},
  year = {2001},
  type = {Journal Article},
}


@article{Pospisilik:2001aa,
  author = {Pospisilik, J. A. and Hinke, S. A. and Pederson, R. A. and Hoffmann, T. and Rosche, F. and Schlenzig, D. and Glund, K. and Heiser, U. and McIntosh, C. H. and Demuth, H.},
  title = {{Metabolism of glucagon by dipeptidyl peptidase IV (CD26)}},
  journal = {Regul Pept},
  volume = {96},
  number = {3},
  pages = {133-41},
  note = {Pospisilik, J A Hinke, S A Pederson, R A Hoffmann, T Rosche, F Schlenzig, D Glund, K Heiser, U McIntosh, C H Demuth, H NETHERLANDS Regul Pept. 2001 Jan 12;96(3):133-41.},
  abstract = {Glucagon is a 29-amino acid polypeptide released from pancreatic islet alpha-cells that acts to maintain euglycemia by stimulating hepatic glycogenolysis and gluconeogenesis. Despite its importance, there remains controversy about the mechanisms responsible for glucagon clearance in the body. In the current study, enzymatic metabolism of glucagon was assessed using sensitive mass spectrometric techniques to identify the molecular products. Incubation of glucagon with purified porcine dipeptidyl peptidase IV (DP IV) yielded sequential production of glucagon(3-29) and glucagon(5-29). In human serum, degradation to glucagon(3-29) was rapidly followed by N-terminal cyclization of glucagon, preventing further DP IV-mediated hydrolysis. Bioassay of glucagon, following incubation with purified DP IV or normal rat serum demonstrated a significant loss of hyperglycemic activity, while a similar incubation in DP IV-deficient rat serum did not show any loss of glucagon bioactivity. Degradation, monitored by mass spectrometry and bioassay, was blocked by the specific DP IV inhibitor, isoleucyl thiazolidine. These results identify DP IV as a primary enzyme involved in the degradation and inactivation of glucagon. These findings have important implications for the determination of glucagon levels in human plasma.},
  keywords = {Animals Blood Proteins/isolation & purification/metabolism/pharmacology Dipeptidyl Peptidase 4/blood/isolation & purification/*metabolism/pharmacology Glucagon/chemistry/*metabolism/pharmacology Humans Isoleucine/analogs & derivatives/pharmacology Kinetics Male Peptide Fragments/chemistry/metabolism/pharmacology Rats Rats, Wistar Serine Proteinase Inhibitors/pharmacology Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization Swine Thiazoles/pharmacology},
  issn = {0167-0115 (Print) 0167-0115 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/11111019 http://ac.els-cdn.com/S0167011500001701/1-s2.0-S0167011500001701-main.pdf?_tid=eb8b9c9c-ea5b-11e4-8689-00000aab0f6b&acdnat=1429864304_25d2ef446e0197ae2c019396f4cf9ab2 http://ac.els-cdn.com/S0167011500001701/1-s2.0-S0167011500001701-main.pdf?_tid=f96d70ea-fbdd-11e4-8963-00000aacb362&acdnat=1431789331_58114b527ff51095f58efd97245b3a6a},
  year = {2001},
  type = {Journal Article},
}


@article{Shannon:2001:MTC:584091.584093,
  author = {Shannon, C. E.},
  title = {{A mathematical theory of communication}},
  journal = {ACM SIGMOBILE Mobile Computing and Communications Review},
  volume = {5},
  number = {1},
  pages = {3},
  issn = {15591662},
  doi = {10.1145/584091.584093},
  url = {http://doi.acm.org/10.1145/584091.584093 http://dx.doi.org/10.1145/584091.584093 http://delivery.acm.org/10.1145/590000/584093/p3-shannon.pdf?ip=129.96.230.48&id=584093&acc=ACTIVE%20SERVICE&key=65D80644F295BC0D%2E234671BAEEC40A61%2E4D4702B0C3E38B35%2E4D4702B0C3E38B35&CFID=319086468&CFTOKEN=18781727&__acm__=1397318350_b04aa0f23669a2e086a282e7bcade256 http://delivery.acm.org/10.1145/590000/584093/p3-shannon.pdf?ip=129.96.86.111&id=584093&acc=ACTIVE%20SERVICE&key=65D80644F295BC0D%2E234671BAEEC40A61%2E4D4702B0C3E38B35%2E4D4702B0C3E38B35&CFID=674940373&CFTOKEN=19730367&__acm__=1431789457_fb94c005d1c6d7c5b59b99e54f4cfb91},
  year = {2001},
  type = {Journal Article},
}


@article{Venter2001,
  author = {Venter, J. C. and Adams, M. D. and Myers, E. W. and Li, P. W. and Mural, R. J. and Sutton, G. G. and Smith, H. O. and Yandell, M. and Evans, C. A. and Holt, R. A. and Gocayne, J. D. and Amanatides, P. and Ballew, R. M. and Huson, D. H. and Wortman, J. R. and Zhang, Q. and Kodira, C. D. and Zheng, X. H. and Chen, L. and Skupski, M. and Subramanian, G. and Thomas, P. D. and Zhang, J. and Gabor Miklos, G. L. and Nelson, C. and Broder, S. and Clark, A. G. and Nadeau, J. and McKusick, V. A. and Zinder, N. and Levine, A. J. and Roberts, R. J. and Simon, M. and Slayman, C. and Hunkapiller, M. and Bolanos, R. and Delcher, A. and Dew, I. and Fasulo, D. and Flanigan, M. and Florea, L. and Halpern, A. and Hannenhalli, S. and Kravitz, S. and Levy, S. and Mobarry, C. and Reinert, K. and Remington, K. and Abu-Threideh, J. and Beasley, E. and Biddick, K. and Bonazzi, V. and Brandon, R. and Cargill, M. and Chandramouliswaran, I. and Charlab, R. and Chaturvedi, K. and Deng, Z. and Di Francesco, V. and Dunn, P. and Eilbeck, K. and Evangelista, C. and Gabrielian, A. E. and Gan, W. and Ge, W. and Gong, F. and Gu, Z. and Guan, P. and Heiman, T. J. and Higgins, M. E. and Ji, R. R. and Ke, Z. and Ketchum, K. A. and Lai, Z. and Lei, Y. and Li, Z. and Li, J. and Liang, Y. and Lin, X. and Lu, F. and Merkulov, G. V. and Milshina, N. and Moore, H. M. and Naik, A. K. and Narayan, V. A. and Neelam, B. and Nusskern, D. and Rusch, D. B. and Salzberg, S. and Shao, W. and Shue, B. and Sun, J. and Wang, Z. and Wang, A. and Wang, X. and Wang, J. and Wei, M. and Wides, R. and Xiao, C. and Yan, C. and others},
  title = {{The sequence of the human genome}},
  journal = {Science},
  volume = {291},
  number = {5507},
  pages = {1304-51},
  note = {Venter, J C Adams, M D Myers, E W Li, P W Mural, R J Sutton, G G Smith, H O Yandell, M Evans, C A Holt, R A Gocayne, J D Amanatides, P Ballew, R M Huson, D H Wortman, J R Zhang, Q Kodira, C D Zheng, X H Chen, L Skupski, M Subramanian, G Thomas, P D Zhang, J Gabor Miklos, G L Nelson, C Broder, S Clark, A G Nadeau, J McKusick, V A Zinder, N Levine, A J Roberts, R J Simon, M Slayman, C Hunkapiller, M Bolanos, R Delcher, A Dew, I Fasulo, D Flanigan, M Florea, L Halpern, A Hannenhalli, S Kravitz, S Levy, S Mobarry, C Reinert, K Remington, K Abu-Threideh, J Beasley, E Biddick, K Bonazzi, V Brandon, R Cargill, M Chandramouliswaran, I Charlab, R Chaturvedi, K Deng, Z Di Francesco, V Dunn, P Eilbeck, K Evangelista, C Gabrielian, A E Gan, W Ge, W Gong, F Gu, Z Guan, P Heiman, T J Higgins, M E Ji, R R Ke, Z Ketchum, K A Lai, Z Lei, Y Li, Z Li, J Liang, Y Lin, X Lu, F Merkulov, G V Milshina, N Moore, H M Naik, A K Narayan, V A Neelam, B Nusskern, D Rusch, D B Salzberg, S Shao, W Shue, B Sun, J Wang, Z Wang, A Wang, X Wang, J Wei, M Wides, R Xiao, C Yan, C Yao, A Ye, J Zhan, M Zhang, W Zhang, H Zhao, Q Zheng, L Zhong, F Zhong, W Zhu, S Zhao, S Gilbert, D Baumhueter, S Spier, G Carter, C Cravchik, A Woodage, T Ali, F An, H Awe, A Baldwin, D Baden, H Barnstead, M Barrow, I Beeson, K Busam, D Carver, A Center, A Cheng, M L Curry, L Danaher, S Davenport, L Desilets, R Dietz, S Dodson, K Doup, L Ferriera, S Garg, N Gluecksmann, A Hart, B Haynes, J Haynes, C Heiner, C Hladun, S Hostin, D Houck, J Howland, T Ibegwam, C Johnson, J Kalush, F Kline, L Koduru, S Love, A Mann, F May, D McCawley, S McIntosh, T McMullen, I Moy, M Moy, L Murphy, B Nelson, K Pfannkoch, C Pratts, E Puri, V Qureshi, H Reardon, M Rodriguez, R Rogers, Y H Romblad, D Ruhfel, B Scott, R Sitter, C Smallwood, M Stewart, E Strong, R Suh, E Thomas, R Tint, N N Tse, S Vech, C Wang, G Wetter, J Williams, S Williams, M Windsor, S Winn-Deen, E Wolfe, K Zaveri, J Zaveri, K Abril, J F Guigo, R Campbell, M J Sjolander, K V Karlak, B Kejariwal, A Mi, H Lazareva, B Hatton, T Narechania, A Diemer, K Muruganujan, A Guo, N Sato, S Bafna, V Istrail, S Lippert, R Schwartz, R Walenz, B Yooseph, S Allen, D Basu, A Baxendale, J Blick, L Caminha, M Carnes-Stine, J Caulk, P Chiang, Y H Coyne, M Dahlke, C Mays, A Dombroski, M Donnelly, M Ely, D Esparham, S Fosler, C Gire, H Glanowski, S Glasser, K Glodek, A Gorokhov, M Graham, K Gropman, B Harris, M Heil, J Henderson, S Hoover, J Jennings, D Jordan, C Jordan, J Kasha, J Kagan, L Kraft, C Levitsky, A Lewis, M Liu, X Lopez, J Ma, D Majoros, W McDaniel, J Murphy, S Newman, M Nguyen, T Nguyen, N Nodell, M Pan, S Peck, J Peterson, M Rowe, W Sanders, R Scott, J Simpson, M Smith, T Sprague, A Stockwell, T Turner, R Venter, E Wang, M Wen, M Wu, D Wu, M Xia, A Zandieh, A Zhu, X New York, N.Y. Science. 2001 Feb 16;291(5507):1304-51.},
  abstract = {A 2.91-billion base pair (bp) consensus sequence of the euchromatic portion of the human genome was generated by the whole-genome shotgun sequencing method. The 14.8-billion bp DNA sequence was generated over 9 months from 27,271,853 high-quality sequence reads (5.11-fold coverage of the genome) from both ends of plasmid clones made from the DNA of five individuals. Two assembly strategies-a whole-genome assembly and a regional chromosome assembly-were used, each combining sequence data from Celera and the publicly funded genome effort. The public data were shredded into 550-bp segments to create a 2.9-fold coverage of those genome regions that had been sequenced, without including biases inherent in the cloning and assembly procedure used by the publicly funded group. This brought the effective coverage in the assemblies to eightfold, reducing the number and size of gaps in the final assembly over what would be obtained with 5.11-fold coverage. The two assembly strategies yielded very similar results that largely agree with independent mapping data. The assemblies effectively cover the euchromatic regions of the human chromosomes. More than 90% of the genome is in scaffold assemblies of 100,000 bp or more, and 25% of the genome is in scaffolds of 10 million bp or larger. Analysis of the genome sequence revealed 26,588 protein-encoding transcripts for which there was strong corroborating evidence and an additional approximately 12,000 computationally derived genes with mouse matches or other weak supporting evidence. Although gene-dense clusters are obvious, almost half the genes are dispersed in low G+C sequence separated by large tracts of apparently noncoding sequence. Only 1.1% of the genome is spanned by exons, whereas 24% is in introns, with 75% of the genome being intergenic DNA. Duplications of segmental blocks, ranging in size up to chromosomal lengths, are abundant throughout the genome and reveal a complex evolutionary history. Comparative genomic analysis indicates vertebrate expansions of genes associated with neuronal function, with tissue-specific developmental regulation, and with the hemostasis and immune systems. DNA sequence comparisons between the consensus sequence and publicly funded genome data provided locations of 2.1 million single-nucleotide polymorphisms (SNPs). A random pair of human haploid genomes differed at a rate of 1 bp per 1250 on average, but there was marked heterogeneity in the level of polymorphism across the genome. Less than 1% of all SNPs resulted in variation in proteins, but the task of determining which SNPs have functional consequences remains an open challenge.},
  keywords = {Algorithms Animals Chromosome Banding Chromosome Mapping Chromosomes, Artificial, Bacterial Computational Biology Consensus Sequence CpG Islands DNA, Intergenic Databases, Factual Evolution, Molecular Exons Female Gene Duplication Genes Genetic Variation *Genome, Human *Human Genome Project Humans Introns Male Phenotype Physical Chromosome Mapping Polymorphism, Single Nucleotide Proteins/genetics/physiology Pseudogenes Repetitive Sequences, Nucleic Acid Retroelements *Sequence Analysis, DNA/methods Species Specificity},
  issn = {0036-8075 (Print) 0036-8075 (Linking)},
  doi = {10.1126/science.1058040},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/11181995 http://www.sciencemag.org/content/291/5507/1304.full.pdf},
  year = {2001},
  type = {Journal Article},
}


@article{Wang:2001aa,
  author = {Wang, W. and Kollman, P. A.},
  title = {{Computational study of protein specificity: the molecular basis of HIV-1 protease drug resistance}},
  journal = {Proc Natl Acad Sci U S A},
  volume = {98},
  number = {26},
  pages = {14937-42},
  note = {Wang, W Kollman, P A GM-56531/GM/NIGMS NIH HHS/ RR-1081/RR/NCRR NIH HHS/ Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):14937-42.},
  abstract = {Drug resistance has sharply limited the effectiveness of HIV-1 protease inhibitors in AIDS therapy. It is critically important to understand the basis of this resistance for designing new drugs. We have evaluated the free energy contribution of each residue in the HIV protease in binding to one of its substrates and to the five FDA-approved protease drugs. Analysis of these free energy profiles and the variability at each sequence position suggests: (i) single drug resistance mutations are likely to occur at not well conserved residues if they interact more favorably with drugs than with the substrate; and (ii) resistance-evading drugs should have a free energy profile similar to the substrate and interact most favorably with well conserved residues. We also propose an empirical parameter, called the free energy/variability value, which combines free energy calculation and sequence analysis to suggest possible drug resistance mutations on the protease. The free energy/variability value is defined as the product of one residue's contribution to the binding free energy and the variability of that residue. This parameter can assist in designing resistance-evading drugs for any target.},
  keywords = {Drug Resistance, Microbial/*genetics HIV Protease/chemistry/genetics/*metabolism HIV Protease Inhibitors/pharmacology Humans Mutation Poisson Distribution Thermodynamics},
  issn = {0027-8424 (Print) 0027-8424 (Linking)},
  doi = {10.1073/pnas.251265598},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/11752442 http://www.pnas.org/content/98/26/14937.full.pdf},
  year = {2001},
  type = {Journal Article},
}


@inbook{Langner:2002ph,
  author = {Abbott, CatherineA. and Gorrell, MarkD.},
  title = {{The Family of CD26/DPIV and Related Ectopeptidases}},
  booktitle = {Ectopeptidases},
  editor = {Langner, Jrgen and Ansorge, Siegfried},
  publisher = {Springer US},
  pages = {171-195},
  isbn = {978-1-4613-5161-0},
  doi = {10.1007/978-1-4615-0619-5\_7},
  url = {http://dx.doi.org/10.1007/978-1-4615-0619-5_7 http://dx.doi.org/10.1007/978-1-4615-0619-5%7B%5C_%7D7},
  year = {2002},
  type = {Book Section},
}


@article{Ghersi:2002cz,
  author = {Ghersi, G. and Dong, H. and Goldstein, L. A. and Yeh, Y. and Hakkinen, L. and Larjava, H. S. and Chen, W. T.},
  title = {{Regulation of fibroblast migration on collagenous matrix by a cell surface peptidase complex}},
  journal = {J Biol Chem},
  volume = {277},
  number = {32},
  pages = {29231-41},
  note = {Ghersi, Giulio Dong, Huan Goldstein, Leslie A Yeh, Yunyun Hakkinen, Lari Larjava, Hannu S Chen, Wen-Tien R01CA39077/CA/NCI NIH HHS/ R01HL33711/HL/NHLBI NIH HHS/ J Biol Chem. 2002 Aug 9;277(32):29231-41. Epub 2002 May 22.},
  abstract = {The invasion of migratory cells through connective tissues involves metallo- and serine types of cell surface proteases. We show that formation of a novel protease complex, consisting of the membrane-bound prolyl peptidases seprase and dipeptidyl peptidase IV (DPPIV), at invadopodia of migratory fibroblasts is a prerequisite for cell invasion and migration on a collagenous matrix. Seprase and DPPIV form a complex on the cell surface that elicits both gelatin binding and gelatinase activities localized at invadopodia of cells migrating on collagenous fibers. The protease complex participates in the binding to gelatin and localized gelatin degradation, cellular migration, and monolayer wound closure. Serine protease inhibitors can block the gelatinase activity and the localized gelatin degradation by cells. Antibodies to the gelatin-binding domain of DPPIV reduce the cellular abilities of the proteases to degrade gelatin but do not affect cellular adhesion or spreading on type I collagen. Furthermore, expression of the seprase-DPPIV complex is restricted to migratory cells involved in wound closure in vitro and in connective tissue cells during closure of gingival wounds but not in differentiated tissue cells. Thus, we have identified cell surface proteolytic activities, which are non-metalloproteases, seprase and DPPIV, that are responsible for the tissue-invasive phenotype.},
  keywords = {Animals COS Cells Cell Adhesion Cell Differentiation Cell Line Cell Membrane/metabolism Cell Movement Chromatography, Gel Collagen/*metabolism Dipeptidyl Peptidase 4/chemistry/*metabolism Dose-Response Relationship, Drug Fibroblasts/*metabolism Gelatin/metabolism/pharmacology Gelatinases/chemistry/*metabolism Gingiva/pathology Humans Ligands *Membrane Proteins Microscopy, Fluorescence Mutagenesis, Site-Directed Peptide Hydrolases/*chemistry Phenotype Protein Binding Rats *Serine Endopeptidases Time Factors Tumor Cells, Cultured Wound Healing},
  issn = {0021-9258 (Print) 0021-9258 (Linking)},
  doi = {10.1074/jbc.M202770200},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/12023964 http://www.jbc.org/content/277/32/29231.full.pdf},
  year = {2002},
  type = {Journal Article},
}


@article{Hedstrom:2002aa,
  author = {Hedstrom, L.},
  title = {{Serine protease mechanism and specificity}},
  journal = {Chem Rev},
  volume = {102},
  number = {12},
  pages = {4501-24},
  note = {Hedstrom, Lizbeth Chem Rev. 2002 Dec;102(12):4501-24.},
  keywords = {Animals Binding Sites Catalysis Humans Models, Chemical Protein Engineering Serine Endopeptidases/*chemistry/genetics/metabolism Substrate Specificity},
  issn = {0009-2665 (Print) 0009-2665 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/12475199 http://pubs.acs.org/doi/pdfplus/10.1021/cr000033x},
  year = {2002},
  type = {Journal Article},
}


@inbook{Hoffmann2002,
  author = {Hoffmann, Torsten and Demuth, Hans-Ulrich},
  title = {{Therapeutic Strategies Exploiting DP IV Inhibition}},
  booktitle = {Ectopeptidases: CD13/Aminopeptidase N and CD26/Dipeptidylpeptidase IV in Medicine and Biology},
  editor = {Langner, Jrgen and Ansorge, Siegfried},
  publisher = {Springer US},
  address = {Boston, MA},
  pages = {259-278},
  isbn = {978-1-4615-0619-5},
  doi = {10.1007/978-1-4615-0619-5_10},
  url = {http://dx.doi.org/10.1007/978-1-4615-0619-5_10 http://download.springer.com/static/pdf/470/chp%253A10.1007%252F978-1-4615-0619-5_10.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Fchapter%2F10.1007%2F978-1-4615-0619-5_10&token2=exp=1474008275~acl=%2Fstatic%2Fpdf%2F470%2Fchp%25253A10.1007%25252F978-1-4615-0619-5_10.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Fchapter%252F10.1007%252F978-1-4615-0619-5_10*~hmac=4a0debd506e275f8643ba86426869e20cae247c1e3257e606374d0863c25b8fc},
  year = {2002},
  type = {Book Section},
}


@article{Lambeir2002,
  author = {Lambeir, A. M. and Proost, P. and Scharpe, S. and De Meester, I.},
  title = {{A kinetic study of glucagon-like peptide-1 and glucagon-like peptide-2 truncation by dipeptidyl peptidase IV, in vitro}},
  journal = {Biochem Pharmacol},
  volume = {64},
  number = {12},
  pages = {1753-6},
  note = {Lambeir, Anne-Marie Proost, Paul Scharpe, Simon De Meester, Ingrid England Biochem Pharmacol. 2002 Dec 15;64(12):1753-6.},
  abstract = {In vivo inactivation of glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) was found to be associated with the proteolytic removal of their N-terminal dipeptide by the ectopeptidase dipeptidyl peptidase IV (DPP IV). Previous studies suggested that the in vivo metabolism of GLP-1 is much faster than that of GLP-2. In this paper, we investigated the in vitro truncation of GLP-2 and GLP-1 by DPP IV. The slower conversion rate observed for GLP-2 compared to GLP-1 was due to an approximately 10-fold reduction in catalytic rate constant. The selectivity of DPP IV for the glucagon-like peptides was compared with data obtained for other natural substrates using the same enzyme source in identical conditions.},
  keywords = {Amino Acid Sequence Dipeptidyl Peptidase 4/*metabolism Glucagon/*metabolism Glucagon-Like Peptide 1 Glucagon-Like Peptide 2 Humans Kinetics Molecular Sequence Data Peptide Fragments/*metabolism Peptides/*metabolism Protein Precursors/*metabolism Time Factors},
  issn = {0006-2952 (Print) 0006-2952 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/12445864 http://ac.els-cdn.com/S0006295202014156/1-s2.0-S0006295202014156-main.pdf?_tid=48cbc17a-ea5c-11e4-af79-00000aab0f6c&acdnat=1429864460_4898fcebdcda8a31e60f218f2f01f885 http://ac.els-cdn.com/S0006295202014156/1-s2.0-S0006295202014156-main.pdf?_tid=0c1b9d66-fbde-11e4-8682-00000aab0f26&acdnat=1431789363_c89ef871c627492e8e7b3fd31e8a7def},
  year = {2002},
  type = {Journal Article},
}


@book{Langner:0oq,
  author = {Langner, Jrgen and Ansorge, Siegfried},
  title = {{Ectopeptidases : CD13/aminopeptidase N and CD26/dipeptidylpeptidase IV in medicine and biology}},
  publisher = {Kluwer Academic/Plenum},
  address = {New York},
  keywords = {Extracellular enzymes immunology Dipeptidyl Peptidase 4 CD antigens Aminopeptidases Antigens, CD13},
  isbn = {0306467887},
  url = {http://forward.library.wisconsin.edu/catalog/ocm48883936},
  year = {2002},
  type = {Book},
}


@article{Ludwig:2002aa,
  author = {Ludwig, Andreas and Schiemann, Florian and Mentlein, Rolf and Lindner, Buko and Brandt, Ernst},
  title = {{Dipeptidyl peptidase IV (CD26) on T cells cleaves the CXC chemokine CXCL11 (I-TAC) and abolishes the stimulating but not the desensitizing potential of the chemokine.}},
  journal = {J Leukoc Biol},
  volume = {72},
  number = {1},
  pages = {183--191},
  abstract = {Dipeptidyl peptidase IV (DPP IV/CD26) is a costimulatory molecule as well as a protease highly expressed on T cells. Purified DPP IV has been recognized to inactivate peptide hormones, neuropeptides, and some chemokines by cleavage behind a proline residue at the penultimate N-terminal amino acid position. Here, we identified another substrate for DPP IV among the chemokine family: the interferon-inducible T cell alpha chemoattractant (I-TAC/CXCL11). Using a specific DPP IV inhibitor, we demonstrate that DPP IV is responsible for the cleavage of the chemokine by PHA/IL-2-treated T cells. As PHA/IL-2-treated T cells also express the CXCL11 receptor (CXCR3), we investigated whether truncation of CXCL11 would modulate its biological activity for these cells. Truncated CXCL11 [CXCL11(3-73)] had an eightfold reduced potential to bind and to regulate CXCR3, but was completely inactive in calcium flux and chemotaxis assays. However, consistent with its reduced but still considerable ability to down-regulate CXCR3, truncated CXCL11 desensitized T cell chemotaxis in response to the intact chemokine. Hence, CXCL11-induced T cell recruitment may be regulated by DPP IV-mediated proteolytic inactivation of CXCL11 and furthermore by desensitization of T cells via the degradation product CXCL11(3-73).},
  issn = {0741-5400 (Print); 0741-5400 (Linking)},
  url = {http://www.jleukbio.org/content/72/1/183.full.pdf},
  year = {2002},
  type = {Journal Article},
}


@article{McQuibban15082002,
  author = {McQuibban, G. A. and Gong, J. H. and Wong, J. P. and Wallace, J. L. and Clark-Lewis, I. and Overall, C. M.},
  title = {{Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo}},
  journal = {Blood},
  volume = {100},
  number = {4},
  pages = {1160-7},
  note = {McQuibban, G Angus Gong, Jiang-Hong Wong, Julie P Wallace, John L Clark-Lewis, Ian Overall, Christopher M Blood. 2002 Aug 15;100(4):1160-7.},
  abstract = {Monocyte chemoattractant protein (MCP)-3 is inactivated upon cleavage by the matrix metalloproteinase (MMP) gelatinase A (MMP-2). We investigated the susceptibility to proteolytic processing of the 4 human MCPs by 8 recombinant MMPs to determine whether MCP-3 is an isolated example or represents a general susceptibility of chemokines to proteolytic inactivation by these important inflammatory proteases. In addition to MMP-2, MCP-3 is efficiently cleaved by membrane type 1 (MT1)-MMP, the cellular activator of MMP-2, and by collagenase-1 and collagenase-3 (MMP-1, MMP-13) and stromelysin-1 (MMP-3). Specificity was shown by absence of cleavage by matrilysin (MMP-7) and the leukocytic MMPs neutrophil collagenase (MMP-8) and gelatinase B (MMP-9). The closely related chemokines MCP-1, MCP-2, and MCP-4 were not cleaved by MMP-2 or MT1-MMP, but were cleaved by MMP-1 and MMP-3 with varying efficiency. MCPs were typically cleaved between residues 4 and 5, but MCP-4 was further processed at Val7-Pro8. Synthetic MCP analogs corresponding to the MMP-cleaved forms bound CC chemokine receptor (CCR)-2 and CCR-3, but lacked chemoattractant activity in pre-B cells transfected with CCR-2 and CCR-3 or in THP-1 monocytic cells, a transformed leukemic cell line. Moreover, the truncated products of MCP-2 and MCP-4, like MCP-3, were potent antagonists of their cognate CC chemokine receptors in transwell cell migration assays in vitro. When they were injected 24 hours after the initiation of carrageenan-induced inflammation in rat paws, their in vivo antagonist activities were revealed by a greater than 66% reduction in inflammatory edema progression after 12 hours. We propose that MMPs have an important role in modulating inflammatory and immune responses by processing chemokines in wound healing and in disease.},
  keywords = {Amino Acid Sequence Animals *Anti-Inflammatory Agents B-Lymphocytes/metabolism CHO Cells Carrageenan Chemokine CCL2/metabolism Chemokine CCL7 Chemokine CCL8 Collagenases/metabolism Cricetinae *Cytokines Edema/chemically induced/drug therapy Enzyme Activation Female Humans Inflammation/chemically induced/drug therapy Male Matrix Metalloproteinase 1/metabolism Matrix Metalloproteinase 13 Matrix Metalloproteinase 2/metabolism Matrix Metalloproteinase 3/metabolism Matrix Metalloproteinases/*metabolism Matrix Metalloproteinases, Membrane-Associated Metalloendopeptidases/metabolism Monocyte Chemoattractant Proteins/*metabolism Peptide Fragments/metabolism/pharmacology Rats Rats, Wistar Receptors, Chemokine/*antagonists & inhibitors/genetics Recombinant Proteins/metabolism Substrate Specificity Transfection},
  issn = {0006-4971 (Print) 0006-4971 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/12149192 http://www.bloodjournal.org/content/bloodjournal/100/4/1160.full.pdf http://www.bloodjournal.org/content/100/4/1160.full?sso-checked=true http://www.bloodjournal.org/content/100/4/1160.long?sso-checked=true http://www.bloodjournal.org/content/100/4/1160.long},
  year = {2002},
  type = {Journal Article},
}


@article{Musi:2002ct,
  author = {Musi, N. and Hirshman, M. F. and Nygren, J. and Svanfeldt, M. and Bavenholm, P. and Rooyackers, O. and Zhou, G. and Williamson, J. M. and Ljunqvist, O. and Efendic, S. and Moller, D. E. and Thorell, A. and Goodyear, L. J.},
  title = {{Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes}},
  journal = {Diabetes},
  volume = {51},
  number = {7},
  pages = {2074-81},
  note = {Musi, Nicolas Hirshman, Michael F Nygren, Jonas Svanfeldt, Monika Bavenholm, Peter Rooyackers, Olav Zhou, Gaochao Williamson, Joanne M Ljunqvist, Olle Efendic, Suad Moller, David E Thorell, Anders Goodyear, Laurie J AR 45670/AR/NIAMS NIH HHS/ Diabetes. 2002 Jul;51(7):2074-81.},
  abstract = {Metformin is an effective hypoglycemic drug that lowers blood glucose concentrations by decreasing hepatic glucose production and increasing glucose disposal in skeletal muscle; however, the molecular site of metformin action is not well understood. AMP-activated protein kinase (AMPK) activity increases in response to depletion of cellular energy stores, and this enzyme has been implicated in the stimulation of glucose uptake into skeletal muscle and the inhibition of liver gluconeogenesis. We recently reported that AMPK is activated by metformin in cultured rat hepatocytes, mediating the inhibitory effects of the drug on hepatic glucose production. In the present study, we evaluated whether therapeutic doses of metformin increase AMPK activity in vivo in subjects with type 2 diabetes. Metformin treatment for 10 weeks significantly increased AMPK alpha2 activity in the skeletal muscle, and this was associated with increased phosphorylation of AMPK on Thr172 and decreased acetyl-CoA carboxylase-2 activity. The increase in AMPK alpha2 activity was likely due to a change in muscle energy status because ATP and phosphocreatine concentrations were lower after metformin treatment. Metformin-induced increases in AMPK activity were associated with higher rates of glucose disposal and muscle glycogen concentrations. These findings suggest that the metabolic effects of metformin in subjects with type 2 diabetes may be mediated by the activation of AMPK alpha2.},
  keywords = {AMP-Activated Protein Kinases Blood Glucose/metabolism Diabetes Mellitus, Type 2/drug therapy/*enzymology Fatty Acids, Nonesterified/blood Female Hemoglobin A, Glycosylated/metabolism Humans Hypoglycemic Agents/*therapeutic use Insulin/blood Kinetics Lipids/blood Male Metformin/*therapeutic use Middle Aged Multienzyme Complexes/*metabolism Muscle, Skeletal/*enzymology Protein-Serine-Threonine Kinases/*metabolism Time Factors},
  issn = {0012-1797 (Print) 0012-1797 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/12086935 http://diabetes.diabetesjournals.org/content/51/7/2074.full.pdf},
  year = {2002},
  type = {Journal Article},
}


@article{Olsen:2002pt,
  author = {Olsen, C. and Wagtmann, N.},
  title = {{Identification and characterization of human DPP9, a novel homologue of dipeptidyl peptidase IV}},
  journal = {Gene},
  volume = {299},
  number = {1-2},
  pages = {185-93},
  note = {Olsen, Christina Wagtmann, Nicolai Netherlands Gene. 2002 Oct 16;299(1-2):185-93.},
  abstract = {We used an in silico approach to identify new cDNAs with homology to dipeptidyl peptidase IV (DPP IV). DPP IV (EC 3.4.14.5) is a serine protease with a rare enzyme activity having an important role in the regulation of various processes, such as blood glucose control and immune responses. Here, we report the identification and characterization of a novel DPP IV-like molecule, termed dipeptidyl peptidase-like protein 9 (DPP9). The deduced amino acid sequence of DPP9 has a serine protease motif, GWSYG, identical to that found in DPP IV. The presence of this motif, together with a conserved order and spacing of the Ser, Asp, and His residues that form the catalytic triad in DPP IV, places DPP9 in the DPP IV gene family. Northern blots showed that DPP9 is ubiquitously expressed, with the highest expression levels in skeletal muscle, heart, and liver, and the lowest in brain. In vitro translation of the cloned full-length DPP9 sequence resulted in a DPP9 protein product that migrated in sodium dodecyl sulfate-polyacrylamide gel electrophoresis at a position similar to the predicted protein size of 98 kDa. Consistent with the lack of predicted transmembrane domains and a signal sequence, DPP9 was found in a soluble, putative cytosolic form. A DPP9 orthologue in mice was identified by expressed sequence tag database searches and verified by cDNA cloning.},
  keywords = {5' Flanking Region/genetics Amino Acid Sequence Animals Base Sequence DNA, Complementary/chemistry/genetics/isolation & purification Dipeptidyl Peptidase 4/*genetics Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/*genetics Exons Female Gene Expression Genes/genetics HL-60 Cells HeLa Cells Humans Introns K562 Cells Male Mice Molecular Sequence Data Phylogeny Protein Biosynthesis Sequence Analysis, DNA Transcription Initiation Site Tumor Cells, Cultured},
  issn = {0378-1119 (Print) 0378-1119 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/12459266 http://ac.els-cdn.com/S0378111902010594/1-s2.0-S0378111902010594-main.pdf?_tid=0104d35e-ea5c-11e4-87ef-00000aab0f26&acdnat=1429864340_b623901644c2d2594815c7099d5c46e6 http://ac.els-cdn.com/S0378111902010594/1-s2.0-S0378111902010594-main.pdf?_tid=1836091a-fbde-11e4-91d0-00000aab0f26&acdnat=1431789383_e0e577ed688aa17c6674939ebeb63989},
  year = {2002},
  type = {Journal Article},
}


@article{Ong2002,
  author = {Ong, S. E. and Blagoev, B. and Kratchmarova, I. and Kristensen, D. B. and Steen, H. and Pandey, A. and Mann, M.},
  title = {{Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics}},
  journal = {Molecular & Cellular Proteomics},
  volume = {1},
  number = {5},
  pages = {376-386},
  note = {654UX Times Cited:2225 Cited References Count:39},
  abstract = {Quantitative proteomics has traditionally been performed by two-dimensional gel electrophoresis, but recently, mass spectrometric methods based on stable isotope quantitation have shown great promise for the simultaneous and automated identification and quantitation of complex protein mixtures. Here we describe a method, termed SILAC, for stable isotope labeling by amino acids in cell culture, for the in vivo incorporation of specific amino acids into all mammalian proteins. Mammalian cell lines are grown in media lacking a standard essential amino acid but supplemented with a non-radioactive, isotopically labeled form of that amino acid, in this case deuterated leucine (Leu-d3). We find that growth of cells maintained in these media is no different from growth in normal media as evidenced by cell morphology, doubling time, and ability to differentiate. Complete incorporation of Leu-d3 occurred after five doublings in the cell lines and proteins studied. Protein populations from experimental and control samples are mixed directly after harvesting, and mass spectrometric identification is straightforward as every leucine-containing peptide incorporates either all normal leucine or all Leu-d3. We have applied this technique to the relative quantitation of changes in protein expression during the process of muscle cell differentiation. Proteins that were found to be up-regulated during this process include glyceraldehyde-3-phosphate dehydrogenase, fibronectin, and pyruvate kinase M2. SILAC is a simple, inexpensive, and accurate procedure that can be used as a quantitative proteomic approach in any cell culture system.},
  keywords = {desorption/ionization mass-spectrometry coded affinity tags 2-dimensional electrophoresis quantitative-analysis polyacrylamide gels proteins peptide matrix mixtures tool},
  issn = {1535-9476},
  doi = {DOI 10.1074/mcp.M200025-MCP200},
  url = {<Go to ISI>://000181515400004 http://www.mcponline.org/content/1/5/376.full.pdf},
  year = {2002},
  type = {Journal Article},
}


@article{Overall:2002lk,
  author = {Overall, C. M. and McQuibban, G. A. and Clark-Lewis, I.},
  title = {{Discovery of chemokine substrates for matrix metalloproteinases by exosite scanning: a new tool for degradomics}},
  journal = {Biol Chem},
  volume = {383},
  number = {7-8},
  pages = {1059-66},
  note = {Overall, Christopher M McQuibban, G Angus Clark-Lewis, Ian Germany Biol Chem. 2002 Jul-Aug;383(7-8):1059-66.},
  abstract = {Increasingly it is being recognized that matrix metalloproteinases (MMPs) are important processing enzymes that regulate cellular behaviour and immune cell function by selective proteolysis of cell surface receptors and adhesion molecules, cytokines and growth factors. These functions will likely prove to be as important in vivo as the proposed roles of MMPs in pathological matrix degradation. To screen for new protease substrates we have reported a novel 'exosite scanning' strategy that utilizes protease substrate-binding exosite domains as yeast two-hybrid baits. We discovered that the chemokine monocyte chemoattractant protein-3 (MCP-3) binds the hemopexin C domain of gelatinase A (MMP-2) leading to its efficient cleavage, converting an agonist to a potent receptor antagonist. We have now found that other MMPs cleave MCP-1, MCP-2, MCP-3, MCP-4, SDF-lalpha and SDF-1beta indicating that the intersection between the chemokine and MMP families is broad with important implications for the control of inflammatory and immune processes. Use of engineered substrates with altered exosite binding affinities further revealed the power of exosites in dictating proteolytic specificity - either directing cleavage of non-preferred sites or in other cases virtually eliminating proteolysis of readily accessible scissile bonds. Hence, bioinformatic searches for protease substrates based on scissile bond preference will only reveal a subset of substrates unless the influence of exosites is considered.},
  keywords = {Animals Chemokines/*metabolism Extracellular Matrix/metabolism Humans Metalloendopeptidases/chemistry/*metabolism Substrate Specificity *Two-Hybrid System Techniques},
  issn = {1431-6730 (Print) 1431-6730 (Linking)},
  doi = {10.1515/BC.2002.114},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/12437088 http://www.degruyter.com/view/j/bchm.2002.383.issue-7-8/bc.2002.114/bc.2002.114.xml https://www.degruyter.com/view/j/bchm.2002.383.issue-7-8/bc.2002.114/bc.2002.114.xml},
  year = {2002},
  type = {Journal Article},
}


@article{Polgar:2002aa,
  author = {Polgar, L.},
  title = {{The prolyl oligopeptidase family}},
  journal = {Cell Mol Life Sci},
  volume = {59},
  number = {2},
  pages = {349-62},
  note = {Polgar, L Switzerland Cell Mol Life Sci. 2002 Feb;59(2):349-62.},
  abstract = {A group of serine peptidases, the prolyl oligopeptidase family, cannot hydrolyze peptides containing more than about 30 residues. This group is unrelated to the classical trypsin and subtilisin families, and includes dipeptidyl peptidase IV, acylaminoacyl peptidase and oligopeptidase B, in addition to the prototype prolyl oligopeptidase. The recent crystal structure determination of prolyl oligopeptidase (80 kDa) has shown that the enzyme contains a peptidase domain with an alpha/beta hydrolase fold, and its catalytic triad is covered by the central tunnel of an unusual seven-bladed beta-propeller. This domain operates as a gating filter, excluding large, structured peptides from the active site. The binding mode of substrates and the catalytic mechanism differ from that of the classical serine peptidases in several features. The members of the family are important targets of drug design. Prolyl oligopeptidase is involved in amnesia, depression and blood pressure control, dipeptidyl peptidase IV in type 2 diabetes and oligopeptidase B in trypanosomiasis.},
  keywords = {Animals Binding Sites Catalysis Dipeptidyl Peptidase 4/chemistry/metabolism Humans Kinetics Models, Molecular Oligopeptides/metabolism Peptide Hydrolases/chemistry/metabolism Protein Structure, Tertiary Serine Endopeptidases/*chemistry/*metabolism},
  issn = {1420-682X (Print) 1420-682X (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/11915948},
  year = {2002},
  type = {Journal Article},
}


@article{Boonacker:2003aa,
  author = {Boonacker, E. and Elferink, S. and Bardai, A. and Wormmeester, J. and Van Noorden, C. J.},
  title = {{Rapid assay to detect possible natural substrates of proteases in living cells}},
  journal = {Biotechniques},
  volume = {35},
  number = {4},
  pages = {766-8, 770, 772 passim},
  note = {Boonacker, Emil Elferink, Sjoerd Bardai, Abdennasser Wormmeester, Jan Van Noorden, Cornelis J Biotechniques. 2003 Oct;35(4):766-8, 770, 772 passim.},
  abstract = {Proteolysis is a regulatory step in many physiological processes, but which proteases in what cellular sites are involved in activation or degradation of which peptides is not well known. We developed a rapid assay consisting of living cells and fluorogenic protease substrates to determine which bioactive peptides are possible natural substrates of a specific protease with the multifunctional or moonlighting protein CD26/dipeptidyl peptidase IV (DPPIV) as a model. CD26/DPPIV catalyzes cleavage of peptides from the amino terminus of peptides with proline at the penultimate position. Many biologically active peptides, such as beta-casomorphin1-5, contain proline in the penultimate position. We incubated living Jurkat cells, which are T cells that lack CD26/DPPIV, and CD26/DPPIV-transfected Jurkat cells in the presence of the fluorogenic substrate [Ala-Pro]2-cresyl violet (Magic Red) and beta-casomorphin1-5. Fluorescent cresyl violet was generated by CD26/DPPIV-transfected Jurkat cells but not by wild-type Jurkat cells with a Km of 3.7 microM. beta-Casomorphin1-5 appeared to be a possible natural substrate of CD26/DPPIV, because it inhibited production of fluorescence competitively (Ki = 60 microM). The assay using living cells and a fluorogenic protease substrate is an efficient system to determine whether specific peptides are possible natural substrates of a particular protease.},
  keywords = {Biological Assay/*methods Biosensing Techniques/*methods *Dipeptides Dipeptidyl Peptidase 4/*analysis/*metabolism Fluorescent Dyes Humans Jurkat Cells *Oxazines *Rhodamines Spectrometry, Fluorescence/*methods Substrate Specificity},
  issn = {0736-6205 (Print) 0736-6205 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/14579742},
  year = {2003},
  type = {Journal Article},
}


@article{Boonacker:2003mw,
  author = {Boonacker, E. and Van Noorden, C. J.},
  title = {{The multifunctional or moonlighting protein CD26/DPPIV}},
  journal = {Eur J Cell Biol},
  volume = {82},
  number = {2},
  pages = {53-73},
  note = {Boonacker, Emil Van Noorden, Cornelis J F Germany Eur J Cell Biol. 2003 Feb;82(2):53-73.},
  abstract = {CD26/DPPIV can be considered a moonlighting protein because it is a multifunctional protein that exerts its different functions depending on cell type and intra- or extracellular conditions in which it is expressed. In the present review, we summarize all its known functions in relation to physiological and pathophysiological conditions. The protein is a proteolytic enzyme, receptor, costimulatory protein, and is involved in adhesion and apoptosis. The CD26/DPPIV protein plays a major role in immune response. Abnormal expression is found in the case of autoimmune diseases, HIV-related diseases and cancer. Natural substrates for CD26/DPPIV are involved in immunomodulation, psycho/neuronal modulation and physiological processes in general. Therefore, targeting of CD26/ DPPIV and especially its proteolytic activity has many therapeutic potentials. On the other hand, there are homologous proteins with overlapping proteolytic activity, which thus may prevent specific modulation of CD26/DPPIV. In conclusion, CD26/DPPIV is a protein present both in various cellular compartments and extracellularly where it exerts different functions and thus is a true moonlighting protein.},
  keywords = {Animals Apoptosis/physiology Autoimmune Diseases/physiopathology Cell Adhesion/physiology Dipeptidyl Peptidase 4/*physiology Humans Models, Biological},
  issn = {0171-9335 (Print) 0171-9335 (Linking)},
  doi = {10.1078/0171-9335-00302},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/12647932 http://media.proquest.com/media/pq/classic/doc/335299531/fmt/pi/rep/NONE?hl=&cit%3Aauth=Boonacker%2C+Emil%3BCornelis+J+F+Van+Noorden&cit%3Atitle=The+multifunctional+or+moonlighting+protein+CD26%2FDPPIV&cit%3Apub=European+Journal+of+Cell+Biology&cit%3Avol=82&cit%3Aiss=2&cit%3Apg=53&cit%3Adate=Feb+2003&ic=true&cit%3Aprod=ProQuest+Central&_a=ChgyMDE1MDUxNjE1NTUxNTA2MDo3MTE4MTUSBjEwNDgzNxoKT05FX1NFQVJDSCINMTI5Ljk2Ljg2LjExMSoFMzIzNDIyCTIwNDE0MDQxMzoNRG9jdW1lbnRJbWFnZUIBMFIGT25saW5lWgJGVGIDUEZUagoyMDAzLzAyLzAxcgoyMDAzLzAyLzI4egCCATJQLTEwMDcwNjctMTA5MTAtQ1VTVE9NRVItMTAwMDAwMzkvMTAwMDAxNTUtMzg5NDQwNJIBBk9ubGluZcoBB0VuZE5vdGXSARJTY2hvbGFybHkgSm91cm5hbHOaAgdQcmVQYWlkqgIoT1M6RU1TLVBkZkRvY1ZpZXdCYXNlLWdldE1lZGlhVXJsRm9ySXRlbcoCI0dlbmVyYWwgSW5mb3JtYXRpb258RmVhdHVyZXxBcnRpY2xl0gIBWeICAU7yAgA%3D&_s=f2gvrQW%2BOQgLGFDUw%2FY01bSJk%2Bo%3D},
  year = {2003},
  type = {Journal Article},
}


@article{Engel:2003fe,
  author = {Engel, M. and Hoffmann, T. and Wagner, L. and Wermann, M. and Heiser, U. and Kiefersauer, R. and Huber, R. and Bode, W. and Demuth, H. U. and Brandstetter, H.},
  title = {{The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism}},
  journal = {Proc Natl Acad Sci U S A},
  volume = {100},
  number = {9},
  pages = {5063-8},
  note = {Engel, Michael Hoffmann, Torsten Wagner, Leona Wermann, Michael Heiser, Ulrich Kiefersauer, Reiner Huber, Robert Bode, Wolfram Demuth, Hans-Ulrich Brandstetter, Hans Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5063-8. Epub 2003 Apr 10.},
  abstract = {The membrane-bound glycoprotein dipeptidyl peptidase IV (DP IV, CD26) is a unique multifunctional protein, acting as receptor, binding and proteolytic molecule. We have determined the sequence and 1.8 A crystal structure of native DP IV prepared from porcine kidney. The crystal structure reveals a 2-2-2 symmetric tetrameric assembly which depends on the natively glycosylated beta-propeller blade IV. The crystal structure indicates that tetramerization of DP IV is a key mechanism to regulate its interaction with other components. Each subunit comprises two structural domains, the N-terminal eight-bladed beta-propeller with open Velcro topology and the C-terminal alpha/beta-hydrolase domain. Analogy with the structurally related POP and tricorn protease suggests that substrates access the buried active site through the beta-propeller tunnel while products leave the active site through a separate side exit. A dipeptide mimicking inhibitor complexed to the active site discloses key determinants for substrate recognition, including a Glu-Glu motif that distinguishes DP IV as an aminopeptidase and an oxyanion trap that binds and activates the P(2)-carbonyl oxygen necessary for efficient postproline cleavage. We discuss active and nonactive site-directed inhibition strategies of this pharmaceutical target protein.},
  keywords = {Amino Acid Sequence Animals Binding Sites Catalysis Crystallography, X-Ray DNA, Complementary Dipeptidyl Peptidase 4/*chemistry/metabolism Molecular Sequence Data Nuclear Magnetic Resonance, Biomolecular Protease Inhibitors/pharmacology Protein Conformation Sequence Homology, Amino Acid Swine},
  issn = {0027-8424 (Print) 0027-8424 (Linking)},
  doi = {10.1073/pnas.0230620100},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/12690074 http://www.pnas.org/content/100/9/5063.full.pdf},
  year = {2003},
  type = {Journal Article},
}


@book{17570828,
  author = {Hildebrandt, M},
  title = {{Dipeptidyl aminopeptidases in health and disease}},
  publisher = {Dordrecht ; London : Kluwer Academic/Plenum},
  note = {Proceedings of the International Conference on Dipeptidyl Aminopeptidases, held September 26-28, 2002, in Berlin, Germany--T.p. verso},
  isbn = {0306477173},
  year = {2003},
  type = {Book},
}


@article{Hiramatsu:2003kk,
  author = {Hiramatsu, H. and Kyono, K. and Higashiyama, Y. and Fukushima, C. and Shima, H. and Sugiyama, S. and Inaka, K. and Yamamoto, A. and Shimizu, R.},
  title = {{The structure and function of human dipeptidyl peptidase IV, possessing a unique eight-bladed beta-propeller fold}},
  journal = {Biochem Biophys Res Commun},
  volume = {302},
  number = {4},
  pages = {849-54},
  note = {Hiramatsu, Hajime Kyono, Kiyoshi Higashiyama, Yutaka Fukushima, Chiaki Shima, Hideaki Sugiyama, Shigeru Inaka, Koji Yamamoto, Atsushi Shimizu, Ryo Biochem Biophys Res Commun. 2003 Mar 21;302(4):849-54.},
  abstract = {Dipeptidyl peptidase IV (DPPIV) is a serine protease, a member of the prolyl oligopeptidase (POP) family, and has been implicated in several diseases. Therefore, the development of DPPIV selective inhibitors, which are able to control the biological function of DPPIV, is important. We determined the crystal structure of human DPPIV at 2.6A resolution. The molecule consists of a unique eight-bladed beta-propeller domain in the N-terminal region and a serine protease domain in the C-terminal region. Also, the large cave structure, which is thought to control the access of the substrate, is found on the side of the beta-propeller fold. Comparison of the overall amino acid sequence between human DPPIV and POP shows low homology (12.9%). In this paper, we report the structure of human DPPIV, especially focusing on a unique eight-bladed beta-propeller domain. We also discuss the way for the access of the substrate to this domain.},
  keywords = {Amino Acid Sequence Catalytic Domain Dipeptidyl Peptidase 4/*chemistry/genetics Humans Models, Molecular Molecular Sequence Data *Protein Structure, Secondary Protein Structure, Tertiary Sequence Alignment Serine Endopeptidases/chemistry/genetics},
  issn = {0006-291X (Print) 0006-291X (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/12646248 http://ac.els-cdn.com/S0006291X03002584/1-s2.0-S0006291X03002584-main.pdf?_tid=4c0d1e4c-ea5c-11e4-bd4e-00000aab0f6b&acdnat=1429864466_01255f7ae12a0ad28ec8f0b8160817ec http://ac.els-cdn.com/S0006291X03002584/1-s2.0-S0006291X03002584-main.pdf?_tid=228c6c06-fbde-11e4-a164-00000aacb360&acdnat=1431789401_85344edc709aaa56db7b7b6444481dc2},
  year = {2003},
  type = {Journal Article},
}


@article{Huber:2003ee,
  author = {Huber, M. A. and Kraut, N. and Park, J. E. and Schubert, R. D. and Rettig, W. J. and Peter, R. U. and Garin-Chesa, P.},
  title = {{Fibroblast activation protein: differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors}},
  journal = {J Invest Dermatol},
  volume = {120},
  number = {2},
  pages = {182-8},
  note = {Huber, Margit A Kraut, Norbert Park, John E Schubert, Roland D Rettig, Wolfgang J Peter, Ralf U Garin-Chesa, Pilar J Invest Dermatol. 2003 Feb;120(2):182-8.},
  abstract = {Growth and metastasis of solid neoplasms require the recruitment of a supporting tumor stroma. A highly consistent trait of tumor stromal fibroblasts in most epithelial cancers is the induction of fibroblast activation protein (FAP), a member of the serine protease family. Recently it was demonstrated that FAP has both dipeptidyl peptidase and collagenolytic activity capable of degrading gelatin and type I collagen. In this study, we describe the expression and enzyme activity of FAP in benign and malignant melanocytic skin tumors. FAP-positive fibroblasts were detected immunohistochemically in the reactive stroma of all melanocytic nevi tested. In primary and metastatic melanomas an upregulation of FAP expression in the reactive mesenchyme could be observed. Whereas 30% of the nevi revealed additional FAP expression on subsets of melanocytic cells, melanoma cells from primary and metastatic melanomas were FAP negative. This may indicate a possible role for FAP in the control of tumor cell growth and proliferation during melanoma carcinogenesis. Consistent with this in vivo expression pattern FAP enzyme activity could be detected by a specific immunocapture assay in extracts of melanocytic nevi and melanoma metastases, whereas no significant activity was detectable in normal adult skin. Strong protein expression of FAP was observed in patterned structures restricted to a subset of the melanoma metastases. Our findings that these FAP-positive structures showed no overlap with endothelial cell surface markers, nor with various melanoma antigens, suggest that FAP is a marker for specific stromal-cell-derived patterns in cutaneous melanoma metastases.},
  keywords = {Antigens, Neoplasm/biosynthesis/*metabolism Fibroblasts/enzymology Gelatinases Humans Melanoma/metabolism/secondary Membrane Proteins Neoplasms/metabolism/pathology Nevus, Pigmented/*metabolism/pathology Serine Endopeptidases/biosynthesis/*metabolism Skin Neoplasms/*metabolism/pathology Stromal Cells/*enzymology Tumor Markers, Biological/biosynthesis/*metabolism},
  issn = {0022-202X (Print) 0022-202X (Linking)},
  doi = {10.1046/j.1523-1747.2003.12035.x},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/12542520 http://www.nature.com/jid/journal/v120/n2/pdf/5601729a.pdf},
  year = {2003},
  type = {Journal Article},
}


@article{Kajiyama:2003os,
  author = {Kajiyama, H. and Kikkawa, F. and Ino, K. and Shibata, K. and Mizutani, S.},
  title = {{Expression of CD26/dipeptidyl peptidase IV in endometrial adenocarcinoma and its negative correlation with tumor grade}},
  journal = {Adv Exp Med Biol},
  volume = {524},
  pages = {245-8},
  note = {Kajiyama, Hiroaki Kikkawa, Fumitaka Ino, Kazuhiko Shibata, Kiyosumi Mizutani, Shigehiko Adv Exp Med Biol. 2003;524:245-8.},
  keywords = {Adenocarcinoma/*enzymology/pathology Antigens, CD/metabolism Chemokine CCL5/metabolism Dipeptidyl Peptidase 4/*metabolism Endometrial Neoplasms/*enzymology/pathology Endometrium/*enzymology Female Humans Reference Values},
  issn = {0065-2598 (Print) 0065-2598 (Linking)},
  doi = {10.1007/0-306-47920-6_29},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/12675245 http://download-v2.springer.com/static/pdf/661/chp%253A10.1007%252F0-306-47920-6_29.pdf?token2=exp=1431790414~acl=%2Fstatic%2Fpdf%2F661%2Fchp%25253A10.1007%25252F0-306-47920-6_29.pdf*~hmac=fec0028331d1a8087db2ecb30c0e4587bd4cdb0e83f90ef320ed159abd4639da},
  year = {2003},
  type = {Journal Article},
}


@article{Lambeir:2003qf,
  author = {Lambeir, A. M. and Durinx, C. and Scharpe, S. and De Meester, I.},
  title = {{Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV}},
  journal = {Crit Rev Clin Lab Sci},
  volume = {40},
  number = {3},
  pages = {209-94},
  note = {Lambeir, Anne-Marie Durinx, Christine Scharpe, Simon De Meester, Ingrid Crit Rev Clin Lab Sci. 2003 Jun;40(3):209-94.},
  abstract = {Dipeptidyl-peptidase IV/CD26 (DPP IV) is a cell-surface protease belonging to the prolyloligopeptidase family. It selectively removes the N-terminal dipeptide from peptides with proline or alanine in the second position. Apart from its catalytic activity, it interacts with several proteins, for instance, adenosine deaminase, the HIV gp120 protein, fibronectin, collagen, the chemokine receptor CXCR4, and the tyrosine phosphatase CD45. DPP IV is expressed on a specific set of T lymphocytes, where it is up-regulated after activation. It is also expressed in a variety of tissues, primarily on endothelial and epithelial cells. A soluble form is present in plasma and other body fluids. DPP IV has been proposed as a diagnostic or prognostic marker for various tumors, hematological malignancies, immunological, inflammatory, psychoneuroendocrine disorders, and viral infections. DPP IV truncates many bioactive peptides of medical importance. It plays a role in glucose homeostasis through proteolytic inactivation of the incretins. DPP IV inhibitors improve glucose tolerance and pancreatic islet cell function in animal models of type 2 diabetes and in diabetic patients. The role of DPP IV/ CD26 within the immune system is a combination of its exopeptidase activity and its interactions with different molecules. This enables DPP IV/CD26 to serve as a co-stimulatory molecule to influence T cell activity and to modulate chemotaxis. DPP IV is also implicated in HIV-1 entry, malignant transformation, and tumor invasion.},
  keywords = {Amino Acid Sequence Animals Base Sequence Biological Markers/analysis *Dipeptidyl Peptidase 4/chemistry/physiology Disease Models, Animal Humans Molecular Sequence Data T-Lymphocytes/*enzymology},
  issn = {1040-8363 (Print) 1040-8363 (Linking)},
  doi = {10.1080/713609354},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/12892317 http://informahealthcare.com/doi/pdfplus/10.1080/713609354},
  year = {2003},
  type = {Journal Article},
}


@article{Mann2003,
  author = {Mann, M. and Jensen, O. N.},
  title = {{Proteomic analysis of post-translational modifications}},
  journal = {Nat Biotechnol},
  volume = {21},
  number = {3},
  pages = {255-61},
  note = {Mann, Matthias Jensen, Ole N Nat Biotechnol. 2003 Mar;21(3):255-61.},
  abstract = {Post-translational modifications modulate the activity of most eukaryote proteins. Analysis of these modifications presents formidable challenges but their determination generates indispensable insight into biological function. Strategies developed to characterize individual proteins are now systematically applied to protein populations. The combination of function- or structure-based purification of modified 'subproteomes', such as phosphorylated proteins or modified membrane proteins, with mass spectrometry is proving particularly successful. To map modification sites in molecular detail, novel mass spectrometric peptide sequencing and analysis technologies hold tremendous potential. Finally, stable isotope labeling strategies in combination with mass spectrometry have been applied successfully to study the dynamics of modifications.},
  keywords = {Chromatography, Liquid/methods Electrophoresis, Gel, Two-Dimensional/methods Isotope Labeling/methods Mass Spectrometry/*methods Molecular Weight Protein Conformation *Protein Processing, Post-Translational Proteins/*chemistry/genetics/isolation & purification/*metabolism Proteomics/*methods Recombinant Proteins/genetics/isolation & purification/metabolism Sequence Analysis, Protein/methods},
  issn = {1087-0156 (Print) 1087-0156 (Linking)},
  doi = {10.1038/nbt0303-255},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/12610572 http://www.nature.com/nbt/journal/v21/n3/pdf/nbt0303-255.pdf},
  year = {2003},
  type = {Journal Article},
}


@article{Nisse:2003cs,
  author = {Nisse, P. and Mathieu-Nolf, M. and Deveaux, M. and Forceville, X. and Combes, A.},
  title = {{A fatal case of metformin poisoning}},
  journal = {J Toxicol Clin Toxicol},
  volume = {41},
  number = {7},
  pages = {1035-6},
  note = {Nisse, Patrick Mathieu-Nolf, Monique Deveaux, Marc Forceville, Xavier Combes, Alain J Toxicol Clin Toxicol. 2003;41(7):1035-6.},
  keywords = {Adult Drug Overdose/blood/therapy Fatal Outcome Humans Male Metformin/blood/*poisoning},
  issn = {0731-3810 (Print) 0731-3810 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/14705855},
  year = {2003},
  type = {Journal Article},
}


@article{Puente2003,
  author = {Puente, X. S. and Sanchez, L. M. and Overall, C. M. and Lopez-Otin, C.},
  title = {{Human and mouse proteases: a comparative genomic approach}},
  journal = {Nat Rev Genet},
  volume = {4},
  number = {7},
  pages = {544-58},
  note = {Puente, Xose S Sanchez, Luis M Overall, Christopher M Lopez-Otin, Carlos England Nat Rev Genet. 2003 Jul;4(7):544-58.},
  abstract = {The availability of the human and mouse genome sequences has allowed the identification and comparison of their respective degradomes--the complete repertoire of proteases that are produced by these organisms. Because of the essential roles of proteolytic enzymes in the control of cell behaviour, survival and death, degradome analysis provides a useful framework for the global exploration of these protease-mediated functions in normal and pathological conditions.},
  keywords = {Animals Computational Biology *Databases, Factual Endopeptidases/chemistry/*genetics/metabolism *Genome Humans Models, Genetic},
  issn = {1471-0056 (Print) 1471-0056 (Linking)},
  doi = {10.1038/nrg1111},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/12838346},
  year = {2003},
  type = {Journal Article},
}


@article{Rasmussen:2003wq,
  author = {Rasmussen, H. B. and Branner, S. and Wiberg, F. C. and Wagtmann, N.},
  title = {{Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog}},
  journal = {Nat Struct Biol},
  volume = {10},
  number = {1},
  pages = {19-25},
  note = {Rasmussen, Hanne B Branner, Sven Wiberg, Finn C Wagtmann, Nicolai Nat Struct Biol. 2003 Jan;10(1):19-25.},
  abstract = {Dipeptidyl peptidase IV (DPP-IV/CD26) is a multifunctional type II transmembrane serine peptidase. This enzyme contributes to the regulation of various physiological processes, including blood sugar homeostasis, by cleaving peptide hormones, chemokines and neuropeptides. We have determined the 2.5 A structure of the extracellular region of DPP-IV in complex with the inhibitor valine-pyrrolidide. The catalytic site is located in a large cavity formed between the alpha/beta-hydrolase domain and an eight-bladed beta-propeller domain. Both domains participate in inhibitor binding. The structure indicates how substrate specificity is achieved and reveals a new and unexpected opening to the active site.},
  keywords = {Binding Sites Catalysis Catalytic Domain Crystallography, X-Ray/methods Dipeptidyl Peptidase 4/*chemistry/*metabolism Humans Models, Molecular Protein Structure, Tertiary Substrate Specificity},
  issn = {1072-8368 (Print) 1072-8368 (Linking)},
  doi = {10.1038/nsb882},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/12483204 http://www.nature.com/nsmb/journal/v10/n1/pdf/nsb882.pdf},
  year = {2003},
  type = {Journal Article},
}


@article{Rowe2003,
  author = {Rowe, A. and Kalaitzopoulos, D. and Osmond, M. and Ghanem, M. and Guo, Y.},
  title = {{The discovery net system for high throughput bioinformatics}},
  journal = {Bioinformatics},
  volume = {19 Suppl 1},
  number = {suppl 1},
  pages = {i225-31},
  note = {Rowe, Anthony Kalaitzopoulos, Dimitrios Osmond, Michelle Ghanem, Moustafa Guo, Yike England Oxford, England Bioinformatics. 2003;19 Suppl 1:i225-31.},
  abstract = {MOTIVATION: Bioinformatics requires Grid technologies and protocols to build high performance applications without focusing on the low level detail of how the individual Grid components operate. RESULTS: The Discovery Net system is a middleware that allows service developers to integrate tools based on existing and emerging Grid standards such as web services. Once integrated, these tools can be used to compose reusable workflows using these services that can later be deployed as new services for others to use. Using the Discovery Net system and a range of different bioinformatics tools, we built a Grid based application for Genome Annotation. This includes workflows for automatic nucleotide annotation, annotation of predicted proteins and text analysis based on metabolic profiles and text analysis.},
  keywords = {Algorithms Computational Biology/*methods *Computing Methodologies *Databases, Bibliographic *Databases, Genetic Documentation Information Storage and Retrieval/*methods Internet Natural Language Processing Periodicals as Topic *Software *Software Design},
  issn = {1367-4803 (Print) 1367-4803 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/12855463 http://bioinformatics.oxfordjournals.org/content/19/suppl_1/i225.full.pdf},
  year = {2003},
  type = {Journal Article},
}


@article{Sakurada:2003aa,
  author = {Sakurada, C. and Sakurada, S. and Hayashi, T. and Katsuyama, S. and Tan-No, K. and Sakurada, T.},
  title = {{Degradation of endomorphin-2 at the supraspinal level in mice is initiated by dipeptidyl peptidase IV: an in vitro and in vivo study}},
  journal = {Biochemical Pharmacology},
  volume = {66},
  number = {4},
  pages = {653-661},
  note = {713VW Times Cited:34 Cited References Count:28},
  abstract = {Endomorphin-2 (Tyr-Pro-Phe-PheNH(2)) was discovered as an endogenous ligand for the mu-opioid receptor. The physiological function of endomorphin-2 as a neurotransmitter or neuromodulator may cease through the rapid enzymatic process in the synapse of brain, as for other neuropeptides. The present study was conducted to examine the metabolism of endomorphin-2 by synaptic membranes prepared from mouse brain. Major metabolites were free tyrosine, free phenylalanine, Tyr-Pro and PheNH(2). Both the degradation of endomorphin-2 and the accumulation of major metabolites were inhibited by specific inhibitors of dipeptidyl peptidase IV, such as diprotin A and B. On the other hand, the accumulation of Phe-PheNH(2) and Pro-Phe-PheNH(2) was increased in the presence of bestatin, an aminopeptidase inhibitor, whereas that of free phenylalanine and PheNH(2), was decreased. Furthermore, purified dipeptidyl peptidase IV hydrolyzed endomorphin-2 at the cleavage site, Pro(2)-Phe(3) bond. Thus, degradation of endomorphin-2 by brain synaptic membranes seems to take place mainly through the cleavage of Pro(2)-Phe(3) bond by dipeptidyl peptidase IV, followed by release of free phenylalanine and PheNH(2) from the liberated fragment, Phe-PheNH, by aminopeptidase. We have also examined that the effect of diprotin A on the antinociception induced by intracerebroventricularly administered endomorphin-2 in the mouse paw withdrawal test. Diprotin A simultaneously injected with endomorphin-2 enhanced endomorphin-2-induced antinociception. These results indicate that dipeptidyl peptidase IV may be an important peptidase responsible for terminating endomorphin-2-induced antinociception at the supraspinal level in mice. (C) 2003 Elsevier Inc. All rights reserved.},
  keywords = {antinociception dipeptidyl peptidase iv endomorphin-2 metabolic pathway mouse brain synaptic membranes mu-opioid receptor rat-brain antinociception identification inactivation enkephalins mouse cns},
  issn = {0006-2952},
  doi = {Doi 10.1016/S0006-2952(03)00391-5},
  url = {<Go to ISI>://000184879500013 http://ac.els-cdn.com/S0006295203003915/1-s2.0-S0006295203003915-main.pdf?_tid=de75850e-ea5b-11e4-9dd3-00000aacb35e&acdnat=1429864282_70393e9eaf183c10124f09f12fb2343c http://ac.els-cdn.com/S0006295203003915/1-s2.0-S0006295203003915-main.pdf?_tid=324c32c0-fbde-11e4-98b7-00000aab0f6c&acdnat=1431789427_95eda23d0e0faebc0b6e07816c31a12f},
  year = {2003},
  type = {Journal Article},
}


@article{Sickmann2003,
  author = {Sickmann, A. and Mreyen, M. and Meyer, H. E.},
  title = {{Mass spectrometry--a key technology in proteome research}},
  journal = {Adv Biochem Eng Biotechnol},
  volume = {83},
  pages = {141-76},
  note = {Sickmann, Albert Mreyen, Marcus Meyer, Helmut E Germany Adv Biochem Eng Biotechnol. 2003;83:141-76.},
  abstract = {The rapid developments in the field of mass spectrometry have transformed it into a key technology in proteome research. Increased sensitivity in mass spectrometry, as a result of more efficient ionisation techniques and better detectors, has allowed the stepwise reduction of protein quantity for analysis. Protein spots of 2D-PAGE separated samples are now quantitatively sufficient for an unequivocal identification of a protein by mass spectrometry. In addition to protein identification a closer look at posttranslational modifications is now also possible. It is speculated that modifications like phosphorylation or glycosylation exist on every second protein and that they are important for the protein function. This review highlights the different mass spectrometric methods and gives a brief overview of strategies and methods used to identify modifications.},
  keywords = {Amino Acid Sequence Glycolysis Mass Spectrometry/instrumentation/*methods/trends Molecular Sequence Data Phosphorylation *Protein Processing, Post-Translational Proteome/*analysis/*chemistry/metabolism Sequence Analysis, Protein/*methods Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/instrumentation/methods},
  issn = {0724-6145 (Print) 0724-6145 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/12934929},
  year = {2003},
  type = {Journal Article},
}


@article{Thoma:2003le,
  author = {Thoma, R. and Loffler, B. and Stihle, M. and Huber, W. and Ruf, A. and Hennig, M.},
  title = {{Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV}},
  journal = {Structure},
  volume = {11},
  number = {8},
  pages = {947-959},
  note = {711NF Times Cited:108 Cited References Count:71},
  abstract = {Inhibition of dipeptidyl peptidase IV (DPP-IV), the main glucagon-like peptide I (GLP1)-degrading enzyme, has been proposed for the treatment of type 11 diabetes. We expressed and purified the ectodomain of human DPP-IV in Pichia pastoris and determined the X-ray structure at 2.1 Angstrom resolution. The enzyme consists of two domains, the catalytic domain, with an alpha/beta hydrolase fold, and a beta propeller domain with an 8-fold repeat of a four-strand beta sheet motif. The beta propeller domain contributes two important functions to the molecule that have not been reported for such structures, an extra beta sheet motif that forms part of the dimerization interface and an additional short helix with a double Glu sequence motif. The Glu motif provides recognition and a binding site for the N terminus of the substrates, as revealed by the complex structure with diprotin A, a substrate with low turnover that is trapped in the tetrahedral intermediate of the reaction in the crystal.},
  keywords = {beta-propeller domain t-cell-activation amino-acid-sequence adenosine-deaminase prolyl oligopeptidase thermotoga-maritima crystal-structure binding cd26 protein},
  issn = {0969-2126},
  doi = {Doi 10.1016/S0969-2126(03)00160-6},
  url = {<Go to ISI>://000184747400009 http://ac.els-cdn.com/S0969212603001606/1-s2.0-S0969212603001606-main.pdf?_tid=d2b21a5c-ea5b-11e4-a73e-00000aab0f6c&acdnat=1429864262_6942260bf62637d4bb4c1ed4cd5d4caa http://ac.els-cdn.com/S0969212603001606/1-s2.0-S0969212603001606-main.pdf?_tid=44cb0aa2-fbde-11e4-91d0-00000aab0f26&acdnat=1431789458_52d568693f9bbccf96f5d32e40a6bf4b},
  year = {2003},
  type = {Journal Article},
}


@article{Aertgeerts:2004aa,
  author = {Aertgeerts, K. and Ye, S. and Tennant, M. G. and Kraus, M. L. and Rogers, J. and Sang, B. C. and Skene, R. J. and Webb, D. R. and Prasad, G. S.},
  title = {{Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation}},
  journal = {Protein Sci},
  volume = {13},
  number = {2},
  pages = {412-21},
  note = {Aertgeerts, Kathleen Ye, Sheng Tennant, Mike G Kraus, Michelle L Rogers, Joe Sang, Bi-Ching Skene, Robert J Webb, David R Prasad, G Sridhar Protein Sci. 2004 Feb;13(2):412-21. Epub 2004 Jan 10.},
  abstract = {Dipeptidyl peptidase IV (DPPIV) is a member of the prolyl oligopeptidase family of serine proteases. DPPIV removes dipeptides from the N terminus of substrates, including many chemokines, neuropeptides, and peptide hormones. Specific inhibition of DPPIV is being investigated in human trials for the treatment of type II diabetes. To understand better the molecular determinants that underlie enzyme catalysis and substrate specificity, we report the crystal structures of DPPIV in the free form and in complex with the first 10 residues of the physiological substrate, Neuropeptide Y (residues 1-10; tNPY). The crystal structure of the free form of the enzyme reveals two potential channels through which substrates could access the active site-a so-called propeller opening, and side opening. The crystal structure of the DPPIV/tNPY complex suggests that bioactive peptides utilize the side opening unique to DPPIV to access the active site. Other structural features in the active site such as the presence of a Glu motif, a well-defined hydrophobic S1 subsite, and minimal long-range interactions explain the substrate recognition and binding properties of DPPIV. Moreover, in the DPPIV/tNPY complex structure, the peptide is not cleaved but trapped in a tetrahedral intermediate that occurs during catalysis. Conformational changes of S630 and H740 between DPPIV in its free form and in complex with tNPY were observed and contribute to the stabilization of the tetrahedral intermediate. Our results facilitate the design of potent, selective small molecule inhibitors of DPPIV that may yield compounds for the development of novel drugs to treat type II diabetes.},
  keywords = {Animals Binding Sites Catalytic Domain Cells, Cultured Crystallization Crystallography, X-Ray Dipeptidyl Peptidase 4/*chemistry/*metabolism Humans Insects Models, Molecular Neuropeptide Y/*chemistry Oligopeptides/*chemistry/*metabolism Protein Structure, Tertiary Substrate Specificity},
  issn = {0961-8368 (Print) 0961-8368 (Linking)},
  doi = {10.1110/ps.03460604},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/14718659 http://onlinelibrary.wiley.com/store/10.1110/ps.03460604/asset/130412_ftp.pdf?v=1&t=i8vcd8e2&s=9f216a0f781fb0ef03dbdabba17a575b9c4ce879 http://onlinelibrary.wiley.com/store/10.1110/ps.03460604/asset/130412_ftp.pdf?v=1&t=i9r6d4n2&s=6ddf9ed463a90c3754b0b486526e97f456cf3020 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2286704/pdf/0130412.pdf},
  year = {2004},
  type = {Journal Article},
}


@article{Ajami:2004qq,
  author = {Ajami, K. and Abbott, C. A. and McCaughan, G. W. and Gorrell, M. D.},
  title = {{Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity}},
  journal = {Biochim Biophys Acta},
  volume = {1679},
  number = {1},
  pages = {18-28},
  note = {Ajami, Katerina Abbott, Catherine A McCaughan, Geoffrey W Gorrell, Mark D Netherlands Biochim Biophys Acta. 2004 Jul 13;1679(1):18-28.},
  abstract = {Dipeptidyl peptidase (DP) IV has a distinct substrate specificity in hydrolyzing a post-proline bond. Here we present novel data on the sizes and tissue distribution of human and rat gene products and the peptidase activity of the DPIV-related gene DP9. A short cDNA of 2589 bp and a long cDNA of 3006 bp of DP9 were cloned. A ubiquitous predominant DP9 mRNA transcript at 4.4 kb represented the short form, whereas a less abundant 5.0-kb transcript present predominantly in muscle represented the long form. Both forms of DP9 have no transmembrane domain and two potential N-linked glycosylation sites. DP9 exhibited post-proline dipeptidyl aminopeptidase activity and was a cytoplasmic, 110-kDa monomer. Thus, the six DPIV gene family members have diverse characteristics: only DP9 and DP8 have exclusively cytoplasmic localization and only DP9, DP8, fibroblast activation protein (FAP) and DPIV have peptidase activity.},
  keywords = {Adenosine Deaminase/*metabolism Alternative Splicing Amino Acid Sequence Animals Base Sequence Cell Line Cloning, Molecular Cytoplasm/*metabolism DNA Primers *Dipeptidyl Peptidase 4 Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/chemistry/genetics/*metabolism Glycoproteins/*metabolism Humans Molecular Sequence Data Rats Sequence Homology, Amino Acid},
  issn = {0006-3002 (Print) 0006-3002 (Linking)},
  doi = {10.1016/j.bbaexp.2004.03.010},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/15245913 http://ac.els-cdn.com/S0167478104000788/1-s2.0-S0167478104000788-main.pdf?_tid=491d48ae-fbde-11e4-b779-00000aab0f6b&acdnat=1431789465_5eb29550bc4adb3e5fde33fe40e94c2f},
  year = {2004},
  type = {Journal Article},
}


@article{Chen:2004dw,
  author = {Chen, Y. S. and Chien, C. H. and Goparaju, C. M. and Hsu, J. T. and Liang, P. H. and Chen, X.},
  title = {{Purification and characterization of human prolyl dipeptidase DPP8 in Sf9 insect cells}},
  journal = {Protein Expr Purif},
  volume = {35},
  number = {1},
  pages = {142-6},
  note = {Chen, Yuan-Shou Chien, Chia-Hui Goparaju, Chandra M Hsu, John Tsu-An Liang, Po-Huang Chen, Xin Protein Expr Purif. 2004 May;35(1):142-6.},
  abstract = {DPP8 is a new member of the prolyl dipeptidases, many of which have important biological functions in vivo. DPP8 catalyzes the cleavage at the carboxyl side of the proline residue at the penultimate position. To study its structure and biochemical properties, we have overexpressed the human DPP8 protein in baculovirus infected Sf9 cells. The protein is soluble and can be purified to homogeneity. Using the chromogenic H-Gly-Pro-pNA as the substrate, a kinetic study shows that purified DPP8 is active and has a similar kcat value as that of DPP-IV, a prolyl dipeptidase that is a drug target for type II diabetes. The kinetic constants of DPP8 are also determined for other chromogenic substrates, and the results indicate that DPP8 has substrate preference at both the P1 and P2 sites. The expression system provides means of better understanding the structure, catalytic mechanism, and biological function of DPP8 protein.},
  keywords = {Animals Baculoviridae/genetics/metabolism Cell Line Dipeptidases/genetics/*isolation & purification/*metabolism Humans Insects Peptides/metabolism},
  issn = {1046-5928 (Print) 1046-5928 (Linking)},
  doi = {10.1016/j.pep.2003.12.019},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/15039077 http://ac.els-cdn.com/S1046592804000312/1-s2.0-S1046592804000312-main.pdf?_tid=84cc1a8a-ea5c-11e4-9af7-00000aab0f6c&acdnat=1429864561_bd488c28db02dbab58da63f1fbbcc7b1 http://ac.els-cdn.com/S1046592804000312/1-s2.0-S1046592804000312-main.pdf?_tid=35b5df2e-fbde-11e4-a5d5-00000aab0f27&acdnat=1431789433_f7958e6b1239384ae81bdde138a65aef},
  year = {2004},
  type = {Journal Article},
}


@article{Cohen:2004aa,
  author = {Cohen, M. and Fruitier-Arnaudin, I. and Piot, J. M.},
  title = {{Hemorphins: substrates and/or inhibitors of dipeptidyl peptidase IV. Hemorphins N-terminus sequence influence on the interaction between hemorphins and DPPIV}},
  journal = {Biochimie},
  volume = {86},
  number = {1},
  pages = {31-7},
  note = {Cohen, M Fruitier-Arnaudin, I Piot, J M France Biochimie. 2004 Jan;86(1):31-7.},
  abstract = {Hemorphins are endogenous peptides belonging to the family of atypical opioid peptides released from sequentially hydrolyzed hemoglobin. In this paper, we report an inhibitory effect of these peptides on dipeptidyl peptidase IV (DPPIV) activity, known to be involved in regulatory functions such as the activation or inactivation of peptides. The structure activity research revealed that hemorphins N-terminus sequence influences nature of the interaction between hemorphins and DPPIV. Kinetic studies conducted with purified DPPIV demonstrated that hemorphin-7 (H7) constitutes a good substrate (K(cat)/K(m) of 137 mM(-1) s(-1)) for this enzyme but could also act as a selective competitive inhibitor by substrate binding site competition. These blood-derived peptides could represent endogenous regulators of this enzyme activity.},
  keywords = {Animals Dipeptidyl Peptidase 4/chemistry/*metabolism Enzyme Activation/drug effects Enzyme Inhibitors/metabolism/pharmacology Hemoglobins/chemistry/*metabolism/pharmacology Kidney/*enzymology Male Microsomes/*enzymology Peptide Fragments/metabolism/pharmacology Protein Binding Rats Rats, Wistar Substrate Specificity},
  issn = {0300-9084 (Print) 0300-9084 (Linking)},
  doi = {10.1016/j.biochi.2003.11.001},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/14987798 http://ac.els-cdn.com/S0300908403002098/1-s2.0-S0300908403002098-main.pdf?_tid=81b36204-ea5c-11e4-a7cc-00000aacb35d&acdnat=1429864556_ac7e9ff2257fb336812473748d745d06 http://ac.els-cdn.com/S0300908403002098/1-s2.0-S0300908403002098-main.pdf?_tid=39257af2-fbde-11e4-9152-00000aacb35d&acdnat=1431789438_ec1111ca18cba0b50b284f326c828381},
  year = {2004},
  type = {Journal Article},
}


@article{Crooks2004,
  author = {Crooks, G. E. and Hon, G. and Chandonia, J. M. and Brenner, S. E.},
  title = {{WebLogo: a sequence logo generator}},
  journal = {Genome Res},
  volume = {14},
  number = {6},
  pages = {1188-90},
  note = {Crooks, Gavin E Hon, Gary Chandonia, John-Marc Brenner, Steven E 1-K22-HG00056/HG/NHGRI NIH HHS/ 1-P50-GM62412/GM/NIGMS NIH HHS/ Genome Res. 2004 Jun;14(6):1188-90.},
  abstract = {WebLogo generates sequence logos, graphical representations of the patterns within a multiple sequence alignment. Sequence logos provide a richer and more precise description of sequence similarity than consensus sequences and can rapidly reveal significant features of the alignment otherwise difficult to perceive. Each logo consists of stacks of letters, one stack for each position in the sequence. The overall height of each stack indicates the sequence conservation at that position (measured in bits), whereas the height of symbols within the stack reflects the relative frequency of the corresponding amino or nucleic acid at that position. WebLogo has been enhanced recently with additional features and options, to provide a convenient and highly configurable sequence logo generator. A command line interface and the complete, open WebLogo source code are available for local installation and customization.},
  keywords = {*Amino Acid Sequence *Base Sequence *Computer Graphics Cyclic AMP Receptor Protein/chemistry DNA, Bacterial/chemistry Escherichia coli Proteins/chemistry *Internet Nucleic Acid Conformation Protein Structure, Quaternary *Software},
  issn = {1088-9051 (Print) 1088-9051 (Linking)},
  doi = {10.1101/gr.849004},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/15173120 http://genome.cshlp.org/content/14/6/1188.full.pdf},
  year = {2004},
  type = {Journal Article},
}


@article{Pollak:2004aa,
  author = {Pollak, M. N. and Schernhammer, E. S. and Hankinson, S. E.},
  title = {{Insulin-like growth factors and neoplasia}},
  journal = {Nat Rev Cancer},
  volume = {4},
  number = {7},
  pages = {505-18},
  note = {Pollak, Michael N Schernhammer, Eva S Hankinson, Susan E England Nat Rev Cancer. 2004 Jul;4(7):505-18.},
  keywords = {Aging/physiology Animals Apoptosis Cell Division Cell Transformation, Neoplastic Clinical Trials as Topic Disease Susceptibility Energy Metabolism Homeostasis Humans Insulin Resistance/physiology Insulin-Like Growth Factor Binding Proteins/physiology Life Style Longevity/physiology Mice Models, Biological Neoplasms/drug therapy/epidemiology/*metabolism Receptors, Somatomedin/antagonists & inhibitors/physiology Risk Factors Signal Transduction Somatomedins/antagonists & inhibitors/*physiology Somatostatin/analogs & derivatives/therapeutic use},
  issn = {1474-175X (Print) 1474-175X (Linking)},
  doi = {10.1038/nrc1387},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/15229476},
  year = {2004},
  type = {Journal Article},
}


@article{Ramirez-Montagut:2004xw,
  author = {Ramirez-Montagut, T. and Blachere, N. E. and Sviderskaya, E. V. and Bennett, D. C. and Rettig, W. J. and Garin-Chesa, P. and Houghton, A. N.},
  title = {{FAPalpha, a surface peptidase expressed during wound healing, is a tumor suppressor}},
  journal = {Oncogene},
  volume = {23},
  number = {32},
  pages = {5435-46},
  note = {Ramirez-Montagut, Teresa Blachere, Nathalie E Sviderskaya, Elena V Bennett, Dorothy C Rettig, Wolfgang J Garin-Chesa, Pilar Houghton, Alan N England Oncogene. 2004 Jul 15;23(32):5435-46.},
  abstract = {Fibroblast activation protein-alpha (FAP) is a cell surface serine protease expressed at sites of tissue remodeling in embryonic development. FAP is not expressed by mature somatic tissues except activated melanocytes and fibroblasts in wound healing or tumor stroma. FAP expression is specifically silenced in proliferating melanocytic cells during malignant transformation. To study the role of FAP as a tumor suppressor, the gene for mouse fap was cloned and mutated at the catalytic domain (FAP serine mutant, FSM). We found that expression of FAP or FSM at physiologic levels in mouse melanoma cells abrogated tumorigenicity. Remarkably, the mutant form FSM lacking specific serine protease activity was a more potent tumor suppressor. Tumor rejection was not due to adaptive immune responses because RAG1-/- mice challenged with melanoma cells expressing either FAP or FSM were not tumorigenic. In in vitro assays, FAP or FSM expression restored contact inhibition, led to cell cycle arrest at G0/G1 phase, and increased susceptibility to stress-induced apoptosis. Cell death in FAP+ or FSM+ melanoma cells was readily triggered by depletion of survival factors from the media, leading to subsequent activation of caspases via the intrinsic pathway. These results show that expression of FAP is a tumor suppressor that abrogates tumorigenicity through regulation of cell growth and survival.},
  keywords = {Animals Apoptosis/genetics/physiology Cell Cycle/genetics/physiology Contact Inhibition/genetics/physiology Dipeptidyl Peptidase 4/genetics/metabolism Gelatinases/genetics/*metabolism Melanocytes/*metabolism Melanoma/*metabolism Membrane Proteins/genetics/*metabolism Mice Mutation Serine/genetics/metabolism Serine Endopeptidases/genetics/*metabolism Transfection Tumor Suppressor Proteins/*metabolism Wound Healing/genetics},
  issn = {0950-9232 (Print) 0950-9232 (Linking)},
  doi = {10.1038/sj.onc.1207730},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/15133496 http://www.nature.com/onc/journal/v23/n32/pdf/1207730a.pdf},
  year = {2004},
  type = {Journal Article},
}


@article{Strop:2004la,
  author = {Strop, P. and Bankovich, A. J. and Hansen, K. C. and Garcia, K. C. and Brunger, A. T.},
  title = {{Structure of a human A-type potassium channel interacting protein DPPX, a member of the dipeptidyl aminopeptidase family}},
  journal = {J Mol Biol},
  volume = {343},
  number = {4},
  pages = {1055-65},
  note = {Strop, Pavel Bankovich, Alexander J Hansen, Kirk C Garcia, K Christopher Brunger, Axel T England J Mol Biol. 2004 Oct 29;343(4):1055-65.},
  abstract = {It has recently been reported that dipeptidyl aminopeptidase X (DPPX) interacts with the voltage-gated potassium channel Kv4 and that co-expression of DPPX together with Kv4 pore forming alpha-subunits, and potassium channel interacting proteins (KChIPs), reconstitutes properties of native A-type potassium channels in vitro. Here we report the X-ray crystal structure of the extracellular domain of human DPPX determined at 3.0A resolution. This structure reveals the potential for a surface electrostatic change based on the protonation state of histidine. Subtle changes in extracellular pH might modulate the interaction of DPPX with Kv4.2 and possibly with other proteins. We propose models of DPPX interaction with the voltage-gated potassium channel complex. The dimeric structure of DPPX is highly homologous to the related protein DPP-IV. Comparison of the active sites of DPPX and DPP-IV reveals loss of the catalytic serine residue but the presence of an additional serine near the active site. However, the arrangement of residues is inconsistent with that of canonical serine proteases and DPPX is unlikely to function as a protease (dipeptidyl aminopeptidase).},
  keywords = {Alternative Splicing Catalytic Domain Cystine/chemistry/genetics/metabolism Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/*chemistry/metabolism Glycosylation Humans Isoenzymes/chemistry/metabolism Potassium Channels, Voltage-Gated/*metabolism Protein Structure, Quaternary Protein Structure, Tertiary Shal Potassium Channels Static Electricity},
  issn = {0022-2836 (Print) 0022-2836 (Linking)},
  doi = {10.1016/j.jmb.2004.09.003},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/15476821 http://ac.els-cdn.com/S0022283604011179/1-s2.0-S0022283604011179-main.pdf?_tid=4c85ef64-fbde-11e4-bd75-00000aab0f02&acdnat=1431789471_2dc788bd3ed177c5d5d5b49ad17c7ced},
  year = {2004},
  type = {Journal Article},
}


@inbook{Tatemoto2004,
  author = {Tatemoto, K.},
  title = {{Neuropeptide Y: History and Overview}},
  booktitle = {Neuropeptide Y and Related Peptides},
  editor = {Michel, Martin C.},
  publisher = {Springer Berlin Heidelberg},
  address = {Berlin, Heidelberg},
  pages = {1-21},
  isbn = {978-3-642-18764-3},
  doi = {10.1007/978-3-642-18764-3_1},
  url = {http://dx.doi.org/10.1007/978-3-642-18764-3_1 http://download.springer.com/static/pdf/371/chp%253A10.1007%252F978-3-642-18764-3_1.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Fchapter%2F10.1007%2F978-3-642-18764-3_1&token2=exp=1472190900~acl=%2Fstatic%2Fpdf%2F371%2Fchp%25253A10.1007%25252F978-3-642-18764-3_1.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Fchapter%252F10.1007%252F978-3-642-18764-3_1*~hmac=00895707a5f616639f28de183ae798b906181d20ad24491572d6a16846bab282},
  year = {2004},
  type = {Book Section},
}


@article{Wesley:2004kl,
  author = {Wesley, U. V. and Tiwari, S. and Houghton, A. N.},
  title = {{Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells}},
  journal = {Int J Cancer},
  volume = {109},
  number = {6},
  pages = {855-66},
  note = {Wesley, Umadevi V Tiwari, Shakuntala Houghton, Alan N Int J Cancer. 2004 May 10;109(6):855-66.},
  abstract = {Lung cancer is the leading cause of cancer death. Lung cancers produce a variety of mitogenic growth factors that stimulate tumor cell proliferation and migration. The cell surface protease, dipeptidyl peptidase IV (DPPIV), is involved in diverse biologic functions, including peptide-mediated cellular growth and differentiation. DPPIV is expressed in various normal tissues, including lung tissue, and its expression is lost in many types of human cancers. DPPIV expression and its enzymatic activity are detected in normal bronchial and alveolar epithelium but different histologic subtypes of lung carcinomas lose DPPIV expression. To investigate the role of DPPIV in lung carcinoma, we examined the expression of DPPIV at both mRNA and protein levels in non small cell lung cancer (NSCLC) cell lines and normal human bronchial epithelial cells. DPPIV expression was detectable in normal lung epithelial cells, but was absent or markedly reduced in all NSCLC cell lines at both mRNA and protein levels. Restoration of DPPIV expression in NSCLC cells resulted in profound morphologic changes, inhibition of cell proliferation, anchorage-independent growth, in vitro cell migration and tumorigenicity in nude mice. DPPIV reexpression also correlated with increased p21 expression, leading to induction of apoptosis and cell cycle arrest in G1 stage. These effects were accompanied by increased expression of cell surface proteins, fibroblast-activating protein (Fapalpha) and CD44 that are associated with suppression of tumor growth and metastasis. Thus, DPPIV functions as a tumor suppressor, and its downregulation may contribute to the loss of growth control in NSCLC cells.},
  keywords = {Animals Antigens, CD44/metabolism Apoptosis Carcinoma, Non-Small-Cell Lung/*enzymology/pathology Cell Adhesion Cell Movement Cyclin-Dependent Kinase Inhibitor p21 Cyclins/metabolism Dipeptidyl Peptidase 4/*genetics/*metabolism Down-Regulation *Gelatinases Gene Expression Profiling Gene Expression Regulation, Enzymologic/*physiology Humans In Situ Nick-End Labeling Lung Neoplasms/*enzymology/pathology Membrane Proteins/metabolism Mice Mice, Inbred BALB C Mice, Nude Mutation Oligonucleotide Array Sequence Analysis RNA, Messenger/metabolism Serine Endopeptidases/metabolism Tumor Cells, Cultured},
  issn = {0020-7136 (Print) 0020-7136 (Linking)},
  doi = {10.1002/ijc.20091},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/15027119 http://onlinelibrary.wiley.com/store/10.1002/ijc.20091/asset/20091_ftp.pdf?v=1&t=i9r6dr48&s=7196a46962a75549967d4895c994fe4eda501d45},
  year = {2004},
  type = {Journal Article},
}


@article{Aertgeerts:2005qo,
  author = {Aertgeerts, K. and Levin, I. and Shi, L. and Snell, G. P. and Jennings, A. and Prasad, G. S. and Zhang, Y. and Kraus, M. L. and Salakian, S. and Sridhar, V. and Wijnands, R. and Tennant, M. G.},
  title = {{Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha}},
  journal = {J Biol Chem},
  volume = {280},
  number = {20},
  pages = {19441-4},
  note = {Aertgeerts, Kathleen Levin, Irena Shi, Lihong Snell, Gyorgy P Jennings, Andy Prasad, G Sridhar Zhang, Yanming Kraus, Michelle L Salakian, Shant Sridhar, Vandana Wijnands, Robert Tennant, Mike G J Biol Chem. 2005 May 20;280(20):19441-4. Epub 2005 Apr 4.},
  abstract = {Fibroblast activation protein alpha (FAPalpha) is highly expressed in epithelial cancers and has been implicated in extracellular matrix remodeling, tumor growth, and metastasis. We present the first high resolution structure for the apoenzyme as well as kinetic data toward small dipeptide substrates. FAPalpha exhibits a dipeptidyl peptidase IV (DPPIV)-like fold, featuring an alpha/beta-hydrolase domain and an eight-bladed beta-propeller domain. Known DPPIV dipeptides are cleaved by FAPalpha with an approximately 100-fold decrease in catalytic efficiency compared with DPPIV. Moreover, FAPalpha, but not DPPIV, possesses endopeptidase activity toward N-terminal benzyloxycarbonyl (Z)-blocked peptides. Comparison of the crystal structures of FAPalpha and DPPIV revealed one major difference in the vicinity of the Glu motif (Glu(203)-Glu(204) for FAPalpha; Glu(205)-Glu(206) for DPPIV) within the active site of the enzyme. Ala(657) in FAPalpha, instead of Asp(663) as in DP-PIV, reduces the acidity in this pocket, and this change could explain the lower affinity for N-terminal amines by FAPalpha. This hypothesis was tested by kinetic analysis of the mutant FAPalpha/A657D, which shows on average an approximately 60-fold increase in the catalytic efficiency, as measured by k(cat)/K(m), for the cleavage of dipeptide substrates. Furthermore, the catalytic efficiency of the mutant is reduced by approximately 350-fold for cleavage of Z-Gly-Pro-7-amino-4-methylcoumarin. Our data provide a clear understanding of the molecular determinants responsible for the substrate specificity and endopeptidase activity of FAPalpha.},
  keywords = {Amino Acid Motifs Catalytic Domain/genetics Crystallography, X-Ray Dipeptides/chemistry/metabolism Dipeptidyl Peptidase 4/chemistry/genetics/metabolism Fluorescent Dyes Gelatinases/chemistry/genetics/*metabolism Humans Kinetics Membrane Proteins/chemistry/genetics/*metabolism Models, Molecular Mutagenesis, Site-Directed Protein Conformation Protein Structure, Tertiary Recombinant Proteins/chemistry/genetics/metabolism Serine Endopeptidases/chemistry/genetics/*metabolism Substrate Specificity},
  issn = {0021-9258 (Print) 0021-9258 (Linking)},
  doi = {10.1074/jbc.C500092200},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/15809306 http://www.jbc.org/content/280/20/19441.full.pdf},
  year = {2005},
  type = {Journal Article},
}


@article{Boyd:2005aa,
  author = {Boyd, S. E. and Pike, R. N. and Rudy, G. B. and Whisstock, J. C. and Garcia de la Banda, M.},
  title = {{PoPS: a computational tool for modeling and predicting protease specificity}},
  journal = {J Bioinform Comput Biol},
  volume = {3},
  number = {3},
  pages = {551-85},
  note = {Boyd, Sarah E Pike, Robert N Rudy, George B Whisstock, James C Garcia de la Banda, Maria England J Bioinform Comput Biol. 2005 Jun;3(3):551-85.},
  abstract = {Proteases play a fundamental role in the control of intra- and extra-cellular processes by binding and cleaving specific amino acid sequences. Identifying these targets is extremely challenging. Current computational attempts to predict cleavage sites are limited, representing these amino acid sequences as patterns or frequency matrices. Here we present PoPS, a publicly accessible bioinformatics tool (http://pops.csse.monash.edu.au/) that provides a novel method for building computational models of protease specificity, which while still being based on these amino acid sequences, can be built from any experimental data or expert knowledge available to the user. PoPS specificity models can be used to predict and rank likely cleavages within a single substrate, and within entire proteomes. Other factors, such as the secondary or tertiary structure of the substrate, can be used to screen unlikely sites. Furthermore, the tool also provides facilities to infer, compare and test models, and to store them in a publicly accessible database.},
  keywords = {*Algorithms *Artificial Intelligence Binding Sites Computer Simulation Enzyme Activation *Models, Chemical *Models, Molecular Peptide Hydrolases/analysis/*chemistry/classification Protein Binding Sequence Analysis, Protein/*methods *Software Structure-Activity Relationship Substrate Specificity},
  issn = {0219-7200 (Print) 0219-7200 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/16108084},
  year = {2005},
  type = {Journal Article},
}


@article{Kikkawa:2005qf,
  author = {Kikkawa, F. and Kajiyama, H. and Shibata, K. and Ino, K. and Nomura, S. and Mizutani, S.},
  title = {{Dipeptidyl peptidase IV in tumor progression}},
  journal = {Biochim Biophys Acta},
  volume = {1751},
  number = {1},
  pages = {45-51},
  note = {Kikkawa, Fumitaka Kajiyama, Hiroaki Shibata, Kiyosumi Ino, Kazuhiko Nomura, Seiji Mizutani, Shigehiko Netherlands Biochim Biophys Acta. 2005 Aug 1;1751(1):45-51. Epub 2004 Oct 22.},
  abstract = {Dipeptidyl peptidase IV (DPPIV) is a 110-kDa glycoprotein with ubiquitous expression. Several recent studies have shown that DPPIV affects tumor progression in several human malignancies. We found that ovarian carcinoma cell lines with higher DPPIV expression showed less invasive potential. Furthermore, introduction of DPPIV cDNA into SKOV3 cells (SKDPIV), derived from serous cystadenocarcinoma showing little DPPIV expression, caused a significant decrease in both migration and invasive potential. In addition, nude mice inoculated with SKDPIV cells showed significantly less peritoneal dissemination and longer survival time than those inoculated with parental or vector-transfected cells. We further examined the mechanisms of anti-invasive ability of DPPIV. The expression of E-cadherin was positively correlated with DPPIV expression among five independent ovarian carcinoma cell lines. The SKDPIV cells showed enhanced expression of E-cadherin with a cellular morphological change from a fibroblastic and motile phenotype to an epithelial phenotype compared to parental and MOCK cells. In addition, matrix metalloproteinase 2 (MMP-2) and membrane type 1 matrix metalloprotease (MT1-MMP), which are important markers associated with invasive and metastatic potential, were remarkably reduced in SKDPIV cells. In contrast, tissue inhibitors of matrix metalloproteinases (TIMPs) were enhanced by DPPIV transfection. These findings imply that DPPIV may functionally suppress peritoneal dissemination and progression of ovarian carcinoma by regulating the expression levels of several molecules associated with carcinoma cell invasion and progression.},
  keywords = {Adenocarcinoma/pathology/physiopathology Animals Cadherins/biosynthesis Dipeptidyl Peptidase 4/genetics/immunology/*physiology Female Humans Mice Mice, Nude Neoplasm Invasiveness/pathology/*physiopathology Ovarian Neoplasms/pathology/*physiopathology Transfection},
  issn = {0006-3002 (Print) 0006-3002 (Linking)},
  doi = {10.1016/j.bbapap.2004.09.028},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/16054016 http://ac.els-cdn.com/S1570963904002857/1-s2.0-S1570963904002857-main.pdf?_tid=65308c18-fbde-11e4-afc4-00000aacb360&acdnat=1431789512_c87d77a6026512ecbdd5b2738b9f7acc},
  year = {2005},
  type = {Journal Article},
}


@article{Lankas:2005lq,
  author = {Lankas, G. R. and Leiting, B. and Roy, R. S. and Eiermann, G. J. and Beconi, M. G. and Biftu, T. and Chan, C. C. and Edmondson, S. and Feeney, W. P. and He, H. and Ippolito, D. E. and Kim, D. and Lyons, K. A. and Ok, H. O. and Patel, R. A. and Petrov, A. N. and Pryor, K. A. and Qian, X. and Reigle, L. and Woods, A. and Wu, J. K. and Zaller, D. and Zhang, X. and Zhu, L. and Weber, A. E. and Thornberry, N. A.},
  title = {{Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9}},
  journal = {Diabetes},
  volume = {54},
  number = {10},
  pages = {2988-94},
  note = {Lankas, George R Leiting, Barbara Roy, Ranabir Sinha Eiermann, George J Beconi, Maria G Biftu, Tesfaye Chan, Chi-Chung Edmondson, Scott Feeney, William P He, Huaibing Ippolito, Dawn E Kim, Dooseop Lyons, Kathryn A Ok, Hyun O Patel, Reshma A Petrov, Aleksandr N Pryor, Kelly Ann Qian, Xiaoxia Reigle, Leah Woods, Andrea Wu, Joseph K Zaller, Dennis Zhang, Xiaoping Zhu, Lan Weber, Ann E Thornberry, Nancy A Diabetes. 2005 Oct;54(10):2988-94.},
  abstract = {Dipeptidyl peptidase (DPP)-IV inhibitors are a new approach to the treatment of type 2 diabetes. DPP-IV is a member of a family of serine peptidases that includes quiescent cell proline dipeptidase (QPP), DPP8, and DPP9; DPP-IV is a key regulator of incretin hormones, but the functions of other family members are unknown. To determine the importance of selective DPP-IV inhibition for the treatment of diabetes, we tested selective inhibitors of DPP-IV, DPP8/DPP9, or QPP in 2-week rat toxicity studies and in acute dog tolerability studies. In rats, the DPP8/9 inhibitor produced alopecia, thrombocytopenia, reticulocytopenia, enlarged spleen, multiorgan histopathological changes, and mortality. In dogs, the DPP8/9 inhibitor produced gastrointestinal toxicity. The QPP inhibitor produced reticulocytopenia in rats only, and no toxicities were noted in either species for the selective DPP-IV inhibitor. The DPP8/9 inhibitor was also shown to attenuate T-cell activation in human in vitro models; a selective DPP-IV inhibitor was inactive in these assays. Moreover, we found DPP-IV inhibitors that were previously reported to be active in models of immune function to be more potent inhibitors of DPP8/9. These results suggest that assessment of selectivity of potential clinical candidates may be important to an optimal safety profile for this new class of antihyperglycemic agents.},
  keywords = {Animals Diabetes Mellitus, Type 2/*drug therapy Dipeptidases/*antagonists & inhibitors *Dipeptidyl Peptidase 4/genetics/physiology Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/*antagonists & inhibitors Dogs Female Humans *Hypoglycemic Agents/therapeutic use/toxicity Isoleucine/analogs & derivatives/chemistry/therapeutic use/toxicity Isomerism Male Mice Mice, Inbred C57BL Mice, Knockout Protease Inhibitors/*therapeutic use/toxicity Rats Recombinant Proteins/antagonists & inhibitors Thiazoles/chemistry/therapeutic use/toxicity},
  issn = {0012-1797 (Print) 0012-1797 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/16186403 http://diabetes.diabetesjournals.org/content/54/10/2988.full.pdf},
  year = {2005},
  type = {Journal Article},
}


@article{Marnett:2005vn,
  author = {Marnett, A. B. and Craik, C. S.},
  title = {{Papa's got a brand new tag: advances in identification of proteases and their substrates}},
  journal = {Trends Biotechnol},
  volume = {23},
  number = {2},
  pages = {59-64},
  note = {Marnett, Alan B Craik, Charles S CA72006/CA/NCI NIH HHS/ GM56531/GM/NIGMS NIH HHS/ England Trends Biotechnol. 2005 Feb;23(2):59-64.},
  abstract = {Characterization of proteolytic enzymes and their substrates presents a formidable challenge in the context of biological systems. Despite the fact that an estimated 2% of the human genome codes for proteases, only a small fraction of these enzymes have well-characterized functions. Much of the difficulty in understanding protease biology is a direct result of the complexity of regulation, localization and activation exhibited by this class of enzymes. Here, we focus on several recently developed techniques representing crucial advances toward identification of proteases and their natural substrates.},
  keywords = {Animals Electrophoresis, Gel, Two-Dimensional Fluorescent Dyes/chemistry Humans Isotope Labeling Peptide Hydrolases/chemistry/*metabolism Proteome/analysis Substrate Specificity},
  issn = {0167-7799 (Print) 0167-7799 (Linking)},
  doi = {10.1016/j.tibtech.2004.12.010},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/15661339 http://ac.els-cdn.com/S0167779904003385/1-s2.0-S0167779904003385-main.pdf?_tid=61cf744e-fbde-11e4-8682-00000aab0f26&acdnat=1431789507_dd9a2030302552ebe5eb8b7f55c68866},
  year = {2005},
  type = {Journal Article},
}


@article{McDonald:2005fu,
  author = {McDonald, L. and Robertson, D. H. and Hurst, J. L. and Beynon, R. J.},
  title = {{Positional proteomics: selective recovery and analysis of N-terminal proteolytic peptides}},
  journal = {Nat Methods},
  volume = {2},
  number = {12},
  pages = {955-7},
  note = {McDonald, Lucy Robertson, Duncan H L Hurst, Jane L Beynon, Robert J Nat Methods. 2005 Dec;2(12):955-7. Epub 2005 Nov 18.},
  abstract = {Bottom-up proteomics is the analysis of peptides derived from single proteins or protein mixtures, and because each protein generates tens of peptides, there is scope for controlled reduction in complexity. We report here a new strategy for selective isolation of the N-terminal peptides of a protein mixture, yielding positionally defined peptides. The method is tolerant of several fragmentation methods, and the databases that must be searched are substantially less complex.},
  keywords = {Animals Biotinylation Mass Spectrometry Mice Muscle Proteins/chemistry/isolation & purification Muscle, Skeletal/chemistry Peptide Fragments/*chemistry/isolation & purification Peptide Mapping Proteins/*chemistry/isolation & purification Proteomics/*methods Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/*methods},
  issn = {1548-7091 (Print) 1548-7091 (Linking)},
  doi = {10.1038/nmeth811},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/16299481 http://www.nature.com/nmeth/journal/v2/n12/pdf/nmeth811.pdf},
  year = {2005},
  type = {Journal Article},
}


@article{McFarland2005,
  author = {McFarland, Melinda A. and Marshall, Alan G. and Hendrickson, Christopher L. and Nilsson, Carol L. and Fredman, Pam and Mnsson, Jan-Eric},
  title = {{Structural characterization of the GM1 ganglioside by infrared multiphoton dissociation, electron capture dissociation, and electron detachment dissociation electrospray ionization FT-ICR MS/MS}},
  journal = {Journal of the American Society for Mass Spectrometry},
  volume = {16},
  number = {5},
  pages = {752-762},
  abstract = {Gangliosides play important biological roles and structural characterization of both the carbohydrate and the lipid moieties is important. The FT-ICR MS/MS techniques of electron capture dissociation (ECD), electron detachment dissociation (EDD), and infrared multiphoton dissociation (IRMPD) provide extensive fragmentation of the protonated and deprotonated GM1 ganglioside. ECD provides extensive structural information, including identification of both halves of the ceramide and cleavage of the acetyl moiety of the N-acetylated sugars. IRMPD provides similar glycan fragmentation but no cleavage of the acetyl moiety. Cleavage between the fatty acid and the long-chain base of the ceramide moiety is seen in negative-ion IRMPD but not in positive-ion IRMPD of GM1. Furthermore, this extent of fragmentation requires a range of laser powers, whereas all information is available from a single ECD experiment. However, stepwise fragmentation by IRMPD may be used to map the relative labilities for a series of cleavages. EDD provides the alternative of electron-induced fragmentation for negative ions with extensive fragmentation, but suffers from low efficiency as well as complication of data analysis by frequent loss of hydrogen atoms. We also show that analysis of MS/MS data for glycolipids is greatly simplified by classification of product ion masses to specific regions of the ganglioside based solely on mass defect graphical analysis.},
  issn = {1879-1123},
  doi = {10.1016/j.jasms.2005.02.001},
  url = {http://dx.doi.org/10.1016/j.jasms.2005.02.001 http://ac.els-cdn.com/S1044030505001133/1-s2.0-S1044030505001133-main.pdf?_tid=cde32e08-edab-11e6-859e-00000aab0f02&acdnat=1486523463_d1f0186dd7815251d45fab9ca4c269cf},
  year = {2005},
  type = {Journal Article},
}


@article{Wang:2005xi,
  author = {Wang, X. M. and Yu, D. M. and McCaughan, G. W. and Gorrell, M. D.},
  title = {{Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line}},
  journal = {Hepatology},
  volume = {42},
  number = {4},
  pages = {935-45},
  note = {Wang, Xin Maggie Yu, Denise Ming Tse McCaughan, Geoffrey W Gorrell, Mark D Baltimore, Md. Hepatology. 2005 Oct;42(4):935-45.},
  abstract = {Injury and repair in chronic liver disease involve cell adhesion, migration, apoptosis, proliferation, and a wound healing response. In liver, fibroblast activation protein (FAP) has both collagenase and dipeptidyl peptidase IV (DPIV) activities and is expressed only by activated hepatic stellate cells (HSC) and myofibroblasts, which produce and degrade extracellular matrix (ECM). FAP was colocalized with collagen fibers, fibronectin, and collagen type I in human liver. FAP function was examined in vitro by expressing green fluorescent protein FAP fusion protein in cell lines cultured on collagen-I, fibronectin, and Matrigel. Glutamates at 203 and 204 as well as serine624 of FAP were essential for peptidase activity. Human embryonic kidney 293T cells overexpressing FAP showed reduced adhesion and migration. FAP overexpression in the human HSC line LX-2 caused increased cell adhesion and migration on ECM proteins as well as invasion across transwells in the absence or presence of transforming growth factor beta-1. FAP overexpression enhanced staurosporine streptomyces-stimulated apoptosis in both cell lines. Interestingly, the enzyme activity of FAP was not required for these functions. Overexpressing FAP increased the expression of matrix metalloproteinase-2 and CD44 and reduced integrin-beta1 expression in 293T cells, suggesting potential pathways of FAP-mediated impairment of cell adhesion and migration in this epithelial cell line. In conclusion, these findings further support a pro-fibrogenic role for FAP by indicating that, in addition to its enzymatic functions, FAP has important nonenzymatic functions that in chronic liver injury may facilitate tissue remodeling through FAP-mediated enhancement of HSC cell adhesion, migration, and apoptosis.},
  keywords = {Antigens, Neoplasm/*genetics/metabolism Apoptosis/*physiology Cell Adhesion/physiology Cell Division/physiology Cell Line Cell Movement/*physiology Collagen Type I/metabolism Cytoskeleton/physiology Dipeptidyl Peptidase 4/genetics/metabolism Fibronectins/metabolism Gelatinases Gene Expression/physiology Green Fluorescent Proteins/genetics Hepatocytes/*cytology/*physiology Humans Membrane Proteins Phenotype Recombinant Fusion Proteins/genetics/metabolism Serine Endopeptidases/*genetics/metabolism Tumor Markers, Biological/*genetics/metabolism Wound Healing/physiology},
  issn = {0270-9139 (Print) 0270-9139 (Linking)},
  doi = {10.1002/hep.20853},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/16175601 http://onlinelibrary.wiley.com/store/10.1002/hep.20853/asset/20853_ftp.pdf?v=1&t=i8vc53eg&s=9595d7492ab6383670f2705e10540e95e48fde88 http://onlinelibrary.wiley.com/store/10.1002/hep.20853/asset/20853_ftp.pdf?v=1&t=i9r6ejxo&s=f617b61df9a52fdd272589e64b6c066abe8de8a6},
  year = {2005},
  type = {Journal Article},
}


@book{Abadi2006,
  author = {Abadi, Martin and Cardelli, Luca},
  title = {{A Theory of Objects}},
  publisher = {Springer-Verlag New York, Inc.},
  pages = {396},
  year = {2006},
  type = {Book},
}


@article{2006,
  author = {Anonymous},
  title = {{Standard operating procedures}},
  journal = {Nature biotechnology},
  volume = {24},
  number = {11},
  pages = {1299-1299},
  note = {106TP Times Cited:0 Cited References Count:0},
  abstract = {Understanding the complexities of standards development does not top the list of priorities for most biological researchers. Although standardized measurements ( SI Units) and nomenclature systems are routinely used in research, few biologists have ever had to consider standardizing the way in which they report the experimental conditions, controls and parameters under which their data are generated. But this is just what is now being proposed by the developers of several new 'standards' initiatives that aim to facilitate the reporting and sharing of data in various fields of biology.},
  keywords = {Biotechnology/methods/standards/statistics & numerical data Oligonucleotide Array Sequence Analysis/methods/*standards/statistics & numerical data Reproducibility of Results Research Design/*standards Statistics as Topic/*standards},
  issn = {1087-0156},
  doi = {Doi 10.1038/Nbt1106-1299},
  url = {<Go to ISI>://000242124700001 http://www.nature.com/nbt/journal/v24/n11/pdf/nbt1106-1299.pdf},
  year = {2006},
  type = {Journal Article},
}


@article{Bjelke:2006aa,
  author = {Bjelke, J. R. and Christensen, J. and Nielsen, P. F. and Branner, S. and Kanstrup, A. B. and Wagtmann, N. and Rasmussen, H. B.},
  title = {{Dipeptidyl peptidases 8 and 9: specificity and molecular characterization compared with dipeptidyl peptidase IV}},
  journal = {Biochem J},
  volume = {396},
  number = {2},
  pages = {391-9},
  note = {Bjelke, Jais R Christensen, Jesper Nielsen, Per F Branner, Sven Kanstrup, Anders B Wagtmann, Nicolai Rasmussen, Hanne B England Biochem J. 2006 Jun 1;396(2):391-9.},
  abstract = {Dipeptidyl peptidases 8 and 9 have been identified as gene members of the S9b family of dipeptidyl peptidases. In the present paper, we report the characterization of recombinant dipeptidyl peptidases 8 and 9 using the baculovirus expression system. We have found that only the full-length variants of the two proteins can be expressed as active peptidases, which are 882 and 892 amino acids in length for dipeptidyl peptidase 8 and 9 respectively. We show further that the purified proteins are active dimers and that they show similar Michaelis-Menten kinetics and substrate specificity. Both cleave the peptide hormones glucagon-like peptide-1, glucagon-like peptide-2, neuropeptide Y and peptide YY with marked kinetic differences compared with dipeptidyl peptidase IV. Inhibition of dipeptidyl peptidases IV, 8 and 9 using the well-known dipeptidyl peptidase IV inhibitor valine pyrrolidide resulted in similar K(i) values, indicating that this inhibitor is non-selective for any of the three dipeptidyl peptidases.},
  keywords = {Amino Acid Sequence Baculoviridae/genetics/metabolism Chromatography, Gel Dipeptidases/*chemistry/genetics/isolation & purification/metabolism Dipeptidyl Peptidase 4/*chemistry/metabolism Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/*chemistry/genetics/isolation & purification/metabolism Enzyme Activation Enzyme Inhibitors/metabolism/pharmacology Humans Kinetics Molecular Sequence Data Peptide Fragments/chemistry/metabolism Protein Structure, Quaternary Pyrroles/metabolism/pharmacology Recombinant Proteins/genetics/isolation & purification/metabolism Sequence Alignment Substrate Specificity Valine/metabolism/pharmacology},
  issn = {1470-8728 (Electronic) 0264-6021 (Linking)},
  doi = {10.1042/BJ20060079},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/16475979 http://www.biochemj.org/bj/396/0391/3960391.pdf},
  year = {2006},
  type = {Journal Article},
}


@article{Chiti:2006vn,
  author = {Chiti, F. and Dobson, C. M.},
  title = {{Protein misfolding, functional amyloid, and human disease}},
  journal = {Annu Rev Biochem},
  volume = {75},
  pages = {333-66},
  note = {Chiti, Fabrizio Dobson, Christopher M Annu Rev Biochem. 2006;75:333-66.},
  abstract = {Peptides or proteins convert under some conditions from their soluble forms into highly ordered fibrillar aggregates. Such transitions can give rise to pathological conditions ranging from neurodegenerative disorders to systemic amyloidoses. In this review, we identify the diseases known to be associated with formation of fibrillar aggregates and the specific peptides and proteins involved in each case. We describe, in addition, that living organisms can take advantage of the inherent ability of proteins to form such structures to generate novel and diverse biological functions. We review recent advances toward the elucidation of the structures of amyloid fibrils and the mechanisms of their formation at a molecular level. Finally, we discuss the relative importance of the common main-chain and side-chain interactions in determining the propensities of proteins to aggregate and describe some of the evidence that the oligomeric fibril precursors are the primary origins of pathological behavior.},
  keywords = {Amino Acid Sequence *Amyloid/chemistry/genetics/metabolism *Amyloidosis/metabolism/pathology/physiopathology Humans Models, Molecular *Neurodegenerative Diseases/metabolism/pathology/physiopathology Polymorphism, Genetic *Protein Conformation *Protein Folding},
  issn = {0066-4154 (Print) 0066-4154 (Linking)},
  doi = {10.1146/annurev.biochem.75.101304.123901},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/16756495 http://www.annualreviews.org/doi/pdf/10.1146/annurev.biochem.75.101304.123901},
  year = {2006},
  type = {Journal Article},
}


@article{DunbrackJr2006,
  author = {Dunbrack Jr, R. L.},
  title = {{Sequence comparison and protein structure prediction}},
  journal = {Current Opinion in Structural Biology},
  volume = {16},
  number = {3},
  pages = {374-384},
  note = {Cited By (since 1996):85 Export Date: 25 August 2013 Source: Scopus References: Canutescu, A.A., Dunbrack Jr., R.L., MollDE: a homology modeling framework you can click with (2005) Bioinformatics, 21, pp. 2914-2916; Altschul, S.F., Madden, T.L., Schffer, A.A., Zhang, J., Zhang, Z., Miller, W., Lipman, D.J., Gapped BLAST and PSI-BLAST: a new generation of database programs (1997) Nucleic Acids Res, 25, pp. 3389-3402; Murzin, A.G., Brenner, S.E., Hubbard, T., Chothia, C., SCOP: a structural classification of proteins database for the investigation of sequences and structures (1995) J Mol Biol, 247, pp. 536-540; Sauder, J.M., Arthur, J.W., Dunbrack Jr., R.L., Large-scale comparison of protein sequence alignment algorithms with structure alignments (2000) Proteins, 40, pp. 6-22; Yona, G., Levitt, M., Within the twilight zone: a sensitive profile-profile comparison tool based on information theory (2002) J Mol Biol, 315, pp. 1257-1275; Wang, G., Dunbrack Jr., R.L., Scoring profile-to-profile sequence alignments (2004) Protein Sci, 13, pp. 1612-1626. , The authors present a comparison of several algorithmic choices in the alignment of profiles, including the scoring function, sequence weighting, sequence choice, determination of gap penalties and inclusion of structural information; Cline, M., Hughey, R., Karplus, K., Predicting reliable regions in protein sequence alignments (2002) Bioinformatics, 18, pp. 306-314; Thompson, J.D., Koehl, P., Ripp, R., Poch, O., BAliBASE 3.0: latest developments of the multiple sequence alignment benchmark (2005) Proteins, 61, pp. 127-136; Stebbings, L.A., Mizuguchi, K., HOMSTRAD: recent developments of the homologous protein structure alignment database (2004) Nucleic Acids Res, 32, pp. D203-D207; Wang, G., Jin, Y., Dunbrack Jr., R.L., Assessment of fold recognition predictions in CASP6 (2005) Proteins, 61, pp. 46-66; Zemla, A., LGA: a method for finding 3D similarities in protein structures (2003) Nucleic Acids Res, 31, pp. 3370-3374; Zhang, Y., Skolnick, J., Scoring function for automated assessment of protein structure template quality (2004) Proteins, 57, pp. 702-710. , The authors present a scoring function for comparing models of proteins with their experimental structures that overcomes some of the deficiencies of the GDT-TS measure commonly used at the CASP meetings; Karplus, K., Katzman, S., Shackleford, G., Koeva, M., Draper, J., Barnes, B., Soriano, M., Hughey, R., SAM-T04: what is new in protein-structure prediction for CASP6 (2005) Proteins, 61 (SUPPL. 7), pp. 135-142; Rice, D.W., Eisenberg, D., A 3D-1D substitution matrix for protein fold recognition that includes predicted secondary structure of the sequence (1997) J Mol Biol, 267, pp. 1026-1038; Chelliah, V., Blundell, T., Mizuguchi, K., Functional restraints on the patterns of amino acid substitutions: application to sequence-structure homology recognition (2005) Proteins, 61, pp. 722-731; Huang, Y.M., Bystroff, C., Improved pairwise alignments of proteins in the twilight zone using local structure predictions (2006) Bioinformatics, 22, pp. 413-422; Bystroff, C., Thorsson, V., Baker, D., HMMSTR: a hidden Markov model for local sequence-structure correlations in proteins (2000) J Mol Biol, 301, pp. 173-190; Gelly, J.C., Chiche, L., Gracy, J., EvDTree: structure-dependent substitution profiles based on decision tree classification of 3D environments (2005) BMC Bioinformatics, 6, p. 4; Yu, Y.K., Altschul, S.F., The construction of amino acid substitution matrices for the comparison of proteins with non-standard compositions (2005) Bioinformatics, 21, pp. 902-911; Wrabl, J.O., Grishin, N.V., Grouping of amino acid types and extraction of amino acid properties from multiple sequence alignments using variance maximization (2005) Proteins, 61, pp. 523-534; Atchley, W.R., Zhao, J., Fernandes, A.D., Druke, T., Solving the protein sequence metric problem (2005) Proc Natl Acad Sci USA, 102, pp. 6395-6400; Xu, W., Miranker, D.P., A metric model of amino acid substitution (2004) Bioinformatics, 20, pp. 1214-1221; Sonnhammer, E.L., Hollich, V., Scoredist: a simple and robust protein sequence distance estimator (2005) BMC Bioinformatics, 6, p. 108. , The authors propose a correction-based protein sequence distance estimator that uses a logarithmic correction of observed divergence based on the alignment score according to the BLOSUM62 score matrix. Scoredist is more robust than other methods for measuring the evolutionary distance of two sequences; Qian, B., Goldstein, R.A., Distribution of Indel lengths (2001) Proteins, 45, pp. 102-104; Benner, S.A., Cohen, M.A., Gonnet, G.H., Empirical and structural models for insertions and deletions in the divergent evolution of proteins (1993) J Mol Biol, 229, pp. 1065-1082; Goonesekere, N.C., Lee, B., Frequency of gaps observed in a structurally aligned protein pair database suggests a simple gap penalty function (2004) Nucleic Acids Res, 32, pp. 2838-2843; Chang, M.S., Benner, S.A., Empirical analysis of protein insertions and deletions determining parameters for the correct placement of gaps in protein sequence alignments (2004) J Mol Biol, 341, pp. 617-631; Zachariah, M.A., Crooks, G.E., Holbrook, S.R., Brenner, S.E., A generalized affine gap model significantly improves protein sequence alignment accuracy (2005) Proteins, 58, pp. 329-338; Wrabl, J.O., Grishin, N.V., Gaps in structurally similar proteins: towards improvement of multiple sequence alignment (2004) Proteins, 54, pp. 71-87; Thompson, J.D., Higgins, D.G., Gibson, T.J., CLUSTALW: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice (1994) Nucleic Acids Res, 22, pp. 4673-4680; Notredame, C., Higgins, D.G., Heringa, J., T-Coffee: a novel method for fast and accurate multiple sequence alignment (2000) J Mol Biol, 302, pp. 205-217; Edgar, R.C., MUSCLE: multiple sequence alignment with high accuracy and high throughput (2004) Nucleic Acids Res, 32, pp. 1792-1797. , MUSCLE is a robust, accurate and fast multiple sequence alignment program that is becoming a standard in the field; Edgar, R.C., MUSCLE: a multiple sequence alignment method with reduced time and space complexity (2004) BMC Bioinformatics, 5, p. 113; Lassmann, T., Sonnhammer, E.L., Kalign-an accurate and fast multiple sequence alignment algorithm (2005) BMC Bioinformatics, 6, p. 298; Subramanian, A.R., Weyer-Menkhoff, J., Kaufmann, M., Morgenstern, B., DIALIGN-T: an improved algorithm for segment-based multiple sequence alignment (2005) BMC Bioinformatics, 6, p. 66; Morgenstern, B., Werner, N., Prohaska, S.J., Steinkamp, R., Schneider, I., Subramanian, A.R., Stadler, P.F., Weyer-Menkhoff, J., Multiple sequence alignment with user-defined constraints at GOBICS (2005) Bioinformatics, 21, pp. 1271-1273; Lu, C.L., Huang, Y.P., A memory-efficient algorithm for multiple sequence alignment with constraints (2005) Bioinformatics, 21, pp. 20-30; Tsai, Y.T., Huang, Y.P., Yu, C.T., Lu, C.L., MuSiC: a tool for multiple sequence alignment with constraints (2004) Bioinformatics, 20, pp. 2309-2311; O'Sullivan, O., Suhre, K., Abergel, C., Higgins, D.G., Notredame, C., 3DCoffee: combining protein sequences and structures within multiple sequence alignments (2004) J Mol Biol, 340, pp. 385-395. , 3D-Coffee uses a mixture of pairwise sequence alignments and pairwise structure comparison methods to generate more accurate multiple sequence alignments; Shatsky, M., Nussinov, R., Wolfson, H.J., Optimization of multiple-sequence alignment based on multiple-structure alignment (2006) Proteins, 62, pp. 209-217; Petrey, D., Xiang, Z., Tang, C.L., Xie, L., Gimpelev, M., Mitros, T., Soto, C.S., Schlessinger, A., Using multiple structure alignments, fast model building, and energetic analysis in fold recognition and homology modeling (2003) Proteins, 53 (SUPPL. 6), pp. 430-435; Tang, C.L., Xie, L., Koh, I.Y., Posy, S., Alexov, E., Honig, B., On the role of structural information in remote homology detection and sequence alignment: new methods using hybrid sequence profiles (2003) J Mol Biol, 334, pp. 1043-1062; Shah, P.K., Aloy, P., Bork, P., Russell, R.B., Structural similarity to bridge sequence space: finding new families on the bridges (2005) Protein Sci, 14, pp. 1305-1314; Sillitoe, I., Dibley, M., Bray, J., Addou, S., Orengo, C., Assessing strategies for improved superfamily recognition (2005) Protein Sci, 14, pp. 1800-1810; Zhou, H., Zhou, Y., Fold recognition by combining sequence profiles derived from evolution and from depth-dependent structural alignment of fragments (2005) Proteins, 58, pp. 321-328. , The SP 3 method combines profile-profile alignment with structural information from protein fragments in a way that is more successful than other similar methods of using structure to produce better profiles; Wistrand, M., Sonnhammer, E.L., Improving profile HMM discrimination by adapting transition probabilities (2004) J Mol Biol, 338, pp. 847-854; Wistrand, M., Sonnhammer, E.L., Improved profile HMM performance by assessment of critical algorithmic features in SAM and HMMER (2005) BMC Bioinformatics, 6, p. 99; Karplus, K., Karchin, R., Shackelford, G., Hughey, R., Calibrating E-values for hidden Markov models using reverse-sequence null models (2005) Bioinformatics, 21, pp. 4107-4115; Johnston, C.R., Shields, D.C., A sequence sub-sampling algorithm increases the power to detect distant homologues (2005) Nucleic Acids Res, 33, pp. 3772-3778; Mihalek, I., Res, I., Lichtarge, O., A structure and evolution-guided Monte Carlo sequence selection strategy for multiple alignment-based analysis of proteins (2006) Bioinformatics, 22, pp. 149-156. , The authors employ a strategy for optimally choosing sequences in multiple sequence alignments for determining probable interaction surfaces of proteins. The concept of optimally choosing sequences for multiple alignments has implications for the determination of profiles for remote homology detection and alignment; Sadreyev, R.I., Grishin, N.V., Quality of alignment comparison by COMPASS improves with inclusion of diverse confident homologs (2004) Bioinformatics, 20, pp. 818-828; Rosenberg, M.S., Multiple sequence alignment accuracy and evolutionary distance estimation (2005) BMC Bioinformatics, 6, p. 278; Pietrokovski, S., Searching databases of conserved sequence regions by aligning protein multiple-alignments (1996) Nucleic Acids Res, 24, pp. 3836-3845; Rychlewski, L., Jaroszewski, L., Li, W., Godzik, A., Comparison of sequence profiles. Strategies for structural predictions using sequence information (2000) Protein Sci, 9, pp. 232-241; Ohlson, T., Wallner, B., Elofsson, A., Profile-profile methods provide improved fold-recognition: a study of different profile-profile alignment methods (2004) Proteins, 57, pp. 188-197; Marti-Renom, M.A., Madhusudhan, M.S., Sali, A., Alignment of protein sequences by their profiles (2004) Protein Sci, 13, pp. 1071-1087; Edgar, R.C., Sjolander, K., A comparison of scoring functions for protein sequence profile alignment (2004) Bioinformatics, 20, pp. 1301-1308; Skolnick, J., Kihara, D., Zhang, Y., Development and large scale benchmark testing of the PROSPECTOR_3 threading algorithm (2004) Proteins, 56, pp. 502-518. , A large benchmark of the successful Prospector threading algorithm is presented; Zhang, Y., Arakaki, A.K., Skolnick, J., TASSER: an automated method for the prediction of protein tertiary structures in CASP6 (2005) Proteins, 61 (SUPPL. 7), pp. 91-98; Simossis, V.A., Kleinjung, J., Heringa, J., Homology-extended sequence alignment (2005) Nucleic Acids Res, 33, pp. 816-824; Chung, R., Yona, G., Protein family comparison using statistical models and predicted structural information (2004) BMC Bioinformatics, 5, p. 183; Ohlson, T., Elofsson, A., ProfNet, a method to derive profile-profile alignment scoring functions that improves the alignments of distantly related proteins (2005) BMC Bioinformatics, 6, p. 253. , Rather than testing previously proposed scoring functions, the authors derive a scoring function for profile-profile alignments by optimizing the discrimination between correctly and incorrectly aligned positions as a function of distance of aligned structures; Tomii, K., Hirokawa, T., Motono, C., Protein structure prediction using a variety of profile libraries and 3D verification (2005) Proteins, 61 (SUPPL. 7), pp. 114-121; Edgar, R.C., Sjolander, K., COACH: profile-profile alignment of protein families using hidden Markov models (2004) Bioinformatics, 20, pp. 1309-1318; Kahsay, R.Y., Wang, G., Gao, G., Liao, L., Dunbrack, R., Quasi-consensus-based comparison of profile hidden Markov models for protein sequences (2005) Bioinformatics, 21, pp. 2287-2293; Sding, J., Protein homology detection by HMM-HMM comparison (2005) Bioinformatics, 21, pp. 951-960. , An algorithm for remote homology detection by comparison of the match and insertion-deletion states of two profile HMMs is presented. The algorithm is shown to be more sensitive than sequence-HMM and profile-profile comparison methods; Sadreyev, R., Grishin, N., COMPASS: a tool for comparison of multiple protein alignments with assessment of statistical significance (2003) J Mol Biol, 326, pp. 317-336; Nguyen, M.N., Rajapakse, J.C., Multi-class support vector machines for protein secondary structure prediction (2003) Genome Inform Ser Workshop Genome Inform, 14, pp. 218-227; Busuttil, S., Abela, J., Pace, G.J., Support vector machines with profile-based kernels for remote protein homology detection (2004) Genome Inform Ser Workshop Genome Inform, 15, pp. 191-200; Garg, A., Bhasin, M., Raghava, G.P., Support vector machine-based method for subcellular localization of human proteins using amino acid compositions, their order and similarity search (2005) J Biol Chem, 280, pp. 14427-14432; Bradford, J.R., Westhead, D.R., Improved prediction of protein-protein binding sites using a support vector machines approach (2005) Bioinformatics, 21, pp. 1487-1494; Jaakkola, T., Diekhans, M., Haussler, D., A discriminative framework for detecting remote protein homologies (2000) J Comput Biol, 7, pp. 95-114; Leslie, C., Eskin, E., Noble, W.S., The spectrum kernel: a string kernel for SVM protein classification (2002) Pac Symp Biocomput, pp. 564-575; Liao, L., Noble, W.S., Combining pairwise sequence similarity and support vector machines for detecting remote protein evolutionary and structural relationships (2003) J Comput Biol, 10, pp. 857-868; Hou, Y., Hsu, W., Lee, M.L., Bystroff, C., Efficient remote homology detection using local structure (2003) Bioinformatics, 19, pp. 2294-2301; Leslie, C.S., Eskin, E., Cohen, A., Weston, J., Noble WS, Mismatch string kernels for discriminative protein classification (2004) Bioinformatics, 20, pp. 467-476; Hou, Y., Hsu, W., Lee, M.L., Bystroff, C., Remote homolog detection using local sequence-structure correlations (2004) Proteins, 57, pp. 518-530; Webb, B.J., Liu, J.S., Lawrence, C.E., BALSA: Bayesian algorithm for local sequence alignment (2002) Nucleic Acids Res, 30, pp. 1268-1277; Webb-Robertson, B.J., Oehmen, C., Matzke, M., SVM-BALSA: remote homology detection based on Bayesian sequence alignment (2005) Comput Biol Chem, 29, pp. 440-443; Han, S., Lee B-c, Yu, S.T., Jeong C-s, Lee, S., Kim, D., Fold recognition by combining profile-profile alignment and support vector machine (2005) Bioinformatics, 21, pp. 2667-2673; Saigo, H., Vert, J.P., Ueda, N., Akutsu, T., Protein homology detection using string alignment kernels (2004) Bioinformatics, 20, pp. 1682-1689; Rangwala, H., Karypis, G., Profile-based direct kernels for remote homology detection and fold recognition (2005) Bioinformatics, 21, pp. 4239-4247. , The authors present a remote homology detection method that combines profile-profile comparison with SVMs; Weston, J., Leslie, C., Ie, E., Zhou, D., Elisseeff, A., Noble, W.S., Semi-supervised protein classification using cluster kernels (2005) Bioinformatics, 21, pp. 3241-3247. , An improvement of this group's string kernels is presented that uses both labeled and unlabeled data to derive more powerful remote homology detection methods by SVMs; Tress, M., Ezkurdia, I., Grana, O., Lopez, G., Valencia, A., Assessment of predictions submitted for the CASP6 comparative modeling category (2005) Proteins, 61 (SUPPL. 7), pp. 27-45; Vincent, J.J., Tai, C.H., Sathyanarayana, B.K., Lee, B., Assessment of CASP6 predictions for new and nearly new fold targets (2005) Proteins, 61 (SUPPL. 7), pp. 67-83; Lundstrom, J., Rychlewski, L., Bujnicki, J., Elofsson, A., Pcons: a neural-network-based consensus predictor that improves fold recognition (2001) Protein Sci, 10, pp. 2354-2362; Fischer, D., 3D-SHOTGUN: a novel, cooperative, fold-recognition meta-predictor (2003) Proteins, 51, pp. 434-441; Ginalski, K., Elofsson, A., Fischer, D., Rychlewski, L., 3D-Jury: a simple approach to improve protein structure predictions (2003) Bioinformatics, 19, pp. 1015-1018; Bujnicki, J.M., Elofsson, A., Fischer, D., Rychlewski, L., Structure prediction meta server (2001) Bioinformatics, 17, pp. 750-751; Wallner, B., Elofsson, A., Pcons5: combining consensus, structural evaluation and fold recognition scores (2005) Bioinformatics, 21, pp. 4248-4254; Ginalski, K., von Grotthuss, M., Grishin, N.V., Rychlewski, L., Detecting distant homology with Meta-BASIC (2004) Nucleic Acids Res, 32, pp. W576-W581. , A method for remote homology detection based on a consensus of profile-profile alignments that use different scoring methods is presented. This method performed well at CASP6; Margelevicius, M., Venclovas, C., PSI-BLAST-ISS: an intermediate sequence search tool for estimation of the position-specific alignment reliability (2005) BMC Bioinformatics, 6, p. 185; Tress, M.L., Grana, O., Valencia, A., SQUARE-determining reliable regions in sequence alignments (2004) Bioinformatics, 20, pp. 974-975; Tress, M.L., Jones, D., Valencia, A., Predicting reliable regions in protein alignments from sequence profiles (2003) J Mol Biol, 330, pp. 705-718; Sadreyev, R.I., Grishin, N.V., Estimates of statistical significance for comparison of individual positions in multiple sequence alignments (2004) BMC Bioinformatics, 5, p. 106; Lassmann, T., Sonnhammer, E.L., Automatic assessment of alignment quality (2005) Nucleic Acids Res, 33, pp. 7120-7128; Pettitt, C.S., McGuffin, L.J., Jones, D.T., Improving sequence-based fold recognition by using 3D model quality assessment (2005) Bioinformatics, 21, pp. 3509-3515. , MQAPs based on threading-type potentials are shown to improve the scoring of models produced by other methods, such as profile-profile alignment; Hendlich, M., Lackner, P., Weitckus, S., Flckner, H., Froschauer, R., Gottsbacher, K., Casari, G., Sippl, M.J., Identification of native protein folds amongst a large number of incorrect models (1990) J Mol Biol, 216, pp. 167-180; Jaroszewski, L., Rychlewski, L., Li, Z., Li, W., Godzik, A., FFAS03: a server for profile-profile sequence alignments (2005) Nucleic Acids Res, 33, pp. W284-W288; Tress, M., Tai, C.H., Wang, G., Ezkurdia, I., Lopez, G., Valencia, A., Lee, B., Dunbrack Jr., R.L., Domain definition and target classification for CASP6 (2005) Proteins, 61, pp. 8-18; Kryshtafovych, A., Venclovas, C., Fidelis, K., Moult, J., Progress over the first decade of CASP experiments (2005) Proteins, 61 (SUPPL. 7), pp. 225-236; Kryshtafovych, A., Milostan, M., Szajkowski, L., Daniluk, P., Fidelis, K., CASP6 data processing and automatic evaluation at the protein structure prediction center (2005) Proteins, 61 (SUPPL. 7), pp. 19-23; Rychlewski, L., Fischer, D., LiveBench-8: the large-scale, continuous assessment of automated protein structure prediction (2005) Protein Sci, 14, pp. 240-245; Grishin, N.V., Fold change in evolution of protein structures (2001) J Struct Biol, 134, pp. 167-185; Bradley, P., Malmstrom, L., Qian, B., Schonbrun, J., Chivian, D., Kim, D.E., Meiler, J., Baker, D., Free modeling with Rosetta in CASP6 (2005) Proteins, 61 (SUPPL. 7), pp. 128-134; Sali, A., Blundell, T.L., Comparative protein modelling by satisfaction of spatial restraints (1993) J Mol Biol, 234, pp. 779-815; Misura, K.M., Baker, D., Progress and challenges in high-resolution refinement of protein structure models (2005) Proteins, 59, pp. 15-29},
  abstract = {Sequence comparison is a major step in the prediction of protein structure from existing templates in the Protein Data Bank. The identification of potentially remote homologues to be used as templates for modeling target sequences of unknown structure and their accurate alignment remain challenges, despite many years of study. The most recent advances have been in combining as many sources of information as possible - including amino acid variation in the form of profiles or hidden Markov models for both the target and template families, known and predicted secondary structures of the template and target, respectively the combination of structure alignment for distant homologues and sequence alignment for close homologues to build better profiles and the anchoring of certain regions of the alignment based on existing biological data. Newer technologies have been applied to the problem including the use of support vector machines to tackle the fold classification problem for a target sequence and the alignment of hidden Markov models. Finally, using the consensus of many fold recognition methods whether based on profile-profile alignments, threading or other approaches continues to be one of the most successful strategies for both recognition and alignment of remote homologues. Although there is still room for improvement in identification and alignment methods, additional progress may come from model building and refinement methods that can compensate for large structural changes between remotely related targets and templates, as well as for regions of misalignment.  2006 Elsevier Ltd. All rights reserved.},
  year = {2006},
  type = {Journal Article},
}


@article{Edosada:2006tx,
  author = {Edosada, C. Y. and Quan, C. and Tran, T. and Pham, V. and Wiesmann, C. and Fairbrother, W. and Wolf, B. B.},
  title = {{Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly(2)-Pro(1)-cleaving specificity}},
  journal = {FEBS Lett},
  volume = {580},
  number = {6},
  pages = {1581-6},
  note = {Edosada, Conrad Yap Quan, Clifford Tran, Thuy Pham, Victoria Wiesmann, Christian Fairbrother, Wayne Wolf, Beni B Netherlands FEBS Lett. 2006 Mar 6;580(6):1581-6. Epub 2006 Feb 3.},
  abstract = {Fibroblast activation protein (FAP) is a serine protease of undefined endopeptidase specificity implicated in tumorigenesis. To characterize FAP's P(4)-P(2)(') specificity, we synthesized intramolecularly quenched fluorescent substrate sets based on the FAP cleavage site in alpha(2)-antiplasmin (TSGP-NQ). FAP required substrates with Pro at P(1) and Gly or d-amino acids at P(2) and preferred small, uncharged amino acids at P(3), but tolerated most amino acids at P(4), P(1)(') and P(2)('). These substrate preferences allowed design of peptidyl-chloromethyl ketones that inhibited FAP, but not the related protease, dipeptidyl peptidase-4. Thus, FAP is a narrow specificity endopeptidase and this can be exploited for inhibitor design.},
  keywords = {Amino Acid Chloromethyl Ketones/chemistry/pharmacology Antigens, Neoplasm/*chemistry Dipeptidyl Peptidase 4/chemistry/drug effects *Drug Design Gelatinases Humans Membrane Proteins Models, Molecular Oligopeptides/chemistry Peptides/chemistry Serine Endopeptidases/*chemistry/*drug effects Serine Proteinase Inhibitors/*chemistry/pharmacology Substrate Specificity Tumor Markers, Biological/*antagonists & inhibitors/*chemistry alpha-2-Antiplasmin/chemistry},
  issn = {0014-5793 (Print) 0014-5793 (Linking)},
  doi = {10.1016/j.febslet.2006.01.087},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/16480718 http://ac.els-cdn.com/S0014579306001578/1-s2.0-S0014579306001578-main.pdf?_tid=7641dc50-fbde-11e4-9b72-00000aab0f6b&acdnat=1431789541_3e4839742188b911cce954967dc84e23},
  year = {2006},
  type = {Journal Article},
}


@article{Engel:2006xr,
  author = {Engel, M. and Hoffmann, T. and Manhart, S. and Heiser, U. and Chambre, S. and Huber, R. and Demuth, H. U. and Bode, W.},
  title = {{Rigidity and flexibility of dipeptidyl peptidase IV: crystal structures of and docking experiments with DPIV}},
  journal = {J Mol Biol},
  volume = {355},
  number = {4},
  pages = {768-83},
  note = {Engel, Michael Hoffmann, Torsten Manhart, Susanne Heiser, Ulrich Chambre, Sylvie Huber, Robert Demuth, Hans-Ulrich Bode, Wolfram England J Mol Biol. 2006 Jan 27;355(4):768-83. Epub 2005 Nov 22.},
  abstract = {Dipeptidyl peptidase IV (DPIV) is an alpha,beta-hydrolase-like serine exopeptidase, which removes dipeptides, preferentially with a C-terminal l-Pro residue, from the N terminus of longer peptide substrates. Previously, we determined the tetrameric 1.8A crystal structure of native porcine DPIV. Each monomer is composed of a beta-propeller and a catalytic domain, which together embrace an internal cavity housing the active centre. This cavity is connected to the bulk solvent by a propeller opening and a side opening. Here, we analyse DPIV complexes with a t-butyl-Gly-Pro-Ile tripeptide, Pro-boroPro, a piperazine purine compound, and aminoethyl phenyl sulfonylfluoride. The latter two compounds bind to the active-site groove in a compact and a quite bulky manner, respectively, causing considerable shifts of the catalytic Ser630 side-chain and of the Tyr547 phenolic group, which forms the oxyanion hole. The tripeptide, mimicking a peptide substrate, is clamped to the active site through tight interactions via its N-terminal alpha-ammonium group, the P2 carbonyl group, the P1-l-Pro side-chain, the C-terminal carboxylate group, and the stable orthoacid ester amide formed between the scissile peptide carbonyl group and Ser630 O(gamma). This stable trapping of the tripeptide could be due to stabilization of the protonated His740 imidazolium cation by the adjacent negatively charged C-terminal carboxylate group, preventing proton transfer to the leaving group nitrogen atom. Docking experiments with the compact rigid 58 residue protein aprotinin, which had been shown to be processed by DPIV, indicate that the Arg1-Pro2 N terminus can access the DPIV active site only upon widening of its side openings, probably by separation of the first and the last propeller blades, and/or of the catalytic and the propeller domain.},
  keywords = {Animals Crystallography, X-Ray Dipeptidyl Peptidase 4/*chemistry/*metabolism Models, Molecular Peptides/chemistry/metabolism Pliability Protease Inhibitors/chemistry/metabolism Protein Structure, Quaternary Protein Structure, Tertiary Structural Homology, Protein Sulfones/chemistry/metabolism Swine},
  issn = {0022-2836 (Print) 0022-2836 (Linking)},
  doi = {10.1016/j.jmb.2005.11.014},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/16330047 http://ac.els-cdn.com/S0022283605014002/1-s2.0-S0022283605014002-main.pdf?_tid=6f9b5de2-ea5c-11e4-a73e-00000aab0f6c&acdnat=1429864525_bf8f75d6ae46013bbcb97fb1cb1113af http://ac.els-cdn.com/S0022283605014002/1-s2.0-S0022283605014002-main.pdf?_tid=79b471f4-fbde-11e4-ac25-00000aacb35d&acdnat=1431789547_c7c4697bcb4efdd52076f30414fed835},
  year = {2006},
  type = {Journal Article},
}


@article{Friedrich:2006fy,
  author = {Friedrich, Oliver},
  title = {{Critical illness myopathy: what is happening?}},
  journal = {Current Opinion in Clinical Nutrition and Metabolic Care},
  volume = {9},
  number = {4},
  abstract = {Purpose of review: The current review focuses on recent studies, both clinical and from basic sciences, which approach possible pathomechanisms of critical illness myopathy in order to better derive potential clinical strategies for a preventive or curative clinical setting. Trends and concepts of clinical diagnosis and handling will be evaluated and their implications for muscle physiology and nutritional/metabolic intervention discussed. Recent findings: Conventional electrophysiology was combined with direct muscle stimulation to better differentiate critical illness myopathy from other neuromuscular disorders in critical illness. Muscle weakness was the result of impaired excitation--contraction-coupling at the level of the sarcolemma and the sarcoplasmic reticulum membrane. Critical illness may alter sodium and ryanodine receptor calcium-release channels. Also, increased muscle proteolysis contributes to weakness in critical illness myopathy. Myosin loss is due to the risk factors systemic inflammatory response syndrome/sepsis, steroids and neuromuscular blocking agents. Steroids can also induce necrosis and apoptosis in muscle. Inflammatory mediators aggravated muscle metabolic failure in critical illness myopathy. Ubiquitin--proteasome pathways, cyclooxygenase activation, altered glucose transporter expression, MyoD suppression, impaired respiratory chain enzymes, ATP depletion, glucose toxicity and insulin resistance can all contribute to the critical illness myopathy pathomechanism. Summary: The search for pathomechanisms is an important task for both clinical and basic sciences. Targets for treatment or prevention of critical illness myopathy include systemic inflammatory response, increased proteolysis and reduced antioxidative capacitance in critically ill patients.},
  keywords = {critical illness ec-coupling myopathy pathomechanism SIRS steroids ubiquitin},
  url = {http://journals.lww.com/co-clinicalnutrition/Fulltext/2006/07000/Critical_illness_myopathy__what_is_happening_.11.aspx},
  year = {2006},
  type = {Journal Article},
}


@article{Ghersi:2006sy,
  author = {Ghersi, G. and Zhao, Q. and Salamone, M. and Yeh, Y. and Zucker, S. and Chen, W. T.},
  title = {{The protease complex consisting of dipeptidyl peptidase IV and seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices}},
  journal = {Cancer Res},
  volume = {66},
  number = {9},
  pages = {4652-61},
  note = {Ghersi, Giulio Zhao, Qiang Salamone, Monica Yeh, Yunyun Zucker, Stanley Chen, Wen-Tien R01 CA039077-21/CA/NCI NIH HHS/ R01 EB002065-19/EB/NIBIB NIH HHS/ R01CA39077/CA/NCI NIH HHS/ R01EB002065/EB/NIBIB NIH HHS/ Cancer Res. 2006 May 1;66(9):4652-61.},
  abstract = {Dipeptidyl peptidase IV (DPP4/CD26) and seprase/fibroblast activation protein alpha are homologous type II transmembrane, homodimeric glycoproteins that exhibit unique prolyl peptidase activities. Human DPP4 is ubiquitously expressed in epithelial and endothelial cells and serves multiple functions in cleaving the penultimate positioned prolyl bonds at the NH(2) terminus of a variety of physiologically important peptides in the circulation. Recent studies showed a linkage between DPP4 and down-regulation of certain chemokines and mitogenic growth factors, and degradation of denatured collagens (gelatin), suggesting a role of DPP4 in the cell invasive phenotype. Here, we found the existence of a novel protease complex consisting of DPP4 and seprase in human endothelial cells that were activated to migrate and invade in the extracellular matrix in vitro. DPP4 and seprase were coexpressed with the three major protease systems (matrix metalloproteinase, plasminogen activator, and type II transmembrane serine protease) at the cell surface and organize as a complex at invadopodia-like protrusions. Both proteases were colocalized at the endothelial cells of capillaries, but not large blood vessels, in invasive breast ductal carcinoma in vivo. Importantly, monoclonal antibodies against the gelatin-binding domain of DPP4 blocked the local gelatin degradation by endothelial cells in the presence of the major metallo- and serine protease systems that modified pericellular collagenous matrices and subsequent cell migration and invasion. Thus, we have identified a novel mechanism involving the DPP4 gelatin-binding domain of the DPP4-seprase complex that facilitates the local degradation of the extracellular matrix and the invasion of the endothelial cells into collagenous matrices.},
  keywords = {Antibodies, Monoclonal/pharmacology Cell Movement/*physiology Cell Surface Extensions/*enzymology Collagen/*metabolism Dipeptidyl Peptidase 4/biosynthesis/*metabolism Endothelial Cells/*cytology/*enzymology Extracellular Matrix/*metabolism Gelatin/metabolism Humans Peptide Hydrolases/biosynthesis/*metabolism Serine Endopeptidases/biosynthesis/*metabolism Up-Regulation},
  issn = {0008-5472 (Print) 0008-5472 (Linking)},
  doi = {10.1158/0008-5472.CAN-05-1245},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/16651416 http://cancerres.aacrjournals.org/content/66/9/4652.full.pdf},
  year = {2006},
  type = {Journal Article},
}


@article{Gorrell:2006cr,
  author = {Gorrell, M. D. and Wang, X. M. and Park, J. and Ajami, K. and Yu, D. M. and Knott, H. and Seth, D. and McCaughan, G. W.},
  title = {{Structure and function in dipeptidyl peptidase IV and related proteins}},
  journal = {Adv Exp Med Biol},
  volume = {575},
  pages = {45-54},
  note = {Gorrell, Mark D Wang, Xin M Park, Joohong Ajami, Katerina Yu, Denise Ming Tse Knott, Heather Seth, Devanshi McCaughan, Geoffrey W Adv Exp Med Biol. 2006;575:45-54.},
  keywords = {Animals Antigens, Neoplasm/chemistry/genetics/metabolism Binding Sites Dipeptidases/chemistry/genetics/metabolism Dipeptidyl Peptidase 4/*chemistry/genetics/*metabolism Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/chemistry/genetics/metabolism Extracellular Matrix/metabolism Gelatinases Humans Membrane Proteins Models, Molecular Molecular Sequence Data Multigene Family Neoplasms/enzymology Nerve Tissue Proteins/chemistry/genetics/metabolism Peptide Hydrolases/chemistry/genetics/metabolism Potassium Channels/chemistry/genetics/metabolism Protein Conformation Serine Endopeptidases/chemistry/genetics/metabolism Tumor Markers, Biological/chemistry/genetics/metabolism},
  issn = {0065-2598 (Print) 0065-2598 (Linking)},
  doi = {10.1007/0-387-32824-6_5},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/16700507 http://link.springer.com/chapter/10.1007%2F0-387-32824-6_5 http://download-v2.springer.com/static/pdf/820/chp%253A10.1007%252F0-387-32824-6_5.pdf?token2=exp=1431790571~acl=%2Fstatic%2Fpdf%2F820%2Fchp%25253A10.1007%25252F0-387-32824-6_5.pdf*~hmac=9d8037ef02c7b0052f3c8a59548de5d58dd296a33a9dc635080cbf959ec340cb},
  year = {2006},
  type = {Journal Article},
}


@article{Guieu:2006dk,
  author = {Guieu, R. and Fenouillet, E. and Devaux, C. and Fajloun, Z. and Carrega, L. and Sabatier, J. M. and Sauze, N. and Marguet, D.},
  title = {{CD26 modulates nociception in mice via its dipeptidyl-peptidase IV activity}},
  journal = {Behav Brain Res},
  volume = {166},
  number = {2},
  pages = {230-5},
  note = {Guieu, Regis Fenouillet, Emmanuel Devaux, Christiane Fajloun, Ziad Carrega, Louis Sabatier, Jean-Marc Sauze, Nicole Marguet, Didier Netherlands Behav Brain Res. 2006 Jan 30;166(2):230-5. Epub 2005 Sep 8.},
  abstract = {BACKGROUND: CD26 is a multifunctional cell surface glycoprotein expressed by T and B cells. It exhibits a dipeptidyl-peptidase activity (DPP-IV) that cleaves the penultimate proline from the N-terminus of polypeptides, thereby regulating their activity and concentration. METHODS: Using CD26-/- mice resulting from targeted inactivation of the gene, we examined the consequences of a DPP-IV defect on behavioural response to nociceptive stimuli and concentration of the pain modulator peptides substance P (SP) and endomorphin 2, two DPP-IV substrates. RESULTS: CD26 inactivation induced a three-fold decrease in circulating endopeptidase activity while that found in brain extracts was normal, albeit very weak. CD26-/- mice had high SP concentrations in plasma (3.4+/-1 pg/ml versus 1.5+/-0.3 pg/ml, P<10(-3)) but not in brain extracts (35+/-12 pg/ml versus 32+/-9 pg/ml, P>0.05). Endomorphin-2 levels in the two groups were in the same range for plasma and brain extracts. CD26-/- mice displayed short latencies to nociceptive stimuli (hot plate test: 6.6+/-1.2 s versus 8.6+/-1.5 s, P<10(-4); tail pinch test: 3.1+/-0.6 s versus 4.2+/-0.8 s, P<10(-3)). Administration of an SP (NK1) receptor antagonist or DPP-IV to CD26-/- mice normalised latencies. DPP-IV inhibitors decreased latencies only in CD26+/+ mice. CONCLUSIONS: Our observations represent the first fundamental evidence showing that DPP-IV influences pain perception via modulation of the peripheral SP concentration. Our work also highlights the role of peripheral NK1 receptors in nociception.},
  keywords = {Analysis of Variance Androstanes/pharmacology Animals Benzimidazoles/pharmacology Dipeptidyl Peptidase 4/genetics/*physiology/therapeutic use Dose-Response Relationship, Drug Female Lymphocytes/metabolism Male Mice Mice, Inbred C57BL Mice, Knockout Oligopeptides/blood Pain/diet therapy/genetics/*metabolism Pain Measurement/methods Reaction Time/drug effects/physiology Substance P/blood},
  issn = {0166-4328 (Print) 0166-4328 (Linking)},
  doi = {10.1016/j.bbr.2005.08.003},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/16154213 http://ac.els-cdn.com/S0166432805003323/1-s2.0-S0166432805003323-main.pdf?_tid=8160d6a4-fbde-11e4-9642-00000aab0f26&acdnat=1431789560_f37389e4458f4b33521ba1bc84bbc18c},
  year = {2006},
  type = {Journal Article},
}


@article{Kurmasheva:2006aa,
  author = {Kurmasheva, R. T. and Houghton, P. J.},
  title = {{IGF-I mediated survival pathways in normal and malignant cells}},
  journal = {Biochim Biophys Acta},
  volume = {1766},
  number = {1},
  pages = {1-22},
  note = {Kurmasheva, Raushan T Houghton, Peter J CA21675/CA/NCI NIH HHS/ CA23099/CA/NCI NIH HHS/ CA77776/CA/NCI NIH HHS/ CA96696/CA/NCI NIH HHS/ Netherlands Biochim Biophys Acta. 2006 Aug;1766(1):1-22. Epub 2006 Jun 7.},
  abstract = {The type-I and -II insulin-like growth factors (IGF-I, II) are now established as survival- or proliferation-factors in many in vitro systems. Of note IGFs provide trophic support for multiple cell types or organ cultures explanted from various species, and delay the onset of programmed cell death (apoptosis) through the mitochondrial (intrinsic pathway) or by antagonizing activation of cytotoxic cytokine signaling (extrinsic pathway). In some instances, IGFs protect against other forms of death such as necrosis or autophagy. The effect of IGFs on cell survival appears to be context specific, being determined both by the cell origin (tissue specific) and the cellular stress that induces loss of cellular viability. In many human cancers, there is a strong association with dysregulated IGF signaling, and this association has been extensively reviewed recently. IGF-regulation is also disrupted in childhood cancers as a consequence of chromosomal translocations. IGFs are implicated also in acute renal failure, traumatic injury to brain tissue, and cardiac disease. This article focuses on the role of IGFs and their cellular signaling pathways that provide survival signals in stressed cells.},
  keywords = {Animals Apoptosis *Cell Survival Humans Insulin-Like Growth Factor I/*pharmacology Mitochondria/physiology Neoplasms/*pathology Receptor, IGF Type 1/*physiology *Signal Transduction},
  issn = {0006-3002 (Print) 0006-3002 (Linking)},
  doi = {10.1016/j.bbcan.2006.05.003},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/16844299 http://ac.els-cdn.com/S0304419X0600031X/1-s2.0-S0304419X0600031X-main.pdf?_tid=38984f4e-ea5c-11e4-acca-00000aacb35f&acdnat=1429864433_ebd8f94c120a6562086b48a02be9e28f http://ac.els-cdn.com/S0304419X0600031X/1-s2.0-S0304419X0600031X-main.pdf?_tid=84e53fd6-fbde-11e4-8eb1-00000aacb361&acdnat=1431789566_ef16999176d5f775d94df25eed77d94f},
  year = {2006},
  type = {Journal Article},
}


@article{Lee:2006ys,
  author = {Lee, H. J. and Chen, Y. S. and Chou, C. Y. and Chien, C. H. and Lin, C. H. and Chang, G. G. and Chen, X.},
  title = {{Investigation of the dimer interface and substrate specificity of prolyl dipeptidase DPP8}},
  journal = {J Biol Chem},
  volume = {281},
  number = {50},
  pages = {38653-62},
  note = {Lee, Hong-Jen Chen, Yuan-Shou Chou, Chi-Yuan Chien, Chia-Hui Lin, Chun-Hung Chang, Gu-Gang Chen, Xin J Biol Chem. 2006 Dec 15;281(50):38653-62. Epub 2006 Oct 13.},
  abstract = {DPP8 belongs to the family of prolyl dipeptidases, which are capable of cleaving the peptide bond after a penultimate proline residue. Unlike DPP-IV, a drug target for type II diabetes, no information is available on the crystal structure of DPP8, the regulation of its enzymatic activity, or its substrate specificity. In this study, using analytical ultracentrifugation and native gel electrophoresis, we show that the DPP8 protein is predominantly dimeric when purified or in the cell extracts. Four conserved residues in the C-terminal loop of DPP8 (Phe(822), Val(833), Tyr(844), and His(859)), corresponding to those located at the dimer interface of DPP-IV, were individually mutated to Ala. Surprisingly, unlike DPP-IV, these single-site mutations abolished the enzymatic activity of DPP8 without disrupting its quaternary structure, indicating that dimerization itself is not sufficient for the optimal enzymatic activity of DPP8. Moreover, these mutations not only decreased k(cat), as did the corresponding DPP-IV mutations, but also dramatically increased K(m). We further show that the K(m) effect is independent of the substrate assayed. Finally, we identified the distinctive and strict substrate selectivity of DPP8 for hydrophobic or basic residues at the P2 site, which is in sharp contrast to the much less discriminative substrate specificity of DPP-IV. Our study has identified the residues absolutely required for the optimal activity of DPP8 and its unique substrate specificity. This study extends the functional importance of the C-terminal loop to the whole family of prolyl dipeptidases.},
  keywords = {Amino Acid Sequence Base Sequence DNA Primers Dimerization Dipeptidases/chemistry/genetics/isolation & purification/*metabolism Electrophoresis, Polyacrylamide Gel Humans Molecular Sequence Data Mutagenesis, Site-Directed Sequence Homology, Amino Acid Substrate Specificity},
  issn = {0021-9258 (Print) 0021-9258 (Linking)},
  doi = {10.1074/jbc.M603895200},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/17040910 http://www.jbc.org/content/281/50/38653.full.pdf},
  year = {2006},
  type = {Journal Article},
}


@inbook{Lendeckel:2006qv,
  author = {Lendeckel, Uwe and Reinhold, Dirk and Bank, Ute and Gorrell, MarkD. and Wang, XinM. and Park, Joohong and Ajami, Katerina and Yu, DeniseMingTse and Knott, Heather and Seth, Devanshi and McCaughan, GeoffreyW.},
  title = {{Advances in Experimental Medicine and Biology}},
  booktitle = {Dipeptidyl Aminopeptidases},
  publisher = {Springer US},
  volume = {575},
  pages = {45-54},
  isbn = {978-0-387-29058-4},
  doi = {10.1007/0-387-32824-6\_5},
  url = {http://dx.doi.org/10.1007/0-387-32824-6_5 http://dx.doi.org/10.1007/0-387-32824-6%7B%5C_%7D5},
  year = {2006},
  type = {Book Section},
}


@inbook{Lewis:2006vn,
  author = {Lewis, J. Kathleen and Wei, Jing and Siuzdak, Gary},
  title = {{Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry in Peptide and Protein Analysis}},
  booktitle = {Encyclopedia of Analytical Chemistry},
  publisher = {John Wiley \& Sons, Ltd},
  isbn = {9780470027318},
  doi = {10.1002/9780470027318.a1621},
  url = {http://dx.doi.org/10.1002/9780470027318.a1621 http://onlinelibrary.wiley.com/doi/10.1002/9780470027318.a1621/abstract http://onlinelibrary.wiley.com/doi/10.1002/9780470027318.a1621/abstract?systemMessage=Wiley+Online+Library+will+be+unavailable+on+Saturday+3rd+September+2016+at+08.30+BST%2F+03%3A30+EDT%2F+15%3A30+SGT+for+5+hours+and+Sunday+4th+September+at+10%3A00+BST%2F+05%3A00+EST%2F+17%3A00+SGT+for+1+hour++for+essential+maintenance.+Apologies+for+the+inconvenience http://onlinelibrary.wiley.com/doi/10.1002/9780470027318.a1621/abstract?systemMessage=WOL+Usage+report+download+page+will+be+unavailable+on+Friday+27th+January+2017+at+23%3A00+GMT%2F+18%3A00+EST%2F+07%3A00+SGT+%28Saturday+28th+Jan+for+SGT%29++for+up+to+2+hours+due+to+essential+server+maintenance.+Apologies+for+the+inconvenience. http://onlinelibrary.wiley.com/doi/10.1002/9780470027318.a1621/abstract?systemMessage=Pay+per+view+article+purchase%28PPV%29+on+Wiley+Online+Library+will+be+unavailable+on+Saturday+11th+March+from+05%3A00-14%3A00+GMT+%2F+12%3A00-09%3A00+EST+%2F+13%3A00-22%3A00+SGT+for+essential+maintenance.++Apologies+for+the+inconvenience.},
  year = {2006},
  type = {Book Section},
}


@article{Pitman:2006jo,
  author = {Pitman, M. R. and Menz, R. I. and Abbott, C. A.},
  title = {{Prediction of dipeptidyl peptidase (DP) 8 structure by homology modelling}},
  journal = {Adv Exp Med Biol},
  volume = {575},
  pages = {33-42},
  note = {Pitman, Melissa R Menz, R Ian Abbott, Catherine A Adv Exp Med Biol. 2006;575:33-42.},
  keywords = {Binding Sites Dipeptidases/*chemistry/genetics Dipeptidyl Peptidase 4/chemistry/genetics Dipeptidyl-Peptidases and Tripeptidyl-Peptidases Humans *Models, Molecular Molecular Sequence Data Nerve Tissue Proteins/chemistry/genetics Peptide Hydrolases/chemistry/genetics Potassium Channels/chemistry/genetics *Protein Structure, Tertiary Sequence Homology, Amino Acid Serine Endopeptidases/chemistry/genetics},
  issn = {0065-2598 (Print) 0065-2598 (Linking)},
  doi = {10.1007/0-387-32824-6_4},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/16700506 http://download-v2.springer.com/static/pdf/819/chp%253A10.1007%252F0-387-32824-6_4.pdf?token2=exp=1431790675~acl=%2Fstatic%2Fpdf%2F819%2Fchp%25253A10.1007%25252F0-387-32824-6_4.pdf*~hmac=a2e04542019ad150dec857b1f1bd197817e279a6d1e7631d53149b8f493cca70},
  year = {2006},
  type = {Journal Article},
}


@article{Sebolt-Leopold2006,
  author = {Sebolt-Leopold, J. S. and English, J. M.},
  title = {{Mechanisms of drug inhibition of signalling molecules}},
  journal = {Nature},
  volume = {441},
  number = {7092},
  pages = {457-62},
  note = {Sebolt-Leopold, Judith S English, Jessie M England Nature. 2006 May 25;441(7092):457-62.},
  abstract = {The emergence of tumour-specific, molecularly targeted agents signifies a paradigm shift in cancer therapy, with less reliance on drugs that non-discriminately kill tumour and host cells. Although the diversity of targets giving rise to this new generation of anticancer drugs has expanded, many challenges persist in the design of effective treatment regimens. The complex interplay of signal-transduction pathways further complicates the customization of cancer treatments to target single mechanisms. However, despite uncertainty over precise or dominant mechanisms of action, especially for compounds targeting multiple gene products, emerging agents are producing significant therapeutic advances against a broad range of human cancers.},
  keywords = {Animals Antineoplastic Agents/administration & dosage/chemistry/*pharmacology/*therapeutic use Humans Neoplasms/*drug therapy/enzymology/genetics/*metabolism Phosphotransferases/antagonists & inhibitors/metabolism Protein Kinase Inhibitors/chemistry/*pharmacology/therapeutic use Signal Transduction/*drug effects Substrate Specificity},
  issn = {1476-4687 (Electronic) 0028-0836 (Linking)},
  doi = {10.1038/nature04874},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/16724058 http://www.nature.com/nature/journal/v441/n7092/pdf/nature04874.pdf},
  year = {2006},
  type = {Journal Article},
}


@article{Yu:2006ai,
  author = {Yu, D. M. and Wang, X. M. and McCaughan, G. W. and Gorrell, M. D.},
  title = {{Extraenzymatic functions of the dipeptidyl peptidase IV-related proteins DP8 and DP9 in cell adhesion, migration and apoptosis}},
  journal = {FEBS J},
  volume = {273},
  number = {11},
  pages = {2447-60},
  note = {Yu, Denise M T Wang, Xin M McCaughan, Geoffrey W Gorrell, Mark D England FEBS J. 2006 Jun;273(11):2447-60.},
  abstract = {The dipeptidyl peptidase IV gene family contains the four peptidases dipeptidyl peptidase IV, fibroblast activation protein, dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Dipeptidyl peptidase IV and fibroblast activation protein are involved in cell-extracellular matrix interactions and tissue remodeling. Fibroblast activation protein is upregulated and dipeptidyl peptidase IV is dysregulated in chronic liver disease. The effects of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 on cell adhesion, cell migration, wound healing and apoptosis were measured by using green fluorescent protein fusion proteins to identify transfected cells. Dipeptidyl peptidase 9-overexpressing cells exhibited impaired cell adhesion, migration in transwells and monolayer wound healing on collagen I, fibronectin and Matrigel. Dipeptidyl peptidase 8-overexpressing cells exhibited impaired cell migration on collagen I and impaired wound healing on collagen I and fibronectin in comparison to the green fluorescent protein-transfected controls. Dipeptidyl peptidase 8 and dipeptidyl peptidase 9 enhanced induced apoptosis, and dipeptidyl peptidase 9 overexpression increased spontaneous apoptosis. Mechanistic investigations showed that neither the catalytic serine of dipeptidyl peptidase 8 or dipeptidyl peptidase 9 nor the Arg-Gly-Asp integrin-binding motif in dipeptidyl peptidase 9 were required for the impairment of cell survival, cell adhesion or wound healing. We have previously shown that the in vitro roles of dipeptidyl peptidase IV and fibroblast activation protein in cell-extracellular matrix interactions and apoptosis are similarly independent of catalytic activity. Dipeptidyl peptidase 9 overexpression reduced beta-catenin, tissue inhibitor of matrix metalloproteinases 2 and discoidin domain receptor 1 expression. This is the first demonstration that dipeptidyl peptidase 8 and dipeptidyl peptidase 9 influence cell-extracellular matrix interactions, and thus may regulate tissue remodeling.},
  keywords = {Adenosine Deaminase/*metabolism Apoptosis/*physiology Base Sequence Cell Adhesion/*physiology Cell Movement/*physiology DNA Primers DNA, Complementary/genetics Dipeptidases/genetics/*metabolism Dipeptidyl Peptidase 4/*metabolism Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/genetics/*metabolism Glycoproteins/*metabolism Humans Molecular Sequence Data Mutagenesis Recombinant Proteins/metabolism},
  issn = {1742-464X (Print) 1742-464X (Linking)},
  doi = {10.1111/j.1742-4658.2006.05253.x},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/16704418 http://onlinelibrary.wiley.com/store/10.1111/j.1742-4658.2006.05253.x/asset/j.1742-4658.2006.05253.x.pdf?v=1&t=i8vc4rja&s=93f5a71fe52b9097ddb29cb8925a1e15ef5e00fb http://onlinelibrary.wiley.com/store/10.1111/j.1742-4658.2006.05253.x/asset/j.1742-4658.2006.05253.x.pdf?v=1&t=i9r6if1z&s=fae2decde865f45ac11fc03c6c6ac29048991ff0},
  year = {2006},
  type = {Journal Article},
}


@article{Baggio:2007fy,
  author = {Baggio, L. L. and Drucker, D. J.},
  title = {{Biology of incretins: GLP-1 and GIP}},
  journal = {Gastroenterology},
  volume = {132},
  number = {6},
  pages = {2131-57},
  note = {Baggio, Laurie L Drucker, Daniel J Gastroenterology. 2007 May;132(6):2131-57.},
  abstract = {This review focuses on the mechanisms regulating the synthesis, secretion, biological actions, and therapeutic relevance of the incretin peptides glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). The published literature was reviewed, with emphasis on recent advances in our understanding of the biology of GIP and GLP-1. GIP and GLP-1 are both secreted within minutes of nutrient ingestion and facilitate the rapid disposal of ingested nutrients. Both peptides share common actions on islet beta-cells acting through structurally distinct yet related receptors. Incretin-receptor activation leads to glucose-dependent insulin secretion, induction of beta-cell proliferation, and enhanced resistance to apoptosis. GIP also promotes energy storage via direct actions on adipose tissue, and enhances bone formation via stimulation of osteoblast proliferation and inhibition of apoptosis. In contrast, GLP-1 exerts glucoregulatory actions via slowing of gastric emptying and glucose-dependent inhibition of glucagon secretion. GLP-1 also promotes satiety and sustained GLP-1-receptor activation is associated with weight loss in both preclinical and clinical studies. The rapid degradation of both GIP and GLP-1 by the enzyme dipeptidyl peptidase-4 has led to the development of degradation-resistant GLP-1-receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes. These agents decrease hemoglobin A1c (HbA1c) safely without weight gain in subjects with type 2 diabetes. GLP-1 and GIP integrate nutrient-derived signals to control food intake, energy absorption, and assimilation. Recently approved therapeutic agents based on potentiation of incretin action provide new physiologically based approaches for the treatment of type 2 diabetes.},
  keywords = {Animals Clinical Trials as Topic Diabetes Mellitus, Type 2/metabolism Gastric Inhibitory Polypeptide/*metabolism Gastrointestinal Hormones/metabolism Glucagon-Like Peptide 1/*metabolism Hemoglobin A, Glycosylated Hemoglobins/analysis Humans Insulin-Secreting Cells/*metabolism Receptors, Glucagon/*metabolism Signal Transduction},
  issn = {0016-5085 (Print) 0016-5085 (Linking)},
  doi = {10.1053/j.gastro.2007.03.054},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/17498508 http://ac.els-cdn.com/S001650850700580X/1-s2.0-S001650850700580X-main.pdf?_tid=96daf430-ea5c-11e4-af79-00000aab0f6c&acdnat=1429864591_41b961ed379ce0ddd19602b87e3a8311 http://ac.els-cdn.com/S001650850700580X/1-s2.0-S001650850700580X-main.pdf?_tid=db24c92a-fbde-11e4-b4aa-00000aab0f02&acdnat=1431789710_b6674cbcdcfaafa6dde023493bc05bc5},
  year = {2007},
  type = {Journal Article},
}


@article{Barsun:2007aa,
  author = {Barsun, M. and Jajcanin, N. and Vukelic, B. and Spoljaric, J. and Abramic, M.},
  title = {{Human dipeptidyl peptidase III acts as a post-proline-cleaving enzyme on endomorphins}},
  journal = {Biol Chem},
  volume = {388},
  number = {3},
  pages = {343-8},
  note = {Barsun, Marina Jajcanin, Nina Vukelic, Bojana Spoljaric, Jasminka Abramic, Marija Germany Biol Chem. 2007 Mar;388(3):343-8.},
  abstract = {Dipeptidyl peptidase III (DPP III) is a zinc exopeptidase with an implied role in the mammalian pain-modulatory system owing to its high affinity for enkephalins and localisation in the superficial laminae of the spinal cord dorsal horn. Our study revealed that this human enzyme hydrolyses opioid peptides belonging to three new groups, endomorphins, hemorphins and exorphins. The enzymatic hydrolysis products of endomorphin-1 were separated and quantified by capillary electrophoresis and the kinetic parameters were determined for human DPP III and rat DPP IV. Both peptidases cleave endomorphin-1 at comparable rates, with liberation of the N-terminal Tyr-Pro. This is the first evidence of DPP III acting as an endomorphin-cleaving enzyme.},
  keywords = {Aminopeptidases/metabolism Animals Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/*metabolism Humans Oligopeptides/*metabolism Proline Rats Serine Endopeptidases/*metabolism},
  issn = {1431-6730 (Print) 1431-6730 (Linking)},
  doi = {10.1515/BC.2007.039},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/17338643 http://www.degruyter.com/view/j/bchm.2007.388.issue-3/bc.2007.039/bc.2007.039.xml http://www.degruyter.com/view/j/bchm.2007.388.issue-3/bc.2007.039/bc.2007.039.xml;jsessionid=42AFC31E11B9B9CE22806417032AACD9 http://www.degruyter.com/view/j/bchm.2007.388.issue-3/bc.2007.039/bc.2007.039.xml;jsessionid=82557E53EB797744A35917E22480C32F http://www.degruyter.com/view/j/bchm.2007.388.issue-3/bc.2007.039/bc.2007.039.xml;jsessionid=00ABC9A735994D2A5797DB9C2F0F3755 http://www.degruyter.com/view/j/bchm.2007.388.issue-3/bc.2007.039/bc.2007.039.xml;jsessionid=53E9E20F3AC621A29E90DEC101DD5BC9 http://www.degruyter.com/view/j/bchm.2007.388.issue-3/bc.2007.039/bc.2007.039.xml;jsessionid=034120FA38DFCC10661D0E25358866FD https://www.degruyter.com/view/j/bchm.2007.388.issue-3/bc.2007.039/bc.2007.039.xml},
  year = {2007},
  type = {Journal Article},
}


@article{Bock:2007bq,
  author = {Bock, P. E. and Panizzi, P. and Verhamme, I. M.},
  title = {{Exosites in the substrate specificity of blood coagulation reactions}},
  journal = {J Thromb Haemost},
  volume = {5 Suppl 1},
  pages = {81-94},
  note = {Bock, P E Panizzi, P Verhamme, I M A HL038779/HL/NHLBI NIH HHS/ HL080018/HL/NHLBI NIH HHS/ R00 HL094533/HL/NHLBI NIH HHS/ R01 HL038779-21/HL/NHLBI NIH HHS/ England J Thromb Haemost. 2007 Jul;5 Suppl 1:81-94.},
  abstract = {The specificity of blood coagulation proteinases for substrate, inhibitor, and effector recognition is mediated by exosites on the surfaces of the catalytic domains, physically separated from the catalytic site. Some thrombin ligands bind specifically to either exosite I or II, while others engage both exosites. The involvement of different, overlapping constellations of exosite residues enables binding of structurally diverse ligands. The flexibility of the thrombin structure is central to the mechanism of complex formation and the specificity of exosite interactions. Encounter complex formation is driven by electrostatic ligand-exosite interactions, followed by conformational rearrangement to a stable complex. Exosites on some zymogens are in low affinity proexosite states and are expressed concomitant with catalytic site activation. The requirement for exosite expression controls the specificity of assembly of catalytic complexes on the coagulation pathway, such as the membrane-bound factor Xa*factor Va (prothrombinase) complex, and prevents premature assembly. Substrate recognition by prothrombinase involves a two-step mechanism with initial docking of prothrombin to exosites, followed by a conformational change to engage the FXa catalytic site. Prothrombin and its activation intermediates bind prothrombinase in two alternative conformations determined by the zymogen to proteinase transition that are hypothesized to involve prothrombin (pro)exosite I interactions with FVa, which underpin the sequential activation pathway. The role of exosites as the major source of substrate specificity has stimulated development of exosite-targeted anticoagulants for treatment of thrombosis.},
  keywords = {*Blood Coagulation Blood Coagulation Factors/chemistry/*metabolism Humans Models, Molecular Substrate Specificity},
  issn = {1538-7933 (Print) 1538-7836 (Linking)},
  doi = {10.1111/j.1538-7836.2007.02496.x},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/17635714 http://onlinelibrary.wiley.com/store/10.1111/j.1538-7836.2007.02496.x/asset/j.1538-7836.2007.02496.x.pdf?v=1&t=i8vccm2b&s=a3d91c6180e5277fe94580daeb109e606625fb42 http://onlinelibrary.wiley.com/store/10.1111/j.1538-7836.2007.02496.x/asset/j.1538-7836.2007.02496.x.pdf?v=1&t=i9r6j3xg&s=53389ca7750e45a3477fb5c3409e0ac308f9c259},
  year = {2007},
  type = {Journal Article},
}


@article{Chen:2007qa,
  author = {Chen, T. and Muratore, T. L. and Schaner-Tooley, C. E. and Shabanowitz, J. and Hunt, D. F. and Macara, I. G.},
  title = {{N-terminal alpha-methylation of RCC1 is necessary for stable chromatin association and normal mitosis}},
  journal = {Nat Cell Biol},
  volume = {9},
  number = {5},
  pages = {596-603},
  note = {Chen, Ting Muratore, Tara L Schaner-Tooley, Christine E Shabanowitz, Jeffrey Hunt, Donald F Macara, Ian G CA040042/CA/NCI NIH HHS/ GM070902/GM/NIGMS NIH HHS/ GM37537/GM/NIGMS NIH HHS/ England Nat Cell Biol. 2007 May;9(5):596-603. Epub 2007 Apr 15.},
  abstract = {Regulator of chromatin condensation 1 (RCC1) is the only known guanine nucleotide-exchange factor for the Ran GTPase and has pivotal roles in nucleo-cytoplasmic transport, mitosis, and nuclear-envelope assembly. RCC1 associates dynamically with chromatin through binding to histones H2A and/or H2B in a Ran-regulated manner. Here, we report that, unexpectedly, the amino-terminal serine or proline residue of RCC1 is uniquely methylated on its alpha-amino group. Methylation requires removal of the initiating methionine, and the presence of proline and lysine at positions 3 and 4, respectively. Methylation-defective mutants of RCC1 bind less effectively than wild-type protein to chromatin during mitosis, which causes spindle-pole defects. We propose a bimodal attachment mechanism for RCC1 in which the tail promotes stable RCC1 association with chromatin through DNA binding in an alpha-N-methylation-dependent manner. These data provide the first known function for N-terminal protein methylation.},
  keywords = {Animals Cell Cycle Proteins/chemistry/genetics/*metabolism Chromatin/*metabolism *Chromatin Assembly and Disassembly Cloning, Molecular DNA/metabolism Dogs Guanine Nucleotide Exchange Factors/chemistry/genetics/*metabolism HeLa Cells Histones/metabolism Humans Kinetics Luminescent Proteins/genetics/metabolism Methionine/chemistry Methylation Mitosis/*physiology Mutation Nuclear Proteins/chemistry/genetics/*metabolism Proline/metabolism Protein Binding Protein Conformation Protein Methyltransferases/*metabolism *Protein Processing, Post-Translational Recombinant Fusion Proteins/metabolism Serine/metabolism ran GTP-Binding Protein/metabolism},
  issn = {1465-7392 (Print) 1465-7392 (Linking)},
  doi = {10.1038/ncb1572},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/17435751},
  year = {2007},
  type = {Journal Article},
}


@article{Diamond200746,
  author = {Diamond, S. L.},
  title = {{Methods for mapping protease specificity}},
  journal = {Curr Opin Chem Biol},
  volume = {11},
  number = {1},
  pages = {46-51},
  note = {Diamond, Scott L R01-HL56621/HL/NHLBI NIH HHS/ R33-HL87317/HL/NHLBI NIH HHS/ U54-HG3915/HG/NHGRI NIH HHS/ England Curr Opin Chem Biol. 2007 Feb;11(1):46-51. Epub 2006 Dec 6.},
  abstract = {The study of protease specificity provides information on active-site structure and function, protein-protein interaction, regulation of intracellular and extracellular pathways, and evolution of protease and substrate genes. Peptide libraries that include fluorogenic and binding tags are often generated by solid-phase synthesis. Even larger explorations of cleavage site preferences employ positional scanning libraries or phage display. Microarrays enable presentation of individual peptides to proteases, DNA sequences for capture of peptide nucleic acid encoded peptides, or nanodroplets containing soluble peptide sequences. These new methods continue to inform the design of chemical inhibitors and the identification of substrates of proteases.},
  keywords = {Amino Acid Sequence Binding Sites Cell Membrane/chemistry/metabolism Fluorescence Microarray Analysis/*methods Molecular Sequence Data Peptide Fragments/chemistry/genetics/*metabolism *Peptide Hydrolases/chemistry/genetics/metabolism *Peptide Library Peptide Mapping/*methods Sensitivity and Specificity Staining and Labeling Substrate Specificity},
  issn = {1367-5931 (Print) 1367-5931 (Linking)},
  doi = {10.1016/j.cbpa.2006.11.021},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/17157549 http://ac.els-cdn.com/S1367593106001852/1-s2.0-S1367593106001852-main.pdf?_tid=df938fb4-fbde-11e4-8963-00000aacb362&acdnat=1431789718_37c961361e3f731499ca6496d81f682d},
  year = {2007},
  type = {Journal Article},
}


@book{Dubitzky2007,
  author = {Dubitzky, Werner; Granzow, Martin; Berrar Daniel P. (Eds.)},
  title = {{Fundamentals of Data Mining in Genomics and Proteomics}},
  publisher = {Springer US: Boston, MA},
  address = {Boston, MA},
  keywords = {Life Sciences -- Bioinformatics Life Sciences -- Computer Appl. in Life Sciences Life Sciences -- Biotechnology Life Sciences -- Proteomics Life Sciences -- Cancer Research Life Sciences -- Human Genetics},
  year = {2007},
  type = {Book},
}


@article{Ekins:2007aa,
  author = {Ekins, S. and Mestres, J. and Testa, B.},
  title = {{In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling}},
  journal = {Br J Pharmacol},
  volume = {152},
  number = {1},
  pages = {9-20},
  note = {Ekins, S Mestres, J Testa, B England Br J Pharmacol. 2007 Sep;152(1):9-20. Epub 2007 Jun 4.},
  abstract = {Pharmacology over the past 100 years has had a rich tradition of scientists with the ability to form qualitative or semi-quantitative relations between molecular structure and activity in cerebro. To test these hypotheses they have consistently used traditional pharmacology tools such as in vivo and in vitro models. Increasingly over the last decade however we have seen that computational (in silico) methods have been developed and applied to pharmacology hypothesis development and testing. These in silico methods include databases, quantitative structure-activity relationships, pharmacophores, homology models and other molecular modeling approaches, machine learning, data mining, network analysis tools and data analysis tools that use a computer. In silico methods are primarily used alongside the generation of in vitro data both to create the model and to test it. Such models have seen frequent use in the discovery and optimization of novel molecules with affinity to a target, the clarification of absorption, distribution, metabolism, excretion and toxicity properties as well as physicochemical characterization. The aim of this review is to illustrate some of the in silico methods for pharmacology that are used in drug discovery. Further applications of these methods to specific targets and their limitations will be discussed in the second accompanying part of this review.},
  keywords = {Animals Computer Graphics *Computer-Aided Design/history *Databases as Topic *Drug Design Gene Regulatory Networks History, 19th Century History, 20th Century Humans *Ligands Metabolic Networks and Pathways Models, Biological Models, Molecular Molecular Structure Pharmacokinetics Protein Conformation Quantitative Structure-Activity Relationship Signal Transduction *Systems Biology *User-Computer Interface},
  issn = {0007-1188 (Print) 0007-1188 (Linking)},
  doi = {10.1038/sj.bjp.0707305},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/17549047 http://onlinelibrary.wiley.com/store/10.1038/sj.bjp.0707305/asset/sj.bjp.0707305.pdf?v=1&t=i8vcbjxn&s=55c14eaed7570a8180f771ad2184e479e11b378c http://onlinelibrary.wiley.com/store/10.1038/sj.bjp.0707305/asset/sj.bjp.0707305.pdf?v=1&t=i9r6irsy&s=d8e75efe19e72aa98189f53475ca0331fc113384},
  year = {2007},
  type = {Journal Article},
}


@article{BPH:BPH505,
  author = {Ekins, S. and Mestres, J. and Testa, B.},
  title = {{In silico pharmacology for drug discovery: applications to targets and beyond}},
  journal = {Br J Pharmacol},
  volume = {152},
  number = {1},
  pages = {21-37},
  note = {Ekins, S Mestres, J Testa, B England Br J Pharmacol. 2007 Sep;152(1):21-37. Epub 2007 Jun 4.},
  abstract = {Computational (in silico) methods have been developed and widely applied to pharmacology hypothesis development and testing. These in silico methods include databases, quantitative structure-activity relationships, similarity searching, pharmacophores, homology models and other molecular modeling, machine learning, data mining, network analysis tools and data analysis tools that use a computer. Such methods have seen frequent use in the discovery and optimization of novel molecules with affinity to a target, the clarification of absorption, distribution, metabolism, excretion and toxicity properties as well as physicochemical characterization. The first part of this review discussed the methods that have been used for virtual ligand and target-based screening and profiling to predict biological activity. The aim of this second part of the review is to illustrate some of the varied applications of in silico methods for pharmacology in terms of the targets addressed. We will also discuss some of the advantages and disadvantages of in silico methods with respect to in vitro and in vivo methods for pharmacology research. Our conclusion is that the in silico pharmacology paradigm is ongoing and presents a rich array of opportunities that will assist in expediting the discovery of new targets, and ultimately lead to compounds with predicted biological activity for these novel targets.},
  keywords = {Animals Anti-Bacterial Agents/chemistry Antiviral Agents/chemistry Carrier Proteins/chemistry Computer Graphics *Computer-Aided Design/trends *Databases as Topic *Drug Design Enzymes/chemistry Gene Regulatory Networks Humans Ion Channels/chemistry *Ligands Metabolic Networks and Pathways Models, Biological Models, Molecular Molecular Structure Pharmacokinetics Pharmacology/*methods/trends Protein Conformation Quantitative Structure-Activity Relationship Receptors, Cell Surface/chemistry Receptors, Cytoplasmic and Nuclear/chemistry Signal Transduction *Systems Biology/trends Transcription Factors/chemistry *User-Computer Interface},
  issn = {0007-1188 (Print) 0007-1188 (Linking)},
  doi = {10.1038/sj.bjp.0707306},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/17549046 http://onlinelibrary.wiley.com/store/10.1038/sj.bjp.0707306/asset/sj.bjp.0707306.pdf?v=1&t=i8vcbctr&s=1dd51c84093b934d674e9e85beadf5aaa0f138fc http://onlinelibrary.wiley.com/store/10.1038/sj.bjp.0707306/asset/sj.bjp.0707306.pdf?v=1&t=i9r6ixjn&s=023768d00e4a6c068beb30e9befb8adc935cb0bf},
  year = {2007},
  type = {Journal Article},
}


@article{Frerker:2007rw,
  author = {Frerker, N. and Wagner, L. and Wolf, R. and Heiser, U. and Hoffmann, T. and Rahfeld, J. U. and Schade, J. and Karl, T. and Naim, H. Y. and Alfalah, M. and Demuth, H. U. and von Horsten, S.},
  title = {{Neuropeptide Y (NPY) cleaving enzymes: structural and functional homologues of dipeptidyl peptidase 4}},
  journal = {Peptides},
  volume = {28},
  number = {2},
  pages = {257-68},
  note = {Frerker, Nadine Wagner, Leona Wolf, Raik Heiser, Ulrich Hoffmann, Torsten Rahfeld, Jens-Ulrich Schade, Jutta Karl, Tim Naim, Hassan Y Alfalah, Marwan Demuth, Hans-Ulrich von Horsten, Stephan Peptides. 2007 Feb;28(2):257-68. Epub 2007 Jan 16.},
  abstract = {N-terminal truncation of NPY has important physiological consequences, because the truncated peptides lose their capability to activate the Y1-receptor. The sources of N-terminally truncated NPY and related peptides are unknown and several proline specific peptidases may be involved. First, we therefore provide an overview on the peptidases, belonging to structural and functional homologues of dipeptidyl peptidase 4 (DP4) as well as aminopeptidase P (APP) and thus, represent potential candidates of NPY cleavage in vivo. Second, applying selective inhibitors against DP4, DP8/9 and DP2, respectively, the enzymatic distribution was analyzed in brain extracts from wild type and DP4 deficient F344 rat substrains and human plasma samples in activity studies as well as by matrix assisted laser desorption/ionisation-time of flight (MALDI-TOF)-mass spectrometry. Third, co-transfection of Cos-1 cells with Dpp4 and Npy followed by confocal lasermicroscopy illustrated that hNPY-dsRed1-N1 was transported in large dense core vesicles towards the membrane while rDP4-GFP-C1 was transported primarily in different vesicles thereby providing no clear evidence for co-localization of NPY and DP4. Nevertheless, the review and experimental results of activity and mass spectrometry studies support the notion that at least five peptidases (DP4, DP8, DP9, XPNPEP1, XPNPEP2) are potentially involved in NPY cleavage while the serine protease DP4 (CD26) could be the principal peptidase involved in the N-terminal truncation of NPY. However, DP8 and DP9 are also capable of cleaving NPY, whereas no cleavage could be demonstrated for DP2.},
  keywords = {Animals Base Sequence COS Cells Cercopithecus aethiops DNA Primers Dipeptidyl Peptidase 4/*metabolism Hydrolysis Microscopy, Confocal Microscopy, Fluorescence Neuropeptide Y/*metabolism Rats Rats, Inbred F344 Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization},
  issn = {0196-9781 (Print) 0196-9781 (Linking)},
  doi = {10.1016/j.peptides.2006.09.027},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/17223229 http://ac.els-cdn.com/S0196978106005389/1-s2.0-S0196978106005389-main.pdf?_tid=6c68cba0-ea5c-11e4-b899-00000aacb35f&acdnat=1429864520_8fa43126d446daf59248340c3a9ac9cc http://ac.els-cdn.com/S0196978106005389/1-s2.0-S0196978106005389-main.pdf?_tid=e786d62c-fbde-11e4-96ad-00000aacb360&acdnat=1431789731_093f86bb5fc2783089f807e487424d1b},
  year = {2007},
  type = {Journal Article},
}


@article{Galperin2007,
  author = {Galperin, M. Y.},
  title = {{The Molecular Biology Database Collection: 2007 update}},
  journal = {Nucleic Acids Res},
  volume = {35},
  number = {Database issue},
  pages = {D3-4},
  note = {Galperin, Michael Y Z99 LM999999/LM/NLM NIH HHS/ England Nucleic Acids Res. 2007 Jan;35(Database issue):D3-4. Epub 2006 Dec 5.},
  abstract = {The NAR online Molecular Biology Database Collection is a public resource that contains links to the databases described in this issue of Nucleic Acids Research, previous NAR database issues, as well as a selection of other molecular biology databases that are freely available on the web and might be useful to the molecular biologist. The 2007 update includes 968 databases, 110 more than the previous one. Many databases that have been described in earlier issues of NAR come with updated summaries, which reflect recent progress and, in some instances, an expanded scope of these databases. The complete database list and summaries are available online on the Nucleic Acids Research web site http://nar.oxfordjournals.org/.},
  keywords = {*Databases, Genetic/statistics & numerical data/utilization Internet *Molecular Biology},
  issn = {1362-4962 (Electronic) 0305-1048 (Linking)},
  doi = {10.1093/nar/gkl1008},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/17148484 http://nar.oxfordjournals.org/content/35/suppl_1/D3.full.pdf},
  year = {2007},
  type = {Journal Article},
}


@article{Kang:2007qp,
  author = {Kang, N. S. and Ahn, J. H. and Kim, S. S. and Chae, C. H. and Yoo, S. E.},
  title = {{Docking-based 3D-QSAR study for selectivity of DPP4, DPP8, and DPP9 inhibitors}},
  journal = {Bioorg Med Chem Lett},
  volume = {17},
  number = {13},
  pages = {3716-21},
  note = {Kang, Nam Sook Ahn, Jin Hee Kim, Sung Soo Chae, Chong Hak Yoo, Sung-Eun England Bioorg Med Chem Lett. 2007 Jul 1;17(13):3716-21. Epub 2007 Apr 13.},
  abstract = {In order to obtain information regarding the design of selective DPP4 inhibitors, a 3D-QSAR study was conducted using DPP4, DPP8, and DPP9 inhibitors including newly synthesized six- and seven-membered cyclic hydrazine derivatives (KR64300, KR64301), which were evaluated in vitro for their inhibition of DPP4, DPP8, and DPP9. In this study, a highly predictive CoMFA model based on the fast-docking for DPP4, DPP8, and DPP9 inhibitors was obtained. This reliable model showed leave-one-out cross-validation q(2) and conventional r(2) values of 0.68 and 0.96 for the DPP4 inhibitors, 0.58 and 0.98 for the DPP8 inhibitors, and 0.68 and 0.97 for the DPP9 inhibitors, respectively. The validation of the CoMFA model was confirmed by the compounds in the test set, including the synthesized six- and seven-membered cyclic hydrazines. According to this study, to obtain selective DPP4 inhibitors compared to their isozymes, the interaction of the inhibitors with the S3 site and S1' site in DPP4 must be considered. The proposed newly synthesized compounds, KR64300 and KR64301, interact well with the sites mentioned above, showing excellent selectivity.},
  keywords = {*Adenosine Deaminase Inhibitors Binding Sites Chemistry, Pharmaceutical/*methods Dipeptidases/*antagonists & inhibitors Dipeptidyl Peptidase 4 *Dipeptidyl-Peptidase IV Inhibitors Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/*antagonists & inhibitors Drug Design *Drug Evaluation, Preclinical Enzyme Inhibitors/*chemical synthesis/pharmacology Glycoproteins/*antagonists & inhibitors Humans Inhibitory Concentration 50 Models, Chemical Molecular Structure Protein Conformation Quantitative Structure-Activity Relationship Substrate Specificity},
  issn = {0960-894X (Print) 0960-894X (Linking)},
  doi = {10.1016/j.bmcl.2007.04.031},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/17462890 http://ac.els-cdn.com/S0960894X07004519/1-s2.0-S0960894X07004519-main.pdf?_tid=3f1f557e-ea5c-11e4-b804-00000aacb360&acdnat=1429864444_33ca30f50dcff9c980b8af5b4222e14f http://ac.els-cdn.com/S0960894X07004519/1-s2.0-S0960894X07004519-main.pdf?_tid=eab9971c-fbde-11e4-8375-00000aab0f26&acdnat=1431789736_8fc9afa02bda16058d1903db2eebc7ab},
  year = {2007},
  type = {Journal Article},
}


@article{Klipp2007,
  author = {Klipp, Edda and Liebermeister, Wolfram and Helbig, Anselm and Kowald, Axel and Schaber, Jorg},
  title = {{Systems biology standards[mdash]the community speaks}},
  journal = {Nat Biotech},
  volume = {25},
  number = {4},
  pages = {390-391},
  note = {10.1038/nbt0407-390},
  year = {2007},
  type = {Journal Article},
}


@article{Lauster2007,
  author = {Lauster, Colleen D. and McKaveney, Teresa P. and Muench, Sarah V.},
  title = {{Vildagliptin: a novel oral therapy for type 2 diabetes mellitus.(Drug overview)}},
  journal = {American Journal of Health-System Pharmacy},
  volume = {64},
  number = {12},
  pages = {1265},
  keywords = {Hypoglycemic Agents},
  url = {http://graphics.tx.ovid.com/ovftpdfs/FPDDNCLBMFLKAN00/fs046/ovft/live/gv025/00043627/00043627-200706150-00012.pdf},
  year = {2007},
  type = {Journal Article},
}


@article{Maes:2007dw,
  author = {Maes, M. B. and Dubois, V. and Brandt, I. and Lambeir, A. M. and Van der Veken, P. and Augustyns, K. and Cheng, J. D. and Chen, X. and Scharpe, S. and De Meester, I.},
  title = {{Dipeptidyl peptidase 8/9-like activity in human leukocytes}},
  journal = {J Leukoc Biol},
  volume = {81},
  number = {5},
  pages = {1252-7},
  note = {Maes, Marie-Berthe Dubois, Veronique Brandt, Inger Lambeir, Anne-Marie Van der Veken, Pieter Augustyns, Koen Cheng, Jonathan D Chen, Xin Scharpe, Simon De Meester, Ingrid J Leukoc Biol. 2007 May;81(5):1252-7. Epub 2007 Feb 7.},
  abstract = {The proline-specific dipeptidyl peptidases (DPPs) are emerging as a protease family with important roles in the regulation of signaling by peptide hormones. Inhibitors of DPPs have an intriguing, therapeutic potential, with clinical efficacy seen in patients with diabetes. Until now, only recombinant forms of DPP8 and DPP9 have been characterized. Their enzymatic activities have not been demonstrated in or purified from any natural source. Using several selective DPP inhibitors, we show that DPP activity, attributable to DPP8/9 is present in human PBMC. All leukocyte types tested (lymphocytes, monocytes, Jurkat, and U937 cells) were shown to contain similar DPP8/9-specific activities, and DPPII- and DPPIV-specific activities varied considerably. The results were confirmed by DPPIV/CD26 immunocapture experiments. Subcellular fractionation localized the preponderance of DPP8/9 activity to the cytosol and DPPIV in the membrane fractions. Using Jurkat cell cytosol as a source, a 30-fold, enriched DPP preparation was obtained, which had enzymatic characteristics closely related to the ones of DPP8 and/or -9, including inhibition by allo-Ile-isoindoline and affinity for immobilized Lys-isoindoline.},
  keywords = {Adamantane/analogs & derivatives/chemistry/pharmacology Antibodies, Monoclonal/metabolism Dipeptidases/antagonists & inhibitors/*metabolism Dipeptidyl Peptidase 4/immunology Dipeptidyl-Peptidase IV Inhibitors Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/antagonists & inhibitors/*metabolism Enzyme Activation/drug effects Humans Indoles/chemistry/pharmacology Isoleucine/analogs & derivatives/chemistry/pharmacology Leukocytes/*immunology Molecular Conformation Nitriles/chemistry/pharmacology Organophosphonates/chemistry/pharmacology Piperidines/chemistry/pharmacology Proline/analogs & derivatives/chemistry/pharmacology Protease Inhibitors/chemistry/pharmacology Pyrrolidines/chemistry/pharmacology Stereoisomerism Structure-Activity Relationship},
  issn = {0741-5400 (Print) 0741-5400 (Linking)},
  doi = {10.1189/jlb.0906546},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/17287297 http://www.jleukbio.org/content/81/5/1252.full.pdf},
  year = {2007},
  type = {Journal Article},
}


@article{Overall:2007dp,
  author = {Overall, C. M. and Blobel, C. P.},
  title = {{In search of partners: linking extracellular proteases to substrates}},
  journal = {Nat Rev Mol Cell Biol},
  volume = {8},
  number = {3},
  pages = {245-57},
  note = {Overall, Christopher M Blobel, Carl P England Nat Rev Mol Cell Biol. 2007 Mar;8(3):245-57. Epub 2007 Feb 14.},
  abstract = {Proteases function as molecular switches in signalling circuits at the cell surface and in the extracellular milieu. In light of the many proteases that are encoded by the genome, and the even larger number of bioactive substrates, it is crucial to identify which proteases cleave a particular substrate and which substrates individual proteases cleave. Elucidating the substrate degradomes of proteases will help us to understand the function of proteases in development and disease and to validate proteases as drug targets.},
  keywords = {Animals Humans Peptide Hydrolases/*chemistry/genetics/*metabolism Proteomics/*methods Substrate Specificity},
  issn = {1471-0072 (Print) 1471-0072 (Linking)},
  doi = {10.1038/nrm2120},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/17299501},
  year = {2007},
  type = {Journal Article},
}


@article{Rummey:2007hh,
  author = {Rummey, C. and Metz, G.},
  title = {{Homology models of dipeptidyl peptidases 8 and 9 with a focus on loop predictions near the active site}},
  journal = {Proteins},
  volume = {66},
  number = {1},
  pages = {160-71},
  note = {Rummey, Christian Metz, Gunther Proteins. 2007 Jan 1;66(1):160-71.},
  abstract = {Dipeptidyl peptidase 4 (DP4) inhibitors are currently under intensive investigation in late-stage clinical trials as a treatment for type II diabetes. Lack of selectivity toward the related enzymes DP8 and DP9 has recently emerged as a possible source of drug-induced toxicity. Unlike DP4, X-ray structures of DP8 and DP9 are not yet available. As an aid to understanding the structural basis for selectivity, the authors have constructed homology models of DP8 and DP9 based on the X-ray coordinates of DP4. Accurate sequence alignment reveals common structural features indicative for a well-preserved overall fold comprising two domains, namely, a hydrolase domain and a so-called beta-propeller, which together form the active site deeply buried within the protein. The conformation of two loops inside this deep cavity is particularly relevant for the active sites. The authors used a published protocol for loop prediction based on conformational sampling and energy analysis to generate plausible solutions for these two loops. The predictive power of the approach was successfully evaluated for the template protein DP4 and two additional known structures from the same protein family, namely, FAP and DPX. The authors also show that inclusion of the covalent ligand NVP-728 greatly enhances the refinement. Based on the established evaluation protocol, the corresponding loops of DP8 and DP9 were predicted and the resulting active sites were compared with DP4. In particular, the authors conclude that differences in the P2-pocket are relevant for the design of selective DP4 inhibitors. The loss of key interactions in DP8 and DP9 as predicted from their models is consistent with the selectivity profile of the DP4 clinical candidate MK-431.},
  keywords = {Adenosine Deaminase/chemistry/metabolism Amino Acid Sequence Binding Sites Crystallography, X-Ray Dipeptidases/*chemistry Dipeptidyl Peptidase 4/chemistry/metabolism Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/*chemistry Glycoproteins/chemistry/metabolism Humans Hydrolases/chemistry Ligands *Models, Molecular Molecular Sequence Data Protein Conformation Protein Structure, Tertiary Sequence Alignment Structural Homology, Protein Structure-Activity Relationship},
  issn = {1097-0134 (Electronic) 0887-3585 (Linking)},
  doi = {10.1002/prot.21138},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/17068815 http://onlinelibrary.wiley.com/store/10.1002/prot.21138/asset/21138_ftp.pdf?v=1&t=i9r6jegm&s=e25ca594baede007ce5bf3bb21ff064cd073dcb5},
  year = {2007},
  type = {Journal Article},
}


@article{Thompson:2007aa,
  author = {Thompson, M. A. and Ohnuma, K. and Abe, M. and Morimoto, C. and Dang, N. H.},
  title = {{CD26/dipeptidyl peptidase IV as a novel therapeutic target for cancer and immune disorders}},
  journal = {Mini-Reviews in Medicinal Chemistry},
  volume = {7},
  number = {3},
  pages = {253-273},
  note = {135MR Times Cited:29 Cited References Count:217},
  abstract = {CD26 is a 110 kDa surface glycoprotein with intrinsic dipeptidyl peptidase IV (DPPIV) activity that is expressed on numerous cell types and has a multitude of biological functions. An important aspect of CD26 biology is its peptidase activity and its functional and physical association with molecules with key roles in various cellular pathways and biological programs. CD26 role in immune regulation has been extensively characterized, with recent findings elucidating its linkage with signaling pathways and structures involved in T-lymphocyte activation as well as antigen presenting cell-T-cell interaction. Recent work also suggests that CD26 has a significant role in tumor biology, being both a marker of disease behavior clinically as well as playing an important role in tumor pathogenesis and development. In this paper, we will review emerging data that suggest CD26 may be an appropriate therapeutic target for the treatment of selected neoplasms and immune disorders. Through the use of various experimental approaches and agents to influence CD26/DPPIV expression and activity, such as anti-CD26 antibodies, CD26/DPPIV chemical inhibitors, siRNAs to inhibit CD26 expression, overexpressing CD26 transfectants and soluble CD26 molecules, our group has shown that CD26 interacts with structures with essential cellular functions. Its association with such key molecules as topoisomerase II alpha, p38 MAPK, and integrin PI, has important clinical implications, including its potential ability to regulate tumor sensitivity to selected chemotherapies and to influence tumor migration/metastases and tumorigenesis. Importantly, our recent in vitro and in vivo data support the hypothesis that CD26 may indeed be an appropriate target for therapy for selected cancers and immune disorders.},
  keywords = {cd26 dipeptidyl peptidase iv (dppiv, dpp4) adenosine deaminase (ada) autoimmune t-cell t-cell-activation dipeptidyl aminopeptidase-iv adenosine-deaminase-binding human-immunodeficiency-virus improved glucose-tolerance non-hodgkins-lymphomas beta-propeller domain gastric-inhibitory polypeptide topoisomerase-ii inhibitors amino-terminal truncation},
  issn = {1389-5575},
  doi = {Doi 10.2174/138955707780059853},
  url = {<Go to ISI>://000244158200005},
  year = {2007},
  type = {Journal Article},
}


@article{Timmer:2007kl,
  author = {Timmer, J. C. and Enoksson, M. and Wildfang, E. and Zhu, W. and Igarashi, Y. and Denault, J. B. and Ma, Y. and Dummitt, B. and Chang, Y. H. and Mast, A. E. and Eroshkin, A. and Smith, J. W. and Tao, W. A. and Salvesen, G. S.},
  title = {{Profiling constitutive proteolytic events in vivo}},
  journal = {Biochem J},
  volume = {407},
  number = {1},
  pages = {41-8},
  note = {Timmer, John C Enoksson, Mari Wildfang, Eric Zhu, Wenhong Igarashi, Yoshinobu Denault, Jean-Benard Ma, Yuliang Dummitt, Benjamin Chang, Yie-Hwa Mast, Alan E Eroshkin, Alexey Smith, Jeffrey W Tao, W Andy Salvesen, Guy S RR19752/RR/NCRR NIH HHS/ RR20843/RR/NCRR NIH HHS/ U54 RR020843/RR/NCRR NIH HHS/ England Biochem J. 2007 Oct 1;407(1):41-8.},
  abstract = {Most known organisms encode proteases that are crucial for constitutive proteolytic events. In the present paper, we describe a method to define these events in proteomes from Escherichia coli to humans. The method takes advantage of specific N-terminal biotinylation of protein samples, followed by affinity enrichment and conventional LC (liquid chromatography)-MS/MS (tandem mass spectrometry) analysis. The method is simple, uses conventional and easily obtainable reagents, and is applicable to most proteomics facilities. As proof of principle, we demonstrate profiles of proteolytic events that reveal exquisite in vivo specificity of methionine aminopeptidase in E. coli and unexpected processing of mitochondrial transit peptides in yeast, mouse and human samples. Taken together, our results demonstrate how to rapidly distinguish real proteolysis that occurs in vivo from the predictions based on in vitro experiments.},
  keywords = {Amino Acid Sequence Aminopeptidases/chemistry/metabolism Animals Aprotinin/chemistry/metabolism Blood Proteins/chemistry/metabolism Caspases/chemistry/metabolism Cells, Cultured Chromatography, Liquid/*methods Genome, Fungal Humans Methionyl Aminopeptidases Methylurea Compounds/pharmacology Mice Mitochondria/metabolism Models, Biological Molecular Sequence Data Peptide Hydrolases/*metabolism Peptides/analysis/chemistry/metabolism Proteome/analysis/metabolism Proteomics/*methods Tandem Mass Spectrometry/*methods},
  issn = {1470-8728 (Electronic) 0264-6021 (Linking)},
  doi = {10.1042/BJ20070775},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/17650073 http://www.biochemj.org/bj/407/0041/4070041.pdf},
  year = {2007},
  type = {Journal Article},
}


@article{Uno2007,
  author = {Uno, Y. and Fujiyuki, T. and Morioka, M. and Takeuchi, H. and Kubo, T.},
  title = {{Identification of proteins whose expression is up- or down-regulated in the mushroom bodies in the honeybee brain using proteomics}},
  journal = {FEBS Lett},
  volume = {581},
  number = {1},
  pages = {97-101},
  note = {Uno, Yuko Fujiyuki, Tomoko Morioka, Mizue Takeuchi, Hideaki Kubo, Takeo Netherlands FEBS Lett. 2007 Jan 9;581(1):97-101. Epub 2006 Dec 12.},
  abstract = {To identify protein(s) with different expression patterns in the mushroom bodies (MBs) in the honeybee brain, we compared the protein profiles of MBs and optic lobes (OLs) using proteomics. Two-dimensional gel electrophoresis revealed that five and three spots were selectively expressed in the MBs or OLs, respectively. Liquid chromatography tandem mass spectrometry analysis identified juvenile hormone diol kinase and glyceraldehyde-3-phosphate dehydrogenase as MB- and OL-selective proteins, respectively. In situ hybridization revealed that jhdk expression was upregulated in MB neuron subsets, whereas gapdh expression was downregulated, indicating that MBs have a distinct gene and protein expression profile in the honeybee brain.},
  keywords = {Animals Bees/genetics/*metabolism Brain Chemistry/physiology Down-Regulation/*physiology Electrophoresis, Gel, Two-Dimensional In Situ Hybridization Insect Proteins/*biosynthesis/genetics Mushroom Bodies/metabolism Proteome/*biosynthesis/genetics *Proteomics Up-Regulation/*physiology},
  issn = {0014-5793 (Print) 0014-5793 (Linking)},
  doi = {10.1016/j.febslet.2006.12.004},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/17182037 http://ac.els-cdn.com/S0014579306014347/1-s2.0-S0014579306014347-main.pdf?_tid=cf739cb2-ea5b-11e4-a964-00000aacb35f&acdnat=1429864257_3b7c5a98031576160418456f63287406 http://ac.els-cdn.com/S0014579306014347/1-s2.0-S0014579306014347-main.pdf?_tid=f7b2c934-fbde-11e4-81b0-00000aab0f01&acdnat=1431789758_b19e8d2412f0207f071531f990025911},
  year = {2007},
  type = {Journal Article},
}


@article{Ajami:2008oz,
  author = {Ajami, K. and Pitman, M. R. and Wilson, C. H. and Park, J. and Menz, R. I. and Starr, A. E. and Cox, J. H. and Abbott, C. A. and Overall, C. M. and Gorrell, M. D.},
  title = {{Stromal cell-derived factors 1alpha and 1beta, inflammatory protein-10 and interferon-inducible T cell chemo-attractant are novel substrates of dipeptidyl peptidase 8}},
  journal = {FEBS Lett},
  volume = {582},
  number = {5},
  pages = {819-25},
  note = {Ajami, Katerina Pitman, Melissa R Wilson, Claire H Park, Joohong Menz, R Ian Starr, Amanda E Cox, Jennifer H Abbott, Catherine A Overall, Christopher M Gorrell, Mark D Netherlands FEBS Lett. 2008 Mar 5;582(5):819-25. doi: 10.1016/j.febslet.2008.02.005. Epub 2008 Feb 12.},
  abstract = {N-terminal truncation of chemokines by proteases including dipeptidyl peptidase (DP) IV significantly alters their biological activity; generally ablating cognate G-protein coupled receptor engagement and often generating potent receptor antagonists. DP8 is a recently recognised member of the prolyl oligopeptidase gene family that includes DPIV. Since DPIV is known to process chemokines we surveyed 27 chemokines for cleavage by DP8. We report DP8 cleavage of the N-terminal two residues of IP10 (CXCL10), ITAC (CXCL11) and SDF-1 (CXCL12). This has implications for DP8 substrate specificity. Chemokine cleavage and inactivation may occur in vivo upon cell lysis and release of DP8 or in the inactivation of internalized chemokine/receptor complexes.},
  keywords = {Chemokine CXCL10/chemistry/*metabolism Chemokine CXCL11/chemistry/*metabolism Chemokine CXCL12/chemistry/*metabolism Dipeptidases/isolation & purification/*metabolism Dipeptidyl Peptidase 4/isolation & purification/metabolism Half-Life Humans Kinetics Molecular Weight Protein Processing, Post-Translational Recombinant Proteins/isolation & purification/metabolism Solubility Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization Substrate Specificity},
  issn = {0014-5793 (Print) 0014-5793 (Linking)},
  doi = {10.1016/j.febslet.2008.02.005},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/18275857 http://ac.els-cdn.com/S0014579308001026/1-s2.0-S0014579308001026-main.pdf?_tid=f3abdc22-fbde-11e4-a6cf-00000aab0f27&acdnat=1431789751_8cb56c86e5eabc7c33d7d35a4026ba3c},
  year = {2008},
  type = {Journal Article},
}


@article{Debela:2008bx,
  author = {Debela, M. and Beaufort, N. and Magdolen, V. and Schechter, N. M. and Craik, C. S. and Schmitt, M. and Bode, W. and Goettig, P.},
  title = {{Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7}},
  journal = {Biol Chem},
  volume = {389},
  number = {6},
  pages = {623-32},
  note = {Debela, Mekdes Beaufort, Nathalie Magdolen, Viktor Schechter, Norman M Craik, Charles S Schmitt, Manfred Bode, Wolfram Goettig, Peter CA072006/CA/NCI NIH HHS/ Germany Biol Chem. 2008 Jun;389(6):623-32. doi: 10.1515/BC.2008.075.},
  abstract = {Human kallikrein-related peptidases (KLKs) are (chymo)-trypsin-like serine proteinases that are expressed in a variety of tissues such as prostate, ovary, breast, testis, brain, and skin. Although their physiological functions have been only partly elucidated, many of the KLKs appear to be useful prognostic cancer markers, showing distinct correlations between their expression levels and different stages of cancer. Recent advances in the purification of 'new type' recombinant KLKs allowed solution of the crystal structures of KLK4, KLK5, KLK6, and KLK7. Along with these data, enzyme kinetic studies and extended substrate specificity profiling have led to an understanding of the non-prime-side substrate preferences of KLK4, 5, 6, and 7. The shape and polarity of the specificity pockets S1-S4 explain well their substrate preferences. KLK4, 5, and 6 exhibit trypsin-like specificity, with a strong preference for Arg at the P1 position of substrates. In contrast, KLK7 displays a unique chymotrypsin-like specificity for Tyr, which is also preferred at P2. All four KLKs show little specificity for P3 residues and have a tendency to accept hydrophobic residues at P4. Interestingly, for KLK4, 5, and 7 extended charged surface regions were observed that most likely serve as exosites for physiological substrates.},
  keywords = {Amino Acid Sequence Animals Enzyme Activation Gene Expression Regulation, Enzymologic Humans Kallikreins/*chemistry/genetics/*metabolism Models, Molecular Protein Structure, Tertiary Substrate Specificity},
  issn = {1431-6730 (Print) 1431-6730 (Linking)},
  doi = {10.1515/BC.2008.075},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/18627343 http://www.degruyter.com/view/j/bchm.2008.389.issue-6/bc.2008.075/bc.2008.075.xml https://www.degruyter.com/view/j/bchm.2008.389.issue-6/bc.2008.075/bc.2008.075.xml},
  year = {2008},
  type = {Journal Article},
}


@article{Doucet2008,
  author = {Doucet, A. and Butler, G. S. and Rodriguez, D. and Prudova, A. and Overall, C. M.},
  title = {{Metadegradomics: toward in vivo quantitative degradomics of proteolytic post-translational modifications of the cancer proteome}},
  journal = {Mol Cell Proteomics},
  volume = {7},
  number = {10},
  pages = {1925-51},
  note = {Doucet, Alain Butler, Georgina S Rodriguez, David Prudova, Anna Overall, Christopher M Mol Cell Proteomics. 2008 Oct;7(10):1925-51. doi: 10.1074/mcp.R800012-MCP200. Epub 2008 Jul 2.},
  abstract = {Post-translational modifications enable extra layers of control of the proteome, and perhaps the most important is proteolysis, a major irreversible modification affecting every protein. The intersection of the protease web with a proteome sculpts that proteome, dynamically modifying its state and function. Protease expression is distorted in cancer, so perturbing signaling pathways and the secretome of the tumor and reactive stromal cells. Indeed many cancer biomarkers are stable proteolytic fragments. It is crucial to determine which proteases contribute to the pathology versus their roles in homeostasis and in mitigating cancer. Thus the full substrate repertoire of a protease, termed the substrate degradome, must be deciphered to define protease function and to identify drug targets. Degradomics has been used to identify many substrates of matrix metalloproteinases that are important proteases in cancer. Here we review recent degradomics technologies that allow for the broadly applicable identification and quantification of proteases (the protease degradome) and their activity state, substrates, and interactors. Quantitative proteomics using stable isotope labeling, such as ICAT, isobaric tags for relative and absolute quantification (iTRAQ), and stable isotope labeling by amino acids in cell culture (SILAC), can reveal protease substrates by taking advantage of the natural compartmentalization of membrane proteins that are shed into the extracellular space. Identifying the actual cleavage sites in a complex proteome relies on positional proteomics and utilizes selection strategies to enrich for protease-generated neo-N termini of proteins. In so doing, important functional information is generated. Finally protease substrates and interactors can be identified by interactomics based on affinity purification of protease complexes using exosite scanning and inactive catalytic domain capture strategies followed by mass spectrometry analysis. At the global level, the N terminome analysis of whole communities of proteases in tissues and organs in vivo provides a full scale understanding of the protease web and the web-sculpted proteome, so defining metadegradomics.},
  keywords = {Animals Humans *Metabolome Metabolomics Neoplasms/*metabolism Peptide Hydrolases/metabolism *Protein Processing, Post-Translational Proteome/*metabolism},
  issn = {1535-9484 (Electronic) 1535-9476 (Linking)},
  doi = {10.1074/mcp.R800012-MCP200},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/18596063 http://www.mcponline.org/content/7/10/1925.full.pdf},
  year = {2008},
  type = {Journal Article},
}


@inbook{Edwards:2008ys,
  author = {Edwards, Dylan and Hyer-Hansen, Gunilla and Blasi, Francesco and Sloane, BonnieF. and Cox, JenniferH. and Overall, ChristopherM.},
  title = {{Cytokine Substrates: MMP Regulation of Inflammatory Signaling Molecules}},
  booktitle = {The Cancer Degradome},
  publisher = {Springer New York},
  pages = {519-539},
  isbn = {978-0-387-69056-8},
  doi = {10.1007/978-0-387-69057-5\_26},
  url = {http://dx.doi.org/10.1007/978-0-387-69057-5_26 http://dx.doi.org/10.1007/978-0-387-69057-5%7B%5C_%7D26},
  year = {2008},
  type = {Book Section},
}


@inbook{Enoksson2008,
  author = {Enoksson, Mari and Zhu, Wenhong and Salvesen, Guy S.},
  title = {{Identification of Protease Substrates by Mass Spectrometry Approaches-1}},
  booktitle = {The Cancer Degradome: Proteases and Cancer Biology},
  editor = {Edwards, Dylan and Hyer-Hansen, Gunilla and Blasi, Francesco and Sloane, Bonnie F.},
  publisher = {Springer New York},
  address = {New York, NY},
  pages = {67-82},
  isbn = {978-0-387-69057-5},
  doi = {10.1007/978-0-387-69057-5_5},
  url = {http://dx.doi.org/10.1007/978-0-387-69057-5_5 http://download.springer.com/static/pdf/494/chp%253A10.1007%252F978-0-387-69057-5_5.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Fchapter%2F10.1007%2F978-0-387-69057-5_5&token2=exp=1477893822~acl=%2Fstatic%2Fpdf%2F494%2Fchp%25253A10.1007%25252F978-0-387-69057-5_5.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Fchapter%252F10.1007%252F978-0-387-69057-5_5*~hmac=3df015af8d88e5847aeba72690942880dc0321c53c5e6a56576c21224625d423},
  year = {2008},
  type = {Book Section},
}


@article{Forrester:2008ph,
  author = {Forrester, M. B.},
  title = {{Adult metformin ingestions reported to Texas poison control centers, 2000-2006}},
  journal = {Hum Exp Toxicol},
  volume = {27},
  number = {7},
  pages = {575-83},
  note = {Forrester, M B England Hum Exp Toxicol. 2008 Jul;27(7):575-83. doi: 10.1177/0960327108090589.},
  abstract = {Metformin is an oral hypoglycemic agent used in the management of type 2 diabetes mellitus. Limited information exists on adult metformin ingestions reported to poison control centers. The distribution of adult metformin ingestions reported to Texas poison control centers during 2000-2006 was determined for various factors. In addition, triage guidelines for the management of isolated ingestions were drafted. Of 1528 total metformin ingestions, 58% involved coingestants. Of the 264 ingestions of metformin alone, where the final medical outcome was known, dose ingested was reported for 66%. The mean reported dose was 4739 mg (range 500-60,000 mg). Ingestions of < or =2500 mg and >5000 mg reported doses differed with respect to the proportion involving suspected attempted suicide (6% versus 81%), serious final medical outcome (3% versus 19%), and referral to a health care facility (3% versus 83%). Using 5000 mg as a threshold dose for referral to a health care facility, 91% of cases not already at or en route to a health care facility were managed according drafted triage guidelines.},
  keywords = {Adult Aged Aged, 80 and over Drug Combinations Female Humans Hypoglycemic Agents/*poisoning Male Metformin/*poisoning Middle Aged Poison Control Centers/*statistics & numerical data Poisoning/*epidemiology/therapy Suicide, Attempted Texas Treatment Outcome Triage},
  issn = {0960-3271 (Print) 0960-3271 (Linking)},
  doi = {10.1177/0960327108090589},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/18829734 http://het.sagepub.com/content/27/7/575.full.pdf},
  year = {2008},
  type = {Journal Article},
}


@article{Gonzalez-Gronow:2008rb,
  author = {Gonzalez-Gronow, M. and Kaczowka, S. and Gawdi, G. and Pizzo, S. V.},
  title = {{Dipeptidyl peptidase IV (DPP IV/CD26) is a cell-surface plasminogen receptor}},
  journal = {Frontiers in Bioscience-Landmark},
  volume = {13},
  pages = {1610-1618},
  note = {299SQ Times Cited:13 Cited References Count:61},
  abstract = {Binding of plasminogen (Pg) to cell-surface receptors colocalized with plasminogen activators promotes Pg activation and enables cells to utilize the proteolytic activity of plasmin (Pm). Proteolysis by Pm is necessary in several physiological and pathological processes requiring extracellular matrix degradation including cell migration, tumor cell invasion and metastasis. The binding of Pg to cell-surface receptors is regulated by two major structural features: L-lysine binding sites (LBS) and negatively charged sialic acid residues located on its carbohydrate chains. Pg uses its LBS to bind to a wide spectrum of cell-surface receptors whereas binding through its sialic acid residues is limited only to receptor proteins containing cationic pockets or lectin-like modules. In this review, we discuss both mechanisms, including the identification of DPP IV as a Pg receptor and the possible physiological role of Pg/Pm in complex with DPP IV and adenosine deaminase (ADA) and /or the Na(+)/H(+) exchanger isoform NHE-3 in prostate cancer.},
  keywords = {dpp iv/cd26 plasminogen glycosylation plasminogen receptors ada functions nhe-3 cancer cell proliferation tumor metastasis review linked oligosaccharide unit human synovial fibroblasts exchanger isoform nhe3 prostate-cancer cells adenosine-deaminase rheumatoid-arthritis sialic-acid molecular physiology sequence-analysis crystal-structure},
  issn = {1093-9946},
  doi = {Doi 10.2741/2785},
  url = {<Go to ISI>://000255775700129},
  year = {2008},
  type = {Journal Article},
}


@article{James:1999if,
  author = {James, Michael N. G.},
  title = {{Handbook of proteolytic enzymes}},
  journal = {Protein Science},
  volume = {8},
  number = {3},
  pages = {693-694},
  issn = {09618368},
  doi = {10.1110/ps.8.3.693},
  url = {http://dx.doi.org/10.1110/ps.8.3.693 http://onlinelibrary.wiley.com/store/10.1110/ps.8.3.693/asset/803693_ftp.pdf?v=1&t=i8vc9rql&s=397715ecf7b86243a6819282602a137094f3c5ab http://onlinelibrary.wiley.com/store/10.1110/ps.8.3.693/asset/803693_ftp.pdf?v=1&t=i9r6jxg8&s=d5d37954b9461e82dce7c9702ffb3ad8a230e89b},
  year = {2008},
  type = {Journal Article},
}


@article{Koivisto:2008ys,
  author = {Koivisto, V.},
  title = {{Discovery of dipeptidyl-peptidase IV--a 40 year journey from bench to patient}},
  journal = {Diabetologia},
  volume = {51},
  number = {6},
  pages = {1088-9},
  note = {Koivisto, V Germany Diabetologia. 2008 Jun;51(6):1088-9. doi: 10.1007/s00125-008-0985-0. Epub 2008 Apr 3.},
  keywords = {Amino Acid Sequence Animals Dipeptidyl Peptidase 4/*metabolism Incretins/metabolism Insulin/secretion Kidney/enzymology Rats Substrate Specificity},
  issn = {0012-186X (Print) 0012-186X (Linking)},
  doi = {10.1007/s00125-008-0985-0},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/18385972 http://download-v2.springer.com/static/pdf/80/art%253A10.1007%252Fs00125-008-0985-0.pdf?token2=exp=1431790789~acl=%2Fstatic%2Fpdf%2F80%2Fart%25253A10.1007%25252Fs00125-008-0985-0.pdf*~hmac=85e1b5d66765644642caee09bc473252e4d0e8a062c7f8328c82e0a5553f240f},
  year = {2008},
  type = {Journal Article},
}


@book{principlesofbio_ief,
  author = {Lehninger, Albert and Nelson, David L. and Cox, Michael M.},
  title = {{Lehninger Principles of Biochemistry}},
  publisher = {W. H. Freeman},
  edition = {Fifth Edition},
  abstract = {In the Fifth Edition, authors Dave Nelson and Mike Cox combine the best of the laboratory and best of the classroom, introducing exciting new developments while communicating basic principles through a variety of new learning toolsfrom new in-text worked examples and data analysis problems to the breakthrough eBook, which seamlessly integrates the complete text and its media components.},
  keywords = {file-import-09-11-02, proteomics},
  url = {http://www.amazon.ca/exec/obidos/redirect?tag=citeulike09-20%5C%255C%5C&path=ASIN/1429224169},
  year = {2008},
  type = {Book},
}


@article{Mahrus:2008mi,
  author = {Mahrus, S. and Trinidad, J. C. and Barkan, D. T. and Sali, A. and Burlingame, A. L. and Wells, J. A.},
  title = {{Global sequencing of proteolytic cleavage sites in apoptosis by specific labeling of protein N termini}},
  journal = {Cell},
  volume = {134},
  number = {5},
  pages = {866-76},
  note = {Mahrus, Sami Trinidad, Jonathan C Barkan, David T Sali, Andrej Burlingame, Alma L Wells, James A F32 GM074458/GM/NIGMS NIH HHS/ F32 GM074458-01A1/GM/NIGMS NIH HHS/ F32 GM074458-02/GM/NIGMS NIH HHS/ F32 GM074458-03/GM/NIGMS NIH HHS/ NCRR 01614/PHS HHS/ P01 GM071790-04/GM/NIGMS NIH HHS/ P01 GM71790/GM/NIGMS NIH HHS/ P41 RR001614/RR/NCRR NIH HHS/ P41 RR001614-25/RR/NCRR NIH HHS/ R01 GM054762-08/GM/NIGMS NIH HHS/ R01 GM081051/GM/NIGMS NIH HHS/ R01 GM081051-01/GM/NIGMS NIH HHS/ R01 GM081051-02/GM/NIGMS NIH HHS/ R01 GM54762/GM/NIGMS NIH HHS/ U54 GM074945/GM/NIGMS NIH HHS/ U54 GM074945-03S1/GM/NIGMS NIH HHS/ Cell. 2008 Sep 5;134(5):866-76. doi: 10.1016/j.cell.2008.08.012. Epub 2008 Aug 21.},
  abstract = {The nearly 600 proteases in the human genome regulate a diversity of biological processes, including programmed cell death. Comprehensive characterization of protease signaling in complex biological samples is limited by available proteomic methods. We have developed a general approach for global identification of proteolytic cleavage sites using an engineered enzyme to selectively biotinylate free protein N termini for positive enrichment of corresponding N-terminal peptides. Using this method to study apoptosis, we have sequenced 333 caspase-like cleavage sites distributed among 292 protein substrates. These sites are generally not predicted by in vitro caspase substrate specificity but can be used to predict other physiological caspase cleavage sites. Structural bioinformatic studies show that caspase cleavage sites often appear in surface-accessible loops and even occasionally in helical regions. Strikingly, we also find that a disproportionate number of caspase substrates physically interact, suggesting that these dimeric proteases target protein complexes and networks to elicit apoptosis.},
  keywords = {Antineoplastic Agents, Phytogenic/pharmacology Apoptosis/*drug effects Caspases/chemistry/*metabolism Etoposide/pharmacology Humans Jurkat Cells Protein Binding Proteins/*analysis/*metabolism *Proteomics Substrate Specificity},
  issn = {1097-4172 (Electronic) 0092-8674 (Linking)},
  doi = {10.1016/j.cell.2008.08.012},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/18722006 http://ac.els-cdn.com/S0092867408010209/1-s2.0-S0092867408010209-main.pdf?_tid=1fcb2220-ea5c-11e4-bcb2-00000aacb35f&acdnat=1429864392_52a7055ac0bc327758ef75428ff72e56 http://ac.els-cdn.com/S0092867408010209/1-s2.0-S0092867408010209-main.pdf?_tid=069f7b86-fbdf-11e4-bfbc-00000aacb35f&acdnat=1431789783_212d80aece13bb0457a1667aa146f1f8},
  year = {2008},
  type = {Journal Article},
}


@article{PMIC:PMIC200700592,
  author = {Meinnel, T. and Giglione, C.},
  title = {{Tools for analyzing and predicting N-terminal protein modifications}},
  journal = {PROTEOMICS},
  volume = {8},
  number = {4},
  pages = {626-49},
  note = {Meinnel, Thierry Giglione, Carmela Germany Proteomics. 2008 Feb;8(4):626-49. doi: 10.1002/pmic.200700592.},
  abstract = {The vast majority of the proteins encoded in any genome naturally undergo a large number of different N-terminal modifications, hindering their characterization by routine proteomic approaches. These modifications are often irreversible, usually cotranslational and are crucial, as their occurrence may reflect or affect the status, fate and function of the protein. For example, large signal peptide cleavages and N-blocking mechanisms reflect targeting to various cell compartments, whereas N-ligation events tend to be related to protein half-life. N-terminal positional proteomic strategies hold promise as a new generation of approaches to the fine analysis of such modifications. However, further biological investigation is required to resolve problems associated with particular low-abundance or challenging N-terminal modifications. Recent progress in genomics and bioinformatics has provided us with a means of assessing the impact of these modifications in proteomes. This review focuses on methods for characterizing the occurrence and diversity of N-terminal modifications and for assessing their contribution to function in complete proteomes. Progress is being made towards the annotation of databases containing information for complete proteomes, and should facilitate research into all areas of proteomics.},
  keywords = {5' Untranslated Regions Acetyltransferases/physiology Acyltransferases/physiology Amino Acid Sequence Aminopeptidases/physiology Animals Cell-Free System/metabolism Computational Biology/methods Humans Mass Spectrometry Methionine/physiology Methionine Sulfoxide Reductases Methionyl Aminopeptidases Oxidoreductases/physiology Peptide Mapping Protein Methyltransferases/physiology Protein Processing, Post-Translational Proteins/*chemistry Proteomics/*methods Software},
  issn = {1615-9861 (Electronic) 1615-9853 (Linking)},
  doi = {10.1002/pmic.200700592},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/18203265 http://onlinelibrary.wiley.com/store/10.1002/pmic.200700592/asset/626_ftp.pdf?v=1&t=i9r6kod2&s=2cb5031b2f93452e3bd9a6fdd4e3af99a5e8d351},
  year = {2008},
  type = {Journal Article},
}


@article{OBrien:2008xu,
  author = {O'Brien, P. and O'Connor, B. F.},
  title = {{Seprase: an overview of an important matrix serine protease}},
  journal = {Biochim Biophys Acta},
  volume = {1784},
  number = {9},
  pages = {1130-45},
  note = {O'Brien, Pamela O'Connor, Brendan F Netherlands Biochim Biophys Acta. 2008 Sep;1784(9):1130-45. doi: 10.1016/j.bbapap.2008.01.006. Epub 2008 Jan 26.},
  abstract = {Seprase or Fibroblast Activation Protein (FAP) is an integral membrane serine peptidase, which has been shown to have gelatinase activity. Seprase has a dual function in tumour progression. The proteolytic activity of Seprase has been shown to promote cell invasiveness towards the ECM and also to support tumour growth and proliferation. Seprase appears to act as a proteolytically active 170-kDa dimer, consisting of two 97-kDa subunits. It is a member of the group type II integral serine proteases, which includes dipeptidyl peptidase IV (DPPIV/CD26) and related type II transmembrane prolyl serine peptidases, which exert their mechanisms of action on the cell surface. DPPIV and Seprase exhibit multiple functions due to their abilities to form complexes with each other and to interact with other membrane-associated molecules. Localisation of these protease complexes at cell surface protrusions, called invadopodia, may have a prominent role in processing soluble factors and in the degradation of extracellular matrix components that are essential to the cellular migration and matrix invasion that occur during tumour invasion, metastasis and angiogenesis.},
  keywords = {Amino Acid Sequence Animals Female Gelatinases/*chemistry/genetics/*physiology Humans Male Membrane Proteins/*chemistry/genetics/*physiology Models, Molecular Molecular Sequence Data Neoplasm Invasiveness/genetics/physiopathology Neoplasms/enzymology/genetics Protein Conformation Sequence Homology, Amino Acid Serine Endopeptidases/*chemistry/genetics/*physiology Signal Transduction Substrate Specificity Tissue Distribution},
  issn = {0006-3002 (Print) 0006-3002 (Linking)},
  doi = {10.1016/j.bbapap.2008.01.006},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/18262497 http://ac.els-cdn.com/S1570963908000186/1-s2.0-S1570963908000186-main.pdf?_tid=02e86f66-fbdf-11e4-8133-00000aacb35e&acdnat=1431789777_7e8ab0279ed50f1613d3a6ca1a52a3f5},
  year = {2008},
  type = {Journal Article},
}


@inbook{Prudova2008,
  author = {Prudova, Anna and auf dem Keller, Ulrich and Overall, Christopher M.},
  title = {{Identification of Protease Substrates by Mass Spectrometry Approaches-2}},
  booktitle = {The Cancer Degradome: Proteases and Cancer Biology},
  editor = {Edwards, Dylan and Hyer-Hansen, Gunilla and Blasi, Francesco and Sloane, Bonnie F.},
  publisher = {Springer New York},
  address = {New York, NY},
  pages = {83-100},
  isbn = {978-0-387-69057-5},
  doi = {10.1007/978-0-387-69057-5_6},
  url = {http://dx.doi.org/10.1007/978-0-387-69057-5_6 http://download.springer.com/static/pdf/493/chp%253A10.1007%252F978-0-387-69057-5_6.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Fchapter%2F10.1007%2F978-0-387-69057-5_6&token2=exp=1477893799~acl=%2Fstatic%2Fpdf%2F493%2Fchp%25253A10.1007%25252F978-0-387-69057-5_6.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Fchapter%252F10.1007%252F978-0-387-69057-5_6*~hmac=28143bc2846eb97921f51018ac8ec2a69a02c099ca6769bda160343229d92973},
  year = {2008},
  type = {Book Section},
}


@article{Schade:2008eu,
  author = {Schade, J. and Stephan, M. and Schmiedl, A. and Wagner, L. and Niestroj, A. J. and Demuth, H. U. and Frerker, N. and Klemann, C. and Raber, K. A. and Pabst, R. and von Horsten, S.},
  title = {{Regulation of expression and function of dipeptidyl peptidase 4 (DP4), DP8/9, and DP10 in allergic responses of the lung in rats}},
  journal = {J Histochem Cytochem},
  volume = {56},
  number = {2},
  pages = {147-55},
  note = {Schade, Jutta Stephan, Michael Schmiedl, Andreas Wagner, Leona Niestroj, Andre J Demuth, Hans-Ulrich Frerker, Nadine Klemann, Christian Raber, Kerstin A Pabst, Reinhard von Horsten, Stephan J Histochem Cytochem. 2008 Feb;56(2):147-55. Epub 2007 Oct 29.},
  abstract = {The expression of dipeptidyl peptidase 4 (DP4, CD26) affects T-cell recruitment to lungs in an experimental rat asthma model. Furthermore, the gene of the structural homologous DP10 represents a susceptibility locus for asthma in humans, and the functional homologous DP8/9 are expressed in human leukocytes. Thus, although several mechanisms may account for a role of DP4-like peptidases in asthma, detailed information on their anatomical sites of expression and function in lungs is lacking. Therefore, bronchi and lung parenchyma were evaluated using immunohistochemistry and histochemical/enzymatic activity assays, as well as quantitative real-time PCR for this family of peptidases in naive and asthmatic rat lungs derived from wild-type F344 and DP4-deficient F344 rat strains. Surprisingly, results show not only that the induction of experimental asthma increases DP4 enzymatic activity in the bronchoalveolar lavage fluid and parenchyma, but also that DP8/9 enzymatic activity is regulated and, as well as the expression of DP10, primarily found in the bronchial epithelium of the airways. This is the first report showing a differential and site-specific DP4-like expression and function in the lungs, suggesting a pathophysiologically significant role in asthma.},
  keywords = {Animals Asthma/*enzymology Bronchi/enzymology Dipeptidyl Peptidase 4/biosynthesis/genetics Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/*biosynthesis/genetics Gene Expression Regulation, Enzymologic Immunohistochemistry Lung/*enzymology Male Polymerase Chain Reaction Rats Rats, Inbred F344},
  issn = {0022-1554 (Print) 0022-1554 (Linking)},
  doi = {10.1369/jhc.7A7319.2007},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/17967935 http://jhc.sagepub.com/content/56/2/147.full.pdf},
  year = {2008},
  type = {Journal Article},
}


@article{Wang:2008hi,
  author = {Wang, X. M. and Yao, T. W. and Nadvi, N. A. and Osborne, B. and McCaughan, G. W. and Gorrell, M. D.},
  title = {{Fibroblast activation protein and chronic liver disease}},
  journal = {Front Biosci},
  volume = {13},
  pages = {3168-80},
  note = {Wang, Xin Maggie Yao, Tsun-Wen Nadvi, Naveed A Osborne, Brenna McCaughan, Geoffrey W Gorrell, Mark D Front Biosci. 2008 Jan 1;13:3168-80.},
  abstract = {Fibroblast activation protein (FAP) is the member of Dipeptidyl Peptidase IV (DPIV) gene family that is most similar to DPIV. Four members of this family, DPIV, FAP, DP8 and DP9 possess a rare catalytic activity, hydrolysis of a prolyl bond two residues from the substrate N terminus. Crystal structures show that the soluble form of FAP comprises two domains, an alpha/beta-hydrolase domain and an 8-blade beta-propeller domain. The interface between these two domains forms the catalytic pocket, and an opening for substrate access to the internal active site. The FAP homodimer is structurally very similar to DPIV but FAP glycoprotein expression is largely confined to mesenchymal cells in diseased and damaged tissue, notably the tissue remodelling region in chronically injured liver. FAP peptide substrates include denatured collagen and alpha2-antiplasmin. The functional roles of FAP in tumors and fibrotic tissue are not fully understood. This review places FAP in the context of chronic liver injury pathogenesis.},
  keywords = {Animals Antigens, Neoplasm/*chemistry/*physiology Binding Sites Catalysis Dipeptidyl Peptidase 4/biosynthesis Extracellular Matrix/metabolism Fibroblasts/*metabolism Gelatinases Humans Liver Cirrhosis/metabolism/therapy Liver Diseases/*metabolism Membrane Proteins Models, Biological Molecular Sequence Data Neoplasms/*metabolism/*therapy Protein Conformation Protein Structure, Secondary Serine Endopeptidases/*chemistry/*physiology Tumor Markers, Biological/*chemistry/*physiology},
  issn = {1093-9946 (Print) 1093-4715 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/17981786},
  year = {2008},
  type = {Journal Article},
}


@article{Wolff2008,
  author = {Wolff, Jeremy J. and Laremore, Tatiana N. and Busch, Alexander M. and Linhardt, Robert J. and Amster, I. Jonathan},
  title = {{Influence of charge state and sodium cationization on the electron detachment dissociation and infrared multiphoton dissociation of glycosaminoglycan oligosaccharides}},
  journal = {Journal of the American Society for Mass Spectrometry},
  volume = {19},
  number = {6},
  pages = {790-798},
  abstract = {Electron detachment dissociation (EDD) Fourier transform mass spectrometry has recently been shown to be a useful method for tandem mass spectrometry analysis of sulfated glycosaminoglycans (GAGs). EDD produces abundant glycosidic and cross-ring fragmentations that are useful for localizing sites of sulfation in GAG oligosaccharides. Although EDD fragmentation can be used to characterize GAGs in a single tandem mass spectrometry experiment, SO3 loss accompanies many peaks and complicates the resulting mass spectra. In this work we demonstrate the ability to significantly decrease SO3 loss by selection of the proper ionized state of GAG precursor ions. When the degree of ionization is greater than the number of sulfate groups in an oligosaccharide, a significant reduction in SO3 loss is observed in the EDD mass spectra. These data suggested that SO3 loss is reduced when an electron is detached from carboxylate groups instead of sulfate. Electron detachment occurs preferentially from carboxylate versus sulfate for thermodynamic reasons, provided that carboxylate is in its ionized state. Ionization of the carboxylate group is achieved by selecting the appropriate precursor ion charge state, or by the replacement of protons with sodium cations. Increasing the ionization state by sodium cation addition decreases, but does not eliminate, SO3 loss from infrared multiphoton dissociation of the same GAG precursor ions.},
  issn = {1879-1123},
  doi = {10.1016/j.jasms.2008.03.010},
  url = {http://dx.doi.org/10.1016/j.jasms.2008.03.010 http://ac.els-cdn.com/S1044030508002225/1-s2.0-S1044030508002225-main.pdf?_tid=deca0e80-edab-11e6-a252-00000aab0f6c&acdnat=1486523491_8388b66b503ddbeb3a7a6c22bd2a8552},
  year = {2008},
  type = {Journal Article},
}


@article{Ahren:2009kx,
  author = {Ahrn, Bo},
  title = {{DPP-4 inhibitors}},
  journal = {Insulin},
  volume = {4},
  number = {1},
  pages = {15-31},
  abstract = {Inhibition of dipeptidyl peptidase 4 (DPP-4) is a novel treatment for type-2 diabetes. DPP-4 inhibition prevents the inactivation of glucagon-like peptide I (GLP-I), which increases levels of active GLP-I. This increases insulin secretion and reduces glucagon secretion, thereby low-ering glucose levels. Several DPP-4 inhibitors are in clinical development. Most experience so far has been with sitagliptin (Merck},
  keywords = {glucagon-like peptide-I dipeptidyl peptidase 4 type-2 diabetes sitagliptin vildagliptin treatment},
  issn = {15570843},
  doi = {10.1016/s1557-0843(09)80004-3},
  url = {http://dx.doi.org/10.1016/S1557-0843(09)80004-3 http://ac.els-cdn.com/S1557084309800043/1-s2.0-S1557084309800043-main.pdf?_tid=c780bd78-b92e-11e3-b553-00000aacb361&acdnat=1396309811_4038e16363f88b0bac1a1dafee07e83f},
  year = {2009},
  type = {Journal Article},
}


@article{Ansorge:2009wd,
  author = {Ansorge, S. and Bank, U. and Heimburg, A. and Helmuth, M. and Koch, G. and Tadje, J. and Lendeckel, U. and Wolke, C. and Neubert, K. and Faust, J. and Fuchs, P. and Reinhold, D. and Thielitz, A. and Tager, M.},
  title = {{Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions}},
  journal = {Clin Chem Lab Med},
  volume = {47},
  number = {3},
  pages = {253-61},
  note = {Ansorge, Siegfried Bank, Ute Heimburg, Anke Helmuth, Martin Koch, Gudrun Tadje, Janine Lendeckel, Uwe Wolke, Carmen Neubert, Klaus Faust, Jurgen Fuchs, Petra Reinhold, Dirk Thielitz, Anja Tager, Michael Germany Clin Chem Lab Med. 2009;47(3):253-61. doi: 10.1515/CCLM.2009.063.},
  abstract = {BACKGROUND: In the past, different research groups could show that treatment of immune cells with inhibitors of post-proline splitting dipeptidyl aminopeptidases leads to functional changes in the immune system consistent with immunosuppression. This is due to the inhibition of proliferation of lymphocytes and the production of inflammatory cytokines of the TH1, TH2, and TH17, cells as well as the induction of immunosuppressive cytokines, such as transforming growth factor-beta1 (TGF-beta1) and interleukin (IL)-1RA. Until recently, most of the effects of these inhibitors on immune functions were attributed to the inhibition of dipeptidyl aminopeptidase IV (DPIV/CD26). With the identification of new peptidases of the DPIV family (DASH) with the same or similar substrate specificity [fibroblast activation protein (FAP), DP8/9], the question arose whether and to what extent the inhibition of intracellularly localized enzymes, DP8 and DP9, contribute to the observed immunosuppression. In addition, members of the aminopeptidase N (APN) family are also involved in the regulation of immune functions. Hence, the concept of a combined targeting of both families of peptidases for treatment of inflammatory diseases is a promising strategy. RESULTS/CONCLUSIONS: Summarizing data obtained from the usage of different non-selective and selective inhibitors of DPIV, DP8/9, FAP, and DPII, this review provides evidence that in addition to DPIV, DP8/9 also regulate the immune response via modulation of cell cycle progression and cytokine production. The strongest and most consistent effects in vitro were, however, observed with non-selective inhibitors for the suppression of DNA synthesis and cytokine production. Similar effects were provoked by APN inhibitors, which were also found to suppress DNA synthesis and the production of inflammatory cytokines in vitro. However, different mechanisms and signaling pathways appear to mediate the cellular effects resulting from the inhibition of either APN or DPIV family members. In particular, members of the APN family uniquely influence the function of CD4+CD25+ regulatory T-cells. Consequently, the concomitant inhibition of both APN and DPIV enzyme families by means of two separate inhibitors or by binary inhibitors with specificity for both enzyme families (PETIR, peptidase targeted immunoregulation) synergistically affects immune cells on the level of cell cycle regulation, suppression of TH1, TH2, and TH17 cytokines as well as the activation of regulatory T-cells. Besides leukocytes, dermal cells as sebocytes, keratinocytes, and fibroblasts are also targeted by these inhibitors. This strongly suggests a broad potential of the multiple anti-inflammatory effects of PETIR in treatment of chronic inflammatory diseases, such as autoimmune diseases, allergies, and transplant rejections, as well as of inflammatory skin diseases, such as acne, psoriasis, rosacea or atopic dermatitis. The first active dual inhibitor, IP10.C8, has been developed by IMTM for the treatment of inflammatory skin diseases and has just entered the first phase II study.},
  keywords = {Animals Antigens, CD13/*immunology Dipeptidyl Peptidase 4/*immunology Dipeptidyl-Peptidase IV Inhibitors Humans Protease Inhibitors/pharmacology Skin Diseases/drug therapy/immunology},
  issn = {1434-6621 (Print) 1434-6621 (Linking)},
  doi = {10.1515/CCLM.2009.063},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/19327105 http://www.degruyter.com/dg/viewarticle.fullcontentlink:pdfeventlink/$002fj$002fcclm.2009.47.issue-3$002fcclm.2009.063$002fcclm.2009.063.pdf?t:ac=j$002fcclm.2009.47.issue-3$002fcclm.2009.063$002fcclm.2009.063.xml},
  year = {2009},
  type = {Journal Article},
}


@book{bah2009inkscape,
  author = {Bah, Tavmjong},
  title = {{Inkscape: Guide to a Vector Drawing Program (Digital Short Cut)}},
  publisher = {Pearson Education},
  year = {2009},
  type = {Book},
}


@article{Colaert:2009aa,
  author = {Colaert, N. and Helsens, K. and Martens, L. and Vandekerckhove, J. and Gevaert, K.},
  title = {{Improved visualization of protein consensus sequences by iceLogo}},
  journal = {Nat Methods},
  volume = {6},
  number = {11},
  pages = {786-7},
  note = {Colaert, Niklaas Helsens, Kenny Martens, Lennart Vandekerckhove, Joel Gevaert, Kris Nat Methods. 2009 Nov;6(11):786-7. doi: 10.1038/nmeth1109-786.},
  keywords = {*Consensus Sequence Granzymes/chemistry/metabolism Probability Theory Proteins/*chemistry *Software},
  issn = {1548-7105 (Electronic) 1548-7091 (Linking)},
  doi = {10.1038/nmeth1109-786},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/19876014 http://media.proquest.com/media/pq/classic/doc/1892021061/fmt/pi/rep/NONE?hl=&cit%3Aauth=Colaert%2C+Niklaas%3BHelsens%2C+Kenny%3BMartens%2C+Lennart%3BVandekerckhove%2C+Jo%C3%ABl%3BGevaert%2C+Kris&cit%3Atitle=Improved+visualization+of+protein+consensus+sequences+by+iceLogo&cit%3Apub=Nature+Methods&cit%3Avol=6&cit%3Aiss=11&cit%3Apg=786&cit%3Adate=Nov+2009&ic=true&cit%3Aprod=ProQuest+Central&_a=ChgyMDE1MDUxNjE1NTUxNTA2MDo3MTE4MTUSBjEwNDgzNxoKT05FX1NFQVJDSCINMTI5Ljk2Ljg2LjExMSoFMjgwMTUyCTIyMzIzNTMzNzoNRG9jdW1lbnRJbWFnZUIBMFIGT25saW5lWgJGVGIDUEZUagoyMDA5LzExLzAxcgoyMDA5LzExLzMwegCCATJQLTEwMDcwNjctMTA5MTAtQ1VTVE9NRVItMTAwMDAwMzkvMTAwMDAxNTUtMzg5NDQwNJIBBk9ubGluZcoBB0VuZE5vdGXSARJTY2hvbGFybHkgSm91cm5hbHOaAgdQcmVQYWlkqgIoT1M6RU1TLVBkZkRvY1ZpZXdCYXNlLWdldE1lZGlhVXJsRm9ySXRlbcoCDkNvcnJlc3BvbmRlbmNl0gIBWeICAU7yAgA%3D&_s=iB%2F1%2FM2MPjlG342NPZUf2Fs31yU%3D},
  year = {2009},
  type = {Journal Article},
}


@article{Coon2009,
  author = {Coon, J. J.},
  title = {{Collisions or electrons? Protein sequence analysis in the 21st century}},
  journal = {Anal Chem},
  volume = {81},
  number = {9},
  pages = {3208-15},
  note = {Coon, Joshua J P01 GM081629/GM/NIGMS NIH HHS/ P01 GM081629-01A10001/GM/NIGMS NIH HHS/ R01 GM080148/GM/NIGMS NIH HHS/ R01 GM080148-01A1/GM/NIGMS NIH HHS/ R01 GM080148-02/GM/NIGMS NIH HHS/ R01 GM080148-03/GM/NIGMS NIH HHS/ Anal Chem. 2009 May 1;81(9):3208-15. doi: 10.1021/ac802330b.},
  abstract = {How dissociation is effected determines the upstream sample handling whereas the spectral features it produces regulate the downstream informatics approach. (To listen to a podcast about this feature, please go to the Analytical Chemistry website at pubs.acs.org/journal/ancham.},
  keywords = {Electron Transport *Electrons Humans Informatics Proteins/*chemistry Proteomics Sequence Analysis, Protein/instrumentation/*methods/trends Tandem Mass Spectrometry},
  issn = {1520-6882 (Electronic) 0003-2700 (Linking)},
  doi = {10.1021/ac802330b},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/19364119 http://pubs.acs.org/doi/pdfplus/10.1021/ac802330b},
  year = {2009},
  type = {Journal Article},
}


@article{Dubois:2009rm,
  author = {Dubois, V. and Van Ginneken, C. and De Cock, H. and Lambeir, A. M. and Van der Veken, P. and Augustyns, K. and Chen, X. and Scharpe, S. and De Meester, I.},
  title = {{Enzyme activity and immunohistochemical localization of dipeptidyl peptidase 8 and 9 in male reproductive tissues}},
  journal = {J Histochem Cytochem},
  volume = {57},
  number = {6},
  pages = {531-41},
  note = {Dubois, Veronique Van Ginneken, Chris De Cock, Hilde Lambeir, Anne-Marie Van der Veken, Pieter Augustyns, Koen Chen, Xin Scharpe, Simon De Meester, Ingrid J Histochem Cytochem. 2009 Jun;57(6):531-41. doi: 10.1369/jhc.2009.952739. Epub 2009 Feb 2.},
  abstract = {The mRNA expression pattern of dipeptidyl peptidase (DPP) 8 and DPP9, two DPP4 homologs, was studied previously and showed a broad tissue distribution. In this study, protein expression and activity of DPP8 and DPP9 were investigated in male reproductive tissues of different mammals. Based on specific DPP activities and inhibition profiles, the proline-selective DPP activity in the bovine and rat testis could predominantly be attributed to DPP8/9 and not to DPP4. This is in contrast to the epididymis, where most of the activity was caused by DPP4. Bovine sperm preparations had very low or undetectable DPP8/9 activity. After characterization of polyclonal antibodies specific for DPP8 or DPP9, we could localize both enzymes in seminiferous tubules of the testis. A specific staining for DPP9 was found associated with spermatozoids embedded in the epithelium, just before their release into the lumen, and in spermatids. DPP8 was localized in spermatozoids in an earlier stage of maturation. These findings help to provide insight into the physiological role of DPP4-like enzymes in the male reproductive system. This manuscript contains online supplemental material at http://www.jhc.org. Please visit this article online to view these materials.},
  keywords = {Animals Cattle Dipeptidyl Peptidase 4/metabolism Dipeptidyl-Peptidase IV Inhibitors Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/antagonists & inhibitors/*metabolism Epididymis/enzymology Genitalia, Male/*enzymology Immunoblotting Immunohistochemistry Indoles/pharmacology Isoleucine/analogs & derivatives/pharmacology Male Organ Specificity Piperidines/pharmacology Pyrazines/pharmacology Rats Species Specificity Spermatozoa/enzymology Testis/enzymology Triazoles/pharmacology},
  issn = {0022-1554 (Print) 0022-1554 (Linking)},
  doi = {10.1369/jhc.2009.952739},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/19188489 http://jhc.sagepub.com/content/57/6/531.full.pdf},
  year = {2009},
  type = {Journal Article},
}


@article{Geiss-Friedlander:2009bh,
  author = {Geiss-Friedlander, R. and Parmentier, N. and Moller, U. and Urlaub, H. and Van den Eynde, B. J. and Melchior, F.},
  title = {{The cytoplasmic peptidase DPP9 is rate-limiting for degradation of proline-containing peptides}},
  journal = {J Biol Chem},
  volume = {284},
  number = {40},
  pages = {27211-9},
  note = {Geiss-Friedlander, Ruth Parmentier, Nicolas Moller, Ulrike Urlaub, Henning Van den Eynde, Benoit J Melchior, Frauke J Biol Chem. 2009 Oct 2;284(40):27211-9. doi: 10.1074/jbc.M109.041871. Epub 2009 Aug 10.},
  abstract = {Protein degradation is an essential process that continuously takes place in all living cells. Regulated degradation of most cellular proteins is initiated by proteasomes, which produce peptides of varying length. These peptides are rapidly cleaved to single amino acids by cytoplasmic peptidases. Proline-containing peptides pose a specific problem due to structural constrains imposed by the pyrrolidine ring that prevents most peptidases from cleavage. Here we show that DPP9, a poorly characterized cytoplasmic prolyl-peptidase, is rate-limiting for destruction of proline-containing substrates both in cell extracts and in intact cells. We identified the first natural substrate for DPP9, the RU1(34-42) antigenic peptide (VPYGSFKHV). RU1(34-42) is degraded in vitro by DPP9, and down-regulation of DPP9 in intact cells results in increased presentation of this antigen. Together our findings demonstrate an important role for DPP9 in peptide turnover and antigen presentation.},
  keywords = {Amino Acid Sequence Animals Antigen Presentation Base Sequence Cell Line Cytoplasm/*enzymology Cytosol/metabolism Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/genetics/*metabolism Gene Expression Regulation, Enzymologic HLA-A Antigens/immunology/metabolism Humans Kinetics Mice Oligopeptides/*chemistry/*metabolism Proline/*metabolism Substrate Specificity},
  issn = {1083-351X (Electronic) 0021-9258 (Linking)},
  doi = {10.1074/jbc.M109.041871},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/19667070 http://www.jbc.org/content/284/40/27211.full.pdf},
  year = {2009},
  type = {Journal Article},
}


@article{Kotackova:2009aa,
  author = {Kotackova, L and Balaziova, E and Sedo, A},
  title = {{Expression pattern of dipeptidyl peptidase IV activity and/or structure homologues in cancer.}},
  journal = {Folia Biol (Praha)},
  volume = {55},
  number = {3},
  pages = {77--84},
  abstract = {Proline at the second position of the N-terminus of biologically active peptides involved in cell growth regulation is an evolutionarily conserved motif protecting them against cleavage by non-specific proteases. Just a small number of proline-specific hydrolases including dipeptidyl peptidase IV (DPP-IV) and related molecules is capable of cleaving such post-prolyl bond. DPP-IV, originally described on the basis of its enzymatic activity, is a ubiquitous, multifunctional homodimeric plasma membrane glycoprotein of type II. Subsequently, several other molecules related to DPP-IV by their enzymatic activity and/or sequence were discovered and classified as dipeptidyl peptidase IV activity and/or structure homologues (DASH). Along with canonical DPP-IV this group comprises DPP-IVbeta, DPP-II, DPP6, DPP8, DPP9, DPP10 and fibroblast activation protein alpha (FAP-alpha). Recent observations of deregulated expression of several DASH molecules in multiple human cancers led to the assumptions of their pathogenetic relevance in cancerogenesis. Here we review recent information about selected DASH molecules in human malignancies.},
  issn = {0015-5500 (Print); 0015-5500 (Linking)},
  url = {http://media.proquest.com/media/pq/classic/doc/1798222881/fmt/pi/rep/NONE?hl=&cit%3Aauth=Kotackov%C3%A1%2C+L%3BBal%C3%A1ziov%C3%A1%2C+E%3BSedo%2C+A&cit%3Atitle=Expression+Pattern+of+Dipeptidyl+Peptidase+IV+Activity+and%2For+Structure+Homologues+in+Cancer&cit%3Apub=Folia+Biologica&cit%3Avol=55&cit%3Aiss=3&cit%3Apg=77&cit%3Adate=2009&ic=true&cit%3Aprod=ProQuest+Central&_a=ChgyMDE1MDUxNjE1NTUxNTA2MDo3MTE4MTUSBjEwNDgzNxoKT05FX1NFQVJDSCINMTI5Ljk2Ljg2LjExMSoFMzI0ODQyCTIyMTIyODg5MToNRG9jdW1lbnRJbWFnZUIBMFIGT25saW5lWgJGVGIDUEZUagoyMDA5LzA1LzAxcgoyMDA5LzA2LzMwegCCATJQLTEwMDcwNjctMTA5MTAtQ1VTVE9NRVItMTAwMDAwMzkvMTAwMDAxNTUtMzg5NDQwNJIBBk9ubGluZcoBB0VuZE5vdGXSARJTY2hvbGFybHkgSm91cm5hbHOaAgdQcmVQYWlkqgIoT1M6RU1TLVBkZkRvY1ZpZXdCYXNlLWdldE1lZGlhVXJsRm9ySXRlbcoCD0ZlYXR1cmV8QXJ0aWNsZdICAVniAgFO8gIA&_s=uQPIpzDATdFRqltnL5WaHE7RaZY%3D},
  year = {2009},
  type = {Journal Article},
}


@article{Li2009,
  author = {Li, S. J. and Peng, M. and Li, H. and Liu, B. S. and Wang, C. and Wu, J. R. and Li, Y. X. and Zeng, R.},
  title = {{Sys-BodyFluid: a systematical database for human body fluid proteome research}},
  journal = {Nucleic Acids Res},
  volume = {37},
  number = {Database issue},
  pages = {D907-12},
  note = {Li, Su-Jun Peng, Mao Li, Hong Liu, Bo-Shu Wang, Chuan Wu, Jia-Rui Li, Yi-Xue Zeng, Rong England Nucleic Acids Res. 2009 Jan;37(Database issue):D907-12. doi: 10.1093/nar/gkn849. Epub 2008 Oct 31.},
  abstract = {Recently, body fluids have widely become an important target for proteomic research and proteomic study has produced more and more body fluid related protein data. A database is needed to collect and analyze these proteome data. Thus, we developed this web-based body fluid proteome database Sys-BodyFluid. It contains eleven kinds of body fluid proteomes, including plasma/serum, urine, cerebrospinal fluid, saliva, bronchoalveolar lavage fluid, synovial fluid, nipple aspirate fluid, tear fluid, seminal fluid, human milk and amniotic fluid. Over 10,000 proteins are presented in the Sys-BodyFluid. Sys-BodyFluid provides the detailed protein annotations, including protein description, Gene Ontology, domain information, protein sequence and involved pathways. These proteome data can be retrieved by using protein name, protein accession number and sequence similarity. In addition, users can query between these different body fluids to get the different proteins identification information. Sys-BodyFluid database can facilitate the body fluid proteomics and disease proteomics research as a reference database. It is available at http://www.biosino.org/bodyfluid/.},
  keywords = {Body Fluids/*chemistry/metabolism *Databases, Protein Humans Proteins/chemistry/genetics/metabolism Proteome/*analysis *Proteomics Research},
  issn = {1362-4962 (Electronic) 0305-1048 (Linking)},
  doi = {10.1093/nar/gkn849},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/18978022 http://nar.oxfordjournals.org/content/37/suppl_1/D907.full.pdf},
  year = {2009},
  type = {Journal Article},
}


@article{Pitman:2009mz,
  author = {Pitman, Melissa R and Sulda, Melanie L and Kuss, Bryone and Abbott, Catherine A},
  title = {{Dipeptidyl peptidase 8 and 9--guilty by association?}},
  journal = {Front Biosci},
  volume = {14},
  pages = {3619--3633},
  abstract = {Dipeptidyl peptidases (DP) 8 and 9 are members of the DPIV enzyme family. Other members include DPIV, fibroblast activation protein (FAP) and the non-enzymes DP6 and DP10. DPIV family members have diverse biological roles, and have been implicated in a range of diseases including diabetes, cancer, inflammatory bowel disease, multiple sclerosis (MS), arthritis and asthma. While DP8/9 biological functions are yet to be established, they have been predicted to have similar roles to the other DPs due to high sequence similarities within the active site of the enzymes. While there is mounting evidence towards the involvement of DP8 and/or DP9 in innate and acquired immunity, direct proof for the link between DP8 and DP9 and human disease is yet to be definitively shown, thus DP8 and 9 proteins remain guilty by association.},
  issn = {1093-4715 (Electronic); 1093-4715 (Linking)},
  year = {2009},
  type = {Journal Article},
}


@article{Quesada:2009qf,
  author = {Quesada, V. and Ordonez, G. R. and Sanchez, L. M. and Puente, X. S. and Lopez-Otin, C.},
  title = {{The Degradome database: mammalian proteases and diseases of proteolysis}},
  journal = {Nucleic Acids Res},
  volume = {37},
  number = {Database issue},
  pages = {D239-43},
  note = {Quesada, Victor Ordonez, Gonzalo R Sanchez, Luis M Puente, Xose S Lopez-Otin, Carlos England Nucleic Acids Res. 2009 Jan;37(Database issue):D239-43. doi: 10.1093/nar/gkn570. Epub 2008 Sep 6.},
  abstract = {The degradome is defined as the complete set of proteases present in an organism. The recent availability of whole genomic sequences from multiple organisms has led us to predict the contents of the degradomes of several mammalian species. To ensure the fidelity of these predictions, our methods have included manual curation of individual sequences and, when necessary, direct cloning and sequencing experiments. The results of these studies in human, chimpanzee, mouse and rat have been incorporated into the Degradome database, which can be accessed through a web interface at http://degradome.uniovi.es. The annotations about each individual protease can be retrieved by browsing catalytic classes and families or by searching specific terms. This web site also provides detailed information about genetic diseases of proteolysis, a growing field of great importance for multiple users. Finally, the user can find additional information about protease structures, protease inhibitors, ancillary domains of proteases and differences between mammalian degradomes.},
  keywords = {Animals *Databases, Protein Genetic Diseases, Inborn/genetics Humans Mice Mutation Pan troglodytes Peptide Hydrolases/*chemistry/*genetics Proteome/chemistry/genetics Rats},
  issn = {1362-4962 (Electronic) 0305-1048 (Linking)},
  doi = {10.1093/nar/gkn570},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/18776217 http://nar.oxfordjournals.org/content/37/suppl_1/D239.full.pdf},
  year = {2009},
  type = {Journal Article},
}


@article{Rawlings2009,
  author = {Rawlings, N. D.},
  title = {{A large and accurate collection of peptidase cleavages in the MEROPS database}},
  journal = {Database (Oxford)},
  volume = {2009},
  pages = {bap015},
  note = {Rawlings, Neil D Database (Oxford). 2009;2009:bap015. Epub 2009 Nov 2.},
  abstract = {Peptidases are enzymes that hydrolyse peptide bonds in proteins and peptides. Peptidases are important in pathological conditions such as Alzheimer's disease, tumour and parasite invasion, and for processing viral polyproteins. The MEROPS database is an Internet resource containing information on peptidases, their substrates and inhibitors. The database now includes details of cleavage positions in substrates, both physiological and non-physiological, natural and synthetic. There are 39 118 cleavages in the collection; including 34 606 from a total of 10 513 different proteins and 2677 cleavages in synthetic substrates. The number of cleavages designated as 'physiological' is 13 307. The data are derived from 6095 publications. At least one substrate cleavage is known for 45% of the 2415 different peptidases recognized in the MEROPS database. The website now has three new displays: two showing peptidase specificity as a logo and a frequency matrix, the third showing a dynamically generated alignment between each protein substrate and its most closely related homologues. Many of the proteins described in the literature as peptidase substrates have been studied only in vitro. On the assumption that a physiologically relevant cleavage site would be conserved between species, the conservation of every site in terms of peptidase preference has been examined and a number have been identified that are not conserved. There are a number of cogent reasons why a site might not be conserved. Each poorly conserved site has been examined and a reason postulated. Some sites are identified that are very poorly conserved where cleavage is more likely to be fortuitous than of physiological relevance. This data-set is freely available via the Internet and is a useful training set for algorithms to predict substrates for peptidases and cleavage positions within those substrates. The data may also be useful for the design of inhibitors and for engineering novel specificities into peptidases.Database URL:http://merops.sanger.ac.uk.},
  issn = {1758-0463 (Electronic)},
  doi = {10.1093/database/bap015},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/20157488 http://database.oxfordjournals.org/content/2009/bap015.full.pdf},
  year = {2009},
  type = {Journal Article},
}


@article{Reinhold:2009rr,
  author = {Reinhold, D. and Goihl, A. and Wrenger, S. and Reinhold, A. and Kuhlmann, U. C. and Faust, J. and Neubert, K. and Thielitz, A. and Brocke, S. and Tager, M. and Ansorge, S. and Bank, U.},
  title = {{Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DP IV/CD26-knockout mice}},
  journal = {Clin Chem Lab Med},
  volume = {47},
  number = {3},
  pages = {268-74},
  note = {Reinhold, Dirk Goihl, Alexander Wrenger, Sabine Reinhold, Annegret Kuhlmann, Ulrike C Faust, Jurgen Neubert, Klaus Thielitz, Anja Brocke, Stefan Tager, Michael Ansorge, Siegfried Bank, Ute Germany Clin Chem Lab Med. 2009;47(3):268-74.},
  abstract = {BACKGROUND: Dipeptidyl peptidase IV (DP IV, CD26) and DP IV-like enzymes, such as dipeptidyl peptidase II (DP II), dipeptidyl peptidase 8 (DP8), and dipeptidyl peptidase 9 (DP9), have been recognized to regulate T lymphocyte activation. Lys[Z(NO2)]-thiazolidide (LZNT) and Lys[Z(NO2)]-pyrrolidide (LZNP), non-selective inhibitors of DP IV-like activity known to target DP IV as well as DP II, DP8, and DP9, suppress T lymphocyte proliferation in vitro. Moreover, these inhibitors are capable of attenuating the severity of autoimmune diseases, such as experimental autoimmune encephalomyelitis, the animal model of multiple sclerosis, and experimental arthritis, a model of human rheumatoid arthritis, in vivo, particularly in combination with inhibitors of aminopeptidase N (APN, CD13) enzymatic activity. METHODS: Here, we studied the influence of non-selective and selective inhibitors of DP IV-like enzymes on DNA synthesis in mitogen-stimulated splenocytes from wild-type C57BL/6 mice and DP IV/CD26-knockout (DP IV/CD26-KO) mice. RESULTS: LZNT and LZNP, the non-selective inhibitors of DP IV-like activity, suppressed the DNA synthesis in stimulated splenocytes from wild-type and DP IV/ CD26-KO mice to a comparable extent. Further, a selective inhibitor of DP8/DP9 activity was capable of suppressing DNA synthesis in mitogen-stimulated splenocytes of both wild-type and knockout mice to the same extent. In contrast, selective inhibitors of DP IV and DP II lacked this suppressive activity. CONCLUSIONS: Our data support the hypothesis that DP8 and/or DP9 represent additional pharmacological targets for the suppression of T cell proliferation and for anti-inflammatory therapy.},
  keywords = {Animals Cell Proliferation/drug effects DNA/biosynthesis Dipeptidyl Peptidase 4/*deficiency/genetics Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/antagonists & inhibitors/genetics/*immunology Disease Models, Animal *Lymphocyte Activation Lysine/analogs & derivatives/chemistry/pharmacology Mice Mice, Inbred C57BL Mice, Knockout Pyrrolidines/chemistry/pharmacology Spleen/cytology/immunology T-Lymphocytes/drug effects/*immunology Thiazoles/chemistry/pharmacology},
  issn = {1434-6621 (Print) 1434-6621 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/19676138},
  year = {2009},
  type = {Journal Article},
}


@misc{Ryan:2009bx,
  author = {Ryan, Claire and Pieris-Caldwell, Indrani and of Health, Australian Institute and Welfare and Templeton, Mardi},
  title = {{Diabetes prevalence in Australia : an assessment of national data sources / Mardi Templeton, Claire Ryan and Indrani Pieris-Caldwell.}},
  keywords = {Diabetes -- Australia Diabetes -- Australia -- Statistics},
  isbn = {14448033},
  year = {2009},
  type = {Generic},
}


@article{Tang:2009oq,
  author = {Tang, H. K. and Tang, H. Y. and Hsu, S. C. and Chu, Y. R. and Chien, C. H. and Shu, C. H. and Chen, X.},
  title = {{Biochemical properties and expression profile of human prolyl dipeptidase DPP9}},
  journal = {Arch Biochem Biophys},
  volume = {485},
  number = {2},
  pages = {120-7},
  note = {Tang, Hung-Kuan Tang, Hsiang-Yun Hsu, Shu-Ching Chu, Yue-Ru Chien, Chia-Hui Shu, Chin-Hang Chen, Xin Arch Biochem Biophys. 2009 May 15;485(2):120-7. doi: 10.1016/j.abb.2009.02.015. Epub 2009 Mar 5.},
  abstract = {Dipetidyl peptidase 9 (DPP9) is a prolyl dipeptidase preferentially cleaving the peptide bond after the penultimate proline residue. The biological function of DPP9 is unknown. In this study, we have significantly improved the yield using Strep.Tactin purification system and characterized the biochemical property of DPP9. Moreover, the dimer interaction mode was investigated by introducing a mutation (F842A) at the dimer interface, which abolished the enzymatic activity without disrupting its quaternary structure. Furthermore, DPP9 was found ubiquitously expressed in fibroblasts, epithelial, and blood cells. Surprisingly, contrary to previous report, we found that the expression levels of DPP8 and DPP9 did not change upon the activation of the PBMC or Jurkat cells. These results indicate that the biochemical property of DPP9 is very similar to that of DPP8, its homologous protease. DPP9 and DPP8 are likely redundant proteins carrying out overlapping functions in vivo.},
  keywords = {Amino Acid Sequence Animals Base Sequence Blotting, Western Cell Line DNA Primers Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/chemistry/genetics/*metabolism Flow Cytometry *Gene Expression Profiling Humans Hydrogen-Ion Concentration Molecular Sequence Data Mutation Reverse Transcriptase Polymerase Chain Reaction Sequence Homology, Amino Acid Spodoptera Substrate Specificity},
  issn = {1096-0384 (Electronic) 0003-9861 (Linking)},
  doi = {10.1016/j.abb.2009.02.015},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/19268648 http://ac.els-cdn.com/S0003986109000605/1-s2.0-S0003986109000605-main.pdf?_tid=21f9fd84-fbdf-11e4-8a46-00000aab0f02&acdnat=1431789829_34aa4ca604098e1707aeb26d35e1ecd4},
  year = {2009},
  type = {Journal Article},
}


@article{Verspurten:2009aa,
  author = {Verspurten, J. and Gevaert, K. and Declercq, W. and Vandenabeele, P.},
  title = {{SitePredicting the cleavage of proteinase substrates}},
  journal = {Trends Biochem Sci},
  volume = {34},
  number = {7},
  pages = {319-23},
  note = {Verspurten, Jelle Gevaert, Kris Declercq, Wim Vandenabeele, Peter England Trends Biochem Sci. 2009 Jul;34(7):319-23. doi: 10.1016/j.tibs.2009.04.001. Epub 2009 Jun 21.},
  abstract = {Proteinases are enzymes that play important roles in vital cellular and extracellular processes by hydrolytically cleaving peptide bonds in their protein substrates. This cleavage can be non-specific as part of degradation during protein catabolism or highly specific as part of proteolytic cascades and signal transduction events. Several web tools are available for predicting possible cleavage sites in candidate substrates. Here, we compare existing prediction tools with SitePrediction, a novel and user-friendly tool for identifying potential cleavage sites. This prediction is based on known datasets found in the literature, stored in web-accessible repositories or generated by our own experiments. Comparison of the different programs shows that SitePrediction makes it possible to derive more reliable predictions. In addition, this tool allows the use of a wide range of proteinases.},
  keywords = {Amino Acid Sequence Animals Databases, Protein Humans Peptide Hydrolases/*metabolism Protein Structure, Secondary Proteins/chemistry/*metabolism *Software Substrate Specificity},
  issn = {0968-0004 (Print) 0968-0004 (Linking)},
  doi = {10.1016/j.tibs.2009.04.001},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/19546006 http://ac.els-cdn.com/S0968000409001017/1-s2.0-S0968000409001017-main.pdf?_tid=cbee1ad6-ea5b-11e4-912b-00000aab0f27&acdnat=1429864251_83e5a0b2222c8d0c4fb6d1a82b90282e http://ac.els-cdn.com/S0968000409001017/1-s2.0-S0968000409001017-main.pdf?_tid=25f3cb22-fbdf-11e4-8963-00000aacb362&acdnat=1431789836_7fa5a06ea6f8ffe6fddb5fb2315c5694},
  year = {2009},
  type = {Journal Article},
}


@article{Yazbeck2009,
  author = {Yazbeck, R. and Howarth, G. S. and Abbott, C. A.},
  title = {{Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?}},
  journal = {Trends Pharmacol Sci},
  volume = {30},
  number = {11},
  pages = {600-7},
  note = {Yazbeck, Roger Howarth, Gordon S Abbott, Catherine A England Trends Pharmacol Sci. 2009 Nov;30(11):600-7. doi: 10.1016/j.tips.2009.08.003.},
  abstract = {Dipeptidyl peptidase (DPP)-4 is a member of the S9b serine protease family, which also includes DPP8 and DPP9. DPP4 cleaves a number of regulatory factors, including chemokines and growth factors. DPP4 inhibitors have recently emerged as an effective treatment option for type 2 diabetes. Early in vitro studies demonstrated that DPP4 inhibitors inhibit T-cell proliferation and cytokine production, leading to their investigation in numerous pre-clinical models of inflammatory diseases, including arthritis, multiple sclerosis and inflammatory bowel disease. Recent data suggest that the early DPP4-specific inhibitors might also bind DPP8 and DPP9, thus exerting their effects through non-specific binding. This review highlights recent insights into the applicability of DPP inhibitors as novel pharmacological agents for inflammatory disease.},
  keywords = {Animals Clinical Trials as Topic Dipeptidases/antagonists & inhibitors Dipeptidyl Peptidase 4 Dipeptidyl-Peptidase IV Inhibitors/*pharmacology Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/antagonists & inhibitors *Drug Delivery Systems Drug Evaluation, Preclinical Humans Inflammation/*drug therapy/physiopathology},
  issn = {1873-3735 (Electronic) 0165-6147 (Linking)},
  doi = {10.1016/j.tips.2009.08.003},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/19837468 http://ac.els-cdn.com/S0165614709001382/1-s2.0-S0165614709001382-main.pdf?_tid=298384d0-fbdf-11e4-b2a1-00000aacb360&acdnat=1431789842_1c8a3153d7426aab3e3bc93fd50a6a3c},
  year = {2009},
  type = {Journal Article},
}


@article{Yazbeck:2009la,
  author = {Yazbeck, R. and Howarth, G. S. and Abbott, C. A.},
  title = {{Growth factor based therapies and intestinal disease: is glucagon-like peptide-2 the new way forward?}},
  journal = {Cytokine Growth Factor Rev},
  volume = {20},
  number = {2},
  pages = {175-84},
  note = {Yazbeck, Roger Howarth, Gordon S Abbott, Catherine A England Cytokine Growth Factor Rev. 2009 Apr;20(2):175-84. doi: 10.1016/j.cytogfr.2009.02.008. Epub 2009 Mar 25.},
  abstract = {Inflammatory bowel disease (IBD) is a chronic, debilitating disease associated with severe damage to the intestinal mucosa. Glucagon-like peptide-2 (GLP-2) is a potent and specific gastrointestinal growth factor that is demonstrating therapeutic potential for the prevention or treatment of an expanding number of intestinal diseases, including short bowel syndrome (SBS), small bowel enteritis and IBD. The biological activity of GLP-2 is limited due to proteolytic inactivation by the protease dipeptidyl peptidase (DP)IV. Inhibitors of DPIV activity may represent a novel strategy to prolong the growth promoting actions of GLP-2. This review outlines evidence for the clinical application of GLP-2, its degradation resistant analogue, Teduglutide, and novel DPIV inhibitors in efficacy studies utilizing pre-clinical models of intestinal damage, in particular IBD.},
  keywords = {Animals Dipeptidyl Peptidase 4/metabolism *Dipeptidyl-Peptidase IV Inhibitors Glucagon-Like Peptide 2/*therapeutic use Humans Inflammatory Bowel Diseases/*drug therapy/physiopathology Intestinal Diseases/*drug therapy Neoplasms/chemically induced Peptides/therapeutic use Short Bowel Syndrome/drug therapy},
  issn = {1879-0305 (Electronic) 1359-6101 (Linking)},
  doi = {10.1016/j.cytogfr.2009.02.008},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/19324585 http://ac.els-cdn.com/S1359610109000136/1-s2.0-S1359610109000136-main.pdf?_tid=2d0da162-fbdf-11e4-8133-00000aacb35e&acdnat=1431789848_5e0a0eb57096d6b9315651f96552e91e},
  year = {2009},
  type = {Journal Article},
}


@article{Yu:2009xq,
  author = {Yu, D. M. and Ajami, K. and Gall, M. G. and Park, J. and Lee, C. S. and Evans, K. A. and McLaughlin, E. A. and Pitman, M. R. and Abbott, C. A. and McCaughan, G. W. and Gorrell, M. D.},
  title = {{The in vivo expression of dipeptidyl peptidases 8 and 9}},
  journal = {J Histochem Cytochem},
  volume = {57},
  number = {11},
  pages = {1025-40},
  note = {Yu, Denise M T Ajami, Katerina Gall, Margaret G Park, Joohong Lee, C Soon Evans, Kathryn A McLaughlin, Eileen A Pitman, Melissa R Abbott, Catherine A McCaughan, Geoffrey W Gorrell, Mark D J Histochem Cytochem. 2009 Nov;57(11):1025-40. doi: 10.1369/jhc.2009.953760. Epub 2009 Jul 6.},
  abstract = {The dipeptidyl peptidase IV (DPIV) enzyme family contains both potential and proven therapeutic targets. Recent reports indicate the presence of DP8 and DP9 in peripheral blood lymphocytes, testis, lung, and brain. For a more comprehensive understanding of DP8 and DP9 tissue and cellular expression, mRNA and enzyme activity were examined. Many organs from C57BL/6 wild-type and DPIV gene-knockout mice were examined; DP8/9 enzyme activity was detected in the immune system, brain, testis, muscle, and epithelia. In situ hybridization localized DP8 and DP9 mRNA to lymphocytes and epithelial cells in liver, gastrointestinal tract, lymph node, spleen, and lung. DP8 and DP9 mRNA was detected in baboon and mouse testis, and DP9 expression was elevated in human testicular cancers. DP8 and DP9 mRNA were ubiquitous in day 17 mouse embryo, with greatest expression in epithelium (skin and gastrointestinal tract) and brain. Thus, DP8 and DP9 are widely expressed enzymes. Their expression in lymphocytes and epithelia indicates potential for roles in the digestive and immune systems. This manuscript contains online supplemental material at http://www.jhc.org. Please visit this article online to view these materials.},
  keywords = {Adolescent Animals Central Nervous System/drug effects/metabolism Child Dipeptidyl Peptidase 4/deficiency/*genetics/*metabolism Dipeptidyl-Peptidase IV Inhibitors Endocrine System/drug effects/metabolism Epithelium/drug effects/metabolism Ethylmaleimide/pharmacology *Gene Expression Regulation, Enzymologic Gene Knockout Techniques Humans Immune System/drug effects/metabolism In Situ Hybridization Male Mice Muscles/drug effects/metabolism Papio Protease Inhibitors/pharmacology RNA, Messenger/genetics/metabolism Reproduction Testis/drug effects/metabolism},
  issn = {1551-5044 (Electronic) 0022-1554 (Linking)},
  doi = {10.1369/jhc.2009.953760},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/19581630 http://jhc.sagepub.com/content/57/11/1025.full.pdf},
  year = {2009},
  type = {Journal Article},
}


@article{60108086,
  author = {Arkin, A. and Baliga, N. and Braam, J. and Church, G. and Collins, J. and Cottingham, R. and Ecker, J. and Gerstein, M. and Gilna, P. and Greenberg, J. and Handelsman, J. and Hubbard, S. and Joachimiak, A. and Liao, J. and Looger, L. and Meyerowitz, E. and Mjolness, E. and Petsko, G. and Sayler, G. and Simpson, M. and Stacey, G. and Sussman, M. and Tiedje, J. and Bader, D. and Cessi, P. and Collins, W. and Denning, S. and Dickinson, R. and Easterling, D. and Edmonds, J. and Feddema, J. and Field, C. and Fridlind, A. and Fung, I. and Held, I. and Jackson, R. and Janetos, A. and Large, W. and Leinen, M. and Leung, R. and Long, S. and Mace, G. and Masiello, C. and Meehl, G. and Ort, D. and Otto-Bliesner, B. and Penner, J. and Prather, M. and Randall, D. and Rasch, P. and Schneider, E. and Shugart, H. and Thornton, P. and Washington, W. and Wildung, R. and Wiscombe, W. and Zak, D. and Zhang, M. and Bielicki, J. and Buford, M. and Cleland, E. and Dale, V. and Duke, C. and Ehleringer, J. and Hecht, A. and Kammen, D. and Marland, G. and Pataki, D. and Riley, M. Robertson P. and Hubbard, S.},
  title = {{Grand Challenges for Biological and Environmental Research: A Long-Term Vision}},
  doi = {10.2172/1006492},
  url = {http://dx.doi.org/10.2172/1006492 http://www.osti.gov/scitech/servlets/purl/1006492},
  year = {2010},
  type = {Journal Article},
}


@article{Bork2010,
  author = {Bork, Konrad},
  title = {{Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor}},
  journal = {Allergy, Asthma & Clinical Immunology},
  volume = {6},
  number = {1},
  pages = {1-8},
  abstract = {Until recently it was assumed that hereditary angioedema is a disease that results exclusively from a genetic deficiency of the C1 inhibitor. In 2000, families with hereditary angioedema, normal C1 inhibitor activity and protein in plasma were described. Since then numerous patients and families with that condition have been reported. Most of the patients by far were women. In many of the affected women, oral contraceptives, hormone replacement therapy containing estrogens, and pregnancies triggered the clinical symptoms. Recently, in some families mutations in the coagulation factor XII (Hageman factor) gene were detected in the affected persons.},
  issn = {1710-1492},
  doi = {10.1186/1710-1492-6-15},
  url = {http://dx.doi.org/10.1186/1710-1492-6-15 http://download.springer.com/static/pdf/871/art%253A10.1186%252F1710-1492-6-15.pdf?originUrl=http%3A%2F%2Faacijournal.biomedcentral.com%2Farticle%2F10.1186%2F1710-1492-6-15&token2=exp=1473656709~acl=%2Fstatic%2Fpdf%2F871%2Fart%25253A10.1186%25252F1710-1492-6-15.pdf*~hmac=ae4553046757582cdd571708c157cb45e347d4dab76a9617b5acd557ba719bbe},
  year = {2010},
  type = {Journal Article},
}


@article{Matos2010,
  author = {de Matos, P. and Alcantara, R. and Dekker, A. and Ennis, M. and Hastings, J. and Haug, K. and Spiteri, I. and Turner, S. and Steinbeck, C.},
  title = {{Chemical Entities of Biological Interest: an update}},
  journal = {Nucleic Acids Res},
  volume = {38},
  number = {Database issue},
  pages = {D249-54},
  note = {de Matos, Paula Alcantara, Rafael Dekker, Adriano Ennis, Marcus Hastings, Janna Haug, Kenneth Spiteri, Inmaculada Turner, Steve Steinbeck, Christoph BB/G022747/1/Biotechnology and Biological Sciences Research Council/United Kingdom England Nucleic Acids Res. 2010 Jan;38(Database issue):D249-54. doi: 10.1093/nar/gkp886. Epub 2009 Oct 23.},
  abstract = {Chemical Entities of Biological Interest (ChEBI) is a freely available dictionary of molecular entities focused on 'small' chemical compounds. The molecular entities in question are either natural products or synthetic products used to intervene in the processes of living organisms. Genome-encoded macromolecules (nucleic acids, proteins and peptides derived from proteins by cleavage) are not as a rule included in ChEBI. In addition to molecular entities, ChEBI contains groups (parts of molecular entities) and classes of entities. ChEBI includes an ontological classification, whereby the relationships between molecular entities or classes of entities and their parents and/or children are specified. ChEBI is available online at http://www.ebi.ac.uk/chebi/. This article reports on new features in ChEBI since the last NAR report in 2007, including substructure and similarity searching, a submission tool for authoring of ChEBI datasets by the community and a 30-fold increase in the number of chemical structures stored in ChEBI.},
  keywords = {Agrochemicals/chemistry Animals Biological Products/chemistry Computational Biology/*methods/trends *Databases, Factual Dictionaries, Chemical Humans Information Storage and Retrieval/methods Internet Pharmaceutical Preparations/chemistry Software User-Computer Interface Vocabulary, Controlled},
  issn = {1362-4962 (Electronic) 0305-1048 (Linking)},
  doi = {10.1093/nar/gkp886},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/19854951 http://nar.oxfordjournals.org/content/38/suppl_1/D249.full.pdf},
  year = {2010},
  type = {Journal Article},
}


@article{Gupta:2010aa,
  author = {Gupta, N. and Hixson, K. K. and Culley, D. E. and Smith, R. D. and Pevzner, P. A.},
  title = {{Analyzing protease specificity and detecting in vivo proteolytic events using tandem mass spectrometry}},
  journal = {PROTEOMICS},
  volume = {10},
  number = {15},
  pages = {2833-44},
  note = {Gupta, Nitin Hixson, Kim K Culley, David E Smith, Richard D Pevzner, Pavel A 1-P41-RR024851-01/RR/NCRR NIH HHS/ 5R01RR016522-05/RR/NCRR NIH HHS/ P41 RR024851-01/RR/NCRR NIH HHS/ R01 RR016522-05/RR/NCRR NIH HHS/ RR018522/RR/NCRR NIH HHS/ Howard Hughes Medical Institute/ Germany Proteomics. 2010 Aug;10(15):2833-44. doi: 10.1002/pmic.200900821.},
  abstract = {Although trypsin remains the most commonly used protease in MS, other proteases may be employed for increasing peptide coverage or generating overlapping peptides. Knowledge of the accurate specificity rules of these proteases is helpful for database search tools to detect peptides, and becomes crucial when label-free MS is used to discover in vivo proteolytic cleavages. Since in vivo cleavages are inferred by subtracting digestion-induced cleavages from all observed cleavages, it is important to ensure that the specificity rule used to identify digestion-induced cleavages are broad enough to capture even minor cleavages produced in digestion, to avoid erroneously identifying them as in vivo cleavages. In this study, we describe MS-Proteolysis, a software tool for identifying putative sites of in vivo proteolytic cleavage using label-free MS. The tool is used in conjunction with digestion by trypsin and three other proteases, whose specificity rules are revised and extended before inferring proteolytic cleavages. Finally, we show that comparative analysis of multiple proteases can be used to detect putative in vivo proteolytic sites on a proteome-wide scale.},
  keywords = {Animals Bacterial Proteins/metabolism Chymotrypsin/metabolism Hydrolysis Peptide Hydrolases/*metabolism Serine Endopeptidases/metabolism Shewanella/enzymology Software Staphylococcus aureus/enzymology Substrate Specificity Tandem Mass Spectrometry/*methods Trypsin/metabolism},
  issn = {1615-9861 (Electronic) 1615-9853 (Linking)},
  doi = {10.1002/pmic.200900821},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/20597098 http://onlinelibrary.wiley.com/store/10.1002/pmic.200900821/asset/2833_ftp.pdf?v=1&t=i8vcaiv4&s=5c1b408272aef91036ac0dd9451b8d4441262e49 http://onlinelibrary.wiley.com/store/10.1002/pmic.200900821/asset/2833_ftp.pdf?v=1&t=i9r6m813&s=f72a7ab15982044836503c54bd43fdbc41568855},
  year = {2010},
  type = {Journal Article},
}


@article{Kleifeld:2010pi,
  author = {Kleifeld, O. and Doucet, A. and auf dem Keller, U. and Prudova, A. and Schilling, O. and Kainthan, R. K. and Starr, A. E. and Foster, L. J. and Kizhakkedathu, J. N. and Overall, C. M.},
  title = {{Isotopic labeling of terminal amines in complex samples identifies protein N-termini and protease cleavage products}},
  journal = {Nat Biotechnol},
  volume = {28},
  number = {3},
  pages = {281-8},
  note = {Kleifeld, Oded Doucet, Alain auf dem Keller, Ulrich Prudova, Anna Schilling, Oliver Kainthan, Rajesh K Starr, Amanda E Foster, Leonard J Kizhakkedathu, Jayachandran N Overall, Christopher M STP-53877/Canadian Institutes of Health Research/Canada Nat Biotechnol. 2010 Mar;28(3):281-8. doi: 10.1038/nbt.1611. Epub 2010 Mar 7.},
  abstract = {Effective proteome-wide strategies that distinguish the N-termini of proteins from the N-termini of their protease cleavage products would accelerate identification of the substrates of proteases with broad or unknown specificity. Our approach, named terminal amine isotopic labeling of substrates (TAILS), addresses this challenge by using dendritic polyglycerol aldehyde polymers that remove tryptic and C-terminal peptides. We analyze unbound naturally acetylated, cyclized or labeled N-termini from proteins and their protease cleavage products by tandem mass spectrometry, and use peptide isotope quantification to discriminate between the substrates of the protease of interest and the products of background proteolysis. We identify 731 acetylated and 132 cyclized N-termini, and 288 matrix metalloproteinase (MMP)-2 cleavage sites in mouse fibroblast secretomes. We further demonstrate the potential of our strategy to link proteases with defined biological pathways in complex samples by analyzing mouse inflammatory bronchoalveolar fluid and showing that expression of the poorly defined breast cancer protease MMP-11 in MCF-7 human breast cancer cells cleaves both endoplasmin and the immunomodulator and apoptosis inducer galectin-1.},
  keywords = {Amines/chemistry/*metabolism Animals Bronchoalveolar Lavage Fluid/chemistry Cell Line, Transformed Computer Simulation Fibroblasts/secretion Glycerol/metabolism Isotope Labeling/*methods Matrix Metalloproteinase 2/metabolism Mice Peptide Fragments/chemistry/*metabolism Peptide Hydrolases/*metabolism Polymers/metabolism Proteome/chemistry/metabolism Proteomics/*methods Reproducibility of Results Tandem Mass Spectrometry},
  issn = {1546-1696 (Electronic) 1087-0156 (Linking)},
  doi = {10.1038/nbt.1611},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/20208520 http://www.nature.com/nbt/journal/v28/n3/pdf/nbt.1611.pdf},
  year = {2010},
  type = {Journal Article},
}


@article{Lin:2010aa,
  author = {Lin, C. T. and Tang, H. Y. and Han, Y. S. and Liu, H. P. and Huang, S. F. and Chien, C. H. and Shyy, J. and Chiu, J. J. and Chen, X.},
  title = {{Downregulation of Signaling-active IGF-1 by Dipeptidyl Peptidase IV (DPP-IV)}},
  journal = {Int J Biomed Sci},
  volume = {6},
  number = {4},
  pages = {301-9},
  note = {Lin, Ching-Ting Tang, Hsiang-Yun Han, Yu-San Liu, Hui-Ping Huang, Shiu-Feng Chien, Chia-Hui Shyy, John Chiu, Jeng-Jian Chen, Xin Int J Biomed Sci. 2010 Dec;6(4):301-9.},
  abstract = {Functioning as an extracellular protease, dipeptidyl peptidase IV (DPP-IV) preferentially cleaves the peptide bond after the penultimate proline residue. We report here that DPP-IV cleaves the first two amino acids from insulin-like growth factor 1 (IGF-1), revealed by mass spectrometry. The kinetic parameters of the proteolytic cleavage indicate that this reaction is physiologically relevant. Interestingly, truncated IGF-1 is less potent than the full-length protein in activating the IGF-1R, but binds more readily to IGF-binding protein 3 (IGFBP3). Quantitative RT-PCR showed that the level of DPP-IV mRNA is dramatically lower in lung squamous cell carcinoma tissues than in adjacent nonneoplastic lung tissues. However, this reduction was not observed in lung adenocarcinoma tissues. Our study suggests a possible link between IGF-1 and DPP-IV in cancer development in a specific tumor niche. A DPP-IV-related pathway may be important in mitigating IGF-1 signaling. Consequently, a robust IGF signaling pathway may accelerate early carcinogenesis in environments lacking DPP-IV.},
  keywords = {IGF binding protein 3; IGF signaling pathway; dipeptidyl peptidase IV; insulin-like growth factor-1},
  issn = {1550-9702 (Print) 1550-9702 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/23675206 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3615292/pdf/IJBS-06-301.pdf},
  year = {2010},
  type = {Journal Article},
}


@article{Ospelt:2010wc,
  author = {Ospelt, C. and Mertens, J. C. and Jungel, A. and Brentano, F. and Maciejewska-Rodriguez, H. and Huber, L. C. and Hemmatazad, H. and Wuest, T. and Knuth, A. and Gay, R. E. and Michel, B. A. and Gay, S. and Renner, C. and Bauer, S.},
  title = {{Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts}},
  journal = {Arthritis Rheum},
  volume = {62},
  number = {5},
  pages = {1224-35},
  note = {Ospelt, Caroline Mertens, Joachim C Jungel, Astrid Brentano, Fabia Maciejewska-Rodriguez, Hanna Huber, Lars C Hemmatazad, Hossein Wuest, Thomas Knuth, Alexander Gay, Renate E Michel, Beat A Gay, Steffen Renner, Christoph Bauer, Stefan Arthritis Rheum. 2010 May;62(5):1224-35. doi: 10.1002/art.27395.},
  abstract = {OBJECTIVE: Since fibroblasts in the synovium of patients with rheumatoid arthritis (RA) express the serine proteases fibroblast activation protein (FAP) and dipeptidylpeptidase 4 (DPP-4)/CD26, we undertook the current study to determine the functional role of both enzymes in the invasion of RA synovial fibroblasts (RASFs) into articular cartilage. METHODS: Expression of FAP and DPP-4/CD26 by RASFs was analyzed using fluorescence-activated cell sorting and immunocytochemistry. Serine protease activity was measured by cleavage of fluorogenic substrates and inhibited upon treatment with L-glutamyl L-boroproline. The induction and expression of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in RASFs were detected using real-time polymerase chain reaction. Densitometric measurements of MMPs using immunoblotting confirmed our findings on the messenger RNA level. Stromal cell-derived factor 1 (SDF-1 [CXCL12]), MMP-1, and MMP-3 protein levels were measured using enzyme-linked immunosorbent assay. The impact of FAP and DPP-4/CD26 inhibition on the invasiveness of RASFs was analyzed in the SCID mouse coimplantation model of RA using immunohistochemistry. RESULTS: Inhibition of serine protease activity of FAP and DPP-4/CD26 in vitro led to increased levels of SDF-1 in concert with MMP-1 and MMP-3, which are downstream effectors of SDF-1 signaling. Using the SCID mouse coimplantation model, inhibition of enzymatic activity in vivo significantly promoted invasion of xenotransplanted RASFs into cotransplanted human cartilage. Zones of cartilage resorption were infiltrated by FAP-expressing RASFs and marked by a significantly higher accumulation of MMP-1 and MMP-3, when compared with controls. CONCLUSION: Our results indicate a central role for the serine protease activity of FAP and DPP-4/CD26 in protecting articular cartilage against invasion by synovial fibroblasts in RA.},
  keywords = {Animals Arthritis, Rheumatoid/*metabolism/*pathology Cartilage, Articular/metabolism/*pathology Cells, Cultured Chemokine CXCL12/metabolism Dipeptidyl Peptidase 4/*metabolism Dipeptidyl-Peptidase IV Inhibitors Disease Models, Animal Enzyme Inhibitors/pharmacology Fibroblasts/drug effects/enzymology/pathology Gelatinases/antagonists & inhibitors/*metabolism Humans Matrix Metalloproteinases/metabolism Membrane Proteins/antagonists & inhibitors/*metabolism Mice Mice, SCID Serine Endopeptidases/*metabolism Synovial Membrane/enzymology/pathology},
  issn = {1529-0131 (Electronic) 0004-3591 (Linking)},
  doi = {10.1002/art.27395},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/20155839 http://onlinelibrary.wiley.com/store/10.1002/art.27395/asset/27395_ftp.pdf?v=1&t=i9r6mi0s&s=35378d0d42e5969eac43afe0fe9422a993b4be79},
  year = {2010},
  type = {Journal Article},
}


@article{Pitman:2010oq,
  author = {Pitman, M. R. and Menz, R. I. and Abbott, C. A.},
  title = {{Hydrophilic residues surrounding the S1 and S2 pockets contribute to dimerisation and catalysis in human dipeptidyl peptidase 8 (DP8)}},
  journal = {Biol Chem},
  volume = {391},
  number = {8},
  pages = {959-72},
  note = {Pitman, Melissa R Menz, R Ian Abbott, Catherine A Germany Biol Chem. 2010 Aug;391(8):959-72. doi: 10.1515/BC.2010.111.},
  abstract = {Dipeptidyl peptidase (DP) 8 belongs to the dipeptidyl peptidase IV gene family. DP8 has been implicated in immune function and asthma, although its biological function is yet unknown. Structures of the homologs, fibroblast activation protein (FAP) and DPIV, are known but the DP8 structure is yet to be resolved. To help characterise the DP8 substrate pocket, mutants of residues lining the pocket were produced at DP8(D772), DP8(Y315), DP8(H434) and DP8(D435) and assessed by substrate kinetics and size-exclusion chromatography. Mutations of DP8(D772A/E/S/V) affected catalysis but did not confer endopeptidase activity. Mutations of DP8(H434F), DP8(D435F) and DP8(Y315F) reduced catalytic activity. Furthermore, mutations to DP8(D772A/E/S/V), DP8(H434F), DP8(D435F) and DP8(Y315F) affected dimer stabilisation. Homology modelling of DP8 using DPIV and FAP crystal structures suggested that DP8(D772), DP8(H434) and DP8(D435) were located at the edge of the S2 catalytic pocket, contributing to the junction between the alpha-beta hydrolase and beta-propeller domains. This study provides insights into how the DP8 substrate pocket and dimer interface differ from DPIV and FAP which could be utilised for designing more selective DP8 inhibitors.},
  keywords = {*Biocatalysis *Catalytic Domain Databases, Protein *Dimerization Dipeptidases/*chemistry/genetics/isolation & purification/*metabolism Dipeptidyl Peptidase 4/chemistry Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/chemistry Gelatinases/chemistry Humans Hydrogen-Ion Concentration Hydrophobic and Hydrophilic Interactions Kinetics Membrane Proteins/chemistry Mutagenesis, Site-Directed Mutant Proteins/chemistry/isolation & purification/metabolism *Protein Interaction Domains and Motifs Protein Stability Protein Structure, Quaternary Recombinant Proteins/chemistry/isolation & purification/metabolism Sequence Alignment Sequence Homology, Amino Acid Serine Endopeptidases/chemistry Substrate Specificity},
  issn = {1437-4315 (Electronic) 1431-6730 (Linking)},
  doi = {10.1515/BC.2010.111},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/20536396 http://www.degruyter.com/view/j/bchm.2010.391.issue-8/bc.2010.111/bc.2010.111.xml https://www.degruyter.com/view/j/bchm.2010.391.issue-8/bc.2010.111/bc.2010.111.xml},
  year = {2010},
  type = {Journal Article},
}


@unpublished{PyMOL,
  author = {Schrodinger, LLC},
  title = {{The PyMOL Molecular Graphics System, Version 1.3r1}},
  year = {2010},
  type = {Unpublished Work},
}


@article{Shah:2010zp,
  author = {Shah, D. D. and Fonarow, G. C. and Horwich, T. B.},
  title = {{Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes}},
  journal = {J Card Fail},
  volume = {16},
  number = {3},
  pages = {200-6},
  note = {Shah, Digish D Fonarow, Gregg C Horwich, Tamara B 1K23 HL 085097/HL/NHLBI NIH HHS/ K23 HL085097/HL/NHLBI NIH HHS/ K23 HL085097-01A1/HL/NHLBI NIH HHS/ J Card Fail. 2010 Mar;16(3):200-6. doi: 10.1016/j.cardfail.2009.10.022. Epub 2009 Nov 14.},
  abstract = {BACKGROUND: Although 25% to 44% of patients with heart failure (HF) have diabetes mellitus (DM), the optimal treatment regimen for HF patients with DM is uncertain. We investigated the association between metformin therapy and outcomes in a cohort of advanced, systolic HF patients with DM. METHODS AND RESULTS: Patients with DM and advanced, systolic HF (n = 401) were followed at a single university HF center between 1994 and 2008. The cohort was divided into 2 groups based on the presence or absence of metformin therapy. The cohort had a mean age of 56 +/- 11 years, left ventricular ejection fraction (LVEF) of 24 +/- 7%, with 42% being New York Heart Association (NYHA) III and 45% NYHA IV. Twenty-five percent (n = 99) were treated with metformin therapy. The groups treated and not treated with metformin were similar in terms of age, sex, baseline LVEF, medical history, and baseline glycosylated hemoglobin. Metformin-treated patients had a higher body mass index, lower creatinine, and were less often on insulin. One-year survival in metformin-treated and non-metformin-treated patients was 91% and 76%, respectively (RR = 0.37, CI 0.18-0.76, P = .007). After multivariate adjustment for demographics, cardiac function, renal function, and HF medications, metformin therapy was associated with a nonsignificant trend for improved survival. CONCLUSION: In patients with DM and advanced, systolic HF who are closely monitored, metformin therapy appears to be safe. Prospective studies are needed to determine whether metformin can improve HF outcome.},
  keywords = {Aged Cohort Studies Confidence Intervals Diabetes Mellitus, Type 2/diagnosis/*drug therapy/*epidemiology Female Heart Failure, Systolic/diagnosis/*epidemiology Heart Function Tests Humans Hypoglycemic Agents/*administration & dosage/adverse effects Male Metformin/*administration & dosage/adverse effects Middle Aged Multivariate Analysis Probability Prognosis Proportional Hazards Models Retrospective Studies Severity of Illness Index Survival Analysis Treatment Outcome},
  issn = {1532-8414 (Electronic) 1071-9164 (Linking)},
  doi = {10.1016/j.cardfail.2009.10.022},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/20206893 http://ac.els-cdn.com/S1071916409011324/1-s2.0-S1071916409011324-main.pdf?_tid=49c4e6bc-fbdf-11e4-b2a1-00000aacb360&acdnat=1431789896_f1cdad5ecf7cbd8f975cdb129b3ec0bd},
  year = {2010},
  type = {Journal Article},
}


@article{Smith:2010sj,
  author = {Smith, H. W. and Marshall, C. J.},
  title = {{Regulation of cell signalling by uPAR}},
  journal = {Nat Rev Mol Cell Biol},
  volume = {11},
  number = {1},
  pages = {23-36},
  note = {Smith, Harvey W Marshall, Chris J 10433/Cancer Research UK/United Kingdom 10437/Cancer Research UK/United Kingdom 3955/Cancer Research UK/United Kingdom England Nat Rev Mol Cell Biol. 2010 Jan;11(1):23-36. doi: 10.1038/nrm2821.},
  abstract = {Urokinase-type plasminogen activator receptor (uPAR) expression is elevated during inflammation and tissue remodelling and in many human cancers, in which it frequently indicates poor prognosis. uPAR regulates proteolysis by binding the extracellular protease urokinase-type plasminogen activator (uPA; also known as urokinase) and also activates many intracellular signalling pathways. Coordination of extracellular matrix (ECM) proteolysis and cell signalling by uPAR underlies its important function in cell migration, proliferation and survival and makes it an attractive therapeutic target in cancer and inflammatory diseases. uPAR lacks transmembrane and intracellular domains and so requires transmembrane co-receptors for signalling. Integrins are essential uPAR signalling co-receptors and a second uPAR ligand, the ECM protein vitronectin, is also crucial for this process.},
  keywords = {Animals *Gene Expression Regulation Humans Receptors, Urokinase Plasminogen Activator/*metabolism *Signal Transduction},
  issn = {1471-0080 (Electronic) 1471-0072 (Linking)},
  doi = {10.1038/nrm2821},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/20027185},
  year = {2010},
  type = {Journal Article},
}


@article{Stremenova:2010yo,
  author = {Stremenov, Jarmila and Mares, Vladislav and Lis, Vera and Hilser, Marek and Krepela, Evzen and Vanickov, Zdislava and Syrucek, Martin and Soula, Oldrich and Sedo, Aleksi},
  title = {{Expression of dipeptidyl peptidase-IV activity and/or structure homologs in human meningiomas}},
  journal = {Int J Oncol},
  volume = {36},
  number = {2},
  pages = {351-8},
  abstract = {Meningiomas are tumors derived from arachnoid cap cells that represent approximately 30% of all intracranial tumors. In this study, we investigated 22 human meningiomas for the expression of dipeptidyl peptidase (DPP)-IV activity and/or structure homologs (DASH), including canonical DPP-IV/CD26, fibroblast activation protein-alpha (FAPalpha), DPP8 and DPP9. DPP-IV-like enzymatic activity, including all enzymatically-active DASH molecules, was found in all 18 benign meningiomas WHO grade I and IV atypical meningiomas WHO grade II by continuous rate fluorimetric assay in tissue homogenates and catalytic enzyme histochemistry in situ. In atypical meningiomas, this activity was significantly higher and was associated with higher cell proliferation as detected by Ki67 antigen immunohistochemistry. The expression of DPP-IV/CD26 and FAPalpha demonstrated by real-time RT-PCR and immunohistochemistry was low. As shown histochemically, it occurred most often on the surface of fibrous bundles and whorls rich in extracellular matrix. Compared to DPP-IV/CD26 and FAPalpha, the expression of DPP8 and DPP9 was higher and, in addition, it was present also in the cells inside these structures. Expression of CXCR4, the receptor of pro-proliferative chemokine stromal cell-derived factor-1alpha (SDF-1alpha), DPP-IV substrate, was found in all tumors, suggesting higher values in atypical grade II samples. This is the first report on the expression status of dipeptidyl peptidase-IV and related molecules in meningiomas. It shows that DPP8 and DPP9 prevail over canonical DPP-IV/CD26 and FAPalpha in all examined patients. In addition, the study suggests an increase of DPP-IV-like enzymatic activity in these tumors of WHO grade II.},
  url = {http://www.spandidos-publications.com/ijo/36/2/351/download},
  year = {2010},
  type = {Journal Article},
}


@article{Sulda:2010ay,
  author = {Sulda, M. L. and Abbott, C. A. and Macardle, P. J. and Hall, R. K. and Kuss, B. J.},
  title = {{Expression and prognostic assessment of dipeptidyl peptidase IV and related enzymes in B-cell chronic lymphocytic leukemia}},
  journal = {Cancer Biol Ther},
  volume = {10},
  number = {2},
  pages = {180-9},
  note = {Sulda, Melanie L Abbott, Catherine A Macardle, Peter J Hall, Rachel K Kuss, Bryone J Cancer Biol Ther. 2010 Jul 15;10(2):180-9. Epub 2010 Jul 26.},
  abstract = {Recent observations of the deregulated expression of several dipeptidyl peptidase (DP) IV-like enzymes in human cancers have led to presumptions of their pathogenic role in cancer. To further explore this concept we have characterized the expression of all DPIV-like enzymes in chronic lymphocytic leukemia (CLL). We have demonstrated the constitutive expression of DPIV, DP8, DP9, DPII and PEP mRNA and DPIV, DP8 and DP9 protein in CLL. FAP mRNA was not detected in CLL or normal B-lymphocytes. This correlated with an absence of FAP protein on the cell surface. This study also shows that DP8 mRNA expression is significantly upregulated in CLL compared to normal tonsil B-lymphocytes (p < 0.05) which may suggest biological importance in this disease. DP expression could not be correlated with any molecular or clinical prognostic markers for CLL in this cohort including IgVH mutational status, CD38, ZAP-70 or CD49d expression (n = 58). However, the constitutive expression of the DPIV-like enzymes in CLL and their emergence as potent immune regulators makes them candidate therapeutic targets in this disease.},
  keywords = {Adult Aged Aged, 80 and over Dipeptidases/genetics/metabolism Dipeptidyl Peptidase 4/genetics/*metabolism Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/genetics/metabolism Female Gelatinases/genetics/metabolism Gene Expression Profiling Genes, Immunoglobulin Heavy Chain/genetics Humans Leukemia, Lymphocytic, Chronic, B-Cell/*enzymology/genetics Male Membrane Proteins/genetics/metabolism Middle Aged Mitochondrial Proteins/genetics/metabolism Mutation Prognosis RNA, Messenger/*metabolism Serine Endopeptidases/genetics/metabolism Tumor Markers, Biological/*metabolism Up-Regulation},
  issn = {1555-8576 (Electronic) 1538-4047 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/20534982 http://www.tandfonline.com/doi/pdf/10.4161/cbt.10.2.12168},
  year = {2010},
  type = {Journal Article},
}


@article{Yazbeck:2010qe,
  author = {Yazbeck, R. and Sulda, M. L. and Howarth, G. S. and Bleich, A. and Raber, K. and von Horsten, S. and Holst, J. J. and Abbott, C. A.},
  title = {{Dipeptidyl peptidase expression during experimental colitis in mice}},
  journal = {Inflamm Bowel Dis},
  volume = {16},
  number = {8},
  pages = {1340-51},
  note = {Yazbeck, Roger Sulda, Melanie L Howarth, Gordon S Bleich, Andre Raber, Kerstin von Horsten, Stephan Holst, Jens Juul Abbott, Catherine A Inflamm Bowel Dis. 2010 Aug;16(8):1340-51. doi: 10.1002/ibd.21241.},
  abstract = {BACKGROUND: We have previously demonstrated that inhibition of dipeptidyl peptidase (DP) activity partially attenuates dextran sulfate sodium (DSS) colitis in mice. The aim of this study was to further investigate the mechanisms of this protection. MATERIALS AND METHODS: Wildtype (WT) and DPIV(-/-) mice consumed 2% DSS in drinking water for 6 days to induce colitis. Mice were treated with saline or the DP inhibitors Ile-Pyrr-(2-CN)*TFA or Ile-Thia. DP mRNA and enzyme levels were measured in the colon. Glucagon-like peptide (GLP)-2 and GLP-1 concentrations were determined by radioimmunoassay, regulatory T-cells (Tregs) by fluorescence activated cell sorting (FACS) on FOXp3+T cells in blood, and neutrophil infiltration assessed by myeloperoxidase (MPO) assay. RESULTS: DP8 and DP2 mRNA levels were increased (P < 0.05) in WT+saline mice compared to untreated WT mice with colitis. Cytoplasmic DP enzyme activity was increased (P < 0.05) in DPIV(-/-) mice at day 6 of DSS, while DP2 activity was increased (P < 0.05) in WT mice with colitis. GLP-1 (63%) and GLP-2 (50%) concentrations increased in WT+Ile-Pyrr-(2-CN)*TFA mice compared to day-0 controls. MPO activity was lower in WT+Ile-Thia and WT+Ile-Pyrr-(2-CN)*TFA treated mice compared to WT+saline (P < 0.001) at day 6 colitis. CONCLUSIONS: DP expression and activity are differentially regulated during DSS colitis, suggesting a pathophysiological role for these enzymes in human inflammatory bowel disease (IBD). DP inhibitors impaired neutrophil recruitment and maintenance of the Treg population during DSS-colitis, providing further preclinical evidence for the potential therapeutic use of these inhibitors in IBD. Finally, DPIV appears to play a critical role in mediating the protective effect of DP inhibitors.},
  keywords = {Animals Colitis/chemically induced/*enzymology Colon/chemistry/*enzymology Dextran Sulfate/pharmacology Dipeptidyl-Peptidase IV Inhibitors/pharmacology Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/antagonists & inhibitors/*biosynthesis/genetics Disease Models, Animal Glucagon-Like Peptide 1/analysis Glucagon-Like Peptide 2/analysis Humans Mice Mice, Inbred C57BL Mice, Knockout Neutrophil Infiltration Peroxidase/analysis T-Lymphocytes, Regulatory/drug effects},
  issn = {1536-4844 (Electronic) 1078-0998 (Linking)},
  doi = {10.1002/ibd.21241},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/20186930 http://ovidsp.tx.ovid.com/ovftpdfs/FPDDNCIBDDIBFD00/fs047/ovft/live/gv024/00054725/00054725-201008000-00013.pdf},
  year = {2010},
  type = {Journal Article},
}


@article{Aguilar:2011vl,
  author = {Aguilar, D. and Chan, W. and Bozkurt, B. and Ramasubbu, K. and Deswal, A.},
  title = {{Metformin use and mortality in ambulatory patients with diabetes and heart failure}},
  journal = {Circ Heart Fail},
  volume = {4},
  number = {1},
  pages = {53-8},
  note = {Aguilar, David Chan, Wenyaw Bozkurt, Biykem Ramasubbu, Kumudha Deswal, Anita 5K01-HL092585-02/HL/NHLBI NIH HHS/ K01 HL092585-03/HL/NHLBI NIH HHS/ K01 HL092585-04/HL/NHLBI NIH HHS/ Circ Heart Fail. 2011 Jan;4(1):53-8. doi: 10.1161/CIRCHEARTFAILURE.110.952556. Epub 2010 Oct 15.},
  abstract = {BACKGROUND: Despite the common coexistence of diabetes and heart failure (HF), the optimal medial treatment of diabetes in HF patients has not been well studied. We sought to compare the association between metformin use and clinical outcomes in a cohort of ambulatory patients with diabetes and established HF. METHODS AND RESULTS: Using propensity score-matched samples, we examined the association between metformin use and the risk of death or risk of hospitalization in a national cohort of 6185 patients with HF and diabetes treated in ambulatory clinics at Veteran Affairs medical centers. In this cohort, 1561 (25.2%) patients were treated with metformin. At 2 years of follow-up, death occurred in 246 (15.8%) patients receiving metformin and in 1177 (25.5%) patients not receiving metformin (P<0.001). In the propensity score-matched analysis (n=2874), death occurred in 232 (16.1%) patients receiving metformin compared with 285 (19.8%) patients not receiving metformin (hazard ratio, 0.76; 95% confidence interval, 0.63 to 0.92; P<0.01). In propensity score-matched analyses, HF hospitalization or total hospitalization rates were not significantly different between individuals treated with metformin compared with those not treated with metformin (hazard ratio, 0.93; 95% confidence interval, 0.74 to 1.18; and hazard ratio, 0.94; 95% confidence interval, 0.83 to 1.07, respectively). CONCLUSIONS: Metformin therapy was associated with lower rates of mortality in ambulatory patients with diabetes and HF. Future prospective studies are necessary to define the optimal therapy for diabetic patients with HF.},
  keywords = {Aged Cohort Studies Comorbidity Diabetes Mellitus/*drug therapy/epidemiology/*mortality Female Follow-Up Studies Heart Failure/*drug therapy/epidemiology/*mortality Humans Hypoglycemic Agents/*therapeutic use Male Metformin/*therapeutic use Middle Aged Retrospective Studies Survival Rate Treatment Outcome},
  issn = {1941-3297 (Electronic) 1941-3289 (Linking)},
  doi = {10.1161/CIRCHEARTFAILURE.110.952556},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/20952583 http://circheartfailure.ahajournals.org/content/4/1/53 http://circheartfailure.ahajournals.org/content/4/1/53.full.pdf},
  year = {2011},
  type = {Journal Article},
}


@article{Ben:2011zh,
  author = {Ben, Q. and Xu, M. and Ning, X. and Liu, J. and Hong, S. and Huang, W. and Zhang, H. and Li, Z.},
  title = {{Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies}},
  journal = {Eur J Cancer},
  volume = {47},
  number = {13},
  pages = {1928-37},
  note = {Ben, Qiwen Xu, Maojin Ning, Xiaoyan Liu, Jun Hong, Shangyou Huang, Wen Zhang, Huagao Li, Zhaoshen England Oxford, England : 1990 Eur J Cancer. 2011 Sep;47(13):1928-37. doi: 10.1016/j.ejca.2011.03.003. Epub 2011 Mar 31.},
  abstract = {BACKGROUND: Diabetes mellitus (DM) is widely considered to be associated with risk of pancreatic cancer (PaC), however, whether DM is a cause or a consequence of PaC is still controversial. We examined this association by conducting a detailed meta-analysis of cohort studies. METHODS: Studies were identified by searching Medline and Embase through November 30, 2010. Summary relative risks (RRs) with their corresponding 95% confidence intervals (CIs) were calculated using a random-effects model. RESULTS: A total of thirty-five cohort studies were included in this meta-analysis. DM was associated with an increased risk of PaC (the summary RRs=1.94; 95% CI, 1.66-2.27), with significant evidence of heterogeneity among these studies (p<0.001, I(2)=93.6%). Subgroup analyses revealed that the increased risk of PaC was independent of geographic locations, sex, study design, alcohol consumption, body mass index (BMI) and smoking status. In addition, the relative risk of PaC was correlated negatively with the duration of DM, with the highest risk of PaC found among patients diagnosed within less than 1 year. There was no significant publication bias (p=0.136 for Egger's regression asymmetry test). CONCLUSIONS: Findings from this meta-analysis strongly support that diabetes is associated with an increased risk of PaC in both males and females and that DM is both an early manifestation and an etiologic factor of pancreatic cancer.},
  keywords = {Adult Aged Cohort Studies Diabetes Mellitus, Type 2/complications/*epidemiology Female Humans Male Middle Aged Pancreatic Neoplasms/*epidemiology/etiology Risk Factors},
  issn = {1879-0852 (Electronic) 0959-8049 (Linking)},
  doi = {10.1016/j.ejca.2011.03.003},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/21458985 http://ac.els-cdn.com/S095980491100147X/1-s2.0-S095980491100147X-main.pdf?_tid=5500fab6-fbdf-11e4-99c8-00000aab0f01&acdnat=1431789915_5857dd6e7bf177b93f296ed44d9692e5},
  year = {2011},
  type = {Journal Article},
}


@article{Colaert2011,
  author = {Colaert, N. and Degroeve, S. and Helsens, K. and Martens, L.},
  title = {{Analysis of the resolution limitations of peptide identification algorithms}},
  journal = {J Proteome Res},
  volume = {10},
  number = {12},
  pages = {5555-61},
  note = {Colaert, Niklaas Degroeve, Sven Helsens, Kenny Martens, Lennart J Proteome Res. 2011 Dec 2;10(12):5555-61. doi: 10.1021/pr200913a. Epub 2011 Oct 26.},
  abstract = {Proteome identification using peptide-centric proteomics techniques is a routinely used analysis technique. One of the most powerful and popular methods for the identification of peptides from MS/MS spectra is protein database matching using search engines. Significance thresholding through false discovery rate (FDR) estimation by target/decoy searches is used to ensure the retention of predominantly confident assignments of MS/MS spectra to peptides. However, shortcomings have become apparent when such decoy searches are used to estimate the FDR. To study these shortcomings, we here introduce a novel kind of decoy database that contains isobaric mutated versions of the peptides that were identified in the original search. Because of the supervised way in which the entrapment sequences are generated, we call this a directed decoy database. Since the peptides found in our directed decoy database are thus specifically designed to look quite similar to the forward identifications, the limitations of the existing search algorithms in making correct calls in such strongly confusing situations can be analyzed. Interestingly, for the vast majority of confidently identified peptide identifications, a directed decoy peptide-to-spectrum match can be found that has a better or equal match score than the forward match score, highlighting an important issue in the interpretation of peptide identifications in present-day high-throughput proteomics.},
  keywords = {*Algorithms Amino Acids/chemistry Computational Biology/methods *Databases, Protein Fungal Proteins/chemistry Humans Mass Spectrometry/methods Mutation Peptides/*chemistry Proteomics/methods/standards Reproducibility of Results Search Engine/*methods Yeasts/chemistry},
  issn = {1535-3907 (Electronic) 1535-3893 (Linking)},
  doi = {10.1021/pr200913a},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/21995378 http://pubs.acs.org/doi/pdfplus/10.1021/pr200913a},
  year = {2011},
  type = {Journal Article},
}


@article{Doucet:2011ff,
  author = {Doucet, A. and Overall, C. M.},
  title = {{Broad coverage identification of multiple proteolytic cleavage site sequences in complex high molecular weight proteins using quantitative proteomics as a complement to edman sequencing}},
  journal = {Mol Cell Proteomics},
  volume = {10},
  number = {5},
  pages = {M110 003533},
  note = {Doucet, Alain Overall, Christopher M Canadian Institutes of Health Research/Canada Mol Cell Proteomics. 2011 May;10(5):M110.003533. doi: 10.1074/mcp.M110.003533. Epub 2010 Sep 28.},
  abstract = {Proteolytic processing modifies the pleiotropic functions of many large, complex, and modular proteins and can generate cleavage products with new biological activity. The identification of exact proteolytic cleavage sites in the extracellular matrix laminins, fibronectin, and other extracellular matrix proteins is not only important for understanding protein turnover but is needed for the identification of new bioactive cleavage products. Several such products have recently been recognized that are suggested to play important cellular regulatory roles in processes, including angiogenesis. However, identifying multiple cleavage sites in extracellular matrix proteins and other large proteins is challenging as N-terminal Edman sequencing of multiple and often closely spaced cleavage fragments on SDS-PAGE gels is difficult, thus limiting throughput and coverage. We developed a new liquid chromatography-mass spectrometry approach we call amino-terminal oriented mass spectrometry of substrates (ATOMS) for the N-terminal identification of protein cleavage fragments in solution. ATOMS utilizes efficient and low cost dimethylation isotopic labeling of original N-terminal and proteolytically generated N termini of protein cleavage fragments followed by quantitative tandem mass spectrometry analysis. Being a peptide-centric approach, ATOMS is not dependent on the SDS-PAGE resolution limits for protein fragments of similar mass. We demonstrate that ATOMS reliably identifies multiple proteolytic sites per reaction in complex proteins. Fifty-five neutrophil elastase cleavage sites were identified in laminin-1 and fibronectin-1 with 34 more identified by matrix metalloproteinase cleavage. Hence, our degradomics approach offers a complimentary alternative to Edman sequencing with broad applicability in identifying N termini such as cleavage sites in complex high molecular weight extracellular matrix proteins after in vitro cleavage assays. ATOMS can therefore be useful in identifying new cleavage products of extracellular matrix proteins cleaved by proteases in pathology for bioactivity screening.},
  keywords = {*Amino Acid Motifs Amino Acid Sequence Chromatography, Liquid Fibronectins/*chemistry Humans Laminin/*chemistry Leukocyte Elastase/chemistry Matrix Metalloproteinases/chemistry Molecular Sequence Data Molecular Weight Protein Structure, Tertiary Proteome/*chemistry Sequence Analysis, Protein/*methods Tandem Mass Spectrometry/methods},
  issn = {1535-9484 (Electronic) 1535-9476 (Linking)},
  doi = {10.1074/mcp.M110.003533},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/20876890 http://www.mcponline.org/content/10/5/M110.003533.full.pdf},
  year = {2011},
  type = {Journal Article},
}


@article{Eurich:2011jt,
  author = {Eurich, D. T. and McAlister, F. A.},
  title = {{Wrongfully accused: metformin use in heart failure}},
  journal = {Expert Rev Cardiovasc Ther},
  volume = {9},
  number = {2},
  pages = {147-50},
  note = {Eurich, Dean T McAlister, Finlay A England Expert Rev Cardiovasc Ther. 2011 Feb;9(2):147-50. doi: 10.1586/erc.10.186.},
  abstract = {Evaluation of: Aguilar D, Chan W, Bozkurt B, Ramasubbu K, Deswal A. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ. Heart Fail. 4(1), 53-58 (2010). Metformin has long been the cornerstone of therapy for glycemic control in patients with Type 2 diabetes worldwide. It is recommended as first-line therapy by all major diabetes clinical practice guidelines owing to its efficacy, favorable tolerability profile and beneficial effects in limiting weight gain. Moreover, metformin is the only oral anthyperglycemic agent shown in randomized controlled trials to reduce mortality in newly diagnosed patients with Type 2 diabetes. However, the use of metformin has not been without controversy, in particular in patients with heart failure. This article will review a recent observational study by Aguilar et al. published in Circulation - Heart Failure that reported improved outcomes associated with metformin therapy in patients with diabetes and heart failure.},
  issn = {1744-8344 (Electronic) 1477-9072 (Linking)},
  doi = {10.1586/erc.10.186},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/21453211 http://informahealthcare.com/doi/abs/10.1586/erc.10.186 http://media.proquest.com/media/pq/classic/doc/2282392351/fmt/pi/rep/NONE?hl=&cit%3Aauth=Eurich%2C+Dean+T%3BMcAlister%2C+Finlay+A&cit%3Atitle=Wrongfully+accused%3A+metformin+use+in+heart+failure&cit%3Apub=Expert+Review+of+Cardiovascular+Therapy&cit%3Avol=9&cit%3Aiss=2&cit%3Apg=147&cit%3Adate=Feb+2011&ic=true&cit%3Aprod=ProQuest+Central&_a=ChgyMDE1MDUxNjE1NTUxNTA2MDo3MTE4MTUSBjEwNDgzNxoKT05FX1NFQVJDSCINMTI5Ljk2Ljg2LjExMSoFNTQ1ODEyCTg1NDkxOTk0MjoNRG9jdW1lbnRJbWFnZUIBMFIGT25saW5lWgJGVGIDUEZUagoyMDExLzAyLzAxcgoyMDExLzAyLzI4egCCATJQLTEwMDcwNjctMTA5MTAtQ1VTVE9NRVItMTAwMDAwMzkvMTAwMDAxNTUtMzg5NDQwNJIBBk9ubGluZcoBB0VuZE5vdGXSARJTY2hvbGFybHkgSm91cm5hbHOaAgdQcmVQYWlkqgIoT1M6RU1TLVBkZkRvY1ZpZXdCYXNlLWdldE1lZGlhVXJsRm9ySXRlbcoCCkNvbW1lbnRhcnnSAgFZ4gIBTvICAA%3D%3D&_s=bf76zwD756PjRIji6e82fe1Qpzs%3D},
  year = {2011},
  type = {Journal Article},
}


@techreport{Houghton2011,
  author = {Houghton, J.W.},
  title = {{Costs and Benefits of Data Provision}},
  institution = {Australian National Data Service},
  year = {2011},
  type = {Report},
}


@article{Jiang:2011ta,
  author = {Jiang, Y. and Ben, Q. and Shen, H. and Lu, W. and Zhang, Y. and Zhu, J.},
  title = {{Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies}},
  journal = {Eur J Epidemiol},
  volume = {26},
  number = {11},
  pages = {863-76},
  note = {Jiang, Ying Ben, Qiwen Shen, Hong Lu, Weiqi Zhang, Yong Zhu, Jun Netherlands Eur J Epidemiol. 2011 Nov;26(11):863-76. doi: 10.1007/s10654-011-9617-y. Epub 2011 Sep 22.},
  abstract = {Increasing evidence suggests that a history of diabetes mellitus (DM) may be associated with an increased risk of colorectal cancer (CRC). To provide a quantitative assessment of the association between DM and risk of CRC, We evaluated the relation between DM and incidence and mortality of CRC in a systematic review of cohort studies. Full publications of cohort studies were identified in MEDLINE, EMBASE and Science Citation Index Expanded, through February 28, 2011. Summary relative risks (SRRs) with 95% confidence intervals (CIs) were summarized using a random-effects model. Between-study heterogeneity was assessed using the Cochran's Q and I2 statistics. A total of 41 cohort studies (35 articles) were included in this systematic review. Combining 30 cohort studies which presented results on diabetes and CRC incidence, diabetes was associated with an increased incidence of CRC (SRRs 1.27, 95% CI: 1.21-1.34), with evident heterogeneity among studies (P=0.002, I2=48.4%). Subgroup analysis and meta-regression analysis by controlling the confounders showed that the increased incidence of CRC was independent of geographic locations, sex, family history of colorectal cancer, smoking, physical activity and body mass index. Diabetes was also positively associated with CRC mortality (SRR 1.20, 95% CI: 1.03-1.40), with evidence of heterogeneity between studies (P<0.001, I2=81.4%). Results from this systematic review support that compared to non-diabetic individuals, diabetic individuals have an increased risk of CRC.},
  keywords = {Adult Aged Body Mass Index Cohort Studies Colorectal Neoplasms/complications/*mortality Confidence Intervals Diabetes Mellitus, Type 2/complications/*mortality Female Humans Incidence Male Middle Aged Regression Analysis Risk Assessment Risk Factors},
  issn = {1573-7284 (Electronic) 0393-2990 (Linking)},
  doi = {10.1007/s10654-011-9617-y},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/21938478 http://download-v2.springer.com/static/pdf/720/art%253A10.1007%252Fs10654-011-9617-y.pdf?token2=exp=1431790948~acl=%2Fstatic%2Fpdf%2F720%2Fart%25253A10.1007%25252Fs10654-011-9617-y.pdf*~hmac=9e3122278b87c70f888019c4957b98122f1de4f4c9b44705499a6248c58dbe4c},
  year = {2011},
  type = {Journal Article},
}


@article{Lu:2011uf,
  author = {Lu, C. and Tilan, J. U. and Everhart, L. and Czarnecka, M. and Soldin, S. J. and Mendu, D. R. and Jeha, D. and Hanafy, J. and Lee, C. K. and Sun, J. and Izycka-Swieszewska, E. and Toretsky, J. A. and Kitlinska, J.},
  title = {{Dipeptidyl peptidases as survival factors in Ewing sarcoma family of tumors: implications for tumor biology and therapy}},
  journal = {J Biol Chem},
  volume = {286},
  number = {31},
  pages = {27494-505},
  note = {Lu, Congyi Tilan, Jason U Everhart, Lindsay Czarnecka, Magdalena Soldin, Steven J Mendu, Damodara R Jeha, Dima Hanafy, Jailan Lee, Christina K Sun, Junfeng Izycka-Swieszewska, Ewa Toretsky, Jeffrey A Kitlinska, Joanna 1R01CA123211-01/CA/NCI NIH HHS/ R01 CA123211/CA/NCI NIH HHS/ J Biol Chem. 2011 Aug 5;286(31):27494-505. doi: 10.1074/jbc.M111.224089. Epub 2011 Jun 16.},
  abstract = {Ewing sarcoma family of tumors (ESFT) is a group of aggressive pediatric malignancies driven by the EWS-FLI1 fusion protein, an aberrant transcription factor up-regulating specific target genes, such as neuropeptide Y (NPY) and its Y1 and Y5 receptors (Y5Rs). Previously, we have shown that both exogenous NPY and endogenous NPY stimulate ESFT cell death via its Y1 and Y5Rs. Here, we demonstrate that this effect is prevented by dipeptidyl peptidases (DPPs), which cleave NPY to its shorter form, NPY(3-36), not active at Y1Rs. We have shown that NPY-induced cell death can be abolished by overexpression of DPPs and enhanced by their down-regulation. Both NPY treatment and DPP blockade activated the same cell death pathway mediated by poly(ADP-ribose) polymerase (PARP-1) and apoptosis-inducing factor (AIF). Moreover, the decrease in cell survival induced by DPP inhibition was blocked by Y1 and Y5R antagonists, confirming its dependence on endogenous NPY. Interestingly, similar levels of NPY-driven cell death were achieved by blocking membrane DPPIV and cytosolic DPP8 and DPP9. Thus, this is the first evidence of these intracellular DPPs cleaving releasable peptides, such as NPY, in live cells. In contrast, another membrane DPP, fibroblast activation protein (FAP), did not affect NPY actions. In conclusion, DPPs act as survival factors for ESFT cells and protect them from cell death induced by endogenous NPY. This is the first demonstration that intracellular DPPs are involved in regulation of ESFT growth and may become potential therapeutic targets for these tumors.},
  keywords = {Cell Line, Tumor Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/*metabolism Humans RNA, Small Interfering Reverse Transcriptase Polymerase Chain Reaction Sarcoma, Ewing/enzymology/*metabolism/pathology},
  issn = {1083-351X (Electronic) 0021-9258 (Linking)},
  doi = {10.1074/jbc.M111.224089},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/21680731 http://www.jbc.org/content/286/31/27494.full.pdf},
  year = {2011},
  type = {Journal Article},
}


@article{Magrane:2011fv,
  author = {Magrane, M. and Consortium, U.},
  title = {{UniProt Knowledgebase: a hub of integrated protein data}},
  journal = {Database (Oxford)},
  volume = {2011},
  pages = {bar009},
  note = {Magrane, Michele Consortium, Uniprot 1G08LM010720-01/LM/NLM NIH HHS/ 1U41HG006104-01/HG/NHGRI NIH HHS/ 2P41HG02273-07/HG/NHGRI NIH HHS/ 2U01HG02712-04/HG/NHGRI NIH HHS/ 3P20RR016472-09S2/RR/NCRR NIH HHS/ 3R01GM080646-04S2/GM/NIGMS NIH HHS/ 5R01GM080646-04/GM/NIGMS NIH HHS/ England Database (Oxford). 2011 Mar 29;2011:bar009. doi: 10.1093/database/bar009. Print 2011.},
  abstract = {The UniProt Knowledgebase (UniProtKB) acts as a central hub of protein knowledge by providing a unified view of protein sequence and functional information. Manual and automatic annotation procedures are used to add data directly to the database while extensive cross-referencing to more than 120 external databases provides access to additional relevant information in more specialized data collections. UniProtKB also integrates a range of data from other resources. All information is attributed to its original source, allowing users to trace the provenance of all data. The UniProt Consortium is committed to using and promoting common data exchange formats and technologies, and UniProtKB data is made freely available in a range of formats to facilitate integration with other databases. Database URL: http://www.uniprot.org/},
  keywords = {Amino Acid Sequence *Databases, Protein *Knowledge Bases Molecular Sequence Annotation Protein Binding Proteins/*chemistry Sequence Analysis, Protein},
  issn = {1758-0463 (Electronic)},
  doi = {10.1093/database/bar009},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/21447597 http://database.oxfordjournals.org/content/2011/bar009.full.pdf},
  year = {2011},
  type = {Journal Article},
}


@article{Song:2011aa,
  author = {Song, J. and Tan, H. and Boyd, S. E. and Shen, H. and Mahmood, K. and Webb, G. I. and Akutsu, T. and Whisstock, J. C. and Pike, R. N.},
  title = {{Bioinformatic approaches for predicting substrates of proteases}},
  journal = {J Bioinform Comput Biol},
  volume = {9},
  number = {1},
  pages = {149-78},
  note = {Song, Jiangning Tan, Hao Boyd, Sarah E Shen, Hongbin Mahmood, Khalid Webb, Geoffrey I Akutsu, Tatsuya Whisstock, James C Pike, Robert N England J Bioinform Comput Biol. 2011 Feb;9(1):149-78.},
  abstract = {Proteases have central roles in life and death processes due to their important ability to catalytically hydrolyze protein substrates, usually altering the function and/or activity of the target in the process. Knowledge of the substrate specificity of a protease should, in theory, dramatically improve the ability to predict target protein substrates. However, experimental identification and characterization of protease substrates is often difficult and time-consuming. Thus solving the substrate identification problem is fundamental to both understanding protease biology and the development of therapeutics that target specific protease-regulated pathways. In this context, bioinformatic prediction of protease substrates may provide useful and experimentally testable information about novel potential cleavage sites in candidate substrates. In this article, we provide an overview of recent advances in developing bioinformatic approaches for predicting protease substrate cleavage sites and identifying novel putative substrates. We discuss the advantages and drawbacks of the current methods and detail how more accurate models can be built by deriving multiple sequence and structural features of substrates. We also provide some suggestions about how future studies might further improve the accuracy of protease substrate specificity prediction.},
  keywords = {Algorithms Amino Acid Sequence Animals Artificial Intelligence Catalytic Domain Computational Biology Databases, Protein Humans Molecular Sequence Data Peptide Hydrolases/chemistry/genetics/*metabolism Protein Structure, Secondary Proteins/chemistry/genetics/metabolism Solvents Substrate Specificity},
  issn = {0219-7200 (Print) 0219-7200 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/21328711},
  year = {2011},
  type = {Journal Article},
}


@article{Ta:2011oe,
  author = {Ta, N. N. and Schuyler, C. A. and Li, Y. and Lopes-Virella, M. F. and Huang, Y.},
  title = {{DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice}},
  journal = {J Cardiovasc Pharmacol},
  volume = {58},
  number = {2},
  pages = {157-66},
  note = {Ta, Nga N Schuyler, Corinne A Li, Yanchun Lopes-Virella, Maria F Huang, Yan DE016353/DE/NIDCR NIH HHS/ R01 DE016353-06A1/DE/NIDCR NIH HHS/ J Cardiovasc Pharmacol. 2011 Aug;58(2):157-66. doi: 10.1097/FJC.0b013e31821e5626.},
  abstract = {Dipeptidyl peptidase-4 (DPP-4 or CD26) inhibitors, a new class of antidiabetic compounds, are effective in the treatment of hyperglycemia. Because atherosclerosis-related cardiovascular diseases are the major complications of diabetes, it is important to determine the effect of DPP-4 inhibitors on atherosclerosis. In this study, nondiabetic and diabetic apolipoprotein E-deficient mice were treated with DPP-4 inhibitor alogliptin for 24 weeks, and atherosclerotic lesions in aortic origins were examined. Results showed that diabetes significantly increased atherosclerotic lesions, but alogliptin treatment reduced atherosclerotic lesions in diabetic mice. Metabolic studies showed that diabetes increased plasma glucose and that alogliptin treatment reduced glucose. Furthermore, immunohistochemistry study showed that diabetes increased interleukin-6 (IL-6) and IL-1beta protein expression in atherosclerotic plaques, but alogliptin treatment attenuated diabetes-augmented IL-6 and IL-1beta expression. In consistence with the observations from the mouse models, our in vitro studies showed that alogliptin-inhibited toll-like receptor 4 (TLR-4)-mediated upregulation of IL-6, IL-1beta, and other proinflammatory cytokines by mononuclear cells. Taken together, our findings showed that alogliptin-inhibited atherosclerosis in diabetic apolipoprotein E-deficient mice and that the actions of alogliptin on both glucose and inflammation may contribute to the inhibition.},
  keywords = {Animals Apolipoproteins E/*deficiency/genetics Atherosclerosis/enzymology/etiology/pathology/*prevention & control Blood Glucose/metabolism Cholesterol/metabolism Diabetes Mellitus, Experimental/*complications/enzymology/pathology Dipeptidyl Peptidase 4/*metabolism Dipeptidyl-Peptidase IV Inhibitors/pharmacology/*therapeutic use Enzyme-Linked Immunosorbent Assay Humans Interleukin-1beta/antagonists & inhibitors Interleukin-6/antagonists & inhibitors Male Mice Mice, Knockout Piperidines/pharmacology/*therapeutic use Real-Time Polymerase Chain Reaction Triglycerides/metabolism U937 Cells Uracil/*analogs & derivatives/pharmacology/therapeutic use},
  issn = {1533-4023 (Electronic) 0160-2446 (Linking)},
  doi = {10.1097/FJC.0b013e31821e5626},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/21558879 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155015/pdf/nihms-294762.pdf},
  year = {2011},
  type = {Journal Article},
}


@phdthesis{Wilson:2011kx,
  author = {Wilson, Claire Helena},
  title = {{Identifying the substrate degradome and roles of dipeptidyl peptidase (DP)8 and DP9 in breast and ovarian cancer cell lines}},
  university = {Flinders University, Adelaide, SA, Australia},
  keywords = {Breast -- Cancer -- Research Ovaries -- Cancer -- Research Peptidase Aminopeptidases Proteinase Cell lines Cancer cells -- Growth Biological sciences thesis Doctorate},
  year = {2011},
  type = {Thesis},
}


@article{wilson2011dipeptidyl,
  author = {Wilson, Claire H and Abbott, Catherine A},
  title = {{Dipeptidyl Peptidases: Substrates and Therapeutic Targeting in Human Health and Disease}},
  year = {2011},
  type = {Journal Article},
}


@article{Yao:2011rr,
  author = {Yao, T. W. and Kim, W. S. and Yu, D. M. and Sharbeen, G. and McCaughan, G. W. and Choi, K. Y. and Xia, P. and Gorrell, M. D.},
  title = {{A novel role of dipeptidyl peptidase 9 in epidermal growth factor signaling}},
  journal = {Mol Cancer Res},
  volume = {9},
  number = {7},
  pages = {948-59},
  note = {Yao, Tsun-Wen Kim, Woo-Shin Yu, Denise M T Sharbeen, George McCaughan, Geoffrey W Choi, Kang-Yell Xia, Pu Gorrell, Mark D Mol Cancer Res. 2011 Jul;9(7):948-59. doi: 10.1158/1541-7786.MCR-10-0272. Epub 2011 May 26.},
  abstract = {Dipeptidyl peptidase IV (DPP4), DPP8, DPP9, and fibroblast activation protein (FAP), the four proteases of the DPP4 gene family, have unique peptidase and extra-enzymatic activities that have been implicated in various diseases including cancers. We report here a novel role of DPP9 in regulating cell survival and proliferation through modulating molecular signaling cascades. Akt (protein kinase B) activation was significantly inhibited by human DPP9 overexpression in human hepatoma cells (HepG2 and Huh7) and human embryonic kidney cells (HEK293T), whereas extracellular signal-regulated kinases (ERK1/2) activity was unaffected, revealing a pathway-specific effect. Interestingly, the inhibitory effect of DPP9 on Akt pathway activation was growth factor dependent. DPP9 overexpression caused apoptosis and significantly less epidermal growth factor (EGF)-mediated Akt activation in HepG2 cells. However, such inhibitory effect was not observed in cells stimulated with other growth factors, including connective tissue growth factor, hepatic growth factor, insulin or platelet-derived growth factor-BB. The effect of DPP9 on Akt did not occur when DPP9 enzyme activity was ablated by either mutagenesis or inhibition. The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is a major downstream effector of Ras. We found that DPP9 and DPP8, but not DPP4 or FAP, associate with H-Ras, a key signal molecule of the EGF receptor signaling pathway. These findings suggest an important signaling role of DPP9 in the regulation of survival and proliferation pathways.},
  keywords = {*Apoptosis Cell Line, Tumor *Cell Proliferation Cell Survival Dipeptidases/antagonists & inhibitors/metabolism Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/antagonists & inhibitors/*metabolism Epidermal Growth Factor/*metabolism HEK293 Cells HeLa Cells Humans Liver Cirrhosis/complications/enzymology Liver Neoplasms/enzymology/etiology Phosphatidylinositol 3-Kinases/metabolism Proto-Oncogene Proteins c-akt/metabolism Receptor, Epidermal Growth Factor/metabolism Signal Transduction},
  issn = {1557-3125 (Electronic) 1541-7786 (Linking)},
  doi = {10.1158/1541-7786.MCR-10-0272},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/21622624 http://mcr.aacrjournals.org/content/9/7/948.full.pdf},
  year = {2011},
  type = {Journal Article},
}


@article{Agard2012,
  author = {Agard, N. J. and Mahrus, S. and Trinidad, J. C. and Lynn, A. and Burlingame, A. L. and Wells, J. A.},
  title = {{Global kinetic analysis of proteolysis via quantitative targeted proteomics}},
  journal = {Proc Natl Acad Sci U S A},
  volume = {109},
  number = {6},
  pages = {1913-8},
  note = {Agard, Nicholas J Mahrus, Sami Trinidad, Jonathan C Lynn, Aenoch Burlingame, Alma L Wells, James A 1S10RR026662/RR/NCRR NIH HHS/ F32 AI077177/AI/NIAID NIH HHS/ P41 GM103481/GM/NIGMS NIH HHS/ P41RR001614/RR/NCRR NIH HHS/ R01 CA154802/CA/NCI NIH HHS/ R01 GM081051/GM/NIGMS NIH HHS/ Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):1913-8. doi: 10.1073/pnas.1117158109. Epub 2012 Jan 23.},
  abstract = {Mass spectrometry-based proteomics is a powerful tool for identifying hundreds to thousands of posttranslational modifications in complex mixtures. However, it remains enormously challenging to simultaneously assess the intrinsic catalytic efficiencies (k(cat)/K(M)) of these modifications in the context of their natural interactors. Such fundamental enzymological constants are key to determining substrate specificity and for establishing the timing and importance of cellular signaling. Here, we report the use of selected reaction monitoring (SRM) for tracking proteolysis induced by human apoptotic caspases-3, -7, -8, and -9 in lysates and living cells. By following the appearance of the cleaved peptides in lysate as a function of time, we were able to determine hundreds of catalytic efficiencies in parallel. Remarkably, we find the rates of substrate hydrolysis for individual caspases vary greater than 500-fold indicating a sequential process. Moreover, the rank-order of substrate cutting is similar in apoptotic cells, suggesting that cellular structures do not dramatically alter substrate accessibility. Comparisons of extrinsic (TRAIL) and intrinsic (staurosporine) inducers of apoptosis revealed similar substrate profiles, suggesting the final proteolytic demolitions proceed by similarly ordered plans. Certain biological processes were rapidly targeted by the caspases, including multiple components of the endocyotic pathway and miRNA processing machinery. We believe this massively parallel and quantitative label-free approach to obtaining basic enzymological constants will facilitate the study of proteolysis and other posttranslational modifications in complex mixtures.},
  keywords = {Amino Acid Sequence Apoptosis/drug effects Caspases/metabolism Cell Survival/drug effects Endocytosis/drug effects Enzyme Activation/drug effects Humans Jurkat Cells Kinetics MicroRNAs/metabolism Molecular Sequence Data Peptides/chemistry/metabolism *Proteolysis/drug effects Proteomics/*methods RNA Processing, Post-Transcriptional/drug effects Staurosporine/pharmacology Substrate Specificity/drug effects TNF-Related Apoptosis-Inducing Ligand/pharmacology},
  issn = {1091-6490 (Electronic) 0027-8424 (Linking)},
  doi = {10.1073/pnas.1117158109},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/22308409 http://www.pnas.org/content/109/6/1913.full.pdf http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3277568/pdf/pnas.1117158109.pdf},
  year = {2012},
  type = {Journal Article},
}


@article{Berstein:2012pi,
  author = {Berstein, L. M.},
  title = {{Metformin in obesity, cancer and aging: addressing controversies}},
  journal = {Aging (Albany NY)},
  volume = {4},
  number = {5},
  pages = {320-9},
  note = {Berstein, Lev M Aging (Albany NY). 2012 May;4(5):320-9.},
  abstract = {Metformin, an oral anti-diabetic drug, is being considered increasingly for treatment and prevention of cancer, obesity as well as for the extension of healthy lifespan. Gradually accumulating discrepancies about its effect on cancer and obesity can be explained by the shortage of randomized clinical trials, differences between control groups (reference points), gender- and age-associated effects and pharmacogenetic factors. Studies of the potential antiaging effects of antidiabetic biguanides, such as metformin, are still experimental for obvious reasons and their results are currently ambiguous. Here we discuss whether the discrepancies in different studies are merely methodological or inherently related to individual differences in responsiveness to the drug.},
  keywords = {Aging/*drug effects Animals Body Weight/drug effects Diabetes Mellitus, Type 2/complications/drug therapy Female Humans Hypoglycemic Agents/pharmacology/*therapeutic use Metformin/pharmacology/*therapeutic use Neoplasms/*drug therapy Obesity/complications/*drug therapy Oxidative Stress Polycystic Ovary Syndrome/complications/drug therapy},
  issn = {1945-4589 (Electronic) 1945-4589 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/22589237 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384433/pdf/aging-04-320.pdf},
  year = {2012},
  type = {Journal Article},
}


@article{Hollebeke:2012kl,
  author = {Hollebeke, J. and Van Damme, P. and Gevaert, K.},
  title = {{N-terminal acetylation and other functions of Nalpha-acetyltransferases}},
  journal = {Biol Chem},
  volume = {393},
  number = {4},
  pages = {291-8},
  note = {Hollebeke, Jolien Van Damme, Petra Gevaert, Kris Germany Biol Chem. 2012 Apr;393(4):291-8. doi: 10.1515/hsz-2011-0228.},
  abstract = {Protein N-terminal acetylation by Nalpha-acetyltransferases (NATs) is an omnipresent protein modification that affects a large number of proteins. The exact biological role of N-terminal acetylation has, however, remained enigmatic for the overall majority of affected proteins, and only for a rather small number of proteins, N-terminal acetylation was linked to various protein features including stability, localization, and interactions. This minireview tries to summarize the recent progress made in understanding the functionality of N-terminal protein acetylation and also focuses on noncanonical functions of the NATs subunits.},
  keywords = {Acetylation Acetyltransferases/*metabolism Animals Humans Protein Processing, Post-Translational Proteins/metabolism},
  issn = {1437-4315 (Electronic) 1431-6730 (Linking)},
  doi = {10.1515/hsz-2011-0228},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/22718636 http://www.degruyter.com/view/j/bchm.2012.393.issue-4/hsz-2011-0228/hsz-2011-0228.xml https://www.degruyter.com/view/j/bchm.2012.393.issue-4/hsz-2011-0228/hsz-2011-0228.xml},
  year = {2012},
  type = {Journal Article},
}


@article{Huang:2012zv,
  author = {Huang, W. and Ren, H. and Ben, Q. and Cai, Q. and Zhu, W. and Li, Z.},
  title = {{Risk of esophageal cancer in diabetes mellitus: a meta-analysis of observational studies}},
  journal = {Cancer Causes Control},
  volume = {23},
  number = {2},
  pages = {263-72},
  note = {Huang, Wen Ren, Hongbo Ben, Qiwen Cai, Quancai Zhu, Wei Li, Zhaoshen Netherlands Cancer Causes Control. 2012 Feb;23(2):263-72. doi: 10.1007/s10552-011-9874-9. Epub 2011 Nov 18.},
  abstract = {OBJECTIVE: Inconsistent findings from observational studies have prolonged the controversy over the effects of history of diabetes mellitus (DM) on the risk of esophageal cancer (EC). We conducted a meta-analysis of epidemiologic studies to evaluate the association of a history of DM with the risk of EC. METHODS: We identified studies by a literature search of MEDLINE (from 1 January 1966) and EMBASE (from 1 January 1974), through 28 Feburary 2011, and by searching the reference lists of pertinent articles. Summary relative risks (SRRs) with 95% confidence intervals (CIs) were calculated with a random-effects model. All statistical tests were two-sided. RESULTS: A total of 17 studies (6 case-control studies and 11 cohort studies) fulfilled the inclusion and exclusion criteria. Compared with non-diabetic individuals, diabetic individuals had a modestly increased risk of EC (SRRs 1.30, 95% CI: 1.12-1.50), with significant heterogeneity among studies (p = 0.042). In stratified analysis, the SRRs of EC were 1.28 (1.10-1.49) for diabetic men and 1.07 (95% CI, 0.71-1.62) for diabetic women, respectively. In addition, DM was associated with an increased risk of esophageal adenocarcinoma (SRR 2.12, 95% CI 1.01-4.46). There was no significant publication bias (p = 0.127 for Begg's adjusted rank correlation test and p = 0.629 for Egger's regression test). CONCLUSION: These findings support the hypothesis that men with diabetes may have a modestly increased risk of EC, while diabetic women were not the case.},
  keywords = {Adenocarcinoma/epidemiology Adult Aged Case-Control Studies Cohort Studies Confidence Intervals Diabetes Mellitus/*epidemiology Epidemiologic Studies Esophageal Neoplasms/*epidemiology Female Follow-Up Studies Humans Male Middle Aged Risk Factors},
  issn = {1573-7225 (Electronic) 0957-5243 (Linking)},
  doi = {10.1007/s10552-011-9874-9},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/22094992 http://download-v2.springer.com/static/pdf/266/art%253A10.1007%252Fs10552-011-9874-9.pdf?token2=exp=1431790972~acl=%2Fstatic%2Fpdf%2F266%2Fart%25253A10.1007%25252Fs10552-011-9874-9.pdf*~hmac=435aa2c49c182887c668382d1908a4fc4b649a5227c125aa5f92299fdede3f88},
  year = {2012},
  type = {Journal Article},
}


@article{Kasperkiewicz2012,
  author = {Kasperkiewicz, P. and Gajda, A. D. and Drag, M.},
  title = {{Current and prospective applications of non-proteinogenic amino acids in profiling of proteases substrate specificity}},
  journal = {Biol Chem},
  volume = {393},
  number = {9},
  pages = {843-51},
  note = {Kasperkiewicz, Paulina Gajda, Anna D Drag, Marcin Germany Biol Chem. 2012 Sep;393(9):843-51. doi: 10.1515/hsz-2012-0167.},
  abstract = {Proteases recognize their endogenous substrates based largely on a sequence of proteinogenic amino acids that surrounds the cleavage site. Currently, several methods are available to determine protease substrate specificity based on approaches employing proteinogenic amino acids. The knowledge about the specificity of proteases can be significantly extended by application of structurally diverse families of non-proteinogenic amino acids. From a chemical point of view, this information may be used to design specific substrates, inhibitors, or activity-based probes, while biological functions of proteases, such as posttranslational modifications can also be investigated. In this review, we discuss current and prospective technologies for application of non-proteinogenic amino acids in protease substrate specificity profiling.},
  keywords = {Amino Acids/chemistry/*metabolism Endopeptidases/chemistry/metabolism Humans Peptide Hydrolases/chemistry/*metabolism Substrate Specificity},
  issn = {1437-4315 (Electronic) 1431-6730 (Linking)},
  doi = {10.1515/hsz-2012-0167},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/22944686 http://www.degruyter.com/dg/viewarticle.fullcontentlink:pdfeventlink/$002fj$002fbchm.2012.393.issue-9$002fhsz-2012-0167$002fhsz-2012-0167.pdf?t:ac=j$002fbchm.2012.393.issue-9$002fhsz-2012-0167$002fhsz-2012-0167.xml},
  year = {2012},
  type = {Journal Article},
}


@article{Kourelis:2012yb,
  author = {Kourelis, T. V. and Siegel, R. D.},
  title = {{Metformin and cancer: new applications for an old drug}},
  journal = {Med Oncol},
  volume = {29},
  number = {2},
  pages = {1314-27},
  note = {Kourelis, Taxiarchis V Siegel, Robert D Northwood, London, England Med Oncol. 2012 Jun;29(2):1314-27. doi: 10.1007/s12032-011-9846-7. Epub 2011 Feb 8.},
  abstract = {Metformin, one of most widely prescribed oral hypoglycemic agents, has recently received increased attention because of its potential antitumorigenic effects that are thought to be independent of its hypoglycemic effects. Several potential mechanisms have been suggested for the ability of metformin to suppress cancer growth in vitro and vivo: (1) activation of LKB1/AMPK pathway, (2) induction of cell cycle arrest and/or apoptosis, (3) inhibition of protein synthesis, (4) reduction in circulating insulin levels, (5) inhibition of the unfolded protein response (UPR), (6) activation of the immune system, and (7) eradication of cancer stem cells. There is also a growing number of evidence, mostly in the form of retrospective clinical studies that suggest that metformin may be associated with a decreased risk of developing cancer and with a better response to chemotherapy. There are currently several ongoing randomized clinical trials that incorporate metformin as an adjuvant to classic chemotherapy and aim to evaluate its potential benefits in this setting. This review highlights basic aspects of the molecular biology of metformin and summarizes new advances in basic science as well as intriguing results from recent clinical studies.},
  keywords = {Diabetes Complications/etiology/*prevention & control Diabetes Mellitus, Type 2/*drug therapy/physiopathology Humans Hypoglycemic Agents/*therapeutic use Metformin/*therapeutic use Neoplasms/etiology/*prevention & control Prognosis Risk Reduction Behavior},
  issn = {1559-131X (Electronic) 1357-0560 (Linking)},
  doi = {10.1007/s12032-011-9846-7},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/21301998 http://download-v2.springer.com/static/pdf/512/art%253A10.1007%252Fs12032-011-9846-7.pdf?token2=exp=1431790978~acl=%2Fstatic%2Fpdf%2F512%2Fart%25253A10.1007%25252Fs12032-011-9846-7.pdf*~hmac=afc9d20261b7e92cd9d373738e59b379571241c4fc6be2814beabbf3fc24fcd4},
  year = {2012},
  type = {Journal Article},
}


@inbook{Larson:2012aa,
  author = {Larson, Richard S. and Sacan, Ahmet and Ekins, Sean and Kortagere, Sandhya},
  title = {{Methods in Molecular Biology}},
  booktitle = {Bioinformatics and Drug Discovery},
  publisher = {Humana Press},
  volume = {910},
  pages = {87-124},
  keywords = {Structural bioinformatics Chemoinformatics Structure prediction Virtual screening Hybrid structure-based method QSAR Drug discovery Troubleshooting computational methods},
  isbn = {978-1-61779-964-8},
  doi = {10.1007/978-1-61779-965-5\_6},
  url = {http://dx.doi.org/10.1007/978-1-61779-965-5_6 http://dx.doi.org/10.1007/978-1-61779-965-5%7B%5C_%7D6},
  year = {2012},
  type = {Book Section},
}


@article{Li:2012aa,
  author = {Li, B. Q. and Cai, Y. D. and Feng, K. Y. and Zhao, G. J.},
  title = {{Prediction of protein cleavage site with feature selection by random forest}},
  journal = {PLoS One},
  volume = {7},
  number = {9},
  pages = {e45854},
  note = {Li, Bi-Qing Cai, Yu-Dong Feng, Kai-Yan Zhao, Gui-Jun PLoS One. 2012;7(9):e45854. doi: 10.1371/journal.pone.0045854. Epub 2012 Sep 18.},
  abstract = {Proteinases play critical roles in both intra and extracellular processes by binding and cleaving their protein substrates. The cleavage can either be non-specific as part of degradation during protein catabolism or highly specific as part of proteolytic cascades and signal transduction events. Identification of these targets is extremely challenging. Current computational approaches for predicting cleavage sites are very limited since they mainly represent the amino acid sequences as patterns or frequency matrices. In this work, we developed a novel predictor based on Random Forest algorithm (RF) using maximum relevance minimum redundancy (mRMR) method followed by incremental feature selection (IFS). The features of physicochemical/biochemical properties, sequence conservation, residual disorder, amino acid occurrence frequency, secondary structure and solvent accessibility were utilized to represent the peptides concerned. Here, we compared existing prediction tools which are available for predicting possible cleavage sites in candidate substrates with ours. It is shown that our method makes much more reliable predictions in terms of the overall prediction accuracy. In addition, this predictor allows the use of a wide range of proteinases.},
  keywords = {Algorithms Amino Acid Motifs Amino Acid Sequence Conserved Sequence Decision Trees *Models, Molecular Molecular Sequence Data Peptide Hydrolases/chemistry Proteasome Endopeptidase Complex/chemistry *Proteolysis Sequence Analysis, Protein},
  issn = {1932-6203 (Electronic) 1932-6203 (Linking)},
  doi = {10.1371/journal.pone.0045854},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/23029276 http://www.plosone.org/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0045854&representation=PDF},
  year = {2012},
  type = {Journal Article},
}


@article{Murray:2012px,
  author = {Murray, C. J. and Vos, T. and Lozano, R. and Naghavi, M. and Flaxman, A. D. and Michaud, C. and Ezzati, M. and Shibuya, K. and Salomon, J. A. and Abdalla, S. and Aboyans, V. and Abraham, J. and Ackerman, I. and Aggarwal, R. and Ahn, S. Y. and Ali, M. K. and Alvarado, M. and Anderson, H. R. and Anderson, L. M. and Andrews, K. G. and Atkinson, C. and Baddour, L. M. and Bahalim, A. N. and Barker-Collo, S. and Barrero, L. H. and Bartels, D. H. and Basanez, M. G. and Baxter, A. and Bell, M. L. and Benjamin, E. J. and Bennett, D. and Bernabe, E. and Bhalla, K. and Bhandari, B. and Bikbov, B. and Bin Abdulhak, A. and Birbeck, G. and Black, J. A. and Blencowe, H. and Blore, J. D. and Blyth, F. and Bolliger, I. and Bonaventure, A. and Boufous, S. and Bourne, R. and Boussinesq, M. and Braithwaite, T. and Brayne, C. and Bridgett, L. and Brooker, S. and Brooks, P. and Brugha, T. S. and Bryan-Hancock, C. and Bucello, C. and Buchbinder, R. and Buckle, G. and Budke, C. M. and Burch, M. and Burney, P. and Burstein, R. and Calabria, B. and Campbell, B. and Canter, C. E. and Carabin, H. and Carapetis, J. and Carmona, L. and Cella, C. and Charlson, F. and Chen, H. and Cheng, A. T. and Chou, D. and Chugh, S. S. and Coffeng, L. E. and Colan, S. D. and Colquhoun, S. and Colson, K. E. and Condon, J. and Connor, M. D. and Cooper, L. T. and Corriere, M. and Cortinovis, M. and de Vaccaro, K. C. and Couser, W. and Cowie, B. C. and Criqui, M. H. and Cross, M. and Dabhadkar, K. C. and Dahiya, M. and Dahodwala, N. and Damsere-Derry, J. and Danaei, G. and Davis, A. and De Leo, D. and Degenhardt, L. and Dellavalle, R. and Delossantos, A. and Denenberg, J. and Derrett, S. and Des Jarlais, D. C. and Dharmaratne, S. D. and others},
  title = {{Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010}},
  journal = {Lancet},
  volume = {380},
  number = {9859},
  pages = {2197-223},
  note = {Murray, Christopher J L Vos, Theo Lozano, Rafael Naghavi, Mohsen Flaxman, Abraham D Michaud, Catherine Ezzati, Majid Shibuya, Kenji Salomon, Joshua A Abdalla, Safa Aboyans, Victor Abraham, Jerry Ackerman, Ilana Aggarwal, Rakesh Ahn, Stephanie Y Ali, Mohammed K Alvarado, Miriam Anderson, H Ross Anderson, Laurie M Andrews, Kathryn G Atkinson, Charles Baddour, Larry M Bahalim, Adil N Barker-Collo, Suzanne Barrero, Lope H Bartels, David H Basanez, Maria-Gloria Baxter, Amanda Bell, Michelle L Benjamin, Emelia J Bennett, Derrick Bernabe, Eduardo Bhalla, Kavi Bhandari, Bishal Bikbov, Boris Bin Abdulhak, Aref Birbeck, Gretchen Black, James A Blencowe, Hannah Blore, Jed D Blyth, Fiona Bolliger, Ian Bonaventure, Audrey Boufous, Soufiane Bourne, Rupert Boussinesq, Michel Braithwaite, Tasanee Brayne, Carol Bridgett, Lisa Brooker, Simon Brooks, Peter Brugha, Traolach S Bryan-Hancock, Claire Bucello, Chiara Buchbinder, Rachelle Buckle, Geoffrey Budke, Christine M Burch, Michael Burney, Peter Burstein, Roy Calabria, Bianca Campbell, Benjamin Canter, Charles E Carabin, Helene Carapetis, Jonathan Carmona, Loreto Cella, Claudia Charlson, Fiona Chen, Honglei Cheng, Andrew Tai-Ann Chou, David Chugh, Sumeet S Coffeng, Luc E Colan, Steven D Colquhoun, Samantha Colson, K Ellicott Condon, John Connor, Myles D Cooper, Leslie T Corriere, Matthew Cortinovis, Monica de Vaccaro, Karen Courville Couser, William Cowie, Benjamin C Criqui, Michael H Cross, Marita Dabhadkar, Kaustubh C Dahiya, Manu Dahodwala, Nabila Damsere-Derry, James Danaei, Goodarz Davis, Adrian De Leo, Diego Degenhardt, Louisa Dellavalle, Robert Delossantos, Allyne Denenberg, Julie Derrett, Sarah Des Jarlais, Don C Dharmaratne, Samath D Dherani, Mukesh Diaz-Torne, Cesar Dolk, Helen Dorsey, E Ray Driscoll, Tim Duber, Herbert Ebel, Beth Edmond, Karen Elbaz, Alexis Ali, Suad Eltahir Erskine, Holly Erwin, Patricia J Espindola, Patricia Ewoigbokhan, Stalin E Farzadfar, Farshad Feigin, Valery Felson, David T Ferrari, Alize Ferri, Cleusa P Fevre, Eric M Finucane, Mariel M Flaxman, Seth Flood, Louise Foreman, Kyle Forouzanfar, Mohammad H Fowkes, Francis Gerry R Fransen, Marlene Freeman, Michael K Gabbe, Belinda J Gabriel, Sherine E Gakidou, Emmanuela Ganatra, Hammad A Garcia, Bianca Gaspari, Flavio Gillum, Richard F Gmel, Gerhard Gonzalez-Medina, Diego Gosselin, Richard Grainger, Rebecca Grant, Bridget Groeger, Justina Guillemin, Francis Gunnell, David Gupta, Ramyani Haagsma, Juanita Hagan, Holly Halasa, Yara A Hall, Wayne Haring, Diana Haro, Josep Maria Harrison, James E Havmoeller, Rasmus Hay, Roderick J Higashi, Hideki Hill, Catherine Hoen, Bruno Hoffman, Howard Hotez, Peter J Hoy, Damian Huang, John J Ibeanusi, Sydney E Jacobsen, Kathryn H James, Spencer L Jarvis, Deborah Jasrasaria, Rashmi Jayaraman, Sudha Johns, Nicole Jonas, Jost B Karthikeyan, Ganesan Kassebaum, Nicholas Kawakami, Norito Keren, Andre Khoo, Jon-Paul King, Charles H Knowlton, Lisa Marie Kobusingye, Olive Koranteng, Adofo Krishnamurthi, Rita Laden, Francine Lalloo, Ratilal Laslett, Laura L Lathlean, Tim Leasher, Janet L Lee, Yong Yi Leigh, James Levinson, Daphna Lim, Stephen S Limb, Elizabeth Lin, John Kent Lipnick, Michael Lipshultz, Steven E Liu, Wei Loane, Maria Ohno, Summer Lockett Lyons, Ronan Mabweijano, Jacqueline MacIntyre, Michael F Malekzadeh, Reza Mallinger, Leslie Manivannan, Sivabalan Marcenes, Wagner March, Lyn Margolis, David J Marks, Guy B Marks, Robin Matsumori, Akira Matzopoulos, Richard Mayosi, Bongani M McAnulty, John H McDermott, Mary M McGill, Neil McGrath, John Medina-Mora, Maria Elena Meltzer, Michele Mensah, George A Merriman, Tony R Meyer, Ana-Claire Miglioli, Valeria Miller, Matthew Miller, Ted R Mitchell, Philip B Mock, Charles Mocumbi, Ana Olga Moffitt, Terrie E Mokdad, Ali A Monasta, Lorenzo Montico, Marcella Moradi-Lakeh, Maziar Moran, Andrew Morawska, Lidia Mori, Rintaro Murdoch, Michele E Mwaniki, Michael K Naidoo, Kovin Nair, M Nathan Naldi, Luigi Narayan, K M Venkat Nelson, Paul K Nelson, Robert G Nevitt, Michael C Newton, Charles R Nolte, Sandra Norman, Paul Norman, Rosana O'Donnell, Martin O'Hanlon, Simon Olives, Casey Omer, Saad B Ortblad, Katrina Osborne, Richard Ozgediz, Doruk Page, Andrew Pahari, Bishnu Pandian, Jeyaraj Durai Rivero, Andrea Panozo Patten, Scott B Pearce, Neil Padilla, Rogelio Perez Perez-Ruiz, Fernando Perico, Norberto Pesudovs, Konrad Phillips, David Phillips, Michael R Pierce, Kelsey Pion, Sebastien Polanczyk, Guilherme V Polinder, Suzanne Pope, C Arden 3rd Popova, Svetlana Porrini, Esteban Pourmalek, Farshad Prince, Martin Pullan, Rachel L Ramaiah, Kapa D Ranganathan, Dharani Razavi, Homie Regan, Mathilda Rehm, Jurgen T Rein, David B Remuzzi, Guiseppe Richardson, Kathryn Rivara, Frederick P Roberts, Thomas Robinson, Carolyn De Leon, Felipe Rodriguez Ronfani, Luca Room, Robin Rosenfeld, Lisa C Rushton, Lesley Sacco, Ralph L Saha, Sukanta Sampson, Uchechukwu Sanchez-Riera, Lidia Sanman, Ella Schwebel, David C Scott, James Graham Segui-Gomez, Maria Shahraz, Saeid Shepard, Donald S Shin, Hwashin Shivakoti, Rupak Singh, David Singh, Gitanjali M Singh, Jasvinder A Singleton, Jessica Sleet, David A Sliwa, Karen Smith, Emma Smith, Jennifer L Stapelberg, Nicolas J C Steer, Andrew Steiner, Timothy Stolk, Wilma A Stovner, Lars Jacob Sudfeld, Christopher Syed, Sana Tamburlini, Giorgio Tavakkoli, Mohammad Taylor, Hugh R Taylor, Jennifer A Taylor, William J Thomas, Bernadette Thomson, W Murray Thurston, George D Tleyjeh, Imad M Tonelli, Marcello Towbin, Jeffrey A Truelsen, Thomas Tsilimbaris, Miltiadis K Ubeda, Clotilde Undurraga, Eduardo A van der Werf, Marieke J van Os, Jim Vavilala, Monica S Venketasubramanian, N Wang, Mengru Wang, Wenzhi Watt, Kerrianne Weatherall, David J Weinstock, Martin A Weintraub, Robert Weisskopf, Marc G Weissman, Myrna M White, Richard A Whiteford, Harvey Wiebe, Natasha Wiersma, Steven T Wilkinson, James D Williams, Hywel C Williams, Sean R M Witt, Emma Wolfe, Frederick Woolf, Anthony D Wulf, Sarah Yeh, Pon-Hsiu Zaidi, Anita K M Zheng, Zhi-Jie Zonies, David Lopez, Alan D AlMazroa, Mohammad A Memish, Ziad A 092654/Wellcome Trust/United Kingdom 095009/Wellcome Trust/United Kingdom 098045/Wellcome Trust/United Kingdom ES00260/ES/NIEHS NIH HHS/ ES015459/ES/NIEHS NIH HHS/ G0901214/Medical Research Council/United Kingdom K23 AG034236/AG/NIA NIH HHS/ Department of Health/United Kingdom Medical Research Council/United Kingdom England Lancet. 2012 Dec 15;380(9859):2197-223. doi: 10.1016/S0140-6736(12)61689-4.},
  abstract = {BACKGROUND: Measuring disease and injury burden in populations requires a composite metric that captures both premature mortality and the prevalence and severity of ill-health. The 1990 Global Burden of Disease study proposed disability-adjusted life years (DALYs) to measure disease burden. No comprehensive update of disease burden worldwide incorporating a systematic reassessment of disease and injury-specific epidemiology has been done since the 1990 study. We aimed to calculate disease burden worldwide and for 21 regions for 1990, 2005, and 2010 with methods to enable meaningful comparisons over time. METHODS: We calculated DALYs as the sum of years of life lost (YLLs) and years lived with disability (YLDs). DALYs were calculated for 291 causes, 20 age groups, both sexes, and for 187 countries, and aggregated to regional and global estimates of disease burden for three points in time with strictly comparable definitions and methods. YLLs were calculated from age-sex-country-time-specific estimates of mortality by cause, with death by standardised lost life expectancy at each age. YLDs were calculated as prevalence of 1160 disabling sequelae, by age, sex, and cause, and weighted by new disability weights for each health state. Neither YLLs nor YLDs were age-weighted or discounted. Uncertainty around cause-specific DALYs was calculated incorporating uncertainty in levels of all-cause mortality, cause-specific mortality, prevalence, and disability weights. FINDINGS: Global DALYs remained stable from 1990 (2.503 billion) to 2010 (2.490 billion). Crude DALYs per 1000 decreased by 23% (472 per 1000 to 361 per 1000). An important shift has occurred in DALY composition with the contribution of deaths and disability among children (younger than 5 years of age) declining from 41% of global DALYs in 1990 to 25% in 2010. YLLs typically account for about half of disease burden in more developed regions (high-income Asia Pacific, western Europe, high-income North America, and Australasia), rising to over 80% of DALYs in sub-Saharan Africa. In 1990, 47% of DALYs worldwide were from communicable, maternal, neonatal, and nutritional disorders, 43% from non-communicable diseases, and 10% from injuries. By 2010, this had shifted to 35%, 54%, and 11%, respectively. Ischaemic heart disease was the leading cause of DALYs worldwide in 2010 (up from fourth rank in 1990, increasing by 29%), followed by lower respiratory infections (top rank in 1990; 44% decline in DALYs), stroke (fifth in 1990; 19% increase), diarrhoeal diseases (second in 1990; 51% decrease), and HIV/AIDS (33rd in 1990; 351% increase). Major depressive disorder increased from 15th to 11th rank (37% increase) and road injury from 12th to 10th rank (34% increase). Substantial heterogeneity exists in rankings of leading causes of disease burden among regions. INTERPRETATION: Global disease burden has continued to shift away from communicable to non-communicable diseases and from premature death to years lived with disability. In sub-Saharan Africa, however, many communicable, maternal, neonatal, and nutritional disorders remain the dominant causes of disease burden. The rising burden from mental and behavioural disorders, musculoskeletal disorders, and diabetes will impose new challenges on health systems. Regional heterogeneity highlights the importance of understanding local burden of disease and setting goals and targets for the post-2015 agenda taking such patterns into account. Because of improved definitions, methods, and data, these results for 1990 and 2010 supersede all previously published Global Burden of Disease results. FUNDING: Bill & Melinda Gates Foundation.},
  keywords = {Adolescent Adult Age Factors Aged Aged, 80 and over Child Child, Preschool Female *Health Status Humans Infant Infant, Newborn Male Middle Aged Prevalence *Quality-Adjusted Life Years Sex Factors World Health/*statistics & numerical data Wounds and Injuries/*epidemiology Young Adult},
  issn = {1474-547X (Electronic) 0140-6736 (Linking)},
  doi = {10.1016/S0140-6736(12)61689-4},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/23245608 http://ac.els-cdn.com/S0140673612616894/1-s2.0-S0140673612616894-main.pdf?_tid=73770df0-fbdf-11e4-b402-00000aacb35d&acdnat=1431789966_02365cffaf618b7e17ebe6928db278ca},
  year = {2012},
  type = {Journal Article},
}


@article{Muscelli2012,
  author = {Muscelli, E. and Casolaro, A. and Gastaldelli, A. and Mari, A. and Seghieri, G. and Astiarraga, B. and Chen, Y. and Alba, M. and Holst, J. and Ferrannini, E.},
  title = {{Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes}},
  journal = {J Clin Endocrinol Metab},
  volume = {97},
  number = {8},
  pages = {2818-26},
  note = {Muscelli, Elza Casolaro, Arturo Gastaldelli, Amalia Mari, Andrea Seghieri, Giuseppe Astiarraga, Brenno Chen, Yu Alba, Maria Holst, Jens Ferrannini, Ele J Clin Endocrinol Metab. 2012 Aug;97(8):2818-26. doi: 10.1210/jc.2012-1205. Epub 2012 Jun 8.},
  abstract = {CONTEXT: Dipeptidyl peptidase IV (DPP-4) inhibitors improve glycemic control in patients with type 2 diabetes. The underlying mechanisms (incretin effect, beta-cell function, endogenous glucose production) are not well known. OBJECTIVE: The aim of the study was to examine mechanisms of the antihyperglycemic effect of DPP-4 inhibitors. DESIGN, SETTING, AND PATIENTS: We administered a mixed meal with glucose tracers ([6,6-(2)H(2)]-glucose infused, [1-(2)H]-glucose ingested), and on a separate day, a glucose infusion matched the glucose responses to the meal (isoglycemic test) in 50 type 2 diabetes patients (hemoglobin A(1c) = 7.4 +/- 0.8%) and seven controls; 47 diabetic completers were restudied after 6 wk. Glucose fluxes were calculated, and beta-cell function was assessed by mathematical modeling. The incretin effect was calculated as the ratio of oral to iv insulin secretion. INTERVENTION: We conducted a 6-wk, double-blind, randomized treatment with sitagliptin (100 mg/d; n = 25) or placebo (n = 22). RESULTS: Relative to placebo, meal-induced changes in fasting glucose and glucose area under the curve (AUC) were greater with sitagliptin, in parallel with a lower appearance of oral glucose [difference (post-pre) AUC = -353 +/- 915 vs. +146 +/- 601 mumol . kg(-1) . 5 h] and greater suppression of endogenous glucose production. Insulin sensitivity improved 10%, whereas total insulin secretion was unchanged. During the meal, beta-cell glucose sensitivity improved (+19[29] vs. 5[21] pmol . min(-1) . m(-2) . mm(-1); median [interquartile range]) and glucagon AUC decreased (19.6 +/- 7.5 to 17.3 +/- 7.1 ng . ml(-1) . 5 h), whereas intact glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 AUC increased with sitagliptin vs. placebo. The incretin effect was unchanged because sitagliptin increased beta-cell glucose sensitivity also during the isoglycemic test. CONCLUSIONS: Chronic sitagliptin treatment improves glycemic control by lowering the appearance of oral glucose, postprandial endogenous glucose release, and glucagon response, and by improving insulin sensitivity and beta-cell glucose sensing in response to both oral and iv glucose.},
  keywords = {Adult Aged Blood Glucose/analysis Diabetes Mellitus, Type 2/blood/*drug therapy/physiopathology Double-Blind Method Female Glucagon/blood Glucagon-Like Peptide 1/blood Humans Hypoglycemic Agents/*pharmacology/therapeutic use Insulin-Secreting Cells/drug effects/physiology Male Middle Aged Pyrazines/*pharmacology/therapeutic use Triazoles/*pharmacology/therapeutic use},
  issn = {1945-7197 (Electronic) 0021-972X (Linking)},
  doi = {10.1210/jc.2012-1205},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/22685234 http://graphics.tx.ovid.com/ovftpdfs/FPDDNCLBMFLKAN00/fs047/ovft/live/gv024/00004678/00004678-201208000-00039.pdf},
  year = {2012},
  type = {Journal Article},
}


@article{Sacan:2012aa,
  author = {Sacan, A. and Ekins, S. and Kortagere, S.},
  title = {{Applications and limitations of in silico models in drug discovery}},
  journal = {Methods Mol Biol},
  volume = {910},
  pages = {87-124},
  note = {Sacan, Ahmet Ekins, Sean Kortagere, Sandhya Clifton, N.J. Methods Mol Biol. 2012;910:87-124. doi: 10.1007/978-1-61779-965-5_6.},
  abstract = {Drug discovery in the late twentieth and early twenty-first century has witnessed a myriad of changes that were adopted to predict whether a compound is likely to be successful, or conversely enable identification of molecules with liabilities as early as possible. These changes include integration of in silico strategies for lead design and optimization that perform complementary roles to that of the traditional in vitro and in vivo approaches. The in silico models are facilitated by the availability of large datasets associated with high-throughput screening, bioinformatics algorithms to mine and annotate the data from a target perspective, and chemoinformatics methods to integrate chemistry methods into lead design process. This chapter highlights the applications of some of these methods and their limitations. We hope this serves as an introduction to in silico drug discovery.},
  keywords = {Algorithms *Computational Biology Crystallography, X-Ray Databases, Factual Drug Discovery/*methods High-Throughput Screening Assays Models, Molecular Proteins/chemistry Quantitative Structure-Activity Relationship},
  issn = {1940-6029 (Electronic) 1064-3745 (Linking)},
  doi = {10.1007/978-1-61779-965-5_6},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/22821594},
  year = {2012},
  type = {Journal Article},
}


@article{Sadeghi:2012et,
  author = {Sadeghi, N. and Abbruzzese, J. L. and Yeung, S. C. and Hassan, M. and Li, D.},
  title = {{Metformin use is associated with better survival of diabetic patients with pancreatic cancer}},
  journal = {Clin Cancer Res},
  volume = {18},
  number = {10},
  pages = {2905-12},
  note = {Sadeghi, Navid Abbruzzese, James L Yeung, Sai-Ching J Hassan, Manal Li, Donghui CA016672/CA/NCI NIH HHS/ P20 CA101936/CA/NCI NIH HHS/ P30 CA016672/CA/NCI NIH HHS/ R01 CA098380-05/CA/NCI NIH HHS/ R01 CA98380/CA/NCI NIH HHS/ UL1 RR024148/RR/NCRR NIH HHS/ Clin Cancer Res. 2012 May 15;18(10):2905-12. doi: 10.1158/1078-0432.CCR-11-2994. Epub 2012 Mar 31.},
  abstract = {PURPOSE: Accumulating evidence suggests that metformin has antitumor activity. The aim of this study was to determine whether metformin use has a survival benefit in patients with pancreatic cancer. EXPERIMENTAL DESIGN: We conducted a retrospective study of patients with diabetes and pancreatic cancer treated at The University of Texas MD Anderson Cancer Center (Houston, TX). Information on diabetes history, including treatment modalities and clinical outcome of pancreatic cancer, was collected using personal interviews and medical record review. Survival analysis was carried out using a Kaplan-Meier plot, log-rank test, and Cox proportional hazards regression models. RESULTS: Among the 302 patients identified, there were no significant differences in demographic or major clinical characteristics between the patients who had received metformin (n = 117) and those who had not (n = 185). The 2-year survival rate was 30.1% for the metformin group and 15.4% for the non-metformin group (P = 0.004; chi(2) test). The median overall survival time was 15.2 months for the metformin group, and 11.1 months for the non-metformin group (P = 0.004, log-rank test). Metformin users had a 32% lower risk of death; the HR (95% confidence interval) was 0.68 (0.52-0.89) in a univariate model (P = 0.004), 0.64 (0.48-0.86) after adjusting for other clinical predictors (P = 0.003), and 0.62 (0.44-0.87) after excluding insulin users (P = 0.006). Metformin use was significantly associated with longer survival in patients with nonmetastatic disease only. CONCLUSIONS: Our finding that metformin use was associated with improved outcome of patients with diabetes and pancreatic cancer should be confirmed in independent studies. Future research should prospectively evaluate metformin as a supplemental therapy in this population.},
  keywords = {Adult Aged Aged, 80 and over *Diabetes Complications Diabetes Mellitus/*drug therapy Female Humans Hypoglycemic Agents/pharmacology/therapeutic use Kaplan-Meier Estimate Male Metformin/pharmacology/*therapeutic use Middle Aged Pancreatic Neoplasms/*complications/*drug therapy/mortality Retrospective Studies},
  issn = {1078-0432 (Print) 1078-0432 (Linking)},
  doi = {10.1158/1078-0432.CCR-11-2994},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/22465831 http://clincancerres.aacrjournals.org/content/18/10/2905.full.pdf},
  year = {2012},
  type = {Journal Article},
}


@article{Schiller:2012cr,
  author = {Schiller, J. S. and Lucas, J. W. and Ward, B. W. and Peregoy, J. A.},
  title = {{Summary health statistics for U.S. adults: National Health Interview Survey, 2010}},
  journal = {Vital Health Stat 10},
  number = {252},
  pages = {1-207},
  note = {Schiller, Jeannine S Lucas, Jacqueline W Ward, Brian W Peregoy, Jennifer A Vital Health Stat 10. 2012 Jan;(252):1-207.},
  abstract = {OBJECTIVES: This report presents health statistics from the 2010 National Health Interview Survey (NHIS) for the civilian noninstitutionalized adult population, classified by sex, age, race and Hispanic origin, education, family income, poverty status, health insurance coverage, marital status, and place and region of residence. Estimates are presented for selected chronic conditions and mental health characteristics, functional limitations, health status, health behaviors, health care access and utilization, and human immunodeficiency virus testing. Percentages and percent distributions are presented in both age-adjusted and unadjusted versions. DATA SOURCE: NHIS is a household, multistage probability sample survey conducted annually by interviewers of the U.S. Census Bureau for the Centers for Disease Control and Prevention's National Center for Health Statistics. In 2010, data were collected on 27,157 adults in the Sample Adult questionnaire. The conditional response rate was 77.3%, and the final response rate was 60.8%. The health information for adults in this report was obtained from one randomly selected adult per family. In very rare instances where the sample adult was not able to respond for himself or herself, a proxy was used. HIGHLIGHTS: In 2010, 61% of adults aged 18 years and over had excellent or very good health. Twelve percent of adults had been told by a doctor or health professional that they had heart disease, 25% had been told on two or more visits that they had hypertension, 9% had been told they had diabetes, and 22% had been told they had some form of arthritis, rheumatoid arthritis, gout, lupus, or fibromyalgia. Twenty-one percent of adults were current smokers, and 21% were former smokers. Based on estimates of body mass index, 35% of adults were overweight and 27% were obese.},
  keywords = {Adolescent Adult Age Factors Aged Female *Health Behavior Health Services Accessibility/statistics & numerical data *Health Status Health Surveys/*statistics & numerical data Humans Male Middle Aged Sex Factors Socioeconomic Factors United States/epidemiology Young Adult},
  issn = {0083-1972 (Print) 0083-1972 (Linking)},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/22834228},
  year = {2012},
  type = {Journal Article},
}


@article{Scully:2012bs,
  author = {Scully, Tony},
  title = {{Diabetes in numbers.(OUTLOOK: DIABETES)}},
  journal = {Nature},
  volume = {485},
  number = {7398},
  pages = {S2},
  keywords = {Diabetes Mellitus -- Demographic Aspects Diabetes Mellitus -- Statistics},
  url = {http://graphics.tx.ovid.com/ovftpdfs/FPDDNCLBMFLKAN00/fs046/ovft/live/gv023/00006056/00006056-201205171-00002.pdf},
  year = {2012},
  type = {Journal Article},
}


@article{Song:2012aa,
  author = {Song, J. and Tan, H. and Perry, A. J. and Akutsu, T. and Webb, G. I. and Whisstock, J. C. and Pike, R. N.},
  title = {{PROSPER: an integrated feature-based tool for predicting protease substrate cleavage sites}},
  journal = {PLoS One},
  volume = {7},
  number = {11},
  pages = {e50300},
  note = {Song, Jiangning Tan, Hao Perry, Andrew J Akutsu, Tatsuya Webb, Geoffrey I Whisstock, James C Pike, Robert N PLoS One. 2012;7(11):e50300. doi: 10.1371/journal.pone.0050300. Epub 2012 Nov 29.},
  abstract = {The ability to catalytically cleave protein substrates after synthesis is fundamental for all forms of life. Accordingly, site-specific proteolysis is one of the most important post-translational modifications. The key to understanding the physiological role of a protease is to identify its natural substrate(s). Knowledge of the substrate specificity of a protease can dramatically improve our ability to predict its target protein substrates, but this information must be utilized in an effective manner in order to efficiently identify protein substrates by in silico approaches. To address this problem, we present PROSPER, an integrated feature-based server for in silico identification of protease substrates and their cleavage sites for twenty-four different proteases. PROSPER utilizes established specificity information for these proteases (derived from the MEROPS database) with a machine learning approach to predict protease cleavage sites by using different, but complementary sequence and structure characteristics. Features used by PROSPER include local amino acid sequence profile, predicted secondary structure, solvent accessibility and predicted native disorder. Thus, for proteases with known amino acid specificity, PROSPER provides a convenient, pre-prepared tool for use in identifying protein substrates for the enzymes. Systematic prediction analysis for the twenty-four proteases thus far included in the database revealed that the features we have included in the tool strongly improve performance in terms of cleavage site prediction, as evidenced by their contribution to performance improvement in terms of identifying known cleavage sites in substrates for these enzymes. In comparison with two state-of-the-art prediction tools, PoPS and SitePrediction, PROSPER achieves greater accuracy and coverage. To our knowledge, PROSPER is the first comprehensive server capable of predicting cleavage sites of multiple proteases within a single substrate sequence using machine learning techniques. It is freely available at http://lightning.med.monash.edu.au/PROSPER/.},
  keywords = {Algorithms Animals Artificial Intelligence Catalysis Cattle Computational Biology/methods Granzymes/chemistry Humans Hydrolysis Mice Models, Statistical Peptide Hydrolases/*chemistry Peptides/chemistry Protein Binding Protein Conformation Protein Processing, Post-Translational Proteins/*chemistry ROC Curve Software Solvents/chemistry Substrate Specificity},
  issn = {1932-6203 (Electronic) 1932-6203 (Linking)},
  doi = {10.1371/journal.pone.0050300},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/23209700 http://www.plosone.org/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0050300&representation=PDF},
  year = {2012},
  type = {Journal Article},
}


@article{Wright2012,
  author = {Wright, P. C. and Noirel, J. and Ow, S. Y. and Fazeli, A.},
  title = {{A review of current proteomics technologies with a survey on their widespread use in reproductive biology investigations}},
  journal = {Theriogenology},
  volume = {77},
  number = {4},
  pages = {738-765 e52},
  note = {Wright, P C Noirel, J Ow, S-Y Fazeli, A Theriogenology. 2012 Mar 1;77(4):738-765.e52. doi: 10.1016/j.theriogenology.2011.11.012.},
  abstract = {Proteomics is very much a technology-driven field. The ambition is to identify, quantify and to assess the state of posttranslational modification and interaction partners for every protein in the cell. The proteome is in a state of flux and is thus extremely complex. Analysis of the proteome is exacerbated by the huge dynamic concentration range of proteins in the cellular environment. The impact that mass spectrometry-based proteomics has had on the field of biology has heavily depended on dramatic improvements in mass spectrometry that have been made in recent years. We examined 1541 reports indexed in PubMed relating to proteomics and reproduction to identify trends in the field and to make some broad observations for future work. To set the scene, in the first part of the report, we give a comprehensive overview of proteomics and associated techniques and technologies (such as separations and mass spectrometry). The second part examines the field in light of these techniques and suggests some opportunities for application of these tools in the area of reproduction.},
  keywords = {Animals Female Humans Male Mass Spectrometry Pregnancy Protein Processing, Post-Translational Proteins/analysis Proteomics/methods/*trends Reproduction/*physiology Systems Biology},
  issn = {1879-3231 (Electronic) 0093-691X (Linking)},
  doi = {10.1016/j.theriogenology.2011.11.012},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/22325247 http://ac.els-cdn.com/S0093691X11006091/1-s2.0-S0093691X11006091-main.pdf?_tid=c3e6f702-e506-11e6-8e03-00000aacb35d&acdnat=1485572970_5289a63ceccfe86baed3d3ad81e5c18a},
  year = {2012},
  type = {Journal Article},
}


@article{Yehuda-Shnaidman:2012fx,
  author = {Yehuda-Shnaidman, E. and Schwartz, B.},
  title = {{Mechanisms linking obesity, inflammation and altered metabolism to colon carcinogenesis}},
  journal = {Obes Rev},
  volume = {13},
  number = {12},
  pages = {1083-95},
  note = {Yehuda-Shnaidman, E Schwartz, B England Obes Rev. 2012 Dec;13(12):1083-95. doi: 10.1111/j.1467-789X.2012.01024.x. Epub 2012 Sep 3.},
  abstract = {Due to its prevalence, obesity is now considered a global epidemic. It is linked to increased risk of colorectal cancer, the third most common cancer and the second leading cause of death among adults in Western countries. Obese adipose tissue differs from lean adipose tissue in its immunogenic profile, body fat distribution and metabolic profile. Obese adipose tissue releases free fatty acids, adipokines and many pro-inflammatory chemokines. These factors are known to play a key role in regulating malignant transformation and cancer progression. Obese adipose tissue is infiltrated by macrophages that participate in inflammatory pathways activated within the tissue. Adipose tissue macrophages consist of two different phenotypes. M1 macrophages reside in obese adipose tissue and produce pro-inflammatory cytokines, and M2 macrophages reside in lean adipose tissue and produce anti-inflammatory cytokines, such as interleukin-10 (IL-10). The metabolic networks that confer tumour cells with their oncogenic properties, such as increased proliferation and the ability to avoid apoptosis are still not well understood. We review the interactions between adipocytes and immune cells that may alter the metabolism towards promotion of colorectal cancer.},
  keywords = {Adipose Tissue/immunology/metabolism/*physiology Chronic Disease Colonic Neoplasms/*epidemiology Comorbidity Energy Metabolism/*physiology Humans Inflammation/*epidemiology Macrophages/physiology Obesity/*epidemiology},
  issn = {1467-789X (Electronic) 1467-7881 (Linking)},
  doi = {10.1111/j.1467-789X.2012.01024.x},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/22937964 http://onlinelibrary.wiley.com/store/10.1111/j.1467-789X.2012.01024.x/asset/obr1024.pdf?v=1&t=iygnp2g6&s=d66fab1500eaecc7192af2e3e8cbbdab5ebe3815},
  year = {2012},
  type = {Journal Article},
}


@article{UniProt2013b,
  author = {Apweiler, R. and Martin, M. J. and O'Donovan, C. and Magrane, M. and Alam-Faruque, Y. and Alpi, E. and Antunes, R. and Arganiska, J. and Casanova, E. B. and Bely, B. and Bingley, M. and Bonilla, C. and Britto, R. and Bursteinas, B. and Chan, W. M. and Chavali, G. and Cibrian-Uhalte, E. and Da Silva, A. and De Giorgi, M. and Dimmer, E. and Fazzini, F. and Gane, P. and Fedotov, A. and Castro, L. G. and Garmiri, P. and Hatton-Ellis, E. and Hieta, R. and Huntley, R. and Jacobsen, J. and Jones, R. and Legge, D. and Liu, W. D. and Luo, J. and MacDougall, A. and Mutowo, P. and Nightingale, A. and Orchard, S. and Patient, S. and Pichler, K. and Poggioli, D. and Pundir, S. and Pureza, L. and Qi, G. Y. and Rosanoff, S. and Sawford, T. and Sehra, H. and Turner, E. and Volynkin, V. and Wardell, T. and Watkins, X. and Zellner, H. and Corbett, M. and Donnelly, M. and van Rensburg, P. and Goujon, M. and McWilliam, H. and Lopez, R. and Xenarios, I. and Bougueleret, L. and Bridge, A. and Poux, S. and Redaschi, N. and Auchincloss, A. and Axelsen, K. and Bansal, P. and Baratin, D. and Binz, P. A. and Blatter, M. C. and Boeckmann, B. and Bolleman, J. and Boutet, E. and Breuza, L. and de Castro, E. and Cerutti, L. and Coudert, E. and Cuche, B. and Doche, M. and Dornevil, D. and Duvaud, S. and Estreicher, A. and Famiglietti, L. and Feuermann, M. and Gasteiger, E. and Gehant, S. and Gerritsen, V. and Gos, A. and Gruaz-Gumowski, N. and Hinz, U. and Hulo, C. and James, J. and Jungo, F. and Keller, G. and Lara, V. and Lemercier, P. and Lew, J. and Lieberherr, D. and Martin, X. and Masson, P. and Morgat, A. and Neto, T. and others},
  title = {{Update on activities at the Universal Protein Resource (UniProt) in 2013}},
  journal = {Nucleic Acids Research},
  volume = {41},
  number = {D1},
  pages = {D43-D47},
  note = {062BE Times Cited:81 Cited References Count:21},
  abstract = {The mission of the Universal Protein Resource (UniProt) (http://www.uniprot.org) is to support biological research by providing a freely accessible, stable, comprehensive, fully classified, richly and accurately annotated protein sequence knowledgebase. It integrates, interprets and standardizes data from numerous resources to achieve the most comprehensive catalogue of protein sequences and functional annotation. UniProt comprises four major components, each optimized for different uses, the UniProt Archive, the UniProt Knowledgebase, the UniProt Reference Clusters and the UniProt Metagenomic and Environmental Sequence Database. UniProt is produced by the UniProt Consortium, which consists of groups from the European Bioinformatics Institute (EBI), the SIB Swiss Institute of Bioinformatics (SIB) and the Protein Information Resource (PIR). UniProt is updated and distributed every 4 weeks and can be accessed online for searches or downloads.},
  keywords = {annotation database},
  issn = {0305-1048},
  doi = {Doi 10.1093/Nar/Gks1068},
  url = {<Go to ISI>://000312893300007 http://nar.oxfordjournals.org/content/41/D1/D43.full.pdf},
  year = {2013},
  type = {Journal Article},
}


@article{Keller2013,
  author = {auf dem Keller, U. and Prudova, A. and Eckhard, U. and Fingleton, B. and Overall, C. M.},
  title = {{Systems-level analysis of proteolytic events in increased vascular permeability and complement activation in skin inflammation}},
  journal = {Sci Signal},
  volume = {6},
  number = {258},
  pages = {rs2},
  note = {auf dem Keller, Ulrich Prudova, Anna Eckhard, Ulrich Fingleton, Barbara Overall, Christopher M 5R01CA084360/CA/NCI NIH HHS/ 5R01CA157781/CA/NCI NIH HHS/ R01 CA084360/CA/NCI NIH HHS/ R01 CA157781/CA/NCI NIH HHS/ Canadian Institutes of Health Research/Canada Sci Signal. 2013 Jan 15;6(258):rs2. doi: 10.1126/scisignal.2003512.},
  abstract = {During inflammation, vascular permeability is increased by various proteolytic events, such as the generation of bradykinin, that augment local tissue responses by enabling tissue penetration of serum proteins, including complement and acute-phase proteins. Proteases also govern inflammatory responses by processing extracellular matrix proteins and soluble bioactive mediators. We quantified changes in the proteome and the nature of protein amino termini (the N-terminome) and the altered abundance of murine proteases and inhibitors during skin inflammation. Through analysis of the N-terminome by iTRAQ-TAILS, we identified cotranslational and posttranslational alphaN-acetylation motifs, quantitative increases in protein abundance, and qualitative changes in the proteolytic signature during inflammation. Of the proteins identified in normal skin, about half were cleaved, and phorbol ester-induced inflammation increased the proportion of cleaved proteins, including chemokines and complement proteins, that were processed at previously uncharacterized sites. In response to phorbol ester-induced inflammation, mice deficient in matrix metalloproteinase 2 (MMP2) showed reduced accumulation of serum proteins in the skin and exhibited different proteolytic networks from those of wild-type mice. We found that the complement 1 (C1) inhibitor attenuated the increase in serum protein accumulation in inflamed skin. Cleavage and inactivation of the C1 inhibitor by MMP2 increased complement activation and bradykinin generation in wild-type mice, leading to increased vessel permeability during inflammation, which was diminished in Mmp2(-/-) mice. Thus, our systems-level analysis of proteolysis dissected cleavage events associated with skin inflammation and demonstrated that loss of a single protease could perturb the proteolytic signaling network and enhance inflammation.},
  keywords = {Acetylation Amino Acid Sequence Animals Blood Proteins/metabolism Blotting, Western Bradykinin/metabolism *Capillary Permeability *Complement Activation Complement C1 Inhibitor Protein/metabolism Complement System Proteins/metabolism Dermatitis/etiology/genetics/*metabolism Isotope Labeling/methods Mass Spectrometry/methods Matrix Metalloproteinase 2/deficiency/genetics Mice Mice, Knockout Molecular Sequence Data Proteolysis Proteome/metabolism Proteomics/methods Signal Transduction Skin/*metabolism/pathology Tetradecanoylphorbol Acetate/toxicity},
  issn = {1937-9145 (Electronic)},
  doi = {10.1126/scisignal.2003512},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/23322905 http://stke.sciencemag.org/cgi/content/abstract/sigtrans;6/258/rs2?view=abstract http://stke.sciencemag.org/content/6/258/rs2.abstract http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872078/pdf/nihms528680.pdf},
  year = {2013},
  type = {Journal Article},
}


@article{Gagnon:2013ya,
  author = {Gagnon, J. and Sheppard, E. and Anini, Y.},
  title = {{Metformin directly inhibits ghrelin secretion through AMP-activated protein kinase in rat primary gastric cells}},
  journal = {Diabetes Obes Metab},
  volume = {15},
  number = {3},
  pages = {276-9},
  note = {Gagnon, J Sheppard, E Anini, Y MOP-82795/Canadian Institutes of Health Research/Canada England Diabetes Obes Metab. 2013 Mar;15(3):276-9. doi: 10.1111/dom.12021. Epub 2012 Oct 29.},
  abstract = {The antidiabetic drug Metformin causes weight loss in both diabetic and non-diabetic individuals. Metformin treatment is also associated with lower circulating levels of the orexigenic hormone ghrelin. To test whether Metformin directly affects ghrelin cells, rat primary stomach cells were treated with Metformin and the levels of ghrelin secretion, proghrelin gene expression and activation of adenosine monophosphate-activated protein kinase (AMPK) were examined. Metformin significantly reduced ghrelin secretion and proghrelin mRNA production and both these effects were blocked by co-incubation with the AMPK inhibitor compound C. Furthermore, the AMPK activator 5-amino-1-beta-D-ribofuranosyl-imidazole-4-carboxamide (AICAR) significantly inhibited ghrelin secretion. Additionally, ghrelin cells were shown to express AMPK. Finally, Metformin treatment caused a significant increase in the level of phosphorylated (active) AMPK. Our results show that Metformin directly inhibits stomach ghrelin production and secretion through AMPK. This reduction in ghrelin secretion may be one of the key components in Metformin's mechanism of weight loss.},
  keywords = {AMP-Activated Protein Kinases/drug effects/*metabolism Animals Animals, Newborn Chief Cells, Gastric/*drug effects/*metabolism Female Gene Expression Regulation Ghrelin/drug effects/*metabolism/secretion Metformin/*pharmacology Pregnancy Rats Rats, Sprague-Dawley Signal Transduction/drug effects Stomach/drug effects/metabolism Weight Loss/drug effects},
  issn = {1463-1326 (Electronic) 1462-8902 (Linking)},
  doi = {10.1111/dom.12021},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/23066988 http://onlinelibrary.wiley.com/store/10.1111/dom.12021/asset/dom12021.pdf?v=1&t=iyasqkal&s=3d8b8ce104cc05f0a72e7a835133bfb18c3dec0a},
  year = {2013},
  type = {Journal Article},
}


@article{Itou:2013hp,
  author = {Itou, M. and Kawaguchi, T. and Taniguchi, E. and Sata, M.},
  title = {{Dipeptidyl peptidase-4: a key player in chronic liver disease}},
  journal = {World J Gastroenterol},
  volume = {19},
  number = {15},
  pages = {2298-306},
  note = {Itou, Minoru Kawaguchi, Takumi Taniguchi, Eitaro Sata, Michio China World J Gastroenterol. 2013 Apr 21;19(15):2298-306. doi: 10.3748/wjg.v19.i15.2298.},
  abstract = {Dipeptidyl peptidase-4 (DPP-4) is a membrane-associated peptidase, also known as CD26. DPP-4 has widespread organ distribution throughout the body and exerts pleiotropic effects via its peptidase activity. A representative target peptide is glucagon-like peptide-1, and inactivation of glucagon-like peptide-1 results in the development of glucose intolerance/diabetes mellitus and hepatic steatosis. In addition to its peptidase activity, DPP-4 is known to be associated with immune stimulation, binding to and degradation of extracellular matrix, resistance to anti-cancer agents, and lipid accumulation. The liver expresses DPP-4 to a high degree, and recent accumulating data suggest that DPP-4 is involved in the development of various chronic liver diseases such as hepatitis C virus infection, non-alcoholic fatty liver disease, and hepatocellular carcinoma. Furthermore, DPP-4 occurs in hepatic stem cells and plays a crucial role in hepatic regeneration. In this review, we described the tissue distribution and various biological effects of DPP-4. Then, we discussed the impact of DPP-4 in chronic liver disease and the possible therapeutic effects of a DPP-4 inhibitor.},
  keywords = {Carcinoma, Hepatocellular/*metabolism Dipeptidyl Peptidase 4/*physiology End Stage Liver Disease/*metabolism Extracellular Matrix/metabolism Fatty Liver/*metabolism Gene Expression Regulation, Enzymologic Hepatitis C/*metabolism Humans Incretins/therapeutic use Insulin Resistance Lipid Metabolism Liver Neoplasms/*metabolism},
  issn = {1007-9327 (Print) 1007-9327 (Linking)},
  doi = {10.3748/wjg.v19.i15.2298},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/23613622 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3631980/pdf/WJG-19-2298.pdf},
  year = {2013},
  type = {Journal Article},
}


@article{Lange:2013sp,
  author = {Lange, P. F. and Overall, C. M.},
  title = {{Protein TAILS: when termini tell tales of proteolysis and function}},
  journal = {Curr Opin Chem Biol},
  volume = {17},
  number = {1},
  pages = {73-82},
  note = {Lange, Philipp F Overall, Christopher M Canadian Institutes of Health Research/Canada England Curr Opin Chem Biol. 2013 Feb;17(1):73-82. doi: 10.1016/j.cbpa.2012.11.025. Epub 2013 Jan 6.},
  abstract = {Among the hundreds of posttranslational modifications, limited proteolysis, also known as processing, is special: It is irreversible, near ubiquitous, and by trimming peptide chains from their ends or cutting proteins into two, proteolysis forms shorter chains displaying new termini. The unique chemistry and location of alpha-amino-termini and carboxyl-termini in a protein engender special chemical and physical properties to a protein. Hence, modification of protein termini is often associated with new biological activities of a protein. We highlight recent proteomic developments enabling high throughput identification of protein termini. This has revolutionized degradomics and protein characterization by mapping the specificity of terminal modifications and of proteases, and has been used to directly identify new protease substrates and molecular pathways altered by proteolysis.},
  keywords = {Animals Humans Mass Spectrometry/methods Peptide Hydrolases/*metabolism Protein Processing, Post-Translational Proteins/*chemistry/*metabolism Proteolysis Proteomics/*methods Substrate Specificity},
  issn = {1879-0402 (Electronic) 1367-5931 (Linking)},
  doi = {10.1016/j.cbpa.2012.11.025},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/23298954 http://ac.els-cdn.com/S1367593112001615/1-s2.0-S1367593112001615-main.pdf?_tid=2a179bbe-ea5c-11e4-b7df-00000aab0f02&acdnat=1429864409_fd4f7ba060cf220e1c150e1949775d11 http://ac.els-cdn.com/S1367593112001615/1-s2.0-S1367593112001615-main.pdf?_tid=c9019c8c-e1ce-11e6-94b9-00000aab0f6c&acdnat=1485219073_8b86f4c5f76e563b816e49162a87e068},
  year = {2013},
  type = {Journal Article},
}


@article{Raj:2013pd,
  author = {Raj, V. S. and Mou, H. H. and Smits, S. L. and Dekkers, D. H. W. and Muller, M. A. and Dijkman, R. and Muth, D. and Demmers, J. A. A. and Zaki, A. and Fouchier, R. A. M. and Thiel, V. and Drosten, C. and Rottier, P. J. M. and Osterhaus, A. D. M. E. and Bosch, B. J. and Haagmans, B. L.},
  title = {{Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC}},
  journal = {Nature},
  volume = {495},
  number = {7440},
  pages = {251-254},
  note = {113FP Times Cited:80 Cited References Count:23},
  abstract = {Most human coronaviruses cause mild upper respiratory tract disease but may be associated with more severe pulmonary disease in immunocompromised individuals'. However, SARS coronavirus caused severe lower respiratory disease with nearly 10% mortality and evidence of systemic spread(2). Recently, another coronavirus (human coronavirus-Erasmus Medical Center (hCoV-EMC)) was identified in patients with severe and sometimes lethal lower respiratory tract infection(3,4). Viral genome analysis revealed close relatedness to coronaviruses found in bats'. Here we identify dipeptidyl peptidase 4 (DPP4; also known as CD26) as a functional receptor for hCoV-EMC. DPP4 specifically co-purified with the receptor-binding Si domain of the hCoV-EMC spike protein from lysates of susceptible Huh-7 cells. Antibodies directed against DPP4 inhibited hCoV-EMC infection of primary human bronchial epithelial cells and Huh-7 cells. Expression of human and bat (Pipistrellus pipistrellus) DPP4 in non-susceptible COS-7 cells enabled infection by hCoV-EMC. The use of the evolutionarily conserved DPP4 protein from different species as a functional receptor provides clues about the host range potential of hCoV-EMC. In addition, it will contribute critically to our understanding of the pathogenesis and epidemiology of this emerging human coronavirus, and may facilitate the development of intervention strategies.},
  keywords = {acute-respiratory-syndrome angiotensin-converting enzyme-2 sars coronavirus aminopeptidase-n pathogenesis mechanisms reservoirs bats},
  issn = {0028-0836},
  doi = {Doi 10.1038/Nature12005},
  url = {<Go to ISI>://000316652300054 http://www.nature.com/nature/journal/v495/n7440/pdf/nature12005.pdf},
  year = {2013},
  type = {Journal Article},
}


@article{Rogers:2013qo,
  author = {Rogers, L. D. and Overall, C. M.},
  title = {{Proteolytic post-translational modification of proteins: proteomic tools and methodology}},
  journal = {Mol Cell Proteomics},
  volume = {12},
  number = {12},
  pages = {3532-42},
  note = {Rogers, Lindsay D Overall, Christopher M Canadian Institutes of Health Research/Canada Mol Cell Proteomics. 2013 Dec;12(12):3532-42. doi: 10.1074/mcp.M113.031310. Epub 2013 Jul 25.},
  abstract = {Proteolytic processing is a ubiquitous and irreversible post-translational modification involving limited and highly specific hydrolysis of peptide and isopeptide bonds of a protein by a protease. Cleavage generates shorter protein chains displaying neo-N and -C termini, often with new or modified biological activities. Within the past decade, degradomics and terminomics have emerged as significant proteomics subfields dedicated to characterizing proteolysis products as well as natural protein N and C termini. Here we provide an overview of contemporary proteomics-based methods, including specific quantitation, data analysis, and curation considerations, and highlight exciting new and emerging applications within these fields enabling in vivo analysis of proteolytic events.},
  issn = {1535-9484 (Electronic) 1535-9476 (Linking)},
  doi = {10.1074/mcp.M113.031310},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/23887885 http://www.mcponline.org/content/12/12/3532.full.pdf https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3861706/pdf/zjw3532.pdf},
  year = {2013},
  type = {Journal Article},
}


@misc{UniProt2013,
  author = {UniProt},
  title = {{UniProtKB/Swiss-Prot protein knowledgebase release 2013 08 statistics}},
  number = {19th Sep},
  year = {2013},
  type = {Generic},
}


@misc{UniProt2013a,
  author = {UniProt, Consortium},
  title = {{UniProtKB/TrEMBL PROTEIN DATABASE RELEASE 2013_08 STATISTICS}},
  volume = {2013},
  number = {19th Sep},
  year = {2013},
  type = {Generic},
}


@article{Vandermarliere2013,
  author = {Vandermarliere, E. and Martens, L.},
  title = {{Protein structure as a means to triage proposed PTM sites}},
  journal = {PROTEOMICS},
  volume = {13},
  number = {6},
  pages = {1028-35},
  note = {Vandermarliere, Elien Martens, Lennart Germany Proteomics. 2013 Mar;13(6):1028-35. doi: 10.1002/pmic.201200232. Epub 2013 Feb 4.},
  abstract = {PTMs such as phosphorylation are often important actors in protein regulation and recognition. These functions require both visibility and accessibility to other proteins; that the modification is located at the surface of the protein. Currently, many repositories provide information on PTMs but structural information is often lacking. This study, which focuses on phosphorylation sites available in UniProtKB/Swiss-Prot, illustrates that most phosphorylation sites are indeed found at the surface of the protein, but that some sites are found buried in the core of the protein. Several of these identified buried phosphorylation sites can easily become accessible upon small conformational changes while others would require the whole protein to unfold and are hence most unlikely modification sites. Subsequent analysis of phosphorylation sites available in PRIDE demonstrates that taking the structure of the protein into account would be a good guide in the identification of the actual phosphorylated positions in phophoproteomics experiments. This analysis illustrates that care must be taken when simply accepting the position of a PTM without first analyzing its position within the protein structure if the latter is available.},
  keywords = {Amino Acid Motifs Amino Acid Sequence Binding Sites Databases, Protein Humans Molecular Sequence Annotation/methods Molecular Sequence Data Phosphorylation *Protein Processing, Post-Translational Proteome/*chemistry/metabolism},
  issn = {1615-9861 (Electronic) 1615-9853 (Linking)},
  doi = {10.1002/pmic.201200232},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/23172737 http://onlinelibrary.wiley.com/store/10.1002/pmic.201200232/asset/pmic7296.pdf?v=1&t=i8vc5aaq&s=584f975b02354c6daa0736f02898ed84d81a09c4 http://onlinelibrary.wiley.com/store/10.1002/pmic.201200232/asset/pmic7296.pdf?v=1&t=iygnnt7q&s=0bc82b9dd338973691ccbb4a4a0709c7be5e4940},
  year = {2013},
  type = {Journal Article},
}


@article{Wilson:2013th,
  author = {Wilson, C. H. and Indarto, D. and Doucet, A. and Pogson, L. D. and Pitman, M. R. and McNicholas, K. and Menz, R. I. and Overall, C. M. and Abbott, C. A.},
  title = {{Identifying natural substrates for dipeptidyl peptidases 8 and 9 using terminal amine isotopic labeling of substrates (TAILS) reveals in vivo roles in cellular homeostasis and energy metabolism}},
  journal = {J Biol Chem},
  volume = {288},
  number = {20},
  pages = {13936-49},
  note = {Wilson, Claire H Indarto, Dono Doucet, Alain Pogson, Lisa D Pitman, Melissa R McNicholas, Kym Menz, R Ian Overall, Christopher M Abbott, Catherine A MOP-37937/Canadian Institutes of Health Research/Canada J Biol Chem. 2013 May 17;288(20):13936-49. doi: 10.1074/jbc.M112.445841. Epub 2013 Mar 21.},
  abstract = {Dipeptidyl peptidases (DP) 8 and 9 are homologous, cytoplasmic N-terminal post-proline-cleaving enzymes that are anti-targets for the development of DP4 (DPPIV/CD26) inhibitors for treating type II diabetes. To date, DP8 and DP9 have been implicated in immune responses and cancer biology, but their pathophysiological functions and substrate repertoire remain unknown. This study utilizes terminal amine isotopic labeling of substrates (TAILS), an N-terminal positional proteomic approach, for the discovery of in vivo DP8 and DP9 substrates. In vivo roles for DP8 and DP9 in cellular metabolism and homeostasis were revealed via the identification of more than 29 candidate natural substrates and pathways affected by DP8/DP9 overexpression. Cleavage of 14 substrates was investigated in vitro; 9/14 substrates for both DP8 and DP9 were confirmed by MALDI-TOF MS, including two of high confidence, calreticulin and adenylate kinase 2. Adenylate kinase 2 plays key roles in cellular energy and nucleotide homeostasis. These results demonstrate remarkable in vivo substrate overlap between DP8/DP9, suggesting compensatory roles for these enzymes. This work provides the first global investigation into DP8 and DP9 substrates, providing a number of leads for future investigations into the biological roles and significance of DP8 and DP9 in human health and disease.},
  keywords = {Adenylate Kinase/*metabolism Amino Acid Sequence Calreticulin/*metabolism Cations Cell Line, Tumor Cell Separation Cytoplasm/metabolism Dipeptidases/*metabolism Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/*metabolism Energy Metabolism Flow Cytometry Homeostasis Humans Isotope Labeling Mass Spectrometry Molecular Sequence Data Protein Structure, Tertiary Proteomics/*methods Substrate Specificity},
  issn = {1083-351X (Electronic) 0021-9258 (Linking)},
  doi = {10.1074/jbc.M112.445841},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/23519473 http://www.jbc.org/content/288/20/13936.full.pdf},
  year = {2013},
  type = {Journal Article},
}


@article{Consortium:2014aa,
  author = {Consortium, The UniProt},
  title = {{Activities at the Universal Protein Resource (UniProt)}},
  journal = {Nucleic Acids Research},
  volume = {42},
  number = {D1},
  pages = {D191--D198},
  url = {http://nar.oxfordjournals.org/content/42/D1/D191.abstract%20N2%20-%20The%20mission%20of%20the%20Universal%20Protein%20Resource%20(UniProt)%20(http://www.uniprot.org)%20is%20to%20provide%20the%20scientific%20community%20with%20a%20comprehensive,%20high-quality%20and%20freely%20accessible%20resource%20of%20protein%20sequences%20and%20functional%20annotation.%20It%20integrates,%20interprets%20and%20standardizes%20data%20from%20literature%20and%20numerous%20resources%20to%20achieve%20the%20most%20comprehensive%20catalog%20possible%20of%20protein%20information.%20The%20central%20activities%20are%20the%20biocuration%20of%20the%20UniProt%20Knowledgebase%20and%20the%20dissemination%20of%20these%20data%20through%20our%20Web%20site%20and%20web%20services.%20UniProt%20is%20produced%20by%20the%20UniProt%20Consortium,%20which%20consists%20of%20groups%20from%20the%20European%20Bioinformatics%20Institute%20(EBI),%20the%20SIB%20Swiss%20Institute%20of%20Bioinformatics%20(SIB)%20and%20the%20Protein%20Information%20Resource%20(PIR).%20UniProt%20is%20updated%20and%20distributed%20every%204%20weeks%20and%20can%20be%20accessed%20online%20for%20searches%20or%20downloads.},
  year = {2014},
  type = {Journal Article},
}


@article{Gonzalez-Galarza,
  author = {Gonzalez-Galarza, F. F. and Qi, D. and Fan, J. and Bessant, C. and Jones, A. R.},
  title = {{A tutorial for software development in quantitative proteomics using PSI standard formats}},
  journal = {Biochimica Et Biophysica Acta-Proteins and Proteomics},
  volume = {1844},
  number = {1},
  pages = {88-97},
  note = {A Sp. Iss. SI Aa2fv Times Cited:0 Cited References Count:46},
  abstract = {The Human Proteome Organisation - Proteomics Standards Initiative (HUPO-PSI) has been working for ten years on the development of standardised formats that facilitate data sharing and public database deposition. In this article, we review three HUPO-PSI data standards - mzML, mzIdentML and mzQuantML, which can be used to design a complete quantitative analysis pipeline in mass spectrometry (MS)-based proteomics. In this tutorial, we briefly describe the content of each data model, sufficient for bioinformaticians to devise proteomics software. We also provide guidance on the use of recently released application programming interfaces (APIs) developed in Java for each of these standards, which makes it straightforward to read and write files of any size. We have produced a set of example Java classes and a basic graphical user interface to demonstrate how to use the most important parts of the PSI standards, available from http://code.google.com/p/psi-standard-formats-tutorial. This article is part of a Special Issue entitled: Computational Proteomics in the Post-Identification Era. Guest Editors: Martin Eisenacher and Christian Stephan. (C) 2013 Elsevier B.V. All rights reserved.},
  keywords = {quantitative proteomics software standard formats apis mass-spectrometry data source java api protein identification computational proteomics ms data bioinformatics guidelines peptide tandem ms/ms},
  issn = {1570-9639},
  doi = {DOI 10.1016/j.bbapap2013.04.004},
  url = {<Go to ISI>://000330911400011 http://ac.els-cdn.com/S1570963913001581/1-s2.0-S1570963913001581-main.pdf?_tid=685e3e78-ea5c-11e4-8689-00000aab0f6b&acdnat=1429864513_59a7a745e0b4635121ba225696a71ccb},
  year = {2014},
  type = {Journal Article},
}


@article{Kanehisa01012014,
  author = {Kanehisa, M. and Goto, S. and Sato, Y. and Kawashima, M. and Furumichi, M. and Tanabe, M.},
  title = {{Data, information, knowledge and principle: back to metabolism in KEGG}},
  journal = {Nucleic Acids Res},
  volume = {42},
  number = {Database issue},
  pages = {D199-205},
  note = {Kanehisa, Minoru Goto, Susumu Sato, Yoko Kawashima, Masayuki Furumichi, Miho Tanabe, Mao England Nucleic Acids Res. 2014 Jan;42(Database issue):D199-205. doi: 10.1093/nar/gkt1076. Epub 2013 Nov 7.},
  abstract = {In the hierarchy of data, information and knowledge, computational methods play a major role in the initial processing of data to extract information, but they alone become less effective to compile knowledge from information. The Kyoto Encyclopedia of Genes and Genomes (KEGG) resource (http://www.kegg.jp/ or http://www.genome.jp/kegg/) has been developed as a reference knowledge base to assist this latter process. In particular, the KEGG pathway maps are widely used for biological interpretation of genome sequences and other high-throughput data. The link from genomes to pathways is made through the KEGG Orthology system, a collection of manually defined ortholog groups identified by K numbers. To better automate this interpretation process the KEGG modules defined by Boolean expressions of K numbers have been expanded and improved. Once genes in a genome are annotated with K numbers, the KEGG modules can be computationally evaluated revealing metabolic capacities and other phenotypic features. The reaction modules, which represent chemical units of reactions, have been used to analyze design principles of metabolic networks and also to improve the definition of K numbers and associated annotations. For translational bioinformatics, the KEGG MEDICUS resource has been developed by integrating drug labels (package inserts) used in society.},
  keywords = {*Databases, Chemical Drug-Related Side Effects and Adverse Reactions Genome Internet Knowledge Bases *Metabolic Networks and Pathways/genetics Pharmaceutical Preparations/chemistry/classification Phenotype},
  issn = {1362-4962 (Electronic) 0305-1048 (Linking)},
  doi = {10.1093/nar/gkt1076},
  url = {http://www.ncbi.nlm.nih.gov/pubmed/24214961 http://nar.oxfordjournals.org/content/42/D1/D199.full.pdf http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3965122/pdf/gkt1076.pdf},
  year = {2014},
  type = {Journal Article},
}


@inbook{Lane2016,
  author = {Lane, Nicole M. and Gregorich, Zachery R. and Ge, Ying},
  title = {{Top-Down Proteomics}},
  booktitle = {Manual of Cardiovascular Proteomics},
  editor = {Agnetti, Giulio and Lindsey, Merry L. and Foster, D. Brian},
  publisher = {Springer International Publishing},
  address = {Cham},
  pages = {187-212},
  isbn = {978-3-319-31828-8},
  doi = {10.1007/978-3-319-31828-8_8},
  url = {http://dx.doi.org/10.1007/978-3-319-31828-8_8 http://download.springer.com/static/pdf/280/chp%253A10.1007%252F978-3-319-31828-8_8.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Fchapter%2F10.1007%2F978-3-319-31828-8_8&token2=exp=1486345576~acl=%2Fstatic%2Fpdf%2F280%2Fchp%25253A10.1007%25252F978-3-319-31828-8_8.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Fchapter%252F10.1007%252F978-3-319-31828-8_8*~hmac=ae005ae1c031237bb621bd786c5a601199925d325d63e9b80750f338670a824e http://download.springer.com/static/pdf/280/chp%253A10.1007%252F978-3-319-31828-8_8.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Fchapter%2F10.1007%2F978-3-319-31828-8_8&token2=exp=1486345581~acl=%2Fstatic%2Fpdf%2F280%2Fchp%25253A10.1007%25252F978-3-319-31828-8_8.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Fchapter%252F10.1007%252F978-3-319-31828-8_8*~hmac=1e95b1a93a1a4c999bc70cc3eeaa134ac7e423e4c04fd22ef8fc88f03b34f9c4},
  year = {2016},
  type = {Book Section},
}


@article{Mentlein_1999,
  doi = {10.1016/s0167-0115(99)00089-0},
  url = {https://doi.org/10.1016%2Fs0167-0115%2899%2900089-0},
  year = {1999},
  month = {nov},
  publisher = {Elsevier {BV}},
  volume = {85},
  number = {1},
  pages = {9--24},
  author = {Rolf Mentlein},
  title = {{Dipeptidyl-peptidase {IV} ({CD}26)-role in the inactivation of regulatory peptides}},
  journal = {Regulatory Peptides},
}


@incollection{Abbott_2002,
  doi = {10.1007/978-1-4615-0619-5_7},
  url = {https://doi.org/10.1007%2F978-1-4615-0619-5_7},
  year = {2002},
  publisher = {Springer Nature},
  pages = {171--195},
  author = {Catherine A. Abbott and Mark D. Gorrell},
  title = {{The Family of {CD}26/{DPIV} and Related Ectopeptidases}},
  booktitle = {Ectopeptidases},
}


@article{18606664,
  title = {{Inhibition of CD26/dipeptidyl peptidase IV enhances CCL11/eotaxin-mediated recruitment of eosinophils in vivo.}},
  date = {2008 Jul 15},
  source = {J Immunol},
  authors = {Forssmann, U and Stoetzer, C and Stephan, M and Kruschinski, C and Skripuletz, T and Schade, J and Schmiedl, A and Pabst, R and Wagner, L and Hoffmann, T and Kehlen, A and Escher, SE and Forssmann, WG and Elsner, J and von, Hrsten S},
  author = {Forssmann, U and Stoetzer, C and Stephan, M and Kruschinski, C and Skripuletz, T and Schade, J and Schmiedl, A and Pabst, R and Wagner, L and Hoffmann, T and Kehlen, A and Escher, SE and Forssmann, WG and Elsner, J and von, Hrsten S},
  year = {2008},
  month = {Jul},
  journal = {J Immunol},
  volume = {181},
  number = {},
  pages = {1120-7},
  pubmed_id = {18606664},
}


@article{12173928,
  title = {{The CXCR3 binding chemokine IP-10/CXCL10: structure and receptor interactions.}},
  date = {2002 Aug 20},
  source = {Biochemistry},
  authors = {Booth, V and Keizer, DW and Kamphuis, MB and Clark-Lewis, I and Sykes, BD},
  author = {Booth, V and Keizer, DW and Kamphuis, MB and Clark-Lewis, I and Sykes, BD},
  year = {2002},
  month = {Aug},
  journal = {Biochemistry},
  volume = {41},
  number = {},
  pages = {10418-25},
  pubmed_id = {12173928},
}


@article{10725737,
  title = {{Identification of unique truncated KC/GRO beta chemokines with potent hematopoietic and anti-infective activities.}},
  date = {2000 Apr 1},
  source = {J Immunol},
  authors = {King, AG and Johanson, K and Frey, CL and DeMarsh, PL and White, JR and McDevitt, P and McNulty, D and Balcarek, J and Jonak, ZL and Bhatnagar, PK and Pelus, LM},
  author = {King, AG and Johanson, K and Frey, CL and DeMarsh, PL and White, JR and McDevitt, P and McNulty, D and Balcarek, J and Jonak, ZL and Bhatnagar, PK and Pelus, LM},
  year = {2000},
  month = {Apr},
  journal = {J Immunol},
  volume = {164},
  number = {},
  pages = {3774-82},
  pubmed_id = {10725737},
}


@article{23160239,
  title = {{Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis.}},
  date = {2012 Dec},
  source = {Nat Med},
  authors = {Broxmeyer, HE and Hoggatt, J and O'Leary, HA and Mantel, C and Chitteti, BR and Cooper, S and Messina-Graham, S and Hangoc, G and Farag, S and Rohrabaugh, SL and Ou, X and Speth, J and Pelus, LM and Srour, EF and Campbell, TB},
  author = {Broxmeyer, HE and Hoggatt, J and O'Leary, HA and Mantel, C and Chitteti, BR and Cooper, S and Messina-Graham, S and Hangoc, G and Farag, S and Rohrabaugh, SL and Ou, X and Speth, J and Pelus, LM and Srour, EF and Campbell, TB},
  year = {2012},
  month = {Dec},
  journal = {Nat Med},
  volume = {18},
  number = {},
  pages = {1786-96},
  pubmed_id = {23160239},
}


@article{23000011,
  title = {{Colony stimulating factors and myeloid cell biology in health and disease.}},
  date = {2013 Feb},
  source = {Trends Immunol},
  authors = {Hamilton, JA and Achuthan, A},
  author = {Hamilton, JA and Achuthan, A},
  year = {2013},
  month = {Feb},
  journal = {Trends Immunol},
  volume = {34},
  number = {},
  pages = {81-9},
  pubmed_id = {23000011},
}


@article{12167864,
  title = {{Gut hormone PYY(3-36) physiologically inhibits food intake.}},
  date = {2002 Aug 8},
  source = {Nature},
  authors = {Batterham, RL and Cowley, MA and Small, CJ and Herzog, H and Cohen, MA and Dakin, CL and Wren, AM and Brynes, AE and Low, MJ and Ghatei, MA and Cone, RD and Bloom, SR},
  author = {Batterham, RL and Cowley, MA and Small, CJ and Herzog, H and Cohen, MA and Dakin, CL and Wren, AM and Brynes, AE and Low, MJ and Ghatei, MA and Cone, RD and Bloom, SR},
  year = {2002},
  month = {Aug},
  journal = {Nature},
  volume = {418},
  number = {},
  pages = {650-4},
  pubmed_id = {12167864},
}


@article{16802131,
  title = {{Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY.}},
  date = {2006 Aug},
  source = {Diabetologia},
  authors = {Unniappan, S and McIntosh, CH and Demuth, HU and Heiser, U and Wolf, R and Kieffer, TJ},
  author = {Unniappan, S and McIntosh, CH and Demuth, HU and Heiser, U and Wolf, R and Kieffer, TJ},
  year = {2006},
  month = {Aug},
  journal = {Diabetologia},
  volume = {49},
  number = {},
  pages = {1915-23},
  pubmed_id = {16802131},
}


@article{20380653,
  title = {{Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.}},
  date = {2010 Apr},
  source = {Diabetes Obes Metab},
  authors = {Aaboe, K and Knop, FK and Vilsbll, T and Deacon, CF and Holst, JJ and Madsbad, S and Krarup, T},
  author = {Aaboe, K and Knop, FK and Vilsbll, T and Deacon, CF and Holst, JJ and Madsbad, S and Krarup, T},
  year = {2010},
  month = {Apr},
  journal = {Diabetes Obes Metab},
  volume = {12},
  number = {},
  pages = {323-33},
  pubmed_id = {20380653},
}


@article{12442257,
  title = {{The spectrum of endogenous human chromogranin A-derived peptides identified using a modified proteomic strategy.}},
  date = {2002 Nov},
  source = {Proteomics},
  authors = {Orr, DF and Chen, T and Johnsen, AH and Chalk, R and Buchanan, KD and Sloan, JM and Rao, P and Shaw, C},
  author = {Orr, DF and Chen, T and Johnsen, AH and Chalk, R and Buchanan, KD and Sloan, JM and Rao, P and Shaw, C},
  year = {2002},
  month = {Nov},
  journal = {Proteomics},
  volume = {2},
  number = {},
  pages = {1586-600},
  pubmed_id = {12442257},
}


@article{12039843,
  title = {{Loss of dipeptidylpeptidase IV activity in chronic rhinosinusitis contributes to the neurogenic inflammation induced by substance P in the nasal mucosa.}},
  date = {2002 Jul},
  source = {FASEB J},
  authors = {Grouzmann, E and Monod, M and Landis, B and Wilk, S and Brakch, N and Nicoucar, K and Giger, R and Malis, D and Szalay-Quinodoz, I and Cavadas, C and Morel, DR and Lacroix, JS},
  author = {Grouzmann, E and Monod, M and Landis, B and Wilk, S and Brakch, N and Nicoucar, K and Giger, R and Malis, D and Szalay-Quinodoz, I and Cavadas, C and Morel, DR and Lacroix, JS},
  year = {2002},
  month = {Jul},
  journal = {FASEB J},
  volume = {16},
  number = {},
  pages = {1132-4},
  pubmed_id = {12039843},
}


@article{12690116,
  title = {{The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38).}},
  date = {2003 Jun 20},
  source = {J Biol Chem},
  authors = {Zhu, L and Tamvakopoulos, C and Xie, D and Dragovic, J and Shen, X and Fenyk-Melody, JE and Schmidt, K and Bagchi, A and Griffin, PR and Thornberry, NA and Sinha, Roy R},
  author = {Zhu, L and Tamvakopoulos, C and Xie, D and Dragovic, J and Shen, X and Fenyk-Melody, JE and Schmidt, K and Bagchi, A and Griffin, PR and Thornberry, NA and Sinha, Roy R},
  year = {2003},
  month = {Jun},
  journal = {J Biol Chem},
  volume = {278},
  number = {},
  pages = {22418-23},
  pubmed_id = {12690116},
}


@article{15491793,
  title = {{Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.}},
  date = {2004 Nov 15},
  source = {Regul Pept},
  authors = {Nauck, MA and El-Ouaghlidi, A and Gabrys, B and Hcking, K and Holst, JJ and Deacon, CF and Gallwitz, B and Schmidt, WE and Meier, JJ},
  author = {Nauck, MA and El-Ouaghlidi, A and Gabrys, B and Hcking, K and Holst, JJ and Deacon, CF and Gallwitz, B and Schmidt, WE and Meier, JJ},
  year = {2004},
  month = {Nov},
  journal = {Regul Pept},
  volume = {122},
  number = {},
  pages = {209-17},
  pubmed_id = {15491793},
}
